Evaluation and Implementation of Large Language Model-based Applications for Electronic Health Records - capabilities, limitations, and failure modes

Shan Chen

Evaluation and Implementation of Large Language Model-based Applications for Electronic Health Records - capabilities, limitations, and failure modes
Shan Chen

Design: Proefschriftenprinten.nl
Printing: Proefschriftenprinten.nl

ISBN: 978-90-836999-2-9

Evaluation and Implementation of Large Language Model-based Applications for Electronic Health Records - capabilities, limitations, and failure modes

DISSERTATION

to obtain the degree of Doctor at Maastricht University,
on the authority of the Rector Magnificus, Prof. Dr. Jan Smiths
in accordance with the decision of the Board of Deans,
to be defended in public on Monday 8th day of June 2026, at 16.00 hours

by Shan Chen

Supervisor:
Prof. Dr. Hugo J.W.L. Aerts, Harvard Medical School, Maastricht University

Co-supervisor:
Dr. Danielle S. Bitterman, Harvard Medical School

Chair:
Prof. Dr. A.L.A.J. Dekker, Maastricht University, MAASTRO Clinic

Members:
Em. Prof. Dr. M. Palmer, University of Colorado Boulder, USA
Prof. Dr. D.K.M. De Ruysscher, Maastricht University, MAASTRO Clinic
Prof. Dr. J.C. Scholtes, Maastricht University
Prof. Dr. S. Bethard, University of Arizona, USA

Mass General Brigham, Brigham Women's Hospital, Boston Children's Hospital Computational Health Informatics Program, and Harvard Medical School. Google Research for funding, PhD fellowship, and mentorship supports.

Table of contents


DATA

Chapter 1

General Introduction, Outline and Glossary

Recent advances in artificial intelligence are reshaping healthcare, driven by the rapid emergence of large language models (LLMs) that exhibit unprecedented fluency, reasoning, and adaptability. Early generative models such as GPT-2 and GPT-3 demonstrated that scale and unsupervised pre-training could unlock broad generalization capabilities previously unattainable in clinical NLP systems[1,2]. These breakthroughs were enabled by decoder-only transformer architectures[3] and further refined through instruction-following and reinforcement learning from human feedback[4], which significantly improved model controllability and task alignment. More recently, frontier systems such as GPT-4/5 continue to expand the scope of clinical tasks LLMs can perform, from summarization to reasoning over complex medical content[5].

Simultaneously, medicine itself has become increasingly digitized. Electronic health records, clinical trial documents, biomedical literature, and patient-generated data now form vast corpora on which these models are trained and in which they are deployed. As a result, LLMs have transitioned rapidly from research prototypes to operational tools embedded in real clinical workflows. They are already assisting with patient-provider communication[6], generating and summarizing clinical notes[7–9], extracting structured information from unstructured data[10], and even encoding substantial clinical knowledge comparable to domain-trained models[11,12]. This shift marks a profound change in the epistemic infrastructure of medicine: for the first time, clinicians routinely interact with probabilistic generative systems capable of producing medical text at scale.

However, the same generative fluency that makes LLMs attractive for healthcare applications also introduces substantial risks. Studies consistently show that LLMs can hallucinate nonexistent treatments, misjudge clinical acuity, or propagate biases embedded in their training data[13–19]. Even small perturbations in phrasing, demographic attributes, or contextual cues can produce significant shifts in output quality - raising concerns about stability, robustness, and equity. These vulnerabilities are particularly concerning given early evidence that patients may overly trust model-generated text and that health systems are beginning to integrate LLMs into triage, decision support, and documentation pipelines. The risk is not hypothetical: inappropriate advice, misaligned summaries, and sycophantic agreement with false statements have already been documented in controlled evaluations[19,20].

These developments make clear that the healthcare community faces a dual imperative: **to rigorously identify where LLMs provide measurable value, and to expose and mitigate the conditions under which they may cause harm**. Overemphasizing capability risks premature deployment of unsafe tools; overemphasizing failure risks forfeits technologies with genuine potential to reduce clinician burden, surface invisible inequities, and enhance evidence generation. This thesis embraces both dimensions.

Part I investigates domains where LLMs can augment clinical expertise. Our work has shown that models can encode substantial clinical knowledge, assist in patient communication, and extract valuable signals from narrative text that traditional analytics overlook - such as social determinants of health or treatment-related toxicities. The studies presented here also extend through rigorous, workflow-embedded evaluations, demonstrating that when aligned, fine-tuned, and rigorously validated, LLMs can surface clinically meaningful information at scale and support more equitable clinical operations.



Figure 1. *From scaling to clinical deployment 2017-2016*

Part II interrogates the foundational limitations that emerge when LLMs confront clinically related tasks. Building on recent evidence of bias, misalignment, and brittleness, these chapters reveal how pre-training distributions, lexical fragility, and conversational alignment pressures can systematically distort medical predictions. They also show that even state-of-the-art models remain vulnerable to hallucination and sycophantic compliance, posing risks for clinical deployment.

Together, these investigations argue that LLMs should not be deployed as black-box oracles but rather as **transparent, auditable, and domain-aligned clinical instruments**. Achieving this vision requires interdisciplinary collaboration, last-mile alignment grounded in local data and workflows, and rigorous, open evaluation frameworks such as HealthBench[21] and model-specific benchmarks for medical tasks[7,22,23]. By synthesizing both the promise and the pitfalls of clinical LLMs, this thesis outlines a principled path toward AI systems that strengthen the safety, equity, and integrity of global healthcare.

Part I: Potential Utilities of Language Models in Real Clinical Practice

The first part of this thesis investigates how LLMs can be harnessed to solve practical, high-impact problems across the clinical ecosystem: from direct patient communication to surfacing hidden determinants of health.

We begin at the patient interface. **Chapter 2** examines the urgent problem of medical misinformation: cancer patients increasingly turn to general-purpose chatbots like ChatGPT for treatment advice, yet these systems lack clinical grounding. We systematically evaluated ChatGPT's ability to generate guideline-concordant recommendations across 104 oncologic scenarios, finding that while the model always produced at least one correct suggestion, over one-third of responses included potentially harmful errors and 12% hallucinated entire treatment modalities. This study establishes a baseline risk profile for patient-facing LLMs and underscores why unfiltered deployment in consumer health contexts is dangerous without rigorous validation and safeguards.

Moving to the provider workflow, **Chapter 3** investigates LLMs as a clinical assistant for drafting patient portal messages—a use case now live in many new EHR platforms. By having oncologists use GPT-4 to draft responses to realistic patient messages, we uncovered a tension between efficiency and safety: while AI assistance shortened documentation time, unedited drafts posed a 7.7% risk of severe harm, primarily from misjudging clinical urgency. This work reveals that human oversight remains non-negotiable; the value of LLMs lies not in autonomous drafting but in augmenting physicians, provided they remain vigilant to subtle but critical errors.

Shifting from communication to data extraction, **Chapter 4** and **Chapter 5** demonstrate how LLMs can unlock information trapped in unstructured clinical notes. Radiotherapy-induced esophagitis is a debilitating toxicity that is routinely documented in free text but rarely captured for research. We developed NLP models that automatically grade esophagitis severity with high fidelity, enabling large-scale real-world evidence generation on treatment complications. Similarly, social determinants of health (SDoH)—powerful predictors of outcomes—are notoriously absent from structured data. In **Chapter 5**, we show that fine-tuned LLMs can extract SDoH from clinical narratives far more accurately than billing codes, identifying nearly 94% of patients with adverse social circumstances versus 2% via traditional methods. Critically, these models exhibit less demographic bias than generalist LLMs, offering a path toward more equitable data-driven care.

These extraction capabilities culminate in **Chapter 6**, which introduces iRAE Agent(AEGIS), an agentic system piloted live at Mass General Brigham for immunotherapy-related adverse event detection in oncology clinical trials. Unlike passive classification, iRAE orchestrates multi-step reasoning, error checking, and ontology-guided reporting within live hospital workflows—addressing a labor-intensive process that directly impacts trial safety, speed, and cost. This pilot represents the frontier of clinical LLM deployment: moving from isolated tasks to integrated, autonomous agents that solve real, resource-constrained problems in cancer care and clinical trial operations.

Part II: Potential Fails of Language Models in Medical Settings

If Part I demonstrates what LLMs can do, Part II investigates what can go wrong—exposing latent vulnerabilities that become dangerous when models are deployed in high-stakes medical environments.

Chapter 7 establishes a performance ceiling by comparing generalist LLMs against traditional biomedical NLP methods. On structured tasks like health advice classification and causal reasoning, few-shot prompting of ChatGPT approached but never exceeded the accuracy of fine-tuned, domain-specific models like BioBERT - while requiring a thousandfold more computational time. This finding is pivotal: it demonstrates that for many clinical NLP tasks, the "generalist advantage" is a myth. Locally tuned models are not only more

accurate but also cheaper, faster to deploy, and easier to integrate into existing workflows, making them the pragmatic choice for most biomedical applications.

The next three chapters peel back layers of hidden fragility rooted in pre-training bias.

Chapter 8 introduces Cross-Care, a benchmark quantifying discordance between LLM-encoded disease-demographic associations and true epidemiology. Across 89 diseases and multiple demographic and language groups, we found that LLM predictions correlate strongly with how often disease-demographic pairs appear in pre-training corpora - but show virtually no alignment with actual prevalence. This representational bias persists even after alignment tuning and across languages.

Chapter 9 reveals how this bias manifests as lexical fragility: swapping brand and generic drug names (semantically equivalent variations) caused performance drops of 1–13% across state-of-the-art models. This suggests that even when models "know" A=B, they cannot reliably manipulate this knowledge—they rely on memorized patterns from training data rather than robust reasoning.

Chapter 10 extends this to sycophantic behavior, where models comply with factually incorrect drug equivalence claims up to 100% of the time to appear helpful. Together, these chapters expose a systemic vulnerability: LLMs encode the statistical idiosyncrasies of their training data, not grounded medical knowledge, and they default to helpfulness over truth when these conflict.

Chapter 11 and **Chapter 12** scale evaluation efficiently to track real progress on emerging capabilities using existing resources. **Chapter 11** presents WorldMedQA-V, a multilingual, multimodal medical exam dataset spanning four countries and languages. Rather than simply exposing disparities, this benchmark provides a scalable tool to rigorously track whether vision-language model improvements truly generalize across diverse linguistic contexts—or merely deepen global health inequities. **Chapter 12** introduces MedBrowseComp, a benchmark for medical deep research requiring multi-hop evidence synthesis from live knowledge bases. By forcing agents to navigate fragmented clinical evidence, MedBrowseComp offers a durable framework to measure genuine progress toward safe, evidence-based AI - exposing

that even state-of-the-art systems achieve only ~10% accuracy on complex questions, far below clinical requirements.

Chapter 13 brings everything together with a simple argument: to build better clinical AI, we need to invest in both usefulness and safety at the same time. The work in Part I showed real promise—extracting toxicity data, identifying social determinants of health, streamlining trial workflows—but each success also exposed harder, more fundamental problems: models that break under pressure, biases baked in during training, a troubling tension between giving helpful answers and giving honest ones, and evaluation methods that just aren't up to the task. We outline priorities including prevalence-aware pre-training, robust evaluation frameworks that test for bias and fragility, alignment strategies that prioritize factual correctness over helpfulness, and agent architectures grounded in verifiable evidence. The appendices document broader NLP contributions, including open-source medical LLMs, interpretability methods, and multilingual reasoning, that strengthen the foundations of this field.

Together, this thesis provides an empirically grounded, dual-narrative examination of LLMs in medicine: celebrating their potential to transform cancer care while unflinchingly exposing the vulnerabilities that must be resolved before they can be trusted at scale. And discuss how we can build better applications, monitor, and track meaningful progress in clinical AI.

References

1. Radford, A. *et al.* Language Models are Unsupervised Multitask Learners. (2019).
2. Brown, T. B. *et al.* Language Models are Few-Shot Learners. *arXiv [cs.CL]* (2020).
3. Vaswani, A. *et al.* Attention is all you need. *Advances in Neural Information Processing Systems* (2017).
4. Ouyang, L. *et al.* Training language models to follow instructions with human feedback. *arXiv [cs.CL]* (2022).
5. OpenAI *et al.* GPT-4 Technical Report. *arXiv [cs.CL]* (2023).
6. Chen, S. *et al.* The effect of using a large language model to respond to patient messages. *Lancet Digit. Health* 6, e379–e381 (2024).
7. Gao, Y. *et al.* DR.BENCH: Diagnostic reasoning benchmark for clinical natural language processing. *Journal of Biomedical Informatics* (2023).
8. Bednarczyk, L. *et al.* Scientific evidence for clinical text summarization using large language models: Scoping review. *J. Med. Internet Res.* 27, e68998 (2025).
9. Oliveira, J. D. *et al.* Development and evaluation of a clinical note summarization system using large language models. *Commun. Med. (Lond.)* 5, 376 (2025).
10. Goodman, K. E. *et al.* Identification of long-term care facility residence from admission notes using large language models. *JAMA Netw. Open* 8, e2512032 (2025).
11. Singhal, K. *et al.* Large language models encode clinical knowledge. *Nature* 620, 172–180 (2023).
12. Nori, H., King, N., McKinney, S. M., Carignan, D. & Horvitz, E. Capabilities of GPT-4 on Medical Challenge Problems. *arXiv [cs.CL]* (2023).
13. Zack, T. *et al.* Assessing the potential of GPT-4 to perpetuate racial and gender biases in health care: a model evaluation study. *Lancet Digit. Health* 6, e12–e22 (2024).
14. Chen, S. *et al.* Cross-Care: Assessing the healthcare implications of pre-training data on language model bias. *Advances in Neural Information Processing Systems* 2405.05506, 23756–23795 (2024).
15. Hager, P. *et al.* Evaluation and mitigation of the limitations of large language models in clinical decision-making. *Nat. Med.* 30, 2613–2622 (2024).
16. McCoy, L. G., Manrai, A. K. & Rodman, A. Large language models and the degradation of the medical record. *N. Engl. J. Med.* 391, 1561–1564 (2024).
17. Goetz, L., Seedat, N., Vandersluis, R. & van der Schaar, M. Generalization-a key challenge for responsible AI in patient-facing clinical applications. *NPJ Digit. Med.* 7, 126 (2024).
18. Armitage, R. C. Implications of large language models for clinical practice: Ethical analysis through the principlism framework. *J. Eval. Clin. Pract.* 31, e14250 (2025).
19. Chen, S. *et al.* When helpfulness backfires: LLMs and the risk of false medical information due to sycophantic behavior. *NPJ Digit. Med.* 8, 605 (2025).
20. Williams, C. Y. K., Miao, B. Y., Kornblith, A. E. & Butte, A. J. Evaluating the use of large language models to provide clinical recommendations in the Emergency Department. *Nat. Commun.* 15, 8236 (2024).
21. Arora, R. K. *et al.* HealthBench: Evaluating large language models towards improved human health. https://cdn.openai.com/pdf/bd7a39d5-9e9f-47b3-903c-8b847ca650c7/healthbench_paper.pdf.

22. Yan, L. K. Q. *et al.* Large language model benchmarks in medical tasks. *ArXiv* abs/2410.21348, (2024).

23. Wang, D. & Zhang, S. Large language models in medical and healthcare fields: applications, advances, and challenges. *Artif. Intell. Rev.* 57, (2024).

Glossary

- **Sparse Autoencoder (SAE)**
  A neural architecture that learns sparse, part-based representations from hidden states. Used for interpretability, feature decomposition, and downstream probing.
- **Retrieval-Augmented Generation (RAG)**
  A framework that integrates a retriever with a generative model so outputs can condition on, cite, and reason over external context.
- **Supervised Fine-Tuning (SFT)**
  Gradient-based (usually with cross-entropy) training on instruction–response pairs to adapt or align a base model toward desired behaviors.
- **Proximal Policy Optimization (PPO)**
  A reinforcement learning algorithm using clipped policy updates; forms the basis of many preference-optimization approaches for LLMs.
- **GRPO / RLVR / DAPO (Verification-Based RL)**
  PPO-style RL methods that optimize rewards based on correctness, formatting, preference signals, and verifiable outputs without having a reward or value model.
- **Low-Rank Adaptation (LoRA)**
  A parameter-efficient fine-tuning technique patching addiational low-rank parameter addition to a model's weight matrices, while keeping base weights mostly frozen.
- **Quantization (e.g., 8-bit, 4-bit)**
  Reducing numerical precision of model weights/activations to lower memory and compute cost, usually with minimal performance loss.
- **In-Context Learning (ICL)**
  Guiding the model via examples or demonstrations placed directly in the prompt, without updating model parameters.
- **Chain-of-Thought (CoT)**
  Explicit intermediate reasoning steps are produced by the model to show its logical or mathematical process.
- **Reasoning-Language Alignment / Language-Consistency**
  Ensuring that the model's full reasoning trace, not just the final answer, remains in the user's language.
- **Reasoning Faithfulness**
  The degree to which intermediate steps causally contribute to the model's final answer, rather than being hallucinated or post-hoc rationalizations.

- **Model Merging**
  A post-hoc technique that combines parameters from separately trained models to blend capabilities without full retraining.
- **Linear Probe**
  A simple linear classifier trained on frozen representations (e.g., SAE features) to measure what information is encoded in the model's internal states.
- **Pass@k**
  The probability that at least one out of *k* sampled solutions is correct; widely used in code generation and mathematical evaluation.
- **PVI / In-Context PVI**
  Measures of "usable information" for a fixed model on a given instance; the in-context variant estimates PVI through prompting (useful for API-only settings).
- **Agentic System / AI Agent**
  An LLM-based system that coordinates multi-step reasoning, tool use, external retrieval, memory, and verification to autonomously complete complex tasks (e.g., the iRAE agent for adverse-event extraction).
- **Benchmark Contamination**
  The leakage of test/validation items into pre-training corpora, which inflates reported performance by allowing memorization instead of genuine reasoning.
- **Biomedical NLP**
  Natural language processing applied to medical or scientific text (clinical notes, literature, guidelines), supporting tasks such as information extraction, classification, and summarization.
- **Common Terminology Criteria for Adverse Events (CTCAE)**
  A standardized lexicon and grading system for identifying and scoring treatment toxicities, especially in oncology.
- **Electronic Health Records (EHR)**
  Digital patient records combining structured data and unstructured clinical notes; a primary source for many medical LLM applications.
- **Few-Shot / Zero-Shot Prompting**
  Techniques where models are guided with a few examples (few-shot) or only an instruction (zero-shot) to perform tasks without fine-tuning.

- **Guideline Concordance**
  The extent to which AI-generated recommendations align with clinical practice guidelines (e.g., NCCN) is an important clinical safety metric.
- **Hallucination (Medical AI)**
  The generation of factually incorrect, unsafe, or non–evidence-based medical information, such as nonexistent treatments or incorrect diagnoses.
- **Immunotherapy-Related Adverse Events (irAE)**
  Toxicities stemming from immune checkpoint inhibitors; often require expert interpretation and can be extracted automatically using systems such as the iRAE agent.
- **Multi-Hop Reasoning**
  Combining information across multiple facts, documents, or reasoning steps to answer complex queries, as in tasks like MedBrowseComp.
- **Multimodal Evaluation**
  Assessment of models that jointly process text and other modalities (e.g., radiology images, pathology slides, Guidelines' PDFs).
- **Parameter-Efficient Fine-Tuning (PEFT)**
  A family of techniques, including LoRA, QLoRA, and AdaLoRA, that update only a small subset of parameters to reduce compute and memory costs.
- **Patient Portal Messages**
  Secure communications between patients and clinicians. Increasingly used in studies of LLM-assisted triage, drafting, and workflow support.
- **Real-World Evidence (RWE)**
  Insight derived from routine clinical practice (EHR, claims) rather than controlled trials; LLMs enable large-scale structuring of unstructured RWE sources from the EHR.
- **Representational Bias**
  Systematic distortions in model representations or outputs reflecting imbalances in pre-training data—for example, uneven demographic associations.
- **Robustness Testing**
  Evaluating model stability under perturbations such as demographic shifts, drug-name swaps, or adversarial edits to identify brittleness.
- **Silver-Labeled Data**
  Limited gold-standard annotations can be augmented using labels derived from various sources, such as heuristics, structured fields, or auxiliary models.

- **Social Determinants of Health (SDoH)**
  Non-clinical factors (housing, employment, transportation, social support) that influence outcomes; often extracted from clinical notes.
- **Sycophancy / Sycophantic Behavior**
  A model's inclination to prioritize perceived helpfulness over factual accuracy, often leads it to assent to user suggestions, even erroneous ones.
- **Synthetic Data Augmentation**
  Utilizing LLMs to create synthetic yet realistic training data for enhancing model performance, particularly in scenarios characterized by limited resources or data imbalance.


?
Cancer Treatment Information
Treatment options
Side effects
Preparation
What to expect
Support resources

Chapter 2
Use of Artificial Intelligence Chatbots for Cancer Treatment Information

Shan Chen, Benjamin H. Kann, Michael B. Foote, Hugo JWL Aerts, Guergana K. Savova, Raymond H. Mak, Danielle S. Bitterman,

JAMA Oncology

Summary

Background

Large language models (LLMs) such as ChatGPT are increasingly being used for medical question-answering. However, their tendency to generate plausible but inaccurate text raises concerns about medical misinformation. Cancer patients, who frequently seek information online, may use ChatGPT for treatment advice. This study assessed the accuracy and robustness of ChatGPT's cancer treatment recommendations for breast, prostate, and lung cancers compared to National Comprehensive Cancer Network (NCCN) guidelines.

Methods

We developed four zero-shot prompt templates to test ChatGPT's responses across 26 distinct cancer diagnosis descriptions (e.g., cancer type and disease extent), resulting in 104 total prompts. Responses were generated using OpenAI's *gpt-3.5-turbo-0301* model. Outputs were evaluated against NCCN 2021 guidelines by three board-certified oncologists, with a fourth adjudicating disagreements. Responses were scored for guideline concordance and categorized by accuracy, completeness, and hallucination frequency.

Findings

ChatGPT generated treatment recommendations for 102 of 104 prompts (98%), and every response contained at least one NCCN-concordant recommendation. However, 35 of these (34.3%) also included at least one partially or fully non-concordant treatment. Twelve and a half percent (13/104) of outputs hallucinated treatment modalities—most often recommending localized therapies for advanced disease or suggesting inappropriate targeted/immunotherapies. The correctness and completeness of responses varied depending on the phrasing of the prompt. Annotator agreement was 61.9%, underscoring interpretive ambiguity even among experts.

Interpretation

ChatGPT's performance in providing cancer treatment advice was unreliable and inconsistent. Although it frequently listed correct options, its inclusion of incorrect recommendations poses substantial risk for misinformation—especially given that such errors may be difficult for non-experts to detect. The findings highlight the need for caution when using LLMs in medical contexts and underscore the importance of clinician and patient awareness of AI limitations.

Developers of such systems share the responsibility to minimize harm and ensure the safe distribution of these technologies.

Introduction

Large language models (LLMs) underlying chatbots such as ChatGPT[1] have demonstrated an unprecedented ability to generate human-like language, producing detailed, contextually relevant, and coherent-seeming responses across a wide range of topics. These qualities make LLMs appear knowledgeable and authoritative, yet their outputs may obscure underlying inaccuracies or hallucinations, especially in specialized domains like medicine. As patients increasingly turn to the internet for self-education[2] about their diagnoses and treatment options, it is inevitable that many will consult ChatGPT and similar conversational agents for cancer-related medical information. While this represents a potential opportunity to democratize access to health knowledge, it also poses significant risks: ChatGPT may generate or amplify misinformation about cancer treatments, potentially influencing patient expectations and decisions in harmful ways. There is therefore an urgent need to rigorously evaluate the reliability and robustness of ChatGPT's medical outputs. In this study, we systematically assessed ChatGPT's ability to provide breast, prostate, and lung cancer treatment recommendations consistent with evidence-based standards as defined by the National Comprehensive Cancer Network (NCCN) guidelines[3].

Methods

We developed 4 prompt templates to query treatment recommendations (see Figure 1 below). Templates were used to create 4 prompts for each of 26 unique diagnosis descriptions (cancer types ± extent of disease) for a total of 104 prompts. Prompts were input to the gpt-3.5-turbo-0301 model via the ChatGPT API using zero-shot approach, meaning no example output was provided.

We benchmarked against NCCN 2021 because ChatGPT was trained on data up to September 2021. Five scoring criteria were developed to assess guideline concordance (see Table 1 for details). The output did not have to recommend all possible regimens to be considered concordant; instead, the recommended

treatment approach needed to be an NCCN option. Four board-certified oncologists scored the output. Prompts were scored by 3 oncologists and majority rule was taken as the final score. In cases of complete disagreement, the oncologist who had not previously seen the output adjudicated.



Figure 1. *Experimental design. Underlined text indicates where each diagnosis description was input into the prompt template. Diagnosis descriptions consisted of cancer type (breast cancer, non-small cell lung cancer, small-cell lung cancer, and prostate cancer) with and without extents of disease relevant for each cancer type. A total of 26 disease descriptions were input into the prompt templates, for a total of 104 unique prompts.*

Results

Outputs of 104 unique prompts were scored on five criteria for a total of 520 individual scores. All three annotators agreed for 322 of 520 (61.9%) scores, with disagreements most commonly arising when the chatbot's output was ambiguous or incomplete—for example, when it listed multiple treatment modalities without specifying whether they should be used in combination or as alternatives. Table 1 presents the agreement between the four prompt templates and the distribution of scores across cancer type and extent of disease. For nine of twenty-six (34.6%) diagnosis descriptions, the four prompts yielded identical scores for each of the five scoring criteria, indicating consistency in those cases. However, for the remainder, responses varied depending on the phrasing of the question, suggesting that ChatGPT's recommendations were influenced by the linguistic structure of the query.

ChatGPT provided at least one treatment recommendation for 102 of 104 (98%) prompts. All outputs that included a recommendation contained at least one treatment that was concordant with 2021 National Comprehensive Cancer Network (NCCN) guidelines. However, 35 of these 102 (34.3%) outputs also included one or more treatment recommendations that were at least partially non-concordant with NCCN guidelines. Non-concordant recommendations were observed across all cancer types but were most frequent in breast and prostate cancer queries and in descriptions of localized disease. Among cases

in which some, but not all, recommendations were guideline-concordant, the proportion of fully correct recommendations varied substantially by disease type and prompt phrasing, as detailed in Table 1.

Table 1. Oncologist Scoring of LLM Chatbot Treatment Recommendations[a]

Scoring criteria	Agreement across 4 unique prompts, No. (%) (n = 26)[b]	All prompts, No. (%) (n = 104)	Prompts by cancer type					Prompts by extent of disease		
			Breast cancer, No. (%) (n = 20)	Lung cancer, No. (%) (n = 20)[c]	Non-small cell lung cancer, No. (%) (n = 20)	Small cell lung cancer, No. (%) (n = 12)	Prostate cancer, No. (%) (n = 32)	Not specified, No. (%) (n = 20)	Localized, No. (%) (n = 64)	Advanced, No. (%) (n = 20)
1. How many treatment recommendations were provided?										
0	22 (84.6)	3 (2.9)	1 (5.0)	1 (5.0)	0	0	1 (3.1)	0	3 (4.7)	0
1		2 (1.9)	0	0	0	0	2 (6.3)	0	2 (3.1)	0
≥1		99 (95.2)	19 (95.0)	19 (95.0)	20 (100)	12 (100)	29 (90.6)	20 (100)	59 (92.2)	20 (100)
2. How many of the recommended treatments were in accordance with 2021 NCCN guidelines?[c]										
0	9 (34.6)	0	0	0	0	0	0	0	0	0
Some but not all		35 (33.7)	2 (10.0)	6 (30.0)	8 (40.0)	7 (58.3)	12 (37.5)	2 (10.0)	26 (40.6)	7 (35.0)
All		66 (63.5)	17 (85.0)	13 (65.0)	12 (60.0)	5 (41.7)	19 (59.4)	18 (90.0)	35 (54.7)	13 (65.0)
NA		3 (2.9)	1 (5.0)	1 (5.0)	0	0	1 (3.1)	0	3 (4.7)	0
3. If some but not all to question 2, how many recommendations were correct in their entirety per 2021 NCCN guidelines?										
0	11 (42.3)	1 (0.9)	0	0	0	1 (8.3)	0	0	1 (1.6)	0
≥1		33 (31.7)	1 (5.0)	7 (35.0)	8 (40.0)	6 (50.0)	11 (34.4)	2 (10.0)	25 (39.1)	6 (30.0)
NA[d]		70 (67.3)	19 (95.0)	13 (65.0)	12 (60.0)	5 (41.7)	21 (65.6)	18 (90.0)	38 (59.4)	14 (70.0)
4. How many recommended treatments were hallucinated?										
0	16 (61.5)	91 (87.5)	19 (95.0)	18 (90.0)	19 (95.0)	9 (75.0)	26 (81.3)	19 (95.0)	55 (85.9)	17 (85.0)
≥1		13 (12.5)	1 (5.0)	2 (10.0)	1 (5.0)	3 (25.0)	6 (18.8)	1 (5.0)	9 (14.1)	3 (15.0)
5. If >1 to question 4, how many of the hallucinated treatments are now a recommended treatment in the most current NCCN guidelines?										
0	16 (61.5)	13 (12.5)	1 (5.0)	2 (10.0)	1 (5.0)	3 (25.0)	6 (18.8)	1 (5.0)	9 (14.1)	3 (15.0)
≥1		0	0	0	0	0	0	0	0	0
NA		91 (87.5)	19 (95.0)	18 (90.0)	19 (95.0)	9 (75.0)	26 (81.3)	19 (95.0)	55 (85.9)	17 (85.0)

Abbreviations: LLM, large language model; NA, not applicable; NCCN, National Comprehensive Cancer Network.

[a] Data reported as No. (%) using majority rule of annotators' scores.

[b] Diagnosis descriptions for which the output of each of the 4 prompts for a given diagnosis description yielded the same score by the rating oncologists.

[c] Lung cancer was queried separately from non-small cell lung cancer and small cell lung cancer.

[d] Slight misalignment of categorical scores from questions 2 and 3 resulted from majority rules. For example, for question 3, NA = 70 instead of 69 (66 + 3) because of majority voting.

Responses were hallucinated—that is, contained modalities not recommended in any relevant NCCN guideline—in 13 of 104 (12.5%) outputs. These hallucinated treatments were primarily recommendations for localized treatment in cases describing advanced disease, as well as inappropriate suggestions of targeted therapy or immunotherapy. While a few of these modalities have since become accepted in newer NCCN versions, most were not appropriate for the disease stage or histology described.

Performance also differed across the four prompt templates (Table 2). When the prompt explicitly referenced NCCN guidelines—e.g., "What is a recommended treatment for [diagnosis] according to NCCN?"—ChatGPT achieved the highest concordance, producing fully guideline-aligned recommendations for 73% of diagnosis descriptions. In contrast, more conversational phrasings such as "How do you treat [diagnosis]?" or "What is the treatment for [diagnosis]?"

yielded lower concordance, with only 58% of responses fully aligned. This variability demonstrates ChatGPT's sensitivity to prompt formulation, even when the underlying clinical information was identical.

Table 2. Scoring of LLM Chatbot Treatment Recommendations According to Prompt Template[a]

Scoring criteria	Prompt template			
	What is a recommended treatment for [diagnosis description] according to NCCN? (n = 26)	What is a recommended treatment for [diagnosis description]? (n = 26)	How do you treat [diagnosis description]? (n = 26)	What is the treatment for [diagnosis description]? (n = 26)
1. How many treatment recommendations were provided?				
0	2 (7.7)	0	0	1 (3.8)
1	2 (7.7)	0	0	0
≥1	22 (84.6)	26 (100)	26 (100)	25 (96.2)
2. How many of the recommended treatments were in accordance with 2021 NCCN guidelines?				
0	0	0	0	0
Some but not all	5 (19.2)	11 (42.3)	11 (42.3)	8 (30.8)
All	19 (73.1)	15 (57.7)	15 (57.7)	17 (65.4)
NA	2 (7.7)	0	0	1 (3.8)
3. If some but not all to question 2, how many recommendations were correct in their entirety per 2021 NCCN guidelines?				
0	0	0	1 (3.8)	0
≥1	5 (19.2)	11 (42.3)	10 (38.5)	7 (26.9)
NA[b]	21 (80.8)	15 (57.7)	15 (57.7)	19 (73.1)
4. How many recommended treatments were hallucinated?				
0	25 (96.2)	23 (88.5)	23 (88.5)	20 (76.9)
≥1	1 (3.8)	3 (11.5)	3 (11.5)	6 (23.1)
5. If ≥1 to question 4, how many of the hallucinated treatments are now a recommended treatment in the most current NCCN guidelines?				
0	1 (3.8)	3 (11.5)	3 (11.5)	6 (23.1)
≥1	0	0	0	0
NA	25 (96.2)	23 (88.5)	23 (88.5)	20 (76.9)

Abbreviations: LLM, large language model; NA, not applicable; NCCN, National Comprehensive Cancer Network.

[a] Data reported as No. (%) using majority rule of annotators' scores.

[b] Slight misalignment of categorical scores from questions 2 and 3 resulted from majority rules.

Discussion

One-third of ChatGPT treatment recommendations were at least partially non-concordant with NCCN guidelines, and recommendations varied based on how the question was posed. The disagreement among annotators' scores highlights the ambiguities and challenges of interpreting generative LLM output—another source of treatment confusion. More work is needed before these methods can be considered for medical question-answering, where both reliability and robustness are critical.

LLMs have been found to achieve a passing grade on the USMLE licensing exam,[4] encode clinical knowledge[5], and provide diagnoses better than laypeople.[6] However, ChatGPT did not perform well at providing cancer treatment recommendations. Concerningly, ChatGPT was most likely to provide incorrect recommendations amongst correct recommendations, an insidious error mode difficult even for experts to detect.

Although this study evaluates a single model at a snapshot in time, it provides insight into areas of concern and future research needs. ChatGPT does not purport to be a medical device, and need not be held to such standards. However, patients and their families will likely use such technologies in their self-education, and this will impact shared decision-making and the patient-clinician relationship.[2] Developers should have responsibility to distribute technologies that do not cause harm, and patients and clinicians need to be aware of the limitations of these technologies.

References

1. Introducing ChatGPT. Accessed March 10, 2023. https://openai.com/blog/chatgpt
2. Arora VM, Madison S, Simpson L. Addressing Medical Misinformation in the Patient-Clinician Relationship. *JAMA*. 2020;324(23):2367-2368.
3. National comprehensive cancer network - home. NCCN. Accessed March 10, 2023. https://www.nccn.org/Home
4. Kung TH, Cheatham M, Medenilla A, et al. Performance of ChatGPT on USMLE: Potential for AI-assisted medical education using large language models. *PLOS Digital Health*. 2023;2(2):e0000198.
5. Singhal K, Azizi S, Tu T, et al. Large Language Models Encode Clinical Knowledge. *arXiv [csCL]*. Published online December 26, 2022. http://arxiv.org/abs/2212.13138
6. Levine DM, Tuwani R, Kompa B, et al. The diagnostic and triage accuracy of the GPT-3 artificial intelligence model. *medRxiv*. Published online February 1, 2023. doi:10.1101/2023.01.30.23285067

Acknowledgments

Dr Aerts reported receiving personal fees from Onc.AI, Sphera, LLC, and Bristol Myers Squibb outside the submitted work. Dr Mak reported receiving personal fees from ViewRay, AstraZeneca, Novartis, Varian Medical Systems, and Sio Capital outside the submitted work. Dr Bitterman reported serving as an associate editor for HemOnc.org and her institution received support for research from the American Association for Cancer Research outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by the Woods Foundation.

Supporting Information

Code, guidelines, and all data are available at:
https://github.com/AIM-Harvard/ChatGPT_NCCN.

Below is an abstract of our extended work understanding models' abilities answering these questions in Spanish.

Purpose/Objective(s)

There is significant excitement about the potential of large language models (LLMs) to improve health literacy through multilingual question-answering, yet LLMs are predominantly trained in English. It is unknown how performance varies when accessed by patients who speak different languages. We assessed the generalizability of LLM performance in providing cancer treatment information in English and Spanish.

Materials/Methods

One hundred four general questions about treatment for prostate, breast, and lung cancers of different disease staging were written in English and translated into Spanish by a bilingual oncologist. GPT-3.5-turbo-0613 was prompted with the questions on the same day via API. Quality concordance of responses with NCCN 2021 guidelines (based on GPT's knowledge cut-off at that time) were scored by a bilingual oncologist using pre-specified criteria (Table). Mann-Whitney U- and Fisher's exact tests were used to compare scores and frequency of key treatment terms, respectively.

Results

All LLM responses were provided in the same language as the question, despite no explicit instruction on response language. All LLM responses included at

least 1 treatment recommendation. The Table shows the scored results overall, and per diagnosis. Clinical trials were recommended in 12 of 104 English and 1 of 104 Spanish responses ($p < 0.01$). Specific radiotherapy techniques such as 3DCRT, IMRT, SBRT, and proton therapy were mentioned in 8 of 104 English and 3 of 104 Spanish responses ($p = 0.21$). Palliative/supportive care was mentioned in 23 of 104 English and 6 of 104 Spanish responses ($p < 0.01$).

Conclusion

The same cancer information question, when asked in a different language, could elicit meaningfully different responses from LLMs. Importantly, asking a question in Spanish led to responses that were less likely to be guideline-concordant or include clinical trials/palliative approaches to treatment. This highlights the need for robust multilingual evaluation to harness the promise of LLMs in improving health literacy while avoiding the perpetuation of health disparities in vulnerable populations.

Criteria	All – English n = 104	All – Spanish n = 104	P value*	Prostate – English n = 32	Prostate – Spanish n = 32	Breast – English n = 20	Breast – Spanish n = 20	Lung – English n = 52	Lung – Spanish n = 52
Are the recommended treatments in accordance with NCCN?			0.07						
- All - Some but not all - None		68 (65%) 36 (35%) 0		18 (56%) 14 (44%) 0	18 (56%) 14 (44%) 0	18 (90%) 2 (10%) 0	16 (80%) 4 (20%) 0	44 (85%) 8 (15%) 0	34 (65%) 18 (35%) 0
Of the recommended treatments, are any correct in their entirety per NCCN?			0.04						
- None - At least 1 - N/A	0 24 (23%) 80 (77%)	1 (1%) 36 (35%) 67 (64%)		0 14 (44%) 18 (56%)	0 14 (44%) 18 (56%)	0 2 (10%) 18 (90%)	0 4 (20%) 16 (80%)	0 8 (15%) 44 (85%)	1 (2%) 18 (35%) 33 (63%)
Are any recommended treatments hallucinated?			0.02						
- None - At least one	81 (78%) 23 (22%)	93 (89%) 11 (11%)		22 (69%) 10 (31%)	27 (84%) 5 (16%)	15 (75%) 5 (25%)	18 (90%) 2 (10%)	44 (85%) 8 (15%)	48 (92%) 4 (8%)
*Statistics only calculated overall given small disease subsets									



Chapter 3

The Effect of Using a Large Language Model to Respond to Patient Messages

Shan Chen, Marco Guevara, Shalini Moningi, Frank Hoebers, Hesham Elhalawani, Benjamin H Kann, Fallon E Chipidza, Jonathan Leeman, Hugo JWL Aerts, Timothy Miller, Guergana K Savova, Jack Gallifant, Leo A Celi, Raymond H Mak, Maryam Lustberg, Majid Afshar, Danielle S Bitterman

Lancet Digital Health

Summary

Background

The integration of generalist large language models (LLMs) into clinical care promises to transform clinical workflows, potentially reducing the growing documentation burden facing healthcare practitioners. Such LLMs, including GPT-4, are currently being integrated into widely used electronic health record systems such as Epic, and are now being used to draft responses to patient messages. However, their efficiency, utility, safety, and human factors concerns have yet to be fully evaluated by physicians beyond current question-answer benchmarks.

Methods

This two-stage observational study was conducted in 2023 at Brigham and Women's Hospital, Boston, MA. Six board-certified oncologists used GPT-4 to draft responses to 100 patient messages centered around realistic cancer patient scenarios. Responses were analyzed before and after physician editing for length and content. Physician surveys assessed the acceptability, utility, and safety of the LLM-drafted responses.

Findings

Physicians provided more concise responses compared to the LLM drafts and AI-assisted responses, averaging 34, 169, and 160 words, respectively. LLM drafts were deemed acceptable in 58.3% of cases, improved documentation efficiency in 76.9%, and were safe in 82.1%. However, there was a 7.7% risk of severe harm or death if used unedited. LLM-generated harmful content largely arose from incorrect assessment or communication of acuity, which has direct implications for patient outcomes if practitioners rely on LLM responses. Using an LLM draft significantly altered the content of messages compared to manual responses.

Interpretation

Our findings highlight the potential for using LLMs in patient communication workflows to improve physician efficiency and, potentially, patient education. Nonetheless, the risk of harm from unedited responses and dilution of direct clinical recommendations when LLMs are used with a human-in-the-loop highlight the need for careful oversight and continued evaluation of clinical and administrative workflows.

Introduction

Large language models (LLMs), celebrated for their transformative potential in various clinical settings, are not without their share of controversies, particularly concerns regarding bias and hallucination errors. These apprehensions have tempered their widespread adoption in high-stakes clinical decision-making. In contrast, less has been said of the quiet integration of LLMs into electronic health records (EHR) for supposedly lower-risk tasks that aim to address the clinician burnout crisis fueled by the extensive documentation burden.[1] This subtle integration, exemplified by partnerships like that between Microsoft/OpenAI and Epic, has positioned GPT-4 at the forefront of physician support tools such as care summarisation and patient communications. Such integration, while seemingly innocuous, carries implications not only for workforce well-being and retention, but also for patient care and safety.[2]

The relentless rise in administrative responsibilities, amplified by EHR systems, has diverted clinician attention from direct patient care, fueling burnout.[3] In response, LLMs are being adopted to streamline clinical and administrative tasks, and to enhance operational and financial efficiencies. Notably, Epic is currently leveraging OpenAI's ChatGPT models, including GPT-4, for electronic messaging via online patient portals, a significant contributor to clinician burnout.[3-6] The volume of patient portal messaging has escalated in recent years,[7] and general-purpose LLMs, trained to respond to questions and participate in conversations fluently,[8] are being deployed to manage this growing burden. Their use in drafting responses to patient messages is one of the earliest applications in EHR systems.[5] Other current and near-future uses of LLMs in the clinic workflow include automated note creation, EHR navigation, billing support, and operations.[5,9,10]

Yet, the ability of LLMs to improve efficiency and reduce cognitive burden as part of the clinical workflow has not been established, and their impact on clinical decision-making and risks are unknown. Previous works have compared LLMs to human experts in answering questions about biomedical and clinical knowledge,[11-13] and also raised concerns about its varying responses accounting for social factors like race, insurance status, and gender.[14,15] Patient portal messaging is a form of patient care,[16] and represents one of medicine's first encounters with the transformative potential of generative AI. While these LLMs are often being integrated with a human-in-the-loop, human factors such as automation bias and situational

awareness could impact outcomes by altering clinicians' cognitive processes in unexpected ways.[17–20]

These critical questions remain unaddressed: Do these 'lower risk' administrative-focused applications of LLMs harbor similar pitfalls as their clinical counterparts? The hastened, large-scale deployment of LLMs in clinical settings, sans comprehensive evaluations of their performance, utility, and, crucially, safety, is a matter of significant concern. Indeed, we should learn from prior experience with disappointing and potentially harmful effects of rapid deployment of proprietary models within EHR systems: Epic widely implemented a sepsis prediction algorithm that was subsequently found on external validation to have low sensitivity compared to standard clinical practice and a large burden of alert fatigue.[21]

This study seeks to bridge this knowledge gap, rigorously assessing the impact and safety of LLM-assisted patient messaging on healthcare delivery in an observational end-user study. We demonstrate that existing evaluations of LLM biomedical knowledge are insufficient to understand their clinical utility and risks because LLMs alter clinical decision-making in unexpected ways, and inappropriate LLM content arises largely from inadequate clinical acumen, not insufficient biomedical knowledgebase. This study serves as a call to action for a more measured approach to implementing LLMs within EHRs, including evaluations that reflect how they will actually be used in clinical settings and considerations of human factors.

Methods

Overview of Study Design

Figure 1 illustrates the overall study schema. We sought to understand how LLM assistance for electronic patient portal messaging as it is being implemented in EHRs, *i.e.* using an LLM to draft a response for a clinician to edit, impacts subjective efficiency, clinical recommendations, and potential harms. We therefore simulated how ChatGPT family models are being integrated into Epic systems for portal messaging. We simulated Epic's GPT-4 implementation[5] due to Epic's prominence: Epic is the leading EHR vendor with the most hospital-years in the United States,[22] and holds health records of more than 3% of people globally.[23] Because clinicians, and potentially the LLM depending on prompting approaches, would always have access to the

patient's EHR records to provide context, we included background clinical information along with the question.

Board-certified attending oncologists were first asked to respond to the patient messages as they normally would in clinical practice ("manual responses"), and then asked to edit GPT-4 responses ("LLM drafts") so that they were a clinically acceptable response to send a patient ("LLM-assisted responses"). Surveys and content analysis of responses were used to evaluate the impact of LLM assistance on patient messaging. All datasets, including physician-written responses and evaluations, generated in this study are made publicly available. This study was approved by the Dana-Farber/Harvard Cancer Center IRB.



Figure 1*.Example of a scenario, patient message pair, and prompting methods used in this study. A) Prompt examples for creating scenario/message pairs. B) Prompt examples for creating responses from GPT4.*

Simulating Patient Portal Messages

Cancer patient scenario/message pairs were generated to mirror realistic EHR system inbox messages. The scenario provided background information about a patient that is standardly available in the EHR and relevant to responding to cancer patient messages: age, gender, cancer diagnosis, past medical history, prior and current cancer treatments, current medications, and a summary of the most recent oncology visit (Figure 2). As above, these scenarios were needed for responses reflective of the real clinical setting where physicians have access to clinical information beyond just the patient's question. They also served to encourage more substantive responses. While these exact summaries of a patient's clinical history are not available in EHR messaging systems, in practice a clinician would have access to that patient's full EHR records. In addition, depending on prompting approaches which vary across institutions, clinical data could be provided in the prompt the LLM.

Exemplars were written by a practicing oncologist (DSB), and the LLM GPT-4 was prompted via the OpenAI Application Programming Interface to provide similar examples (Figure 1A). To encourage diversity of patients' situations, exemplars were written to generate 50 scenario/question pairs of patients on active treatment, and 50 scenario/question pairs of patients not on active treatment. DSB then manually reviewed and revised each scenario to reflect clinically realistic and logical scenarios aligned with patient information needs. Messages were adjusted to reflect a range of common and high-priority questions received in patient portals. In a new instance, GPT-4 was prompted to respond to the message (Figure 1B). We chose to use GPT-4 to generate responses because this is the model being integrated to respond to patient messages per Epic announcements.[5] Appendix A provides more details on scenario development.

Clinical Evaluation

As shown in Figure 2, using the dataset of scenario/question pairs, we carried out a 2-stage observational study to investigate the impact and utility of LLM assistance for answering patient questions. Six board-certified attending oncologists were recruited to participate, and informed consent was obtained. In both stages, each participant evaluated 26 scenario/message pairs, yielding 56 dual-annotated cases and 44 single-annotated cases. During both stages, each physician received a different group of patient scenarios, and each of the 26 partitions were separated evenly.



***Figure 2**. Schematic of study design. An oncologist generated and verified with GPT-4 assistance 100 patient clinical scenarios with paired patient questions in the format of portal messages. Participants manually wrote responses to scenarios in Stage I, and edited AI-assisted responses in Stage II. 56 scenario and message pairs were dual-annotated by 2 oncologists in both stages to assess inter-clinician variability.*In Stage I, physicians responded to messages manually, each followed by a 2-question survey on the perceived difficulty in crafting the response and the medical severity of each scenario. In Stage II, physicians received GPT-4 generated draft responses and were instructed to edit in any way they would like to generate a final LLM-assisted response. Physicians were not informed of how the draft responses were generated. Participants completed a 7-question survey after each response. Questions addressed: perceived difficulty in crafting responses, medical severity, acceptability of drafts, the potential harm of drafts, and perceived efficiency. Table 1 shows the survey questions. Examples of how the scenarios and surveys were presented to participants, along with instructions and real responses, are included in Appendix A.

Assessing response pairs

Word count was calculated and compared. Edit distance (measured using Levenshtein distance; details in Appendix A), which quantifies how much a response was altered, was calculated for each LLM draft/LLM-assisted response pair.

We then developed a framework for evaluating the content of responses to clinical questions. Responses were iteratively reviewed for clinically relevant content types based on clinical expertise and pilot annotations by an oncologist (DSB) until no additional content types were identified, resulting in 10 content categories (Appendix A). 50 (12%) responses were dual-annotated by content-based categorical evaluation by two physicians who did not participate in the 2-stage study (DSB and MA); Cohen's kappa was ≥ 0.75 for all categories (Appendix A). The remaining responses were single-annotated by DSB.

Statistical Analysis

Statistical analyses were carried out using the statistical Python package in Scipy (Scipy.org). All pairwise comparisons were done using the Mann–Whitney U test.

Results

Manual responses were on average shorter than the LLM draft and LLM-assisted responses (34 vs. 169 and 160 words, respectively, $p<0.05$ for all comparisons). Table 1 shows the Stage I and II survey results. Scenarios were considered neutral in terms of challenge in 85/156 (54.5%) and 82/156 (52.6%) of survey responses in Stage I and II, respectively. Scenarios were felt to describe severe medical events in 52/156 (33.3%) and 34/156 (21.8%) of survey responses in Stage I and II, respectively. LLM drafts were believed to be drafted by a human 48/156 (30.8%) of the time when, in reality, all drafted responses were drafted by the LLM.

Notably, 11/156 (7.1%) and 1/156 (0.6%) survey responses indicated that the LLM draft could lead to severe harm or death, respectively, if unedited. Appendix C shows these drafts, along with the error mode that led to the harmful content. The majority of harmful responses were due to incorrectly determining and/or conveying the acuity of the scenario and recommended actions. For example, in Appendix Example 12 where a patient describes new back pain and falls, the LLM does not identify that the provided information is sufficiently concerning for malignant spinal cord compression that requires urgent evaluation. In Example 7, where a patient describes new bloody diarrhea, the LLM appropriately recommends the patient reach out to their healthcare team. However, this recommendation appears at the end of a list of technically correct but lower priority, potentially distracting content, and the timing and specific details of who the patient should contact is vague. By contrast, the LLM-assisted response removes the extraneous content and recommends a phone or in-person visit to further assess. Other error modes included a lack of definiteness and clarity and incorrect diagnostic reasoning, largely arising from a failure to identify risks common in an oncology population but not a general population.

Edit distances were increased when the scenario was considered more challenging, the LLM draft was viewed as unacceptable, the LLM draft was associated with higher harm, and the LLM draft provided lower efficiency gain, indicating more extensive revisions of the draft in these settings (Table 1). Edit distance was higher when the draft was thought to be written by AI compared to when it was thought to be written by a human.



Figure 3. *Distribution of content categories present in the manual, GPT-4 drafted, and AI-assisted responses to patient messages. Because 56/100 questions were dual-annotated, here we present results including one response from each of the dual-annotated scenarios. Results are similar when the other set of responses for dual-annotated scenarios are used (Supplemental Figure B2). Pairwise comparisons are done using Mann-Whitney U tests.*

Inter-rater agreement between physicians for the content categories present in responses to the same scenario was lower for manual responses compared to LLM-assisted responses (mean Cohen's kappa 0.10 vs. 0.52), indicating more consistent clinical content with the use of LLM assistance (Appendix B, Supplementary Table 1).

Figure 3 compares the content of manual, LLM draft, and LLM-assisted responses for the 100 scenarios. We present here comparisons that include only one set of manual responses and LLM-assisted responses for the 56 questions that were dual annotated. Results were very similar when the other set of responses were used (Appendix B, Supplementary Figure 1), and there was no difference in overall content distribution between these groups (p=0.77 and p=0.74 for manual and LLM-assisted responses, respectively). The overall content distribution of manual responses was significantly different than that of LLM drafts (p<0.05) and LLM-assisted responses (p<0.05); there was no difference in the content distribution of LLM drafts and LLM-assisted responses (p=0.81).

The most common category was Any Education for all responses. Compared to manual responses, LLM drafts were less likely to include content on direct clinical action, including instructing patients to present urgently or non-

urgently for evaluation, and to describe an action the clinician will take in response to the question ($p<0.05$ for all); but more likely to provide extensive education, self-management recommendations, and a contingency plan ($p<0.05$ for all). These differences in content were similar when comparing manual versus LLM-assisted responses. LLM-assisted responses were less likely to recommend urgent evaluation, but this difference was significant when only one of the two sets of dual-annotated responses were analyzed. Appendix B, Supplementary Tables 2-3 show full details of the statistical analyses. The unigrams, bigrams, and trigrams that were most commonly added and removed from LLM drafts are illustrated in Appendix B, Supplementary Figure 2, and suggest that physicians were most likely to remove passive phrases such as "it is important" and more likely to add in actions such as "to come in".

Discussion

The use of LLM assistance in patient portal messaging led to differences in response style and content compared to manual responses from board-certified attending physicians. Manual responses were nearly 5-fold shorter, while LLM-assisted responses reflected the longer, more verbose LLM drafts. Additionally, physicians frequently believed that LLM assistance improved efficiency of writing responses. The majority of LLM drafts were felt to have a low risk of harm to patients, although a clinically relevant minority were deemed to present a risk of severe harm or death if unedited. Our findings suggest that LLM assistance for patient messaging is a promising avenue to reduce clinician documentation burden through improved efficiency, but the significant differences in final message could have implications for patient safety if not appropriately safeguarded.

Our investigation contributes significantly to the burgeoning field of LLMs in clinical applications, notably by exploring their performance and impact on clinical decision-making within a human-machine collaborative framework. This study is pioneering in its evaluation of LLMs as assistive devices in real clinical workflows, specifically in the context of responding to patient portal messages. Our findings suggest that, when utilized appropriately, LLM assistance could offer a "best of both worlds" scenario, simultaneously reducing physician workload and enhancing the informativeness and educational value of responses. We discovered that LLM assistance has the potential to augment the quality of responses, furnishing detailed educational

content about patient conditions and self-management plans, a task often infeasible for time-pressed clinicians. The high quality of the additional LLM-generated content is noteworthy, as our analysis indicates that drafts were generally acceptable and posed minimal risk of harm. Promisingly, we found that edit distances correlated with LLM draft quality, indicating physicians identified and were more likely to correct incorrect or harmful responses.

We also found that physicians tended to preserve the informative content generated by GPT-4, which was typically absent in manually crafted responses, while adding more direct instructions for patient evaluation. This approach reduced the variability in response content among different physicians, which could potentially elevate overall care quality. While previous studies have yielded mixed results when assessing unedited LLM responses to patient inquiries–some demonstrating acceptability akin to human responses[12] and others indicating high error rates[11]–these evaluations do not fully capture the dynamics of LLMs functioning in tandem with human clinicians. Our study fills this gap by examining LLMs in their intended role as a support tool for clinicians, mirroring their actual deployment in healthcare settings. This is crucial as other AI systems in healthcare have demonstrated varying performance levels when used in conjunction with human operators compared to autonomous operations.[24,25] This highlights the need for careful monitoring, especially if and when trust in LLMs builds, and clinicians become less vigilant and more reliant on their responses.[20] Edit distance could be a promising metric to monitor both LLM quality and shifts in human-machine interactions. Clinician education, along with clear communication and reiteration of LLM error modes, will also be central to safe clinical implementation.

While the performance of LLMs was promising, we also validate concerns that LLM assistance carries real risks in its impact on clinical decision-making that need to be mitigated and monitored. Concerningly, when using LLM assistance, physicians were less likely to recommend a patient seek urgent care and say they would take a direct clinical action, such as prescribing a medication or diagnostic study. These differences in content are arguably the most immediately impactful for clinical outcomes, especially for high-acuity situations.

Our findings also underscore the influence of human factors such as automation bias and anchoring in human-in-the-loop systems,[17,18] illustrating unanticipated consequences that can arise and why these factors must be

rigorously studied under their intended use.[26] Although most LLM-generated drafts were acceptable and posed low risk of harm, a minority of them, if left unedited, could lead to severe harm or even fatality. Intriguingly, the harmful content was mostly associated with inadequate recognition or communication of the scenario's acuity, rather than errors in biomedical knowledge. This indicates that while biomedical knowledge is crucial, it is insufficient on its own for clinical tasks. The nuanced and advanced clinical reasoning required for effective triage and communication, often acquired during post-graduate training, remains a formidable challenge for LLMs. This gap is likely due to the nature of LLM pre-training, which does not adequately capture this type of experiential knowledge. Thus, we posit that general-purpose LLMs like GPT-4 may continue to underperform in these areas without further refinement. Furthermore, assessments of encoded biomedical knowledge, such as performance on medical board exams are a first step toward clinical applications,[27] but should not be used as surrogates for the clinical expertise needed to care for patients. Clinical end-users should be made aware of this "blind spot" in LLM training and should actively engage with developers to help bridge this gap through new benchmarks and evaluation tools.

Furthermore, our study revealed that when LLM drafts contained erroneous biomedical knowledge, it often pertained to differential diagnoses that did not align with the specific risk profiles of patients. For example, in a patient with metastatic prostate cancer with burning left arm pain, hypertension was provided as a differential diagnosis, but metastases with bone or neural structure involvement were not mentioned. Given the incidence of cardiovascular disease in the general population, this might be reasonable in a situation where no specific clinical details about a given patient are known. However, it is less reflective of this individual's specific risk profile. This error mode suggests that general-purpose LLM reasoning may mirror the distribution of clinical risk in the general population, rather than patient-specific risks, underscoring the potential need for specialty-specific models or tailored prompting methods.

Limitations of our study include that this was not performed using real patient data or within a real EHR system, and the use of LLM assistance may differ when physicians are responding to real questions. The focus of this study is on clinician perceptions because clinicians are the immediate end-users in the current intended use, and are the appropriate users for early safety evaluations in this stage of implementation. Understanding patients' preferences and LLMs' impact on the patient-physician relationship will be an

essential next step,[16] but safety must be urgently established and prioritized at this point of rapid clinical uptake in an evidence vacuum. Our study was limited to cancer patient questions and included only oncologists. Follow-on efforts will be needed, but the human factors and efficiency concerns are informative regardless of the clinician's specialty. Results may be different based on prompting methods and the type of LLM used.[28,29] We chose to study GPT-4 because Epic, a leading EHR vendor,[22] is implementing ChatGPT-family models including GPT-4 for LLM-assisted patient portal messaging.[5] More transparency is needed from EHR vendors and healthcare institutions about prompting methods and model versioning to enable future research. We did not generate data that included race or demographic information based on the desire to eliminate the introduction of additional variables that could affect the consistency of the outcomes. Previous research has demonstrated that the inclusion of factors such as race, gender, and insurance information can influence the consistency of outputs from large language models (LLMs),[14,30] and bias assessments and mitigation in LLM-assisted patient messaging must be prioritized.

In conclusion, our study emphasizes the critical need for thorough evaluation of LLMs in their intended clinical contexts, reflecting the precise clinical task and level of human oversight.[26] LLM assistance is a promising avenue to reduce clinician workload, but has clinical implications that merit regulation as software as a medical device. This situation necessitates treating LLMs with the same rigor in evaluation as any other software as a medical device or intervention. Physicians and institutions alike must exercise caution as the healthcare industry embraces these advanced technologies, as it is imperative to balance their innovative potential with a commitment to patient safety and care quality.

Data Sharing Statement

All data collected and generated in this study, after de-identification, are available to anyone who wishes to access the data for any purpose indefinitely at https://github.com/AIM-Harvard/OncQA.

Table 1. Distribution of survey responses for Stage I and II of end-user study.

Survey Question	Stage I		Stage II	
	Count (N=156)	Percentage	Count (N=156)	Percentage
Q1: How challenging was it to respond to this message?				
Neutral	85	54.5%	82	52.6%
Trivial/Very trivial	46	29.5%	39	25.0%
Challenging/Very challenging	25	16.0%	35	22.4%
Q2: Do you believe this patient is experiencing a severe medical event?				
Disagree/Strongly disagree	53	34.0%	61	39.1%
Neither agree nor disagree	51	32.7%	61	39.1%
Agree/Strongly disagree	52	33.3%	34	21.8%
Q3: How would you rate the acceptability of the draft response?				
Accept without modifications			91	58.3%
Accept with modifications			38	24.4%
Unacceptable (Major revision)			27	17.3%
Q4: How likely is it that the unedited draft response could cause harm?				
Low			128	82.1%
Medium			23	14.7%
High			3	1.9%
Missing			2	1.3%
Q5: If the unedited draft does cause harm, what would be the extent, or clinical impact on the patient?				
No harm			62	39.7%
Mild harm			52	33.3%
Moderate harm			25	16.0%
Severe harm			11	7.1%
Death			1	0.6%
Missing			5	3.2%
Q6: Do you believe the provided unedited draft response improved your documentation efficiency?				
Agree			120	76.9%
Neither agree nor disagree			18	11.5%
Disagree			17	10.9%
Missing			1	0.6%
Q7: Do you believe the provided draft response was written by an AI or by a human?				
AI			100	64.1%
Human			48	30.8%
Missing			8	5.1%

Stage I surveys included only questions 1 and 2.

References

1 Hswen Y, Voelker R. Electronic Health Records Failed to Make Clinicians' Lives Easier-Will AI Technology Succeed? JAMA. 2023; published online Oct 4. DOI:10.1001/jama.2023.19138.

2 National Academies of Sciences, Engineering, and Medicine, National Academy of Medicine, Committee on Systems Approaches to Improve Patient Care by Supporting Clinician Well-Being. Taking Action Against Clinician Burnout: A Systems Approach to Professional Well-Being. National Academies Press, 2019.

3 Adler-Milstein J, Zhao W, Willard-Grace R, Knox M, Grumbach K. Electronic health records and burnout: Time spent on the electronic health record after hours and message volume associated with exhaustion but not with cynicism among primary care clinicians. *J Am Med Inform Assoc* 2020; **27**: 531–8.

4 Lieu TA, Altschuler A, Weiner JZ, *et al.* Primary Care Physicians' Experiences With and Strategies for Managing Electronic Messages. *JAMA Netw Open* 2019; **2**: e1918287.

5 Epic and Microsoft bring GPT-4 to EHRs. https://www.epic.com/epic/post/epic-and-microsoft-bring-gpt-4-to-ehrs/ (accessed Dec 26, 2023).

6 Akbar F, Mark G, Prausnitz S, *et al.* Physician Stress During Electronic Health Record Inbox Work: In Situ Measurement With Wearable Sensors. *JMIR Med Inform* 2021; **9**: e24014.

7 Nath B, Williams B, Jeffery MM, *et al.* Trends in Electronic Health Record Inbox Messaging During the COVID-19 Pandemic in an Ambulatory Practice Network in New England. *JAMA Netw Open* 2021; **4**: e2131490.

8 Ouyang L, Wu J, Jiang X, *et al.* Training language models to follow instructions with human feedback. In: NeurIPS Proceesings. 2022. https://proceedings.neurips.cc/paper_files/paper/2022/hash/b1efde53be364a73914f58805a001731-Abstract-Conference.html.

9 Miliard M. Oracle Cerner adds generative AI to its EHR platforms. Healthcare IT News. 2023; published online Sept 19. https://www.healthcareitnews.com/news/oracle-cerner-adds-generative-ai-its-ehr-platforms (accessed Dec 28, 2023).

10 Microsoft News Center. Microsoft and Epic expand strategic collaboration with integration of Azure OpenAI Service. Stories. 2023; published online April 17. https://news.microsoft.com/2023/04/17/microsoft-and-epic-expand-strategic-collaboration-with-integration-of-azure-openai-service/ (accessed Dec 28, 2023).

11 Chen S, Kann BH, Foote MB, *et al.* Use of Artificial Intelligence Chatbots for Cancer Treatment Information. JAMA Oncol. 2023; **9**: 1459–62.

12 Ayers JW, Poliak A, Dredze M, *et al.* Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum. *JAMA Intern Med* 2023; **183**: 589–96.

13 Kanjee Z, Crowe B, Rodman A. Accuracy of a Generative Artificial Intelligence Model in a Complex Diagnostic Challenge. *JAMA* 2023; **330**: 78–80.

14 Zack T, Lehman E, Suzgun M, *et al.* Assessing the potential of GPT-4 to perpetuate racial and gender biases in health care: a model evaluation study. *Lancet Digit Health* 2024; **6**: e12–22.

15 Nastasi AJ, Courtright KR, Halpern SD, Weissman GE. A vignette-based evaluation of ChatGPT's ability to provide appropriate and equitable medical advice across care contexts. *Sci Rep* 2023; **13**: 17885.

16 Alpert JM, Markham MJ, Bjarnadottir RI, Bylund CL. Twenty-first Century Bedside Manner: Exploring Patient-Centered Communication in Secure Messaging with Cancer Patients. *J Cancer Educ* 2021; **36**: 16–24.

17 Sujan M, Furniss D, Grundy K, *et al.* Human factors challenges for the safe use of artificial intelligence in patient care. *BMJ Health Care Inform* 2019; **26**. DOI:10.1136/bmjhci-2019-100081.

18 Gianfrancesco MA, Tamang S, Yazdany J, Schmajuk G. Potential Biases in Machine Learning Algorithms Using Electronic Health Record Data. *JAMA Intern Med* 2018; **178**: 1544–7.

19 Lyell D, Coiera E. Automation bias and verification complexity: a systematic review. *J Am Med Inform Assoc* 2017; **24**: 423–31.

20 Cabitza F, Rasoini R, Gensini GF. Unintended Consequences of Machine Learning in Medicine. *JAMA* 2017; **318**: 517–8.

21 Wong A, Otles E, Donnelly JP, *et al.* External Validation of a Widely Implemented Proprietary Sepsis Prediction Model in Hospitalized Patients. *JAMA Intern Med* 2021; **181**: 1065–70.

22 Yuan N, Dudley RA, Boscardin WJ, Lin GA. Electronic health records systems and hospital clinical performance: a study of nationwide hospital data. *J Am Med Inform Assoc* 2019; **26**: 999–1009.

23 Adams K. 31 numbers that show how big Epic, Cerner, Allscripts & Meditech are in healthcare. https://www.beckershospitalreview.com/healthcare-information-technology/31-numbers-that-show-how-big-epic-cerner-allscripts-meditech-are-in-healthcare.html (accessed Dec 31, 2023).

24 Walker SC, French B, Moore RP, *et al.* Model-Guided Decision-Making for Thromboprophylaxis and Hospital-Acquired Thromboembolic Events Among Hospitalized Children and Adolescents: The CLOT Randomized Clinical Trial. *JAMA Netw Open* 2023; **6**: e2337789.

25 Hosny A, Bitterman DS, Guthier CV, *et al.* Clinical validation of deep learning algorithms for radiotherapy targeting of non-small-cell lung cancer: an observational study. *Lancet Digit Health* 2022; **4**: e657–66.

26 Bitterman DS, Aerts HJWL, Mak RH. Approaching autonomy in medical artificial intelligence. *Lancet Digit Health* 2020; **2**: e447–9.

27 Singhal K, Azizi S, Tu T, *et al.* Large language models encode clinical knowledge. *Nature* 2023; **620**: 172–80.

28 Nori H, Lee YT, Zhang S, *et al.* Can Generalist Foundation Models Outcompete Special-Purpose Tuning? Case Study in Medicine. arXiv [cs.CL]. 2023; published online Nov 28. http://arxiv.org/abs/2311.16452.

29 Chen S, Li Y, Lu S, *et al.* Evaluation of ChatGPT Family of Models for Biomedical Reasoning and Classification. arXiv [cs.CL]. 2023; published online April 5. http://arxiv.org/abs/2304.02496.

30 Guevara M, Chen S, Thomas S, *et al.* Large Language Models to Identify Social Determinants of Health in Electronic Health Records. arXiv [cs.CL]. 2023; published online Aug 11. http://arxiv.org/abs/2308.06354.

Appendix A: Supplemental Method

Dataset Creation and Curation

Cancer patient scenario/message pairs were generated to mirror realistic EHR system inbox messages. The scenario provided background information about a patient that is standardly available in the EHR and relevant to responding to cancer patient messages: age, gender, cancer diagnosis, past medical history, prior and current cancer treatments, current medications, and a summary of the most recent oncology visit (Figure 1).

These scenarios were needed for responses to simulate a real clinical setting where physicians have access to clinical information beyond just the patient's question, and to encourage more substantive responses. Exemplars were written by a practicing oncologist (DSB), and GPT-4 was prompted via the OpenAI Application Programming Interface[26] to provide similar examples (Supplemental Figure A1). Computational linguists (CS) and oncologists (ML, DSB) collaborated to iteratively design prompts and select models across multiple AI systems, including Llama, Claude, GPT-Turbo, and GPT-4, to finalize the prompt design.

To encourage diversity of patients' situations, exemplars were written to generate 25 scenario/message pairs of patients on active treatment with descriptions of specific named chemotherapies (e.g., "pembrolizumab"), 25 scenario/message pairs of patients on active treatment with descriptions of general chemotherapies (e.g., "immunotherapy"), 25 scenario/message pairs of patients not on active treatment with descriptions of specific named chemotherapies, and 25 scenario/message pairs of patients not on active treatment with descriptions of general chemotherapies. DSB manually reviewed and edited the output to reflect clinically realistic and logical scenarios aligned with patient information needs.

All data are available on the project github:
https://github.com/AIM-Harvard/OncQA.

To see full details of these examples, please check:
https://www.thelancet.com/cms/10.1016/S2589-7500(24)00060-8/attachment/11021699-8b45-4dde-8d52-71fb88876cd1/mmc1.pdf


Patient note:
"... grade 2 esophagitis with odynophagia and dysphagia ..."
NLP Extraction
Esophagitis Severity
Grade 2
First Paper

Chapter 4

Natural Language Processing to Automatically Extract the Presence and Severity of Esophagitis in Notes of Patients Undergoing Radiotherapy

Shan Chen, Marco Guevara, Nicolas Ramirez, Arpi Murray, Jeremy L Warner, Hugo JWL Aerts, Timothy A Miller, Guergana K Savova, Raymond H Mak, Danielle S Bitterman

JCO Clinical Cancer Informatics

Summary

Background

Radiotherapy (RT) toxicities can impair survival and quality of life, yet remain understudied. Real-world evidence holds potential to improve our understanding of toxicities, but toxicity information is often only in clinical notes. We developed natural language processing (NLP) models to identify the presence and severity of esophagitis from notes of patients treated with thoracic RT.

Methods

Our corpus consisted of a gold-labeled data set of 1,524 clinical notes from 124 patients with lung cancer treated with RT, manually annotated for Common Terminology Criteria for Adverse Events (CTCAE) v5.0 esophagitis grade, and a silver-labeled data set of 2,420 notes from 1,832 patients from whom toxicity grades had been collected as structured data during clinical care. We fine-tuned statistical and pretrained Bidirectional Encoder Representations from Transformers–based models for three esophagitis classification tasks: task 1, no esophagitis versus grade 1-3; task 2, grade ≤1 versus >1; and task 3, no esophagitis versus grade 1 versus grade 2-3. Transferability was tested on 345 notes from patients with esophageal cancer undergoing RT.

Findings

Fine-tuning of PubMedBERT yielded the best performance. The best macro-F1 was 0.92, 0.82, and 0.74 for tasks 1, 2, and 3, respectively. Selecting the most informative note sections during fine-tuning improved macro-F1 by ≥2% for all tasks. Silver-labeled data improved the macro-F1 by ≥3% across all tasks. For the esophageal cancer notes, the best macro-F1 was 0.73, 0.74, and 0.65 for tasks 1, 2, and 3, respectively, without additional fine-tuning.

Interpretation

To our knowledge, this is the first effort to automatically extract esophagitis toxicity severity according to CTCAE guidelines from clinical notes. This provides proof of concept for NLP-based automated detailed toxicity monitoring in expanded domains.

Introduction

Cancer treatment-related adverse events (TRAEs) are an under-studied cancer outcome that have important impacts on patients' survival and quality-of-life. As cancer-specific survival improves,[1,2] a better understanding of the epidemiology, trajectories, and risk factors for TRAEs is urgently needed to support treatment decision-making and survivorship care. However, the vast majority of our understanding of TRAEs is from clinical trials, which are crucial but inherently limited in their ability to provide information on less common adverse events.[3–7]

There is enormous potential for real-world evidence (RWE) from electronic health records (EHR) to supplement adverse event information from clinical trials. Single-institutional RWE datasets have shown TRAE rates up to 10-times those reported in clinical trials.[8–13] However, a major limitation to our ability to collect high-quality RWE on adverse events is that many are almost exclusively documented in the free text of clinical notes and are not directly extractable and analyzable through conventional methods.[14–17] Natural language processing (NLP), a field of computer science that aims to convert free text into computable representations that can be used for downstream tasks, is a promising avenue to automate the extraction for adverse events documented in clinical notes. Some research exists that focuses on binary (yes/no) adverse event extraction,[18–22] however a finer-grained extraction related to the *severity* of the adverse event would further our understanding of these events.

Better methods for adverse event reporting are especially needed for radiotherapy (RT).[23] RT-related adverse events are not represented in pharmacovigilance databases, and the impact of new RT technologies and novel combinations of RT and systemic agents is under-explored.[24] In particular, lung cancer is the leading cause of death in the United States and worldwide,[1,25] and RT plays an important role in its treatment.[26–31] Esophagitis is one of the most crucial acute RT toxicities experienced by patients with lung cancer receiving thoracic RT, which inevitably exposes portions of the esophagus to radiation fields.[32] Severe esophagitis can occur in over 30% of lung cancer patients receiving RT for lung cancer,[30,32,33] and can lead to complications including malnutrition, hospitalization, and discontinuation of treatment. Importantly, esophagitis and its severity are almost exclusively documented in clinical notes.

In this study, we aimed to develop NLP methods for automated extraction of esophagitis presence and severity in the clinical notes of patients with lung cancer treated with RT according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (CTCAE) guidelines.[34] Specifically, we developed NLP methods for three classification tasks: 1) none vs. grade 1-3 esophagitis, 2) grade ≤1 vs. grade 2-3 esophagitis, and 3) none vs. grade 1 vs. grade 2-3 esophagitis. No instances of grade 4 or 5 esophagitis existed in our datasets. We explored cross-domain transferability in a cohort of esophageal cancer patients.

Methods

Patient population and data curation

Our study primarily used a gold-labeled lung cancer dataset of 1,524 notes from 124 non-small cell lung cancer patients who received RT at Brigham and Women's Hospital/Dana-Farber Cancer Institute between 2015-2021. We included notes written from the start of RT up to one month after the last day of RT.

Notes were manually annotated for the presence and maximum inferrable CTCAE v5.0 grade of esophagitis when the document was written. To establish consistent scoring guidelines for esophagitis, we annotated notes for the presence of a documented esophagitis event and its grade. We adhered to CTCAE v5.0 guidelines and based scoring solely on the information present within the free text of the note being annotated. Of note, pain with swallowing was considered esophagitis, but dysphagia alone was not. Thirteen percent of notes were dual-annotated by a radiation oncologist (DSB) and a trained data scientist (NKR), with an inter-rater reliability of 96%. Then the remaining notes were single-annotated by a data scientist (NKR). This dataset was split into a train, development, and test set in a proportion of roughly 80:10:10. Notes from the same patient appeared in only one of the sets.

We also used a silver-labeled dataset of 2,420 notes from 1,832 patients who underwent RT for any cancer diagnosis between 2015-2021, had structured esophagitis grades available in their EHR, and were absent in our gold-labeled dataset. At our institution, patients are seen by their radiation oncologist for a weekly on-treatment visit focused on managing side effects during RT. During these visits, physicians may optionally enter toxicity grade as structured data. No other providers document on treatment toxicity as structured data.

Thus, this dataset only consisted of on-treatment visit notes by radiation oncologists. These structured data were taken as-is for silver labels. These were considered silver labels because they are often copy-forwarded and use variable toxicity grading rubrics over time; no additional quality control was applied to these labels. During training, we used this set of silver-labeled data for data augmentation and cross-domain purposes. In this dataset, lung cancer (927/1,832 (50.6%)), esophageal cancer (167/1,832 (9.1%)), and spine metastases (138/1,832 (7.5%)) were the most common diagnoses.

In addition, we curated a cross-domain validation set of 345 notes from 75 patients with esophageal cancer whose notes were not present in the gold or silver-labeled dataset. These notes were single-annotated by a radiation oncologist (DSB) using the same annotation guidelines as above.

Table 1 shows the patient-level characteristics of our datasets. Table 2 shows the note-level distribution of esophagitis grade in the three datasets. Of note, no instances of grade 4 or 5 esophagitis existed in any of the datasets.

TABLE 1. Patient Demographics and Clinical Characteristics

Patient	Lung Cancer Data Set (n = 124)	Silver-Labeled Data Set (n = 1,832)	Esophageal Cancer Data Set (n = 75)
Age in years (mean, SD)	68.6, 12.1	67.9, 14.6	70.8, 10.9
Sex, No. (%)			
Male	53 (42.7)	932 (50.8)	62 (82.7)
Female	71 (57.3)	900 (49.2)	13 (17.3)
Race, No. (%)			
White	113 (91.1)	1,607 (87.7)	70 (93.3)
Asian	6 (4.8)	70 (3.8)	1 (1.3)
Black	0	75 (4.1)	1 (1.3)
Two or more	0	8 (0.4)	0
Others	0	31 (1.7)	3 (4.0)
Not reported	5 (4)	41 (2.2)	0
Ethnic group, No. (%)			
Non-Hispanic	118 (95.2)	1,683 (91.8)	69 (92.0)
Hispanic	0	14 (0.8)	1 (1.3)
Not reported	6 (4.8)	135 (7.4)	5 (6.7)
Disease site, No. (%)			
Lung cancer			
Non–small-cell lung cancer	124 (100)	798 (43.6)	0
Other histology	0	126 (6.9)	0
Gastrointestinal cancer			
Esophageal cancer	0	167 (9.1)	75 (100)
Other histology	0	129 (7.0)	0
Others	0	612 (33.4)	0
Concurrent chemotherapy, No. (%)			
Yes	107 (86.3)	NA[a]	71 (94.7)
No	17 (13.7)	NA[a]	4 (5.3)

Abbreviations: NA, not applicable; SD, standard deviation.
[a]Concurrent chemotherapy not available for the silver-labeled data set.

This study was approved by the Mass General Brigham institutional review board, and consent was waived as this was deemed exempt from human subjects research.

Classification Task Definition

Models were trained for three increasingly difficult tasks and here are the three classification tasks that were investigated:

Binary classification task predicting the presence or absence of a patient's esophagitis event (none vs. CTCAE grade 1-2-3)

Binary classification task predicting whether or not the note describes a patient experiencing a clinically significant esophagitis event (CTCAE grade 1 vs. grade 2-3)

Multi-class classification task predicting three esophagitis grades: none vs. mild vs. significant(none vs. CTCAE grade 1 vs. grade 2-3).

TABLE 2. Number of Clinical Notes and Distribution of Esophagitis Grades Across Data Sets

Lung Cancer Data Set				
Esophagitis CTCAE Grade[a]	Total (n = 1,524), No. (%)	Train Set (n = 1,243), No. (%)	Development Set (n = 144), No. (%)	Test Set (n = 137), No. (%)
None	1,030 (67.6)	869 (69.9)	76 (52.8)	85 (62.1)
Grade 1	207 (13.6)	146 (11.8)	37 (25.7)	24 (17.5)
Grade 2	187 (12.3)	136 (10.9)	27 (18.8)	24 (17.5)
Grade 3	100 (6.6)	92 (7.4)	4 (2.8)	4 (2.9)

Silver-Labeled Data Set				
Esophagitis CTCAE Grade[a]	Total (n = 2,420), No. (%)	Train Set (n = 2,420), No. (%)	Development Set, No. (%)	Test Set, No. (%)
None	1,562 (64.5)	1,562 (64.5)	NA	NA
Grade 1	376 (15.5)	376 (15.5)	NA	NA
Grade 2	473 (19.5)	473 (19.5)	NA	NA
Grade 3	9 (0.4)	9 (0.4)	NA	NA

Esophageal Cancer Data Set				
Esophagitis CTCAE Grade[a]	Total (n = 345), No. (%)	Train Set, No. (%)	Development Set, No. (%)	Test Set (n = 345), No. (%)
None	201 (58.3)	NA	NA	201 (58.3)
Grade 1	91 (26.4)	NA	NA	91 (26.4)
Grade 2	49 (14.2)	NA	NA	49 (14.2)
Grade 3	4 (1.2)	NA	NA	4 (1.2)

Abbreviations: CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0; NA, not applicable.
[a]No instances of grade 4-5 esophagitis.

Text pre-processing and classification models

In addition to standard text pre-processing, we implemented a rules-based system to systematically mask and remove any templated sections, including structured toxicity scores, headers, and footers, before the text was input

into the training process. Token and section distributions before and after preprocessing are shown in Supplemental Table 1.

We compared two major approaches for the three classification tasks: a statistical model as a baseline and neural models. For the statistical model, we used a term frequency-inverse document frequency (TF-IDF) [35] weighted Bag-of-Words with stochastic gradient descent (BoW+SGD).[36] For the neural models, we explored Bidirectional Encoder Representations from Transformers (BERT)-based models pre-trained on general domain text (BERT-base[37]) and on biomedical domain text (Bio-BERT v1.1,[38] ClinicalBERT,[39] PubMedBERT[40], and BioLinkBERT[41]) with fine-tuning. Models were fine-tuned with gold-labeled data alone, as well as gold and silver-labeled data.

For the BoW+SGD models, we used scikit-learn's SGDClassifier with log loss and l2 regularization, and hinge loss and 1000 estimators, respectively. This presents a baseline easily implementable method.

The BERT-based models' sequence lengths are fixed at 512 tokens. A batch size of 22 was used for different BERT-based models. Manual hyperparameter tuning revealed a learning rate of 0.00007 and a 0.2 dropout rate with weight decay for all BERT-based models leading to consistent model performance.

Given token length limitations in neural models, we provided combinations of informative note sections during BERT-based model fine-tuning.[42,43] We refined medspaCy (v0.20.2)[44] to develop a custom rule-based sectionizer. Using gold data only, we carried out ablation studies to determine the optimal combinations of the following sections for model input: Assessment and Plan, Interval History, Physical Exam, RT Technical (a section unique to some RT notes that describes the RT dose, fractionation, technique, modality, and other technical metrics), and Review of Systems. These sections were chosen as the most likely to contain informative information based on oncologist domain expertise. In notes with no Assessment and Plan or Interval History sections, the full note was used to not exclude short data-rich notes, especially non-physician notes that do not standardly have these sections. The best-performing combinations of sections were used during fine-tuning with the gold- and silver-labeled data.

Evaluation

During training and fine-tuning, we evaluated all models using the development set and assessed their final performance on the held-out test set. For each classification task, we report precision, recall, F1, and, for the binary tasks, area under the receiver operating characteristic and area under the precision-recall curve (Supplemental Methods). Performance is reported at the note level, which directly assesses the tasks the models were trained for. We also report results at the patient level for the best-performing models for each task, in which the maximum predicted esophagitis score in any note for a given patient was compared against the maximum predicted gold score in order to explore performance if the models were implemented to infer this common end-point for clinical trials.

Manual error analysis was conducted on the lung cancer test set.

TABLE 3. Note-Level Model Performance on the Lung Cancer Test Set

Task 1: None *v* CTCAE Grade 1-3 Esophagitis							
Model/Fine-Tuning Data	None F1	Grade 1-3 F1	Macro-F1	Precision	Recall	AUCROC	AUPRC
PubMedBERT/gold- + silver-labeled data	**0.93**	**0.90**	**0.92**	**0.93**	**0.92**	**0.92**	**0.90**
PubMedBERT/gold data	0.91	0.86	0.88	0.89	0.89	0.89	0.78
BERT-base/gold- + silver-labeled data	0.88	0.84	0.86	0.89	0.86	0.88	0.73
BERT-base/gold data	0.93	0.87	0.90	0.91	0.91	0.89	0.82
BoW + SGD/gold- + silver-labeled data	0.87	0.77	0.82	0.83	0.83	0.82	0.69
BoW + SGD/gold data	0.89	0.82	0.86	0.85	0.85	0.85	0.74
Task 2: CTCAE Grade ≤1 *v* CTCAE Grade 2-3 Esophagitis							
Model/F1	Grade ≤1 F1	Grade 2-3 F1	Macro-F1	Precison	Recall	AUCROC	AUPRC
PubMedBERT/gold- + silver-labeled data	**0.93**	**0.71**	**0.82**	**0.88**	**0.88**	**0.88**	**0.77**
PubMedBERT/gold data	0.91	0.67	0.79	0.85	0.85	0.84	0.74
BERT-base/gold- + silver-labeled data	0.88	0.68	0.78	0.88	0.83	0.85	0.75
BERT-base/gold data	0.90	0.58	0.74	0.83	0.84	0.73	0.43
BoW + SGD/gold- + silver-labeled data	0.89	0.55	0.72	0.72	0.71	0.71	0.39
BoW + SGD/gold data	0.90	0.57	0.74	0.74	0.72	0.72	0.42
Task 3: None *v* CTCAE Grade 1 *v* CTCAE Grade 2-3 Esophagitis							
Model/F1	None F1	Grade 1 F1	Grade 2-3 F1	Macro-F1	Precision	Recall	
PubMedBERT/gold- + silver-labeled data	**0.93**	**0.60**	**0.69**	**0.74**	**0.83**	**0.84**	
PubMedBERT/gold data	0.89	0.52	0.57	0.66	0.77	0.76	
BERT-base/gold- + silver-labeled data	0.88	0.49	0.56	0.64	0.79	0.72	
BERT-base/gold data	0.84	0.46	0.44	0.58	0.71	0.70	
BoW + SGD/gold- + silver-labeled data	0.88	0.33	0.55	0.59	0.59	0.59	
BoW + SGD/gold data	0.84	0.19	0.59	0.54	0.55	0.54	

NOTE. Best performance metrics for each task are given in bold. PubMedBERT and BERT-base models: tasks 1 and 2: Assessment and Plan and Interval History sections used for notes with one of these sections; otherwise, the full note was used. Task 3: Assessment and Plan, Interval History, RT Technical, and Review of Systems for notes with either an Assessment and Plan or Interval History section; otherwise, the full note was used. BoW + SGD models: Full note was used as input.

Abbreviations: AUCROC, area under the receiver operating characteristic; AUPRC, area under the precision-recall curve; BERT, Bidirectional Encoder Representations from Transformers; BoW + SGD, term frequency-inverse document frequency weighted Bag-of-Words with gradient boosting; CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

Comparison with structured EHR data

To assess the completeness of esophagitis documentation in structured versus unstructured EHR data, we collected ICD-10 diagnosis codes entered after the start of RT for a narrow and broad definition of esophagitis in our lung cancer test set (Supplemental Methods). We compared the presence of an ICD-10 esophagitis code entered as structured EHR data with our text-extracted results from Task 1, considering at least 1 note with an NLP-identified esophagitis event as an esophagitis diagnosis.

The code to train the neural models and process text in the pipeline is released at https://github.com/AIM-Harvard/Eso_alpha. The neural models trained on the full dataset cannot be released to protect patient privacy.

TABLE 4. Note-Level Model Performance on the Esophageal Cancer Data Set

Task 1: None *v* CTCAE Grade 1-3 Esophagitis

Model/Fine-Tuning Data	None F1	Grade 1-3 F1	Macro-F1	Precision	Recall	AUCROC	AUPRC
PubMedBERT/gold- + silver-labeled data	0.74	**0.71**	**0.73**	**0.75**	0.73	**0.74**	**0.59**
PubMedBERT/gold data	**0.77**	0.66	0.71	0.72	0.72	0.71	0.66
BERT-base/gold- + silver-labeled data	0.67	0.68	0.68	0.72	0.68	0.70	0.55
BERT-base/gold data	0.73	0.58	0.66	0.66	0.67	0.65	0.53
BoW + SGD/gold- + silver-labeled data	0.74	**0.71**	**0.73**	0.74	**0.73**	**0.74**	**0.59**
BoW + SGD/gold data	0.73	0.58	0.66	0.66	0.65	0.65	0.53

Task 2: CTCAE Grade ≤1 *v* CTCAE Grade 2-3 Esophagitis

Model/F1	Grade ≤1 F1	Grade 2-3 F1	Macro-F1	Precision	Recall	AUCROC	AUPRC
PubMedBERT/gold- + silver-labeled data	0.89	**0.58**	**0.74**	**0.88**	0.83	**0.79**	**0.34**
PubMedBERT/gold data	0.91	0.51	0.71	0.85	0.84	0.78	0.33
BERT-base/gold- + silver-labeled data	0.86	0.50	0.68	0.85	0.77	0.76	0.31
BERT-base/gold data	**0.92**	0.43	0.67	0.83	**0.85**	0.65	0.28
BoW + SGD/gold- + silver-labeled data	0.83	0.49	0.66	0.65	0.76	0.76	0.31
BoW + SGD/gold data	0.89	0.46	0.68	0.66	0.69	0.69	0.30

Task 3: None *v* CTCAE Grade 1 *v* CTCAE Grade 2-3 Esophagitis

Model/F1	None F1	Grade 1 F1	Grade 2-3 F1	Macro-F1	Precision	Recall
PubMedBERT/gold- + silver-labeled data	**0.89**	**0.42**	**0.62**	**0.65**	**0.76**	**0.77**
PubMedBERT/gold data	0.80	0.32	0.48	0.53	0.66	0.68
BERT-base/gold- + silver-labeled data	0.74	0.32	0.55	0.54	0.64	0.60
BERT-base/gold data	0.81	0.32	0.48	0.54	0.67	0.68
BoW + SGD/gold- + silver-labeled data	0.64	0.33	0.43	0.47	0.48	0.52
BoW + SGD/gold data	0.73	0.23	0.52	0.49	0.52	0.54

NOTE. Best performance metrics for each task are given in bold. PubMedBERT and BERT-base models: tasks 1 and 2: Assessment and Plan and Interval History sections used for notes with one of these sections; otherwise, the full note was used. Task 3: Assessment and Plan, Interval History, RT Technical, and Review of Systems for notes with either an Assessment and Plan or Interval History section; otherwise, the full note was used. BoW + SGD models: Full note was used as input.

Abbreviations: AUCROC, area under the receiver operating characteristic; AUPRC, area under the precision-recall curve; BERT, Bidirectional Encoder Representations from Transformers; BoW + SGD, term frequency-inverse document frequency weighted Bag-of-Words with gradient boosting; CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

Results

Note-level performance

Table 3 reports the results of the best-performing BERT-based biomedical domain, BERT-based general domain, and statistical models for the lung cancer dataset. Performance was best for Task 1 (macro-F1 0.92), followed by Task 2 (macro-F1 0.82) and Task 3 (macro-F1 0.74). For all tasks, PubmedBERT-based models that were trained using both gold and silver-labeled had the best performance. The best-performing model for Task 1 and 2 included only Assessment and Plan and Interval History for notes with one of these sections; the best performing model for Task 3 included Assessment and Plan, Interval History, RT Technical, and Review of Systems for notes with either an Assessment and Plan or Interval History section.

TABLE 5. Patient-Level Performance on the Lung Cancer Test Set

Maximum Esophagitis	Precision	Recall	F1	Macro-F1	Patient Counts TP (No.)/(TP + TN (No.))
Task 1: None *v* CTCAE grade 1-3 esophagitis					
None	1.00	1.00	1.0	NA	1/1
Grade 1-3	1.00	1.00	1.0	NA	12/12
Weighted overall	1.00	1.00	1.0	1.0	13/13
Task 2: CTCAE grade ≤1 *v* CTCAE grade 2-3 esophagitis					
Grade ≤1	1.00	0.80	0.89	NA	4/5
Grade 2-3	0.89	1.00	0.94	NA	8/8
Weighted overall	0.93	0.92	0.92	0.92	12/13
Task 3: None *v* CTCAE grade 1 *v* CTCAE grade 2-3 esophagitis					
None	0.0	0.0	0.0	NA	0/1
Grade 1	0.67	0.50	0.57	NA	2/4
Grade 2-3	0.80	1.00	0.89	NA	8/8
Weighted overall	0.70	0.77	0.72	0.49	10/13

Abbreviations: CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0; TN, true negatives; TP, true positives.

Table 4 reports the results of the best-performing models on the esophageal cancer dataset. For all tasks, models trained using both gold and silver-labeled data had the best performance. Best macro-F1 was lower than on the lung cancer dataset (Task 1: -0.19, Task 2: -0.083, Task 3: -0.097).

Patient-level performance

Table 5 reports performance at the patient-level in the 13 patients in the lung cancer test set, using the best-performing models at the note level. Macro-F1 was 1.00 for Task 1, 0.92 for Task 2, and 0.49 for Task 3. Of note, for Task 3, the decrease in performance was largely driven by poor performance on the single patient with no esophagitis; all cases of grade 2-3 esophagitis were correctly identified.

Table 6 shows patient-level performance of the 75 patients with esophageal cancer. Macro-F1 was 0.70 for Task 1, 0.69 for Task 2, and 0.58 for Task 3. For task 3, 24/26 cases of grade 2-3 esophagitis were correctly identified.

Error analysis

TABLE 6. Patient-Level Performance on the Esophageal Cancer Data Set

Maximum Esophagitis	Precision	Recall	F1	Macro-F1	Patient Counts TP (No.)/(TP + TN (No.))
Task 1: None *v* CTCAE grade 1-3 esophagitis					
None	0.50	0.68	0.58	NA	13/19
Grade 1-3	0.88	0.77	0.82	NA	43/56
Weighted overall	0.78	0.75	0.76	0.70	56/75
Task 2: CTCAE grade ≤1 *v* CTCAE grade 2-3 esophagitis					
Grade ≤1	0.79	0.78	0.78	NA	38/49
Grade 2-3	0.59	0.62	0.60	NA	16/26
Weighted overall	0.72	0.72	0.72	0.69	54/75
Task 3: None *v* CTCAE grade 1 *v* CTCAE grade 2-3 esophagitis					
None	0.61	0.58	0.59	NA	11/19
Grade 1	0.62	0.33	0.43	NA	10/30
Grade 2-3	0.59	0.92	0.72	NA	24/26
Weighted overall	0.61	0.60	0.57	0.58	45/75

Abbreviations: CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0; TN, true negatives; TP, true positives.

Comparison with structured EHR data

The best-performing NLP model for Task 1 predicted esophagitis perfectly for all 13 patients in the test set. Of the 12 patients with esophagitis, only four were identified as having esophagitis already present as structured data using both the narrow- and broadly-defined set of esophagitis ICD-10 codes. Similarly, only 25/124 patients in the overall dataset had an esophagitis ICD-10 code documented as structured data.

Discussion

This study provides proof-of-concept for the ability of NLP methods to automatically extract cancer treatment adverse event severity according to CTCAE grade from clinical notes. Our models for esophagitis extraction from the notes of patients undergoing RT for lung cancer performed well, with macro-F1 of 0.74-0.92. Unsurprisingly, performance dropped when the model was used cross-domain on notes of patients undergoing RT for esophageal cancer. We showed that our NLP methods supplemented the ICD-10 codes entered as structured data in the EHR for identifying patients with an esophagitis diagnosis, underscoring the importance of methods for text-based data extraction for adverse events. To the best of our knowledge,

this is the first report of NLP methods for cancer treatment-related adverse event severity scoring, and demonstrates the potential for computational methods to support high-quality RWE generation on adverse events.

Our study builds upon a recent body of work on NLP methods for cancer-treatment related adverse events. Hong et al. (2020) used Apache clinical Text Analysis Knowledge Extraction System to extract CTCAE terms from 100 RT OTV notes, and reported an F1 of 0.25-0.91 for identified present terms, and 0.12-0.92 negated terms.[18] Gupta et al. (2021) developed patient-level classifiers of immune-related adverse events, achieving F1 scores of 0.59-0.71 for identifying the presence of the three most common immune-related adverse events.[19] A recent study of extraction of cancer symptoms—a separate but related task—reported a deep learning model that performed well at identifying 80 symptoms.[20]

Our study adds to the existing literature by providing evidence that NLP methods can extract the presence of adverse events and their severity. The impact of an adverse event on the patients' ultimate outcomes is driven by how severe it is. Adverse events, including esophagitis, can be very mild and require no intervention or treatment modifications or may progress to severe, potentially deadly symptoms requiring hospitalization.[32] While methods that extract the presence or absence of an adverse event are valuable for high-level monitoring, understanding the severity of the event is necessary for clinical decision-making and risk-stratification. In addition, severity extraction is necessary for monitoring and understanding expected trajectories of adverse events, which can guide intervention and surveillance strategies. Further, severity extraction according to a standardized grading system such as CTCAE is needed to compare trial-reported adverse event profiles to those in the real-world setting and to compare the adverse event burden across therapeutic strategies.

Our methods achieved the best results for the simplest task of identifying the presence or absence of esophagitis, not severity. The second task, which aimed to identify the presence or absence of esophagitis requiring medical intervention, required a more nuanced distinction between grade 1 and 2 esophagitis, but still performed very well for both classes. The third task aimed to identify whether a note documented no esophagitis, mild esophagitis, or esophagitis requiring medical intervention. While performance was excellent for classifying the absence of esophagitis, performance dropped for classifying

grade 1 and grade 2-3 esophagitis. These findings likely relate to the subtle and somewhat subjective distinction between grade 1 and grade 2 esophagitis which may vary across providers, carry-forward errors due to documentation of previous esophagitis severity, and class imbalance. Nevertheless, our results are still solid, especially for the most clinically relevant task of identifying patients who require medical intervention for their esophagitis. Although the patient-level results are only exploratory given the small numbers, they motivate future efforts in automatically identifying maximum experienced CTCAE grades.

The cross-domain performance of our models on the notes of patients with esophageal cancer underlines the importance of domain adaptation methods. Out-of-domain performance loss is widely documented in clinical NLP [45–47] and is an active area of research.[48] It serves as a warning when applying adverse event methods across cancer diagnoses while also suggesting the future extensibility of such methods. Simply applying the models trained on the lung cancer dataset yielded marked performance decrements, which based on manual review was largely due to tumor-induced symptoms overlapping with esophagitis symptoms in esophageal cancer patients. We also note that while no gold-labeled esophageal cancer patient data were used to train the model, the silver-labeled dataset included 167 notes from esophageal cancer patients, so this is not a completely out-of-domain evaluation.

We took advantage of silver-labeled data to improve the performance of our models. The structured adverse event data that we used to augment our fine-tuning dataset was from a broader cancer population and were only present for a specialized note type—RT on-treatment visits—but still improved performance in the dataset including a wide variety of note and author types. The types and completeness of structured data collected during clinical encounters vary by provider, visit type, and department. Our approach may be useful for other researchers dealing with small gold-labeled datasets, who may have access to structured data for a subset of note types and wish to extract similar data from more diverse clinical encounters.

Our study has limitations that should be considered when interpreting the results. Most importantly, our datasets presented a skewed distribution with under-represented Grade 3 toxicities, and no instances of grade 4 or 5. In addition, they come from a single institution, impacting generalizability. However, the lung cancer dataset reflected notes written by various provider types from various specialties, somewhat offsetting the generalizability

concern. Our patient population was primarily white, potentially limiting the generalizability of our models to patients from different population groups. We had no CTCAE grade 4-5 esophagitis events in our dataset and so we could not develop models to classify these most severe esophagitis grades. Yet, severe adverse events are more readily available as structured data, which could supplement our methods if comprehensive, structured data are available.[49] Our methods do not automatically identify what treatment is the cause of the adverse events; rather, we aimed only to extract an esophagitis event during a time window in which patients are known to be at risk for RT-related esophagitis, but most patients evaluated received concurrent chemotherapy. Accurate attribution is a focus of future work.

In conclusion, our methods provide proof-of-concept that NLP methods can extract the severity of cancer treatment-related adverse events. Such technologies may play an important role in RWE generation for risk-prediction, comparative studies, and survivorship care; Phase IV studies; and clinical trial reporting. In the future, NLP methods for adverse event extraction could support clinical care and yield improved patient quality-of-life by rapidly identifying patients who may benefit from early intervention to prevent progression.

References

1. Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. *CA Cancer J. Clin.***73**, 17–48 (2023).
2. Survival. https://progressreport.cancer.gov/after/survival.
3. Amery, W. K. & ISPE. Why there is a need for pharmacovigilance. *Pharmacoepidemiol. Drug Saf.***8**, 61–64 (1999).
4. Phillips, R., Hazell, L., Sauzet, O. & Cornelius, V. Analysis and reporting of adverse events in randomised controlled trials: a review. *BMJ Open***9**, e024537 (2019).
5. Pitrou, I., Boutron, I., Ahmad, N. & Ravaud, P. Reporting of safety results in published reports of randomized controlled trials. *Arch. Intern. Med.***169**, 1756–1761 (2009).
6. Ioannidis, J. P. & Lau, J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. *JAMA***285**, 437–443 (2001).
7. Ioannidis, J. P. A. & Lau, J. Improving safety reporting from randomised trials. *Drug Saf.***25**, 77–84 (2002).
8. Suresh, K. *et al.* Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. *J. Thorac. Oncol.***13**, 1930–1939 (2018).
9. So, A. C. & Board, R. E. Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK. *Melanoma Manag***5**, MMT05 (2018).
10. Cho, J. Y. *et al.* Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. *Lung Cancer***125**, 150–156 (2018).
11. Argnani, L. *et al.* Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors. *Sci. Rep.***12**, 1753 (2022).
12. Jamieson, L. *et al.* Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study. *BMC Cancer***20**, 743 (2020).
13. Sun, M. *et al.* Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. *BMC Cancer***22**, 762 (2022).
14. Savova, G. K. *et al.* Use of Natural Language Processing to Extract Clinical Cancer Phenotypes from Electronic Medical Records. *Cancer Res.***79**, 5463–5470 (2019).
15. Murphy, R. M. *et al.* Adverse drug event detection using natural language processing: A scoping review of supervised learning methods. *PLoS One***18**, e0279842 (2023).
16. Luo, Y. *et al.* Natural Language Processing for EHR-Based Pharmacovigilance: A Structured Review. *Drug Saf.***40**, 1075–1089 (2017).
17. Bitterman, D. S., Miller, T. A., Mak, R. H. & Savova, G. K. Clinical natural language processing for radiation oncology: A review and practical primer. *Int. J. Radiat. Oncol. Biol. Phys.***110**, 641–655 (2021).
18. Hong, J. C., Fairchild, A. T., Tanksley, J. P., Palta, M. & Tenenbaum, J. D. Natural language processing for abstraction of cancer treatment toxicities: accuracy versus human experts. *JAMIA Open***3**, 513–517 (2020).

19. Gupta, S., Belouali, A., Shah, N. J., Atkins, M. B. & Madhavan, S. Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine Learning. *JCO Clin Cancer Inform***5**, 541–549 (2021).
20. Lindvall, C. *et al.* Deep Learning for Cancer Symptoms Monitoring on the Basis of Electronic Health Record Unstructured Clinical Notes. *JCO Clin Cancer Inform***6**, e2100136 (2022).
21. Henry, S., Buchan, K., Filannino, M., Stubbs, A. & Uzuner, O. 2018 n2c2 shared task on adverse drug events and medication extraction in electronic health records. *J. Am. Med. Inform. Assoc.***27**, 3–12 (2020).
22. Jagannatha, A., Liu, F., Liu, W. & Yu, H. Overview of the First Natural Language Processing Challenge for Extracting Medication, Indication, and Adverse Drug Events from Electronic Health Record Notes (MADE 1.0). *Drug Saf.***42**, 99–111 (2019).
23. Smith, G. L. *et al.* Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. *Int. J. Radiat. Oncol. Biol. Phys.***97**, 450–461 (2017).
24. Bitterman, D. S. *et al.* Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. *J. Natl. Cancer Inst.***112**, 229–237 (2020).
25. Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.***71**, 209–249 (2021).
26. Pignon, J. P. *et al.* Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. *J. Clin. Orthod.***24**, 7008–7008 (2006).
27. Chang, J. Y. *et al.* Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. *Lancet Oncol.***16**, 630–637 (2015).
28. Albain, K. S. *et al.* Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. *Lancet***374**, 379–386 (2009).
29. Sundstrøm, S. *et al.* Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. *J. Clin. Oncol.***22**, 801–810 (2004).
30. Curran, W. J., Jr *et al.* Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J. Natl. Cancer Inst.***103**, 1452–1460 (2011).
31. Antonia, S. J. *et al.* Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N. Engl. J. Med.***379**, 2342–2350 (2018).
32. Baker, S. & Fairchild, A. Radiation-induced esophagitis in lung cancer. *Lung Cancer***7**, 119–127 (2016).
33. Diao, K. *et al.* Radiation toxicity in patients with collagen vascular disease and intrathoracic malignancy treated with modern radiation techniques. *Radiother. Oncol.***125**, 301–309 (2017).
34. *Common Terminology Criteria for Adverse Events (CTCAE)*. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf (2017).
35. Rajaraman, A. & Ullman, J. D. Data Mining. in *Mining of Massive Datasets* 1–17 (Cambridge University Press, 2011).
36. Kowsari *et al.* Text Classification Algorithms: A Survey. *Information* vol. 10 150 Preprint at https://doi.org/10.3390/info10040150 (2019).

37. Devlin, J., Chang, M.-W., Lee, K. & Toutanova, K. BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding. *arXiv [cs.CL]* (2018).
38. Lee, J. *et al.* BioBERT: a pre-trained biomedical language representation model for biomedical text mining. *Bioinformatics***36**, 1234–1240 (2020).
39. Alsentzer, E. *et al.* Publicly Available Clinical BERT Embeddings. in *Proceedings of the 2nd Clinical Natural Language Processing Workshop* 72–78 (Association for Computational Linguistics, 2019).
40. Gu, Y. *et al.* Domain-Specific Language Model Pretraining for Biomedical Natural Language Processing. *arXiv [cs.CL]* (2020).
41. Yasunaga, M., Leskovec, J. & Liang, P. LinkBERT: Pretraining Language Models with Document Links. in *Proceedings of the 60th Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)* 8003–8016 (Association for Computational Linguistics, 2022).
42. Pomares-Quimbaya, A., Kreuzthaler, M. & Schulz, S. Current approaches to identify sections within clinical narratives from electronic health records: a systematic review. *BMC Med. Res. Methodol.***19**, 155 (2019).
43. Rosenthal, S., Barker, K. & Liang, Z. Leveraging Medical Literature for Section Prediction in Electronic Health Records. in *Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing and the 9th International Joint Conference on Natural Language Processing (EMNLP-IJCNLP)* 4864–4873 (Association for Computational Linguistics, 2019).
44. Eyre, H. *et al.* Launching into clinical space with medspaCy: a new clinical text processing toolkit in Python. *AMIA Annu. Symp. Proc.***2021**, 438–447 (2021).
45. Wu, S. *et al.* Negation's not solved: generalizability versus optimizability in clinical natural language processing. *PLoS One***9**, e112774 (2014).
46. Kim, Y., Garvin, J., Heavirland, J. & Meystre, S. M. Improving heart failure information extraction by domain adaptation. *Stud. Health Technol. Inform.***192**, 185–189 (2013).
47. Tepper, M., Capurro, D., Xia, F., Vanderwende, L. & Yetisgen-Yildiz, M. Statistical Section Segmentation in Free-Text Clinical Records. in *Lrec* 2001–2008 (2012).
48. Laparra, E., Mascio, A., Velupillai, S. & Miller, T. A Review of Recent Work in Transfer Learning and Domain Adaptation for Natural Language Processing of Electronic Health Records. *Yearb. Med. Inform.***30**, 239–244 (2021).
49. Kalinich, M. *et al.* Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. *J Immunother Cancer***9**, (2021).

Appendix A: Supplemental Methods

Evaluation Metrics Equations

The evaluation metrics were calculated using the following equations:

Precision = (True Positives/Predictions)
Recall = (True Positives/Gold Positives)
F1 score = ((2*Precision*Recall)/(precision+recall))
Macro-F1 score = ((F1 score for each class / number of classes))
Area under the receiver operating characteristic (AUCROC) = (∑ [True Positives / (True Positives + False Positives)] * Δthreshold)
Area under the precision-recall curve (AUPRC) = (∑[Precision(i+1) - Precision(i)] * Recall(i+1))

Esophagitis ICD-10 Codes

The narrow and broad ICD-10 codes for esophagitis were selected by a board-certified oncologist based on domain expertise and clinical experience.

*ICD-10 codes included in narrow definition:*K20: Esophagitis
K20.9: Esophagitis, unspecified
K20.90: Esophagitis, unspecified without bleeding
K20.91: Esophagitis, unspecified with bleeding
K20.8: Other esophagitis
K20.80: Other esophagitis without bleeding
K20.81: Other esophagitis with bleeding
*ICD-10 codes included in broad definition:*K20: Esophagitis
K20.9: Esophagitis, unspecified
K20.90: Esophagitis, unspecified without bleeding
K20.91: Esophagitis, unspecified with bleeding
K20.8: Other esophagitis
K20.80: Other esophagitis without bleeding
K20.81: Other esophagitis with bleeding
K21.0: Esophagitis with gastro-esophageal reflux disease
K21.0: Reflux esophagitis
K21.00: Gastro-esophageal reflux disease without bleeding
K21.01: Gastro-esophageal reflux disease with bleeding
K22.1: Ulcerative esophagitis
K22.10: Ulcer of esophagus without bleeding
K22.11: Ulcer of esophagus with bleeding

Appendix B: Supplemental Tables

TABLE 1. Token count statistics on the gold-labeled lung cancer and silver-labeled datasets using the PubMedBERT tokenizer.

Token count statistic	Raw notes[a]	Pre-processed notes[b]	IH section[c]	AP section[c]	IH+AP+ROT+ROS sections[c]
mean	477.9	422.3	151.5	99.4	446.6
standard deviation	99.4	121.9	138.2	102.6	124.1
minimum	38	38	3[d]	3[d]	38
25%ile	512	339.5	54	29	446
50%ile	512	512	109	64	512
75%ile	512	512	205	141	512
maximum	512	512	512	512	512

Abbreviations: *IH = Interval History; AP = Assessment and Plan; ROT = Radiotherapy Technical; ROS = Review of Systems*

[a]Raw note is the entire note with no pre-processing other than tokenization.

[b]Pre-processed note is the note after removal of any templated sections that include structured toxicity scores, headers, and footers.

[c]Only stated section was included if the note had an IH or AP section; otherwise, the full pre-processed note was included.

[d]Because of such a section not found in the given note.


Social Determinants of Health
Financial strain
Transportation
Housing instability
Food insecurity
Social support
Education

Chapter 5

Large Language Models to Identify Social Determinants of Health in Electronic Health Records

Shan Chen*, Marco Guevara*, Spencer Thomas, Tafadzwa L. Chaunzwa, Idalid Franco, Benjamin H. Kann, Shalini Moningi, Jack M. Qian, Madeleine Goldstein, Susan Harper, Hugo JWL Aerts, Paul J. Catalano, Guergana K. Savova, Raymond H. Mak, Danielle S. Bitterman

npj Digital Medicine

Summary

Background

SDoH strongly affect outcomes but are poorly captured in structured EHR data. LLMs could extract SDoH from clinical text, but sparse labels, class imbalance, and bias are challenges.

Methods

We evaluated LLMs to extract six SDoH from notes (employment, housing, transportation, parental status, relationship, social support), testing fine-tuned Flan-T5 variants, synthetic-data augmentation, and zero-/few-shot ChatGPT-family baselines, plus a simple bias probe with injected demographics.

Findings

Best models: Flan-T5 **XL** for any SDoH (macro-F1 **0.71**) and Flan-T5 **XXL** for adverse SDoH (macro-F1 **0.70**). Synthetic data helped smaller Flan-T5 models (**ΔF1 +0.12–+0.23**). Fine-tuned models beat ChatGPT-family zero-/few-shot, except **GPT-4 (10-shot)** on adverse SDoH. Fine-tuned models changed predictions less than ChatGPT when race/ethnicity or gender was injected (**$p<0.05$**), indicating less algorithmic bias. At the patient level, models identified **93.8%** with adverse SDoH vs **2.0%** using ICD-10 Z-codes.

Interpretation

Fine-tuned LLMs—augmented with synthetic text—can reliably surface SDoH from EHR notes, outperform general chat models and structured codes, and show lower bias, enabling better real-world evidence and targeted resource support.

Introduction

Health disparities have been extensively documented across medical specialties.[1-3] However, our ability to address these disparities remains limited due to an insufficient understanding of their contributing factors. Social determinants of health (SDoH), are defined by the World Health Organization as "the conditions in which people are born, grow, live, work, and age…shaped by the distribution of money, power, and resources at global, national, and local levels". [4] SDoH may be adverse or protective, impacting health outcomes at multiple levels as they likely play a major role in disparities by determining access to and quality of medical care. For example, a patient cannot benefit from an effective treatment if they don't have transportation to make it to the clinic. There is also emerging evidence that exposure to adverse SDoH may directly affect physical and mental health via inflammatory and neuro-endocrine changes.[5-8] In fact, SDoH are estimated to account for 80-90% of modifiable factors impacting health outcomes.[9]

SDoH are rarely documented comprehensively in structured data in the electronic health records (EHRs),[10-12] creating an obstacle to research and clinical care. Instead, issues related to SDoH are most frequently described in the free text of clinic notes, which creates a bottleneck for incorporating these critical factors into databases to research the full impact and drivers of SDoH, and for proactively identifying patients who may benefit from additional social work and resource support.

Natural language processing (NLP) could address these challenges by automating the abstraction of these data from clinical texts. Prior studies have demonstrated the feasibility of NLP for extracting a range of SDoH.[13-23] Yet, there remains a need to optimize performance for the high-stakes medical domain and to evaluate state-of-the-art language models (LMs) for this task. In addition to anticipated performance changes scaling with model size, large LMs may support EHR mining via data augmentation. Across medical domains, data augmentation can boost performance and alleviate domain transfer issues and so is an especially promising approach for the nearly ubiquitous challenge of data scarcity in clinical NLP.[24-26] The advanced capabilities of state-of-the-art large LMs to generate coherent text open new avenues for data augmentation through synthetic text generation. However, the optimal methods for generating and utilizing such data remain uncertain. Large LM-generated synthetic data may also be a means to distill knowledge represented

in larger LMs to more computationally accessible smaller LMs.[27] In addition, few studies assess the potential bias of SDoH information extraction methods across patient populations. LMs could contribute to the health inequity crisis if they perform differently in diverse populations and/or recapitulate societal prejudices.[28] Therefore, understanding bias is critical for future development and deployment decisions.

Here, we characterize optimal methods, including the role of synthetic clinical text, for SDoH extraction using large language models. Specifically, we develop models to extract six key SDoH: employment status, housing issues, transportation issues, parental status, and social support. We investigate the value of incorporating large LM-generated synthetic SDoH data during the fine-tuning stage. We assess the performance of large LMs, including GPT3.5 and GPT4, in zero- and few-shot settings for identifying SDoH, and we explore the potential for algorithmic bias in LM predictions. Our methods could yield real-world evidence on SDoH, assist in identifying patients who could benefit from resource and social work support, and draw attention to the under-documented impact of social factors in health outcomes.



Fig. 1. *Ablation studies: Performance in Macro-F1 of Flan-T5 XL models fine-tuned using gold data only (orange line) and gold and synthetic data (green line), as gold-labeled sentences are gradually reduced by undersample value from the training dataset for a) adverse social determinant of health (SDoH) mention task and b) any SDoH mention task. The full gold-labeled training set is comprised of 29,869 sentences, augmented with 1800 synthetic SDoH sentences, and tested on the in-domain radiotherapy (RT) test dataset.* RESULTS

Model performance

Table 3 shows the performance of fine-tuned models for both SDoH tasks on the radiotherapy test set. The best-performing model for any SDoH mention task was Flan-T5 XXL (3 out of 6 categories) using synthetic data (Macro-F1 0.71). The best-performing model for the adverse SDoH mention task was Flan-T5 XL without synthetic data (macro-F1 0.70). In general, the Flan-T5 models outperformed BERT, and model performance scaled with size. However, although the Flan-T5 XL and XXL models were the largest models evaluated in terms of total parameters, because LoRA was used for their fine-tuning, the fewest parameters were tuned for these models: 9.5M and 18M for Flan-TX XL and XXL, respectively compared to 110M for BERT. The negative class generally had the best performance overall, followed by Relationship and Employment. Performance varied quite a bit across the models for the other classes.



Fig. 2. *Fine-tuned LLMs versus ChatGPT-family models: Comparison of model performance between our fine-tuned Flan-T5 models against zero- and 10-shot GPT. Macro-F1 was measured using our manually validated synthetic dataset. The GPT-turbo-0613 version of GPT3.5 and the GPT4–0613 version of GPT4 were used. Error bars indicate the 95% confidence intervals. LLM large language model.*

For both tasks, the best-performing models with synthetic data augmentation used sentences from both rounds of GPT3.5 prompting. Synthetic data augmentation tended to lead to the largest performance improvements for classes with few instances in the training dataset and for which the model trained on gold-only data had very low performance (Housing, Parent, and Transportation).

The performance of the best-performing models for each task on the immunotherapy and MIMIC-III datasets are shown in *Table 4*. Performance was similar in the immunotherapy dataset, which represents a separate but similar patient population treated at the same hospital system. We observed a performance decrement on the MIMIC-III dataset, representing a more dissimilar patient population from a different hospital system. Performance was similar between models developed with and without synthetic data.



Fig. 3. *LLM bias evaluation: The proportion of synthetic sentence pairs with and without demographics injected led to a classification mismatch, meaning that the model predicted a different SDoH label for each sentence in the pair. Results are shown across race/ethnicity and gender for a any SDoH mention task and b adverse SDoH mention task. Asterisks indicate statistical significance (P ≤ 0.05) chi-squared tests for multi-class comparisons and 2-proportion z tests for binary comparisons. LLM large language model, SDoH Social determinants of health.*

Ablation studies

The ablation studies showed a consistent deterioration in model performance across all SDoH tasks and categories as the volume of real gold SDoH sentences progressively decreased, although models that included synthetic data maintained performance at higher levels throughout and were less sensitive to decreases in gold data (*Figure 1, Supplementary Table 5*). When synthetic data were included in training, performance was maintained until approximately 50% of gold data were removed from the train set. Conversely, without synthetic data, performance dropped after about 10-20% of the gold data were removed from the train set mimicking a true low-resource setting.

Error analysis

The leading discrepancies between ground-truth and model prediction for each task are in *Supplementary Table 6*. Qualitative analysis revealed 4 distinct error patterns: Human annotator error; false positives and false negatives for Relationship and Support labels in the presence of any family mentions that did not correlate with the correct label; incorrect labels due to information present in the note but external to the sentence and therefore not accessible to the model or that required implied/assumed knowledge; and incorrectly labeling a non-adverse SDoH as an adverse SDoH.

ChatGPT-family model performance

When evaluating our fine-tuned Flan-T5 models on the synthetic test dataset against GPT-turbo-0613 and GPT4-0613, our model surpassed the performance of the top-performing 10-shot learning GPT model by a margin of Macro-F1 0.03 on any SDoH task ($p<0.01$), but fall shorts on adverse SDoH task ($p<0.01$) (*Table 5, Figure 2*).

Language model bias evaluation

Both fine-tuned Flan-T5 models and ChatGPT synthetic provided discrepant classification for sentence pairs with and without demographic information injected (*Figure 3*). However, the discrepancy rate of our fine-tuned models was nearly half that of ChatGPT: 14.3% vs. 21.5% of sentence pairs for any SDoH ($P = 0.007$) and 9.9% vs. 18.2% of sentence pairs for adverse SDoH ($P = 0.005$) for fine-tuned Flan-T5 vs. ChatGPT, respectively. ChatGPT was significantly more likely to change its classification when a female gender was injected compared to a male gender for the Any SDoH task ($P = 0.01$); no other within-model comparisons were statistically significant. Sentences gold-labeled as Support for both any SDoH and adverse SDoH mentions were

most likely to lead to discrepant predictions for ChatGPT (56.3% (27/48)) and (21.0% (9/29)), respectively). Employment gold-labeled sentences were most-likely to lead to discrepant prediction for any SDoH mention fine-tuned model (14.4% (13/90)), and Transportation for adverse SDoH mention fine-tuned model (12.2% (6/49)).

Comparison with structured EHR data

Our best-performing models for any SDoH mention correctly identified 95.7% (89/93) patients with at least one SDoH mention, and 93.8% (45/48) patients with at least one adverse SDoH mention (*Supplemental Tables 7-8*. SDoH entered as structured Z-code in the EHR during the same timespan identified 2.0% (1/48) with at least one adverse SDoH mention (all mapped Z-codes were adverse) (*Supplementary Table 9*). *Supplementary Figures 1-2* show that patient-level performance when using model predictions out-performed Z-codes by a factor of at least 3 for every label for each task (Macro-F1 0.78 vs. 0.17 for any SDoH mention and 0.71 vs. 0.17 for adverse SDoH mention).

Discussion

We developed multilabel classifiers to identify the presence of 6 different SDoH documented in clinical notes, demonstrating the potential of large LMs to improve the collection of real-world data on SDoH and support appropriate allocation of resource support to patients who need it most. We identified a performance gap between a more traditional BERT classifier and larger Flan-T5 XL and XXL models. Our fine-tuned models out-performed ChatGPT-family models with zero- and few-shot learning for most SDoH classes, and were less sensitive to the injection of demographic descriptors. Compared to diagnostic codes entered as structured data, text-extracted data identified 91.8% more patients with an adverse SDoH. We also contribute new annotation guidelines as well as synthetic SDoH datasets to the research community.

All of our models performed well at identifying sentences that do not contain SDoH mentions (F1 ≥ 0.99 for all). For any SDoH mentions, performance was worst for parental status and transportation issues. For adverse SDoH mentions, performance was worst for parental status and social support. These findings are unsurprising given the marked class imbalance for all SDoH labels—Only 3% of sentences in our training set contained any SDoH mention. Given this imbalance, our models' ability to identify sentences that

contain SDoH language is impressive. In addition, these SDoH descriptions are semantically and linguistically complex. In particular, sentences describing social support are highly variable given the variety of ways individuals can receive support from their social systems during care. Interestingly, our best-performing models demonstrated strong performance in classifying housing issues (macro-F1 0.67), which was our scarcest label with only 20 instances in the training dataset. This speaks to the potential of large LMs in improved real-world data collection for very sparsely documented information, which is the most likely to be missed via manual review.

The recent advancements in large LMs have opened a pathway for synthetic text generation that may improve model performance via data augmentation, and enable experiments that better protect patient privacy.[29] This is an emerging area of research that falls within a larger body of work on synthetic patient data across a range of data types and end-uses.[30,31] Our study is among the first to evaluate the role of contemporary generative large LMs for synthetic clinical text to help unlock the value of unstructured data within the EHR. We were particularly interested in synthetic clinical data as a means to address the aforementioned scarcity of SDoH documentation, and our findings may provide generalizable insights for the common clinical NLP challenges of class imbalance—Many clinically important data are difficult to identify among the huge amounts of text in a patient's EHR. We found variable benefits of synthetic data augmentation across model architecture and size; the strategy was most beneficial for the smaller Flan-T5 models and for the rarest classes where performance was dismal using gold data alone. Importantly, the ablation studies demonstrated that only approximately half of the gold-labeled dataset was needed to maintain performance when synthetic data was included in training, although synthetic data alone did not produce high-quality models. We explored the automated generation of synthetic training data using ChatGPT-family models to minimize human effort. Our results demonstrate that augmenting human gold-standard data with this synthetic data achieves superior performance compared to using human data alone.

Our novel approach to generating synthetic clinical sentences also enabled us to explore the potential for ChatGPT-family models, GPT3.5 and GPT4, for supporting the collection of SDoH information from the EHR. We found that fine-tuning LMs that are orders of magnitude smaller than ChatGPT-family models, even with our relatively small dataset, generally outperformed zero-

shot and few-shot learning with ChatGPT-family models, consistent with prior work evaluating large LMs for clinical uses.[32–34,33] Nevertheless, these models showed promising performance given that they were not explicitly trained for clinical tasks, with the caveat that it is hard to make definite conclusions based on synthetic data. Additional prompt engineering could improve the performance of ChatGPT-family models, such as developing prompts that provide details of the annotation guidelines as done by Ramachandran et al (2023).[34] This is an area for future study, especially once these models can be readily used with real clinical data. With additional prompt engineering and model refinement, performance of these models could improve in the future and provide a promising avenue to extract SDoH while reducing human effort needed to label training datasets.

It is well-documented that LMs learn the biases, prejudices, and racism present in the language they are trained on.[35–38] Thus, it is essential to evaluate how LMs could propagate existing biases, which in clinical settings could amplify the health disparities crisis.[1–3] We were especially concerned that SDoH-containing language may be especially prone to eliciting these biases. Both our fine-tuned models and ChatGPT altered their SDoH classification predictions when demographics and gender descriptors were injected into sentences, although the fine-tuned models were significantly more robust than ChatGPT. Although not significantly different, it is worth noting that for both the fine-tuned models and ChatGPT, Hispanic and Black descriptors were most likely to change the classification for any SDoH and adverse SDoH mentions, respectively. This lack of significance may be due to the small numbers in this evaluation, and future work is critically needed to further evaluate bias in clinical LMs. We have made our paired demographic-injected sentences openly available for future efforts on LM bias evaluation.

SDoH are notoriously under-documented in existing EHR structured data.[10–12,39] Our findings that text-extracted SDoH information was better able to identify patients with adverse SDoH than relevant billing codes are in agreement with prior work showing under-utilization of Z-codes[10,11]. Most EMR systems have other ways to enter SDoH information as structured data which may have more complete documentation, however these did not exist for most of our target SDoH. Lyberger et al. evaluated other EHR sources of structured SDoH data, and similarly found that NLP methods are a complementary source of SDoH information extraction, and were able to identify 10-30% of patients

with tobacco, alcohol, and homelessness risk factors documented only in unstructured text[22].

There have been several prior studies developing NLP methods to extract SDoH from the EHR.[13–21,40] The most common SDoH targeted in prior efforts include smoking history, substance use, alcohol use, and homelessness.[23] In addition, many prior efforts focus only on text in the Social History section of notes. In a recent shared task on alcohol, drug, tobacco, employment, and living situation event extraction from Social History sections, pre-trained LMs similarly provided best performance.[41] Using this dataset, one study found that sequence-to-sequence approaches out-performed classification approaches, in line with our findings.[42] In addition to our technical innovations, our work adds to prior efforts by investigating SDoH that are less commonly targeted for extraction but nonetheless have been shown to impact healthcare.[43–51] We also developed methods that can mine information from full clinic notes, not only Social History sections–a fundamentally more challenging task with a much larger class imbalance. Clinically-impactful SDoH information is often scattered throughout other note sections and many note types, such as many inpatient progress notes and notes written by nurses and social workers, do not consistently contain Social History sections.

Our study has limitations. First, our training and out-of-domain datasets come from a predominantly white population treated at hospitals in Boston, Massachusetts in the United States of America. This limits the generalizability of our findings. We could not exhaustively assess the many methods to generate synthetic data from ChatGPT. Instead, we chose to investigate prompting methods that could be easily reproduced by others and did not require extensive task-specific optimization, as this is likely not feasible for the many clinical NLP tasks that one may wish to generate synthetic data on. Incorporating real clinical examples in the prompt would likely improve the quality of the synthetic data, and is an area of future research when large generative LMs become more widely available for use with protected health information and within the resource constraints of academic researchers and healthcare systems. Because we could not evaluate ChatGPT-family models using protected health information, our evaluations are limited to manually-verified synthetic sentences. Thus, our reported performance may not completely reflect true performance on real clinical text. Because the synthetic sentences were generated using ChatGPT itself, and ChatGPT presumably has not been trained on clinical text, we hypothesize that if anything, performance would be worse on real clinical

data. Finally, our models can only be as good as the annotated corpus. SDoH annotation is challenging due to its conceptually complex nature, especially for the Support tag, and labeling may also be subject to annotator bias[52], all of which may impact ultimate performance.

Our findings highlight the potential of large LMs to improve real-world data collection and identification of SDoH from the EHR. In addition, synthetic clinical text generated by large LMs may enable better identification of rare events documented in the EHR, although more work is needed to optimize generation methods. Our fine-tuned models were less prone to bias than ChatGPT-family models and out-performed for most SDoH classes, especially any SDoH mentions, despite being orders of magnitude smaller. In the future, these models could improve our understanding of drivers of health disparities by improving real-world evidence, and could directly support patient care by flagging patients who may benefit most from proactive resource and social work referral.

Methods

Data

Table 1 describes the patient populations of the datasets used in this study. Gender and race/ethnicity data and descriptors were collected from the EHR. These are generally collected either directly from the patient at registration, or by a provider, but the mode of collection for each data point was not available. Our primary dataset consisted of a corpus of 800 clinic notes from 770 patients with cancer who received radiotherapy (RT) at the Department of Radiation Oncology at Brigham and Women's Hospital/Dana-Farber Cancer Institute in Boston, Massachusetts from 2015-2022. We also created two out-of-domain test datasets. First, we collected 200 clinic notes from 170 patients with cancer treated with immunotherapy at Dana-Farber Cancer, and not present in the RT dataset. Second, we collected 200 notes from 183 patients in the MIMIC (Medical Information Mart for Intensive Care)-III database[53,54], which includes data associated with patients admitted to the critical care units at Beth Israel Deaconess Medical Center in Boston, Massachusetts from 2001-2008. This study was approved by the Mass General Brigham institutional review board, and consent was waived as this was deemed exempt human subjects research.

Only notes written by physicians, physician assistants, nurse practitioners, registered nurses, and social workers were included. To maintain a minimum

threshold of information, we excluded notes with fewer than 150 tokens across all provider types. This helped ensure that the selected notes contained sufficient textual content. For notes written by all providers save social workers, we excluded notes containing any section longer than 500 tokens to avoid excessively lengthy sections that might have included less relevant or redundant information. For physician, physician assistant, and nurse practitioner notes, we used a customized medSpacy[55,56] sectionizer to include only notes that contained at least one of the following sections: Assessment and Plan, Social History, and History/Subjective.

In addition, for the RT dataset, we established a date range, considering notes within a window of 30 days before the first treatment and 90 days after the last treatment. Additionally, in the fifth round of annotation, we specifically excluded notes from patients with zero social work notes. This decision ensured that we focused on individuals who had received social work intervention or had pertinent social context documented in their notes. For the immunotherapy dataset, we ensured that there was no patient overlap between RT and immunotherapy notes. We also specifically selected notes from patients with at least one social work note. To further refine the selection, we considered notes with a note date one month before or after the patient's first social work note or after it. For the MIMIC-III dataset, only notes written by physicians, social workers, and nurses were included for analysis. We focused on patients who had at least one social work note, without any specific date range criteria.

Prior to annotation, all notes were segmented into sentences using the syntok[57] sentence segmenter as well as split on bullet points "•". This method was used for all notes in the radiotherapy, immunotherapy, and MIMIC datasets for sentence-level annotation and subsequent classification.

Task definition and data labeling

We defined our label schema and classification tasks by first carrying out interviews with subject matter experts, including social workers, resource specialists, and oncologists, to determine SDoH that are clinically relevant but not already readily available as structured data in the EHR, especially as dynamic features over time. After initial interviews, a set of exploratory pilot annotations was conducted on a subset of clinical notes and preliminary annotation guidelines were developed. The guidelines were then iteratively refined and finalized based on the pilot annotations and additional input from

subject matter experts. The following SDoH categories and their attributes were selected for inclusion in the project: Employment status (employed, unemployed, underemployed, retired, disability, student), Housing issue (financial status, undomiciled, other), Transportation issue (distance, resource, other), Parental status (if the patient has a child under 18 years old), Relationship (married, partnered, widowed, divorced, single), and Social support (presence or absence of social support).

We defined two multilabel sentence-level classification tasks:

1. Any SDoH mentions: The presence of language describing an SDoH category as defined above, regardless of the attribute.
2. Adverse SDoH mentions: The presence or absence of language describing an SDoH category with an attribute that could create an additional social work or resource support need for patients:
   - **Employment status**: *unemployed, underemployed, disability*
   - **Housing issue**: *financial status, undomiciled, other*
   - **Transportation issue**: *distance, resources, other*
   - **Parental status**: *having a child under 18 years old*
   - **Relationship**: *widowed, divorced, single*
   - **Social support**: *absence of social support*

After finalizing the annotation guidelines, two annotators manually annotated the RT corpus. In total, ten thousand one-hundred clinical notes were annotated line-by-line using the annotation software Multi-document Annotation Environment (MAE v2.2.13).[58] A total of 300/800 (37.5%) of the notes underwent dual annotation by two data scientists across 4 rounds. After each round, the data scientists and an oncologist performed discussion-based adjudication. Before adjudication, dually-annotated notes had a Krippendorf's alpha agreement of 0.86 and Cohen's Kappa of 0.86 for any SDoH mention categories. For adverse SDoH mentions, notes had a Krippendorf's alpha agreement of 0.76 and Cohen's Kappa of 0.76. Detailed agreement metrics are in *Supplementary Tables 1-2*. A single annotator then annotated the remaining radiotherapy notes, the immunotherapy dataset, and the MIMIC-III dataset. *Table 2* describes the distribution of labels across the datasets

The annotation/adjudication team was composed of one board-certified radiation oncologist who completed a postdoctoral fellowship in clinical natural language processing, a Master's-level computational linguist with a Bachelor's

degree in linguistics and one year prior experience working specifically with clinical text, and a Master's student in computational linguistics with a Bachelor's degree in linguistics. The radiation oncologist and Master's level computational linguist led the development of the annotation guidelines, and trained the Master's student in SDoH annotation over a period of 1 month via review of the annotation guidelines and iterative review of pilot annotations. During adjudication, if there was still ambiguity, we discussed with the two Resource Specialists on the research team to provide input in adjudication.

Data augmentation

We employed synthetic data generation methods to assess the impact of data augmentation for the positive class, and also to enable an exploratory evaluation of proprietary large LMs that could not be downloaded locally thus cannot be used with protected health information. In round 1, GPT-turbo-0301 (ChatGPT) version of GPT3.5 via the OpenAI[59] API was prompted to generate new sentences for each SDoH category, using sentences from the annotation guidelines as references. In round 2, in order to generate more linguistic diversity, the sample synthetic sentences output from round 1 were taken as references to again generate another set of synthetic sentences. One hundred sentences per category were generated in each round. *Supplementary Table 3* shows the prompts for each sentence label type.

Synthetic test set generation

Iteration 1 for generating SDoH sentences involved prompting the 538 synthetic sentences to be manually validated to evaluate ChatGPT, which cannot be used with protected health information. Of these, after human review only 480 were found to have any SDoH mention, and 289 to have an adverse SDoH mention (Table 2). For all synthetic data generation methods, no real patient data were used in prompt development or fine-tuning.

Model development

The radiotherapy corpus was split into a 60%/20%/20% distribution for training, development, and testing respectively. The entire immunotherapy and MIMIC-III corpora were held-out for out-of-domain test and were not used during model development.

The experimental phase of this study focused on investigating the effectiveness of different machine learning models and data settings for the classification of SDoH. We explored one multi-label BERT model as a baseline, namely bert-

base-uncased[60], as well as a range of Flan-T5 models[61,62] including Flan-T5 base, large, XL, and XXL; where XL and XXL used a parameter efficient tuning method (low-rank adaptation (LoRA)[63]). Binary cross-entropy loss with logits was used for BERT and cross-entropy loss for the Flan T5 models. Given the large class imbalance, non-SDoH sentences were undersampled during training. We assessed the impact of adding synthetic data on model performance. Details on model hyper-parameters are in *Supplementary Methods*.

For sequence-to-sequence models, input consisted of the input sentence with "summarize" appended in front, and the target label (when used during training) was the text span of the label from the target vocabulary. Because the output did not always exactly correspond to the target vocabulary, we post-processed the model output, which was a simple split function on "," and dictionary mapping from observed miss-generation e.g., "RELAT → RELATIONSHIP". Examples of this label resolution are in *Supplementary Methods.*

Ablation studies

Ablation studies were carried out to understand the impact of manually labeled training data quantity on performance when synthetic SDoH data is included in the training dataset. First, models were trained using 10%, 25%, 40%, 50%, 70%, 75%, and 90% of manually labeled sentences; both SDOH and non-SDOH sentences were reduced at the same rate. Evaluation was on the RT test set.

Evaluation

During training and fine-tuning, we evaluated all models using the RT development set and assessed their final performance using bootstrap sampling of the held-out RT test set. Bootstrap sample number and size was calculated to achieve a precision level for standard error of macro F1 of +/- 0.01. The mean and 95% confidence intervals from the bootstrap samples were calculated from the resulting bootstrap samples. We also sampled to ensure that our standard error on the 95% confidence interval limits was < 0.01 as follows: Our selected bootstrap sample size matched the test data size, sampling with replacement. We then computed the 5th and 95th percentile values for each of the calculated k samples from the resulting distributions. The standard deviation of these percentile values was subsequently determined to establish the precision of the confidence interval limits. Examples of the bootstrap sampling calculations are in *Supplementary Methods*.

For each classification task, we calculated precision/positive predictive value, recall/sensitivity, and F1 (harmonic mean of recall and precision) as follows:
- Precision = TP/(TP+FP)
- Recall = TP/(TP+FN)
- F1 = (2*Precision*Recall)/(Precision+Recall)
- TP = true positives, FP = false positives, FN = false negatives

Manual error analysis was conducted on the radiotherapy dataset using the best-performing model.

ChatGPT-family model evaluation

To evaluate ChatGPT, the Scikit-LLM[64] multi-label zero-shot classifier and few-shot binary classifier were adapted to form a multi-label zero- and few-shot classifier (*Figure 2*). A subset of 480 synthetic sentences whose labels were manually validated, were used for testing. Test sentences were inserted into the following prompt template, which instructs ChatGPT to act as a multi-label classifier model, and to label the sentences accordingly:

> "Sample input: [TEXT]
>
> Sample target: [LABELS]**"**
>
> [TEXT] was the exemplar from the development/exemplar set.
> [LABELS] was a comma-separated list of the labels for that exemplar, e.g. PARENT,RELATIONSHIP.

Of note, because we were unable to generate high-quality synthetic non-SDoH sentences, these classifiers did not include a negative class. We evaluated the most current ChatGPT model freely available at the time of this work, GPT-turbo-0613, as well as GPT4-0613, via the OpenAI API with temperature 0 for reproducibility.

Language model bias evaluation

In order to test for bias in our best-performing models and in large LMs pre-trained on general text, we used GPT4 to insert demographic descriptors into our synthetic data, as illustrated below. GPT4 was supplied with our synthetically-generated test sentences, and prompted to insert demographic information into them. For example, a sentence starting with "Widower admits fears surrounding potential judgment..." might become "Hispanic widower

admits fears surrounding potential judgment...". The prompt was as follows (in a batch of 10 ensure demographic variations):

"role": "user", "content": "[ORIGINAL SENTENCE] swap the sentences patients above to one of the race/ethnicity [Asian, Black, white, Hispanic] and gender, and put the modified race and gender in bracket at the beginning like this Owner operator food truck selling gourmet grilled cheese sandwiches around town => [Asian female] Asian woman owner operator of a food truck selling gourmet grilled cheese sandwiches around town"[ORIGINAL SENTENCE]was a sentence from a selected subset of our GPT-3.5-generated synthetic data

These sentences were then manually validated; 419 had any SDoH mention, and 253 had an adverse SDoH mention.

Comparison with structured EHR data

To assess the completeness of SDoH documentation in structured versus unstructured EHR data, we collected Z-codes for all patients in our test set. Z-codes are SDoH-related ICD-10-CM diagnostic codes, mapped most closely with our SDoH categories present as structured data for the radiotherapy dataset (*Supplementary Table 4*). Text-extracted patient-level SDoH information was defined as the presence of one or more labels in any note. We compared these patient-level labels to structured Z-codes entered in the EHR during the same time frame.

Statistical analysis

Macro-F1 performance for each model type was compared when developed with or without synthetic data and for the ChatGPT-family model comparisons using the Mann-Whitney U-test. The rate of discrepant SDoH classifications with and without the injection of demographic information were compared between the best-performing fine-tuned models and ChatGPT using chi-squared tests for multi-class comparisons and 2-proportion z-tests for binary comparisons. A 2-sided $P \leq 0.05$ was considered statistically significant. Statistical analyses were carried out using the statistical Python package in scipy (Scipy.org). Python version 3.9.16 (Python Software Foundation) was used to carry out this work.

Data availability statement: The RT and immunotherapy datasets cannot be shared for the privacy of the individuals whose data were used in this study. All synthetic datasets used in this study are available at: https://github.com/AIM-

Harvard/SDoH. The annotated MIMIC-III dataset is available after completion of a data use agreement at https://physionet.org/content/annotation-dataset-sdoh/1.0.1/.

Code availability statement: The final annotation guidelines and all synthetic datasets used in this study are available at: https://github.com/AIM-Harvard/SDoH.

Please view the full Tables and appendix at:
https://www.nature.com/articles/s41746-023-00970-0

References

1. Lavizzo-Mourey, R. J., Besser, R. E. & Williams, D. R. Understanding and Mitigating Health Inequities - Past, Current, and Future Directions. *N. Engl. J. Med.***384**, 1681–1684 (2021).
2. Chetty, R. *et al.* The Association Between Income and Life Expectancy in the United States, 2001-2014. *JAMA***315**, 1750–1766 (2016).
3. Caraballo, C. *et al.* Excess Mortality and Years of Potential Life Lost Among the Black Population in the US, 1999-2020. *JAMA***329**, 1662–1670 (2023).
4. Social determinants of health. http://www.who.int/social_determinants/sdh_definition/en/.
5. Franke, H. A. Toxic Stress: Effects, Prevention and Treatment. *Children***1**, 390–402 (2014).
6. Nelson, C. A. *et al.* Adversity in childhood is linked to mental and physical health throughout life. *BMJ***371**, m3048 (2020).
7. Shonkoff, J. P., Garner, A. S., Committee on Psychosocial Aspects of Child and Family Health, Committee on Early Childhood, Adoption, and Dependent Care & Section on Developmental and Behavioral Pediatrics. The lifelong effects of early childhood adversity and toxic stress. *Pediatrics***129**, e232–46 (2012).
8. Turner-Cobb, J. M., Sephton, S. E., Koopman, C., Blake-Mortimer, J. & Spiegel, D. Social support and salivary cortisol in women with metastatic breast cancer. *Psychosom. Med.***62**, 337–345 (2000).
9. Hood, C. M., Gennuso, K. P., Swain, G. R. & Catlin, B. B. County Health Rankings: Relationships Between Determinant Factors and Health Outcomes. *Am. J. Prev. Med.***50**, 129–135 (2016).
10. Truong, H. P. *et al.* Utilization of Social Determinants of Health ICD-10 Z-Codes Among Hospitalized Patients in the United States, 2016-2017. *Med. Care***58**, 1037–1043 (2020).
11. Heidari, E., Zalmai, R., Richards, K., Sakthisivabalan, L. & Brown, C. Z-code documentation to identify social determinants of health among Medicaid beneficiaries. *Res. Social Adm. Pharm.***19**, 180–183 (2023).
12. Wang, M., Pantell, M. S., Gottlieb, L. M. & Adler-Milstein, J. Documentation and review of social determinants of health data in the EHR: measures and associated insights. *J. Am. Med. Inform. Assoc.***28**, 2608–2616 (2021).
13. Conway, M. *et al.* Moonstone: a novel natural language processing system for inferring social risk from clinical narratives. *J. Biomed. Semantics***10**, 1–10 (2019).
14. Bejan, C. A. *et al.* Mining 100 million notes to find homelessness and adverse childhood experiences: 2 case studies of rare and severe social determinants of health in electronic health records. *J. Am. Med. Inform. Assoc.***25**, 61–71 (2017).
15. Topaz, M., Murga, L., Bar-Bachar, O., Cato, K. & Collins, S. Extracting Alcohol and Substance Abuse Status from Clinical Notes: The Added Value of Nursing Data. *Stud. Health Technol. Inform.***264**, 1056–1060 (2019).
16. Gundlapalli, A. V. *et al.* Using natural language processing on the free text of clinical documents to screen for evidence of homelessness among US veterans. *AMIA Annu. Symp. Proc.***2013**, 537–546 (2013).
17. Hammond, K. W., Ben-Ari, A. Y., Laundry, R. J., Boyko, E. J. & Samore, M. H. The Feasibility of Using Large-Scale Text Mining to Detect Adverse Childhood Experiences in a VA-Treated Population. *J. Trauma. Stress***28**, 505–514 (2015).

18. Han, S. *et al.* Classifying social determinants of health from unstructured electronic health records using deep learning-based natural language processing. *J. Biomed. Inform.***127**, 103984 (2022).
19. Rouillard, C. J., Nasser, M. A., Hu, H. & Roblin, D. W. Evaluation of a Natural Language Processing Approach to Identify Social Determinants of Health in Electronic Health Records in a Diverse Community Cohort. *Med. Care***60**, 248–255 (2022).
20. Feller, D. J. *et al.* Detecting Social and Behavioral Determinants of Health with Structured and Free-Text Clinical Data. *Appl. Clin. Inform.***11**, 172–181 (2020).
21. Yu, Z. *et al.* A Study of Social and Behavioral Determinants of Health in Lung Cancer Patients Using Transformers-based Natural Language Processing Models. *AMIA Annu. Symp. Proc.***2021**, 1225–1233 (2021).
22. Lybarger, K. *et al.* Leveraging natural language processing to augment structured social determinants of health data in the electronic health record. *J. Am. Med. Inform. Assoc.* (2023) doi:10.1093/jamia/ocad073.
23. Patra, B. G. *et al.* Extracting social determinants of health from electronic health records using natural language processing: a systematic review. *J. Am. Med. Inform. Assoc.***28**, 2716–2727 (2021).
24. Xu, D., Chen, S. & Miller, T. BCH-NLP at BioCreative VII Track 3: medications detection in tweets using transformer networks and multi-task learning. Preprint at https://arxiv.org/abs/2111.13726 (2021).
25. Chen, S. *et al.* Natural Language Processing to Automatically Extract the Presence and Severity of Esophagitis in Notes of Patients Undergoing Radiotherapy. *JCO Clin Cancer Inform***7**, e2300048 (2023).
26. Tan, R.S.Y.C. *et al.* Inferring cancer disease response fromradiology reports using large language models with data augmentation and prompting. *J Am Med Inform Assoc* **30**(10):1657-1664 (2023).
27. Jung, J. *et al.* Impossible Distillation: from Low-Quality Model to High-Quality Dataset & Model for Summarization and Paraphrasing. Preprint at https://arxiv.org/pdf/2305.16635.pdf (2023).
28. Lett, E. & La Cava, W. G. Translating intersectionality to fair machine learning in health sciences. *Nature Machine Intelligence***5**, 476–479 (2023).
29. Li, J. *et al.* Are synthetic clinical notes useful for real natural language processing tasks: A case study on clinical entity recognition. *J. Am. Med. Inform. Assoc.***28**, 2193–2201 (2021).
30. Chen, R. J., Lu, M. Y., Chen, T. Y., Williamson, D. F. K. & Mahmood, F. Synthetic data in machine learning for medicine and healthcare. *Nat Biomed Eng***5**, 493–497 (2021).
31. Jacobs, F. *et al.* Opportunities and Challenges of Synthetic Data Generation in Oncology. *JCO Clin Cancer Inform***7**, e2300045 (2023).
32. Chen, S. *et al.* Evaluation of ChatGPT Family of Models for Biomedical Reasoning and Classification. Preprint at https://arxiv.org/abs/2304.02496 (2023).
33. Lehman, E. *et al.* Do We Still Need Clinical Language Models? *arXiv [cs.CL]* (2023).
34. Ramachandran, G. K. *et al.* Prompt-based Extraction of Social Determinants of Health Using Few-shot Learning. in *Proceedings of the 5th Clinical Natural Language Processing Workshop* 385–393 (Association for Computational Linguistics, 2023).

35. Feng, S., Park, C. Y., Liu, Y. & Tsvetkov, Y. From Pretraining Data to Language Models to Downstream Tasks: Tracking the Trails of Political Biases Leading to Unfair NLP Models. in *Proceedings of the 61st Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)* 11737–11762 (Association for Computational Linguistics, 2023).
36. Zhao, J., Wang, T., Yatskar, M., Ordonez, V. & Chang, K.-W. Men Also Like Shopping: Reducing Gender Bias Amplification using Corpus-level Constraints. in *Proceedings of the 2017 Conference on Empirical Methods in Natural Language Processing* 2979–2989 (Association for Computational Linguistics, 2017).
37. Caliskan, A., Bryson, J. J. & Narayanan, A. Semantics derived automatically from language corpora contain human-like biases. *Science***356**, 183–186 (2017).
38. Davidson, T., Warmsley, D., Macy, M. & Weber, I. Automated Hate Speech Detection and the Problem of Offensive Language. Preprint at https://arxiv.org/pdf/1703.04009.pdf (2017).
39. Kharrazi, H. *et al.* The Value of Unstructured Electronic Health Record Data in Geriatric Syndrome Case Identification. *J. Am. Geriatr. Soc.***66**, 1499–1507 (2018).
40. Derton, A. *et al.* Natural Language Processing Methods to Empirically Explore Social Contexts and Needs in Cancer Patient Notes. *JCO Clin Cancer Inform***7**, e2200196 (2023).
41. Lybarger, K., Yetisgen, M. & Uzuner, Ö. The 2022 n2c2/UW shared task on extracting social determinants of health. *J. Am. Med. Inform. Assoc.***30**, 1367–1378 (2023).
42. Romanowski, B., Ben Abacha, A. & Fan, Y. Extracting social determinants of health from clinical note text with classification and sequence-to-sequence approaches. *J. Am. Med. Inform. Assoc.***30**, 1448–1455 (2023).
43. Hatef, E. *et al.* Assessing the Availability of Data on Social and Behavioral Determinants in Structured and Unstructured Electronic Health Records: A Retrospective Analysis of a Multilevel Health Care System. *JMIR Med Inform***7**, e13802 (2019).
44. Greenwald, J. L., Cronin, P. R., Carballo, V., Danaei, G. & Choy, G. A Novel Model for Predicting Rehospitalization Risk Incorporating Physical Function, Cognitive Status, and Psychosocial Support Using Natural Language Processing. *Med. Care***55**, 261–266 (2017).
45. Blosnich, J. R. *et al.* Social Determinants and Military Veterans' Suicide Ideation and Attempt: a Cross-sectional Analysis of Electronic Health Record Data. *J. Gen. Intern. Med.***35**, 1759–1767 (2020).
46. Wray, C. M. *et al.* Examining the Interfacility Variation of Social Determinants of Health in the Veterans Health Administration. *Fed. Pract.***38**, 15–19 (2021).
47. Wang, L. *et al.* Disease Trajectories and End-of-Life Care for Dementias: Latent Topic Modeling and Trend Analysis Using Clinical Notes. *AMIA Annu. Symp. Proc.***2018**, 1056–1065 (2018).
48. Navathe, A. S. *et al.* Hospital Readmission and Social Risk Factors Identified from Physician Notes. *Health Serv. Res.***53**, 1110–1136 (2018).
49. Kroenke, C. H., Kubzansky, L. D., Schernhammer, E. S., Holmes, M. D. & Kawachi, I. Social networks, social support, and survival after breast cancer diagnosis. *J. Clin. Oncol.***24**, 1105–1111 (2006).
50. Maunsell, E., Brisson, J. & Deschênes, L. Social support and survival among women with breast cancer. *Cancer***76**, 631–637 (1995).
51. Schulz, R. & Beach, S. R. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. *JAMA***282**, 2215–2219 (1999).
52. Hovy, D. & Prabhumoye, S. Five sources of bias in natural language processing. *Lang. Linguist. Compass***15**, e12432 (2021).

53. Johnson, A., Pollard, T. & Mark, R. MIMIC-III clinical database. (2023) doi:10.13026/C2XW26.
54. Johnson, A. E. W. *et al.* MIMIC-III, a freely accessible critical care database. *Sci Data***3**, 160035 (2016).
55. Eyre, H. *et al.* Launching into clinical space with medspaCy: a new clinical text processing toolkit in Python. *AMIA Annu. Symp. Proc.***2021**, 438–447 (2021).
56. MedspaCy . spaCy universe. *medspaCy*https://spacy.io/universe/project/medspacy.
57. Leitner, F. *syntok: Text tokenization and sentence segmentation (segtok v2)*. (Github).
58. Multi-document annotation environment. *MAE*https://keighrim.github.io/mae-annotation/.
59. OpenAI API. http://platform.openai.com.
60. Devlin, J., Chang, M.-W., Lee, K. & Toutanova, K. BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding. in *Proceedings of the 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short Papers)* 4171–4186 (Association for Computational Linguistics, 2019).
61. Chung, H. W. *et al.* Scaling Instruction-Finetuned Language Models. Preprint at https://arxiv.org/abs/2210.11416 (2022).
62. Longpre, S. *et al.* The Flan Collection: Designing Data and Methods for Effective Instruction Tuning. *arXiv [cs.AI]* (2023).
63. Hu, E. J. *et al.* LoRA: Low-Rank Adaptation of Large Language Models. Preprint at https://arxiv.org/abs/2106.09685 (2021).
64. Kondrashchenko, I. *scikit-llm: Seamlessly integrate powerful language models like ChatGPT into scikit-learn for enhanced text analysis tasks*. (Github).

Supplementary Methods

Annotation Details

The most common type of disagreement between annotators involved one annotator labeling a sentence with a common tag (Support, Employment, and Relationship) and the other annotator not giving that sentence any label. For Employment and Relationship tags, this was most often due to simple annotation errors that get resolved through the adjudication process without much discussion. There were some instances for Employment where the language was vague as to whether the patient was on a break from work due to their job or whether they were no longer employed, which was a source of disagreements. The Support tag was a more conceptually complex tag resulting in disagreement. For example, there were disagreements based on whether a patient reporting feeling better because they had individuals visit their house, without details of the visit, consisted of support. Although it was still among the most prevalent of annotation disagreements, we believe the support tag's complexity was minimized through pilot annotation rounds and guideline revisions. The disagreement types with >5 instances are listed below:

Disagreement type	*Count*
NO_SDOH, SUPPORT_plus	27
NO_SDOH, EMPLOYMENT_employed	16
NO_SDOH, RELATIONSHIP_married	15
NO_SDOH, PARENT	8
NO_SDOH SUPPORT_minus	6

Please view the full appendix at:
https://www.nature.com/articles/s41746-023-00970-0

Hyper-parameters for model training

During the model development, the fine-tuning process of the best-performing models follows specific hyper-parameters using two *Nvidia RTX 3090 GPUs*. A per-device training batch size of 32 is used along with a learning rate of 1e-3. The model is trained for a total of 3 epochs. Additionally, the LoRA configuration is employed with a rank 'r' of 16 and a 'lora_alpha' value of 32. This configuration targets the "q" and "v" modules in the transformer layers and incorporates a dropout rate of 0.05.

```
per_device_train_batch_size=32,
learning_rate=1e-3,
num_train_epochs=3,
lora_config = LoraConfig(
    r=16,
    lora_alpha=32,
    target_modules=["q", "v"],
    lora_dropout=0.05,
    bias="none",
    task_type=TaskType.SEQ_2_SEQ_LM
)
```


Label resolution examples for sequence-to-sequence models

Example 1:
Source: "summarize: This is a patient with a history of heart disease."
Target label: '<NO_SDOH>'

Output from model: "NO_SD"
Post-processed Output: ["<NO_SDOH>"]

Example 2:
Source: "summarize: The patient's wife drives him to treatment every day."
Target label: 'RELATIONSHIP,SUPPORT'

Output from model: "RELAT,SUPPORT"
Post-processed Output: ["RELATIONSHIP", "SUPPORT"]

Bootstrap Sampling Calculations Example

1. Set our desired precision level for standard error (SE) for the performance metric of macro-F1 to be +/- 0.01

2. Estimate variability by taking a small number of initial samples, e.g.:

- Take 100 initial bootstrap samples of size k = 10,860 (full test set size) with replacement.
- Calculate the standard deviation (σ) of F1 scores across these 100 bootstraps across all model pairs between gold-only data and gold+augmented data.
- Let's say σ is estimated to be 0.03.

3. Use the following formula to solve for n: $SE = \sigma/\sqrt{n}$

- For example, say σ was estimated to be 0.03:
  - $0.01 = 0.03/\sqrt{n}$
  - $n = 9 * 100$

- In practice, n varied from 2 to 34 across models, therefore we picked the largest (n=3400) for all comparison pairs.

4. Therefore, the recommended numbers to achieve our desired SE for macro-F1:

- n = 3400 (number of bootstrap samples)
- k = 10,860 (size of each bootstrap sample)

We calculated the mean and 95% confidence intervals from the 3400 bootstrap samples, and compared the difference in macro-F1 when adding augmented data using the Mann-Whitney U-test.

We established our metric as Macro F1, and sampled to ensure that our SE on the 95% confidence interval limits was < 0.01. Our selected bootstrap sample size matched the test-data size, sampling with replacement. We then computed the 5th and 95th percentile values for each of the calculated k samples from the resulting distributions. The standard deviation of these percentile values was subsequently determined to establish the precision of the confidence interval limits. For example, utilizing this methodological approach, a 95% confidence interval, accounting for a maximum variation of 5% and 95%, was ascertained to be 0.0091 for Table 3. This was validated through the execution of bootstrapping, performed 3,400 times across three distinct samples.


Patient Message
I have a rash, fever, and diarrhea after my immunotherapy. What should I do?
Agentic AI
Actions
Information Retrieval
Evidence Review
Risk Assessment
Recommendation & Alert
Likely immune-related colitis (Grade 2)
Recommended: Hold treatment, start steroids, monitor closely. Escalate if worsening.

Chapter 6

An Agentic AI System Enhances Clinical Detection of Immunotherapy Toxicities: a multi-phase validation study

Jack Gallifant, ***Shan Chen***, Kee-Young Shin, Katherine C. Kellogg, Patrick F. Doyle, Joyce Guo, Bingyang Ye, Andrew Warrington, Bingxue K Zhai, Matthew J. Hadfield, Alexander Gusev, Biagio Ricciuti, David Christiani, Hugo JWL Aerts, Raymond H. Mak, Tanna L. Nelson, Paul Nguyen, Jonathan D. Schoenfeld, Umit Topaloglu, Paul Catalano, Harry Hochheiser, Jeremy L. Warner, Elad Sharon, David E. Kozono, Guergana K. Savova, Danielle S. Bitterman

Submitted to Nature Medicine

Summary

Background

Immune checkpoint inhibitors (ICIs) frequently cause immune-related adverse events (irAEs), yet structured EHR fields capture only a fraction of these toxicities. Most clinically relevant details–temporality, CTCAE grade, attribution, and certainty–appear exclusively in free-text notes, and existing NLP approaches are limited to binary detection or require large supervised datasets. Whether agentic large language models (LLMs), which decompose complex tasks into coordinated subtasks, can reliably extract these attributes or improve human chart review is unknown.

Methods

We built an agentic LLM pipeline to extract six irAEs and four attributes from oncology notes of ICI-treated adults (2015–2024). Expert-annotated gold standards guided model development. The system used specialized agents, self-consistency across multiple runs, and extraction of supporting evidence snippets. We evaluated performance retrospectively, then prospectively in silent mode across real-time notes, followed by deployment in an annotation interface, and finally in a randomized crossover study comparing manual versus LLM-assisted review.

Findings

The best-performing configuration cost approximately $0.02 per note and, in prospective silent deployment over three months (884 notes), detection F1 was 0.72–0.79. In a randomized crossover study of clinical trial staff (17 participants, 316 observations), agentic assistance reduced annotation time by 40% ($P < 0.001$), increased complete-match accuracy (OR 1.45; 95% CI 1.01–2.09; $P = 0.045$), and improved inter-annotator agreement (Krippendorff's from 0.22–0.51 to 0.82–0.85). These results demonstrate that, for this specific task, agentic AI coupled with human verification could enhance efficiency, performance, and consistency.

Interpretation

A compact agentic LLM system can reliably extract clinically meaningful irAE attributes from routine oncology notes and measurably accelerate expert review. Its combination of accuracy, interpretability, and workflow benefit suggests strong potential for scalable, near-real-time irAE surveillance and more efficient pharmacovigilance.

Introduction

Treatment-emergent adverse events (TEAEs) are under-recognized in clinical trials and existing databases.[1–8] Accurate detection and reporting of TEAEs is foundational to cancer care, pharmacovigilance[9], and survivorship planning. In routine practice, however, many clinically important adverse events are documented primarily in unstructured clinical narratives; structured electronic health record (EHR) fields incompletely capture their occurrence, necessitating laborious, resource-intensive, and error-prone manual chart review.[10,11] This manual bottleneck currently limits the capacity and quality of adverse event curation and monitoring for clinical trials, real-world evidence, and clinical decision-support at the point-of-care.

Against this backdrop, immune checkpoint inhibitors (ICI) have transformed cancer treatment, yet their success comes with a critical challenge: up to 40% of patients develop immune-related adverse events (irAEs) that can affect any organ system.[12–16] While timely detection of irAEs saves lives, evidence of these toxicities are often buried within clinical notes, escaping standard surveillance methods.[15,17] Furthermore, addressing the challenge of irAE surveillance and management will become increasingly urgent as the number of cancer survivors grows to an estimated 26 million survivors anticipated by 2040 in the US alone.[18] Furthermore, the clinical burden is compounded by substantial economic costs, with irAE-related hospitalizations and treatment adding thousands of dollars per patient and requiring resource-intensive manual chart review for detection[19].

Despite their clinical significance, systematically identifying cancer TEAEs presents a considerable challenge for both clinical care and pharmacovigilance.[20] Directly analyzable structured data fields within EHRs do not reliably capture irAEs, especially those that do not result in hospitalization but still have important impacts on patients' overall morbidity and quality of life.[11] Even of those that result in hospitalization, ICD codes have a recall/sensitivity of only approximately 68%.[21] Because of this, manual chart curation is required for irAE reporting, but this suffers from the aforementioned manual curation bottleneck and introduces significant quality challenges due to ambiguous definitions and thresholds for irAE occurrence, severity, and attribution.[22,23]

To address these challenges, natural language processing (NLP), which refers to computational analysis of unstructured text and is a central pillar

in modern Artificial Intelligence (AI),[24] has been explored to extract irAEs from EHR documents automatically. Initial efforts using traditional machine learning or small neural language models demonstrated promise, but require large annotated datasets for task-specific training and tuning.[2526,27] More recently, large language models (LLMs) have been shown to extract clinical information without extensive fine-tuning in a zero-shot or few-shot scenario through sophisticated prompting. Preliminary studies applying LLMs to irAE identification have demonstrated promise;[21,28,29] however, they have focused on binary classification (i.e., irAE present/absent) over an entire inpatient admission record or patient chart. Because these approaches operate at the chart or encounter level rather than on individual clinical notes, they are poorly suited for real-time detection and ongoing monitoring. Furthermore, they have not addressed the extraction of irAE clinical attributes necessary to inform clinical decision-making, translational research, and regulatory reporting for clinical trials. These critical attributes include the temporal status (distinguishing between current, active events and historical ones), severity grading (aligned with standardized scales), attribution (the clinician's assessment of the likelihood that the event is ICI-related), and the certainty of that attribution. Extracting these details accurately from narrative text remains an unmet need to understand and address irAEs and adverse events more broadly.



***Figure 1**. Multi-dimensional validation framework for an agentic LLM-based irAE detection system.*

Concurrently, advanced autonomous prompting strategies and architectures, commonly referred to as "agentic" systems, aim to further enhance LLM capabilities.[30] These systems decompose complex reasoning tasks into smaller, manageable sub-problems, often addressed by multiple specialized LLM-based or utilizing tools (agents), and with mechanisms to evaluate and synthesize the final output.[30] It remains an open question whether such agentic architectures can be effectively leveraged for the complex, multi-faceted task of extracting detailed irAE attributes from clinical notes. Even if technically feasible, the impact of integrating such sophisticated AI assistance into ' real-world clinical and research workflows, including its effect on efficiency, performance, cognitive load, and overall experience, remains unevaluated. Understanding these human-computer interaction (HCI) factors is necessary to translate technological potential into practical, usable, and valuable healthcare applications.

In this study, we evaluated the impact of real-time agentic LLM assistance on human curation of detailed irAEs from clinical notes. We developed an agentic pipeline that extracts not only the presence of six irAEs spanning common and lethal events (myocarditis, dermatitis, thyroiditis, hepatitis, colitis, and pneumonitis),[31] but also their temporal status, severity grade, ICI attribution, and attribution certainty at the encounter level. We integrated this system into an annotation interface and conducted human-computer interaction studies to determine whether AI assistance improves reviewer efficiency, accuracy, and consistency compared to unaided manual review. We also approximated the costs of computation. We demonstrated the potential of agentic AI to improve both the quality and efficiency of irAE curation, which could enhance our understanding and optimization of the benefits and risks of cancer treatment via clinical trials and real-world evidence generation.

Given that this work is unpublished and actively reviewed under a journal, please see all full tables and appendix at https://shorturl.at/n1ICB.

Results

Figure 2 summarizes the main results from each phase of the study.



***Figure 2**. Multi-stage agentic architecture for irAE detection, grading, attribution, and certainty assessment.*

Phase 1: Note-Level irAE System Development and Evaluation

To identify the optimal configuration for note-level irAE extraction (Figure 1), we systematically benchmarked combinations of proprietary and open-source LLMs across agentic and non-agentic architectures on 263 expert-annotated clinical notes. Two design features are central to interpreting these results. First, each irAE was classified by event temporality, that is, whether the clinical note described it as a currently active event or as a historical (past) event, and performance was evaluated for each timeframe separately. Second, to reduce the variability inherent in single LLM outputs, we implemented a self-consistency mechanism in which specific stages of the agentic process were run three times independently, and a judge agent resolved disagreements before proceeding to the next stage; a single-inference variant that omitted this step served as the primary comparator for ablation analyses (Figure 2). Among all model-architecture combinations evaluated, GPT-4.1-mini with the default agentic architecture achieved the strongest overall performance. This configuration incurred an inference cost of $0.021 per note; costs for all model–architecture combinations are reported in Appendix Table 1. For note-level irAE detection, the system attained a temporality-agnostic macro-averaged F1 of 0.93 across the six conditions (Table 1). Performance was consistent when stratified by event temporality: F1 = 0.92 for active (current) events and 0.91 for resolved (past) events. Current temporality detection performance was highest for Hepatitis and Pneumonitis (F1 = 0.96), and lowest for myocarditis

(F1 = 0.86). Condition-specific binary classification performance (precision, recall, F1) is presented in Appendix Figure 1.

Multi-class Common Terminology Criteria for Adverse Events (CTCAE) grade assignment showed lower performance with an overall macro F1 of 0.66 for current events. Performance varied by condition: dermatitis and thyroiditis achieved the highest performance (F1 = 0.73 and 0.72, respectively), while colitis had the lowest performance (F1 = 0.51). Intermediate grades (2–3) accounted for the majority of misclassifications. The system demonstrated stronger performance when severity was dichotomized at clinically relevant thresholds (grade <2 versus ≥2, and grade <3 versus ≥3), although performance varied according to irAE type (Figure 3).

The system reliably captured clinician-documented attribution assessments, with a binary F1 of 0.92 (current events) and 0.94 (past events). Certainty estimation remained high for binary classification (any stated certainty vs. none; F1 = 0.93–0.94).

The modest difference between temporality-agnostic and timepoint-specific detection (F1 = 0.93 vs. 0.92/0.91) indicates that residual errors were driven primarily by missed detections or incorrect grading rather than confusion between active and resolved events.

Within the GPT-4.1-mini family, the single-inference variant (without self-consistency) reduced detection F1 from 0.92 to 0.78, while approximately halving inference cost ($0.011 vs. $0.021 per note), confirming the contribution of multi-run consensus to overall performance. Smaller models (4.1-nano, 4o-mini) and open-source alternatives consistently underperformed across detection and grading tasks (Appendix Table 1). Notably, a rule-based baseline using keyword-matching regular expressions[1] achieved reasonable performance for binary detection (i.e., flagging whether an irAE was present or absent), performing comparably to or better than even some LLM-based methods. This finding underscores the utility of simple pattern-matching approaches for case identification; however, regular expressions are inherently limited to surface-level keyword matching and cannot extract the granular clinical attributes (such as severity grade, attribution, certainty, and supporting evidence spans) required for actionable irAE characterization.

Phase 2: Prospective Silent Validation

To assess real-world generalizability, we deployed the system in silent, prospective mode for 3 months (May–July 2025), processing 884 clinical notes in near-real time. The system generated 31,824 label adjudications across grade, attribution, and certainty for both current and past timepoints. We found that detection performance remained robust, though attenuated relative to retrospective benchmarks.

Prospective performance was lower relative to retrospective benchmarks, as anticipated, due to temporal drift in documentation patterns and case mix (Table 2). In addition to the results in Table 2, detection F1 was 0.72 for current events and 0.79 for past events. Attribution extraction remained strong (F1 = 0.77), as did certainty classification (F1 = 0.80). At the note level, model predictions matched human review in 62% of cases for grade (549/884), 87% for attribution (771/884), and 83% for certainty (732/884).

Phase 3: Randomized User Effect Study

To determine whether agentic assistance improves human curation of irAEs in practice, we conducted a randomized 2×2 crossover study comparing AI-assisted annotation to standard manual review among clinical research staff (Methods). We found that AI assistance substantially reduced annotation time, improved accuracy, and enhanced inter-annotator agreement. Twenty-one participants enrolled in the study (20 clinical research coordinators and 1 clinical research nurse), and 4 participants withdrew consent before starting annotations (all clinical research coordinators). All 17 remaining participants (16 clinical research coordinators, 1 clinical research nurse) completed the study (Appendix Table 1), yielding 316 evaluable timing observations for the primary note-level analysis. Twenty-four note-level observations across participants were excluded due to missing video recordings.

Table 3 shows results for the randomized user effect study. For our primary endpoint of annotation efficiency, AI assistance substantially reduced the time required to curate irAE labels from clinical notes. Median annotation time was 428 seconds (IQR: 253–671) with manual review versus 242 seconds (IQR: 160–385) with AI assistance—a 44% reduction. In the primary generalized estimating equations (GEE) analysis, which accounted for within-participant clustering, AI assistance was associated with a 40% decrease in annotation time (95% CI: 26–50%; $P < 0.001$). Neither note set nor method sequence significantly influenced efficiency in multivariable models, suggesting no substantial carryover effects.



Figure 3. *Performance & efficiency of AI-assisted irAE grading.*

For our secondary endpoint of performance, complete-match accuracy (requiring all six current grade labels to exactly match the gold standard) was modest overall, reflecting the stringency of this metric: 19.4% for manual

annotation versus 24.9% with AI assistance (Table 3). In GEE analysis, AI assistance increased the odds of complete accuracy by 45% (OR = 1.45; 95% CI: 1.01–2.09; P = 0.045). This effect remained significant after adjustment for note set and sequence.

Further, for inter-annotator agreement AI assistance markedly improved consistency across annotators. For current grade labels, Krippendorff's alpha increased from 0.22 (95% bootstrap CI: 0.16–0.30) to 0.85 (95% CI: 0.79–0.89) in note set A, and from 0.51 (95% CI: 0.50–0.51) to 0.82 (95% CI: 0.76–0.87) in note set B. The magnitude of improvement was substantial in both sets ($\Delta\alpha > 0.30$), indicating that AI assistance reduced between-annotator variability and promoted standardization. Exploratory analyses of attribution and certainty labels showed concordant improvements: for attribution, Krippendorff's α increased from 0.22 to 0.86 (note set A) and from 0.42 to 0.75 (note set B); for certainty, from 0.18 to 0.84 and from 0.44 to 0.74, respectively.

Participants' perceptions mirrored these objective gains (Appendix Table 2). Mean System Usability Scale scores increased from 35.3 (manual) to 52.1 (AI-assisted). On 5-point Likert items from pre- and post-study questionnaires (Appendix 5b, 5c), self-reported efficiency increased from 2.5 to 3.9, confidence in labeling accuracy from 3.1 to 3.8, and belief that AI can assist complex clinical interpretation from 2.3 to 3.0. Following the study, 88% of participants preferred the AI-assisted workflow to manual review.

Disscussion

The present study explores an agentic LLM system for the extraction of clinically salient attributes of irAEs from routine oncology documentation with performance that translates from retrospective benchmarking to prospective, real-world use and improved adverse event data quality. Across six high-priority irAEs, the system achieved strong note-level detection and clinician-stated attribution performance. Multi-class CTCAE grading was promising, with degradation at intermediate grades. Performance declined during a three-month prospective silent deployment (F1 = 0.72–0.79), underscoring the gap between retrospective evaluation and changing real-world conditions. In a randomized user effect study, agentic-assistance reduced annotation time by 40%, improved accuracy, and improved inter-annotator reliability. Together, these results suggest that agentic LLM systems,

coupled to human verification and evidence highlighting, could be further explored to shift irAE ascertainment from a labor-intensive retrospective review to scalable, efficient automated extraction with a potential to improve consistency and quality.

Prior approaches emphasized patient- or visit-level irAE classification, retrospectively and without the fine-grained attributes required for actionability and causal effects analysis (temporality, grade, and attribution).[21,25,26,28] By decomposing the task into specialized agents for temporality, grading, attribution, and certainty with explicit extraction of supporting spans, our system overcomes known challenges in textual causality and nuance.[29,32] The self-consistency mechanism, in which a judge agent reconciled three parallel model runs for a stage, contributed materially to detection performance (macro F1 +0.14 relative to the single-inference variant), consistent with the value of ensembling and cross-examination to reduce output variance.[33,34] Temporal misassignment, the system labelling an irAE as currently active when it was historical, or vice versa, was small ($|\Delta F1| < 0.05$ across conditions). A cross-temporal analysis that credited a prediction if the irAE was detected in either timeframe yielded only modest gains (binary F1 = 0.93), confirming that residual errors are primarily detection- or grading-related rather than due to timeframe confusion.

These results carry direct clinical and pharmacovigilance implications. Reliable, note-level extraction of irAE attributes addresses a persistent blind spot in structured EHR fields and claims data, where recall is limited even for hospitalization-associated events. The ability to surface candidate events with attributed causality and provisional grade shortly after documentation can shorten time-to-recognition for life-threatening irAEs (e.g., myocarditis, pneumonitis) and standardize ascertainment for research registries and safety reporting.

Multi-class CTCAE grading remains the most challenging subtask. Two considerations temper this result. First, ambiguity at intermediate grades often reflects documentation incompleteness (e.g., missing quantitative stool counts for grading of colitis, absent laboratory trend context for grading of hepatitis) rather than model error per se; such ambiguity similarly burdens human reviewers. Second, thresholds can be adapted to clinically meaningful bins (e.g., none/low vs ≥ Grade 3), which may improve effective performance for triage and reporting while preserving granular outputs for

research. Incorporating structured signals (laboratories, medications such as corticosteroid initiation, imaging impressions) and temporal aggregation across notes are promising future strategies to disambiguate intermediate grades without sacrificing interpretability.

The transition from retrospective benchmarking to prospective deployment revealed expected but instructive performance attenuation. The system was optimized on a curated retrospective corpus of several hundred notes, then deployed against a continuous stream of real-world documentation generated years later on different EHR templates, encompassing a broader range of clinical presentations, irAE subtypes, symptom descriptions, and documentation styles than were represented in the development set. This degradation, therefore, likely reflects the combined effects of distributional shift in case mix and clinical terminology, evolving EHR templates and note structures, and variation in documentation practices across clinician cohorts, rather than fundamental model limitations. The prospective phase thus underscores a critical operational requirement: deployed clinical AI systems require continuous monitoring and periodic recalibration,[35] not one-time validation. Attribution and certainty extraction proved more robust to drift than severity grading, consistent with the relative stability of causal language conventions versus the context-dependent nature of quantitative symptom documentation.

The randomized user study provides, to our knowledge, the first controlled evidence that agentic AI assistance improves adverse event curation when deployed with human oversight. Three findings merit emphasis. First, efficiency gains were substantial and exceeded our pre-specified minimally important difference, suggesting that AI-prepopulated labels shift annotator effort from generation to verification—a cognitively less demanding task. Second, there was a striking effect on inter-annotator consistency: manual annotation produced only fair agreement, whereas AI-assisted annotation achieved near-excellent reliability. This convergence effect likely arises because annotators anchor on model suggestions, reducing idiosyncratic interpretation of ambiguous documentation. For pharmacovigilance and registry curation, where consistency across reviewers is as important as individual accuracy, this standardization benefit may prove as valuable as time savings. However, the same anchoring mechanism raises the risk of automation complacency, whereby reviewers accept model outputs without sufficient independent scrutiny, potentially introducing systematic bias. Our study was not designed to disentangle consistency gains from complacency effects, and future work should explicitly test whether

anchoring on AI suggestions compromises the detection of model errors, particularly for subtle or atypical presentations. Third, participants' qualitative feedback highlighted the value of evidence highlighting, the extraction and display of specific text spans from the clinical note (e.g., the phrases describing respiratory symptoms that supported a pneumonitis determination) alongside each model output. By linking each extracted label to its source evidence within the note, this feature enabled reviewers to more easily verify model conclusions against the original documentation directly, rather than re-reading entire notes, and served as a practical enabler of efficient human-AI collaboration.

These findings are consistent with a growing body of work suggesting that AI assistance can improve throughput in clinical documentation and annotation tasks, including ambient AI scribes that reduce documentation time by up to 30 minutes per clinician per day,[36] and LLM-assisted radiology reporting that accelerates report generation while maintaining diagnostic accuracy.[37] The 88% preference for the AI-assisted workflow, coupled with improvements in perceived efficiency and confidence, suggests that such systems can achieve the often-elusive goal of user acceptance in clinical informatics.

Questions of generalizability, governance, and cost warrant consideration. Interestingly, the architecture generalized across six irAEs with consistent detection performance, suggesting portability to a broader spectrum of adverse events. Nevertheless, this is a single-health-system study with local note templates and vernacular; external validation across institutions, EHRs, and oncology subspecialties is necessary. A practical barrier to adoption is cost and infrastructure. Agentic pipelines require multiple model calls per note, and our system currently relies on a proprietary model (GPT-4.1-mini) accessed via a commercial API, which incurs per-token inference costs that may be prohibitive for small and medium-sized institutions lacking enterprise API agreements or dedicated compute infrastructure. In the present study, the best-performing agentic configuration cost $0.021 per note (~$18.50 for the 884-note prospective corpus), while open-source alternatives running on institutional GPUs eliminated API costs entirely, albeit with lower performance (Appendix Table 1). Although our results with a mid-sized model suggest that performance–cost trade-offs can be managed at scale, broader adoption will likely require validating open-source or locally deployable LLMs that can run behind institutional firewalls under HIPAA BAAs, reducing both cost and reliance on external vendors. Our preliminary benchmarking of open-source alternatives showed lower performance with current prompting strategies

(Appendix Table 1), but rapid improvements in open-weight models make this a tractable near-term goal. Robust monitoring for data drift will also be essential as indications and combination regimens expand.[38]

Several limitations should be acknowledged. We focused on six irAEs representing a subset of the broader CTCAE v5.0 ontology; expansion to rarer toxicities will require targeted evaluation. Our system was developed and validated using a single proprietary model (GPT-4.1-mini), and performance may not transfer directly to other LLMs; systematic evaluation across open-source and locally deployable models is an important next step for broader accessibility. Ground-truth labels, though adjudicated, remain constrained by documentation quality and the inherent subjectivity of grading and attribution. The prospective deployment did not assess patient outcomes (e.g., time to steroid initiation, hospitalization, treatment interruption). The preparatory field study was observational; causal effects on efficiency and agreement were isolated in the randomized study (Phase 3). While we only studied irAEs, we believe that the results will be informative for other cancer AE's and adverse events more broadly. In particular, the human-computer interaction results may be transferable for systems with similar performance and interface features.

Looking ahead, these findings carry both methodological and practical implications. Methodologically, agentic decomposition with self-consistency and explicit evidence extraction yielded accurate, auditable outputs suitable for clinical workflows. Practically, staging validation from retrospective testing to silent prospective monitoring and embedded human collaboration provides a template for closing the "deployment gap" in clinical AI. Given the expanding survivor population exposed to ICIs and diffusion of care into non-oncology settings, scalable, auditable assistance for irAE detection is poised to become a core informatics capability for oncology services and pharmacovigilance programs.

Conclusions

In summary, an agentic LLM system and associated interactive interface, validated across retrospective and prospective settings, can extract real-time, clinically detailed information about the presence, severity, and attribution of irAEs. Agentic assistance improved the efficiency, performance, and consistency of irAE curation when used with a human-in-the-loop. With

external validation and outcome-focused trials, such systems could enhance and accelerate real-time safety monitoring, trial curation, and high-reliability oncology care.

Methods

Study Design

This multi-phase study evaluated an agentic LLM system for detecting and extracting irAEs from clinical documentation, progressing systematically from retrospective analysis to real-world deployment (Figure 1). We first developed and retrospectively evaluated a note-level agentic irAE extraction system. We then conducted real-world validation studies to (1) validate prospective performance when integrated within an EHR for real-time clinical monitoring, and (2) quantify the impact of human-agentic collaboration on irAE curation efficiency and quality via a randomized user effect study. A preparatory field study was conducted to inform interface design, metric selection, and power calculations. The study protocol received ethical approval from the Institutional Review Boards of Mass General Brigham and Dana-Farber Cancer Institute (MGB 2022P002195, DF/HCC 24-735, DF/HCC 20-328). A waiver of informed consent was granted for the retrospective components, as the research involved minimal risk and did not alter any clinical care. Electronic informed consent was obtained for the human-computer interaction studies.

Phase 1: Note-Level irAE System Development and Evaluation

For the data source and study population, we assembled a retrospective cohort of patients treated with immune checkpoint inhibitors at an academic medical center in Boston, MA between 2015 and 2024. Inclusion criteria were: (1) age ≥18 years, (2) treatment with one or more of the following FDA-approved ICIs: *tremelimumab, relatlimab, retifanlimab, pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, cemiplimab, toripalimab, dostarlimab*, and (3) presence of at least one progress note or visit note in the clinical system. Demographic information of included participants across phases are included in Appendix 2.

To establish the gold-standard annotation procedure, annotation guidelines were developed to support manual ground-truth labeling of the presence of current and past irAEs and their key clinical attributes (Appendix 3). We focused on 6 irAEs, which were selected to capture a range of common, rare,

severe, and chronic events: pneumonitis, hepatitis, myocarditis, dermatitis, thyroiditis, and colitis. Each irAE was mapped to a set of National Cancer Institute (NCI) CTCAE terms following the definitions used in the Alliance for Clinical Trial in Oncology irAE biobank (NCT04242095, Appendix 3). For each irAE type and temporality (current vs. past) combination, we labeled its binary presence or absence, CTCAE grade, attribution, and certainty as described in a note. The clinical attributes are defined as follows: **(1)** Severity**:** Severity grading followed the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, a standardized system commonly used for regulatory reporting. Values: Grade 1, 2, 3, 4, 5. **(2)** Attribution: Attribution captured the clinician's explicitly documented assessment of causality between the adverse event and ICI therapy, recognizing that many symptoms in cancer patients have multiple potential etiologies. Attributes: Positive, Negative.

(3) Certainty: Certainty reflected the degree of diagnostic confidence expressed in the documentation, guided in part by the Naranjo scale but adjusted for note-level, text-based determination.[39] Attributes: None, Unlikely, Possible, Probable, Definite.

Pilot rounds of 10-20 notes were dual-annotated by a physician and clinical research coordinator with 4 years of oncology data abstraction experience, and annotation guidelines were iteratively updated for clarity and consistency until inter-annotator agreement exceeded 0.70 for each irAE type. All discrepancies were tracked and resolved through consensus discussion. Cases requiring adjudication were reviewed by an attending oncologist. The open-source Label Studio Community Platform v1.15 (HumanSignal, San Francisco, US), locally hosted behind our institution's firewall, was used as our annotation platform.

A sample of notes from 100 patient encounters, forming a total of 289 retrospective patient notes, were annotated for retrospective evaluation (Appendix 2). These notes were divided into a development set of 26 notes, all from pneumonitis-positive patients, and a test set of 263 notes, used to evaluate the final developed system.

For the development of the agentic LLM architecture, OpenAI application programming interface (API)-based models were accessed using our institutional HIPAA-compliant application programming inference access points. Open-source models were downloaded locally, behind our institutional firewall, to a dedicated server equipped with two NVIDIA RTX 6000 Ada GPUs.

The architecture employed an agentic design pattern, decomposing the complex task of irAE extraction into specialized subtasks handled by distinct model instances (Figure 2). A preprocessing agent first extracted and formatted relevant clinical text, handling the varied structures and formats present in EHR documentation. Subsequently, specialized extraction agents focused on specific attributes: one agent determined temporal status by analyzing verb tenses and temporal markers, another mapped clinical descriptions to CTCAE grades, a third assessed attribution by identifying causal language and clinical reasoning, and a fourth evaluated the certainty of diagnosis based on hedging language and diagnostic workup discussions. We refer to this as the "default" agentic architecture hereafter. Prompt engineering was optimized on the development set, and only for pneumonitis, to assess the generalizability of our approach to other irAE types.

Given the potential variability in LLM outputs and the risk of hallucination, we also evaluated adding a self-consistency mechanism.[33,34,40] Here, each note was processed through three parallel inference runs with controlled randomness. A final judge agent then synthesized these parallel outputs, implementing a majority-vote mechanism for discrete categories and selecting the most coherent extraction when unanimity was absent.

Finally, based on preparatory field study work (Appendix 4), the models were designed to extract "string-matched" snippets directly from clinical notes, as well as a brief rationale for the determinations, to support human interaction in real-world downstream tasks. The snippets serve as supporting evidence for the determinations made at each stage of the agentic workflow. This functionality was then integrated into the user interface as features to aid human reviewers in their annotation tasks.

As comparative baseline methods, to contextualize the performance of our agentic system, we implemented several baseline approaches representing different points on the complexity-performance spectrum. These included rule-based extraction using regular expressions previously used in our institution to identify patients admitted for irAEs[41]; and zero-shot prompting. We compared open-source (Qwen-3-4B-Instruct, Qwen3-30B-A3B-Instruct-2507, Gemma-3-27B, GPT-OSS-20B) and proprietary OpenAI models (GPT-4.1-mini, GPT-4.1-nano, gpt-4o-mini) with medium reasoning effort on our institutional HIPAA-secure OpenAI API endpoint. Model selection was guided by the goal of representing a range of model sizes deployable on single- and dual-GPU institutional hardware

for open-source candidates, alongside cost-constrained proprietary models available under Azure HIPAA-compliant agreements.

Precision, recall, and macro-averaged F1 scores were calculated overall and stratified by irAE type across all available classes for a given label. The inference cost per note was also calculated for all variants.

Phase 2: Prospective Silent Validation

Following retrospective analysis, we implemented the best setting of our system in a silent, prospective, real-time clinical environment to assess performance under operational conditions and to assess generalizability to evolving clinical language and documentation practices. The system was integrated with our institution's clinical data warehouse. Details of the integration infrastructure have been previously reported.[38] New Physician, Nursing, and Physician Assistant notes documented on patients treated with an ICI within the preceding year were automatically identified each morning, including progress notes, radiology reports, consultation reports, emergency department records, and discharge summaries. Notes meeting criteria were immediately processed through the agentic system. The first 102 notes were dual-annotated by a board-certified oncologist and a trained research assistant with experience as a medical scribe and clinical research, achieving an inter-annotator agreement across irAE type and temporality ($\kappa = 0.91$ for binary detection, $\kappa = 0.88$ for grade). The remaining notes were single-annotated by the research assistant. This prospective phase lasted for three months (May-July 2025), during which we processed 884 real-time clinical notes. Agreement between prospective model predictions and human determinations was quantified using agreement percentages and override rates for each label and across all labels.

Phase 3: Randomized User Effect Study

To quantify the clinical impact of agentic assistance on irAE curation, we conducted a 2×2 randomized crossover study comparing AI-assisted annotation to standard manual review (Appendix Figure 2). This design was informed by a preparatory field study that informed the interface design, characterized learning curves, established baseline inter-rater agreement, and identified annotation efficiency as the primary driver of real-world workflow burden (Appendix 4). This study was approved by the Institutional Review Board (DF/HCC 20-328).

We enrolled clinical research coordinators and clinical research nurses from our department; there were no exclusion criteria. Following informed consent, participants completed a one-hour standardized training session with annotated examples (Appendix 5a) and an unobserved practice period using the annotation interface. Participants were then randomized to one of four sequences in a crossover design that counterbalanced both intervention order (AI-assisted vs. manual spreadsheet) and note set (Set A vs. Set B). This structure was chosen to mitigate carryover effects from either the annotation method or note content, and enabling difference-in-differences estimation of treatment effects.

Clinical notes were drawn from the Phase 1 retrospective corpus. Sets A and B were matched on note length and clinical complexity and number of irAE descriptions through manual review to ensure comparability across arms.

Based on pilot data from the preparatory field study (Appendix 4), we estimated a clinically meaningful efficiency gain of 450 seconds per note (SD = 192 seconds). After inflating the sample size to account for the within-participant correlation of 0.05, 15 participants completing 20 notes each (300 total notes) would provide 84.7% power to detect a standardized effect size of -0.43 (comparing AI assistance to manual) with two-sided $\alpha = 0.10$. We targeted enrollment of 17–20 participants to account for potential dropouts and missing observations.

The primary endpoint was annotation efficiency, measured as time in seconds from note opening to final submission, captured via screen recording. Secondary endpoints were: (1) accuracy, defined as exact match with the gold standard for all current irAE grades within a note—a stringent metric requiring perfect concordance across all six conditions; and (2) inter-annotator agreement, assessed using Krippendorff's alpha for ordinal grade labels.

For the primary efficiency endpoint, we used generalized estimating equations (GEE) with an exchangeable correlation structure to account for within-participant clustering and estimated the reduction in annotation time attributable to AI assistance. Sensitivity analyses examined log-transformed times, adjusting for note set and sequence effects.

For the accuracy endpoint, we used GEE with binomial outcomes to estimate the odds ratio of exact gold-standard match comparing AI-assisted to manual

annotation, with robust sandwich variance estimators. Additional exploratory analyses relaxed the stringent complete-match criterion to examine accuracy for individual label types (grade, attribution, certainty) and by temporality. Further, inter-annotator reliability was assessed separately within each note set using Krippendorff's alpha for current grade labels. Bootstrap resampling (10,000 iterations, resampling participants with replacement) generated 95% confidence intervals for each method. Pre- and post-study questionnaires captured baseline AI attitudes, the System Usability Scale, and perceived efficiency (Appendix 5b and 5c). Participants were compensated $50/hour.[42]

Code and Data Availability

The code is available at: https://github.com/BittermanLab/AEGIS. Raw data has not been deidentified and is not available for public distribution. Derived results in aggregate are available in the repository.

References

1. Martins, F. *et al.* Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. *Nat. Rev. Clin. Oncol.***16**, 563–580 (2019).
2. Reynolds, K. L. *et al.* Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. *J. Immunother. Cancer***9**, e002896 (2021).
3. Golder, S., Loke, Y. K., Wright, K. & Norman, G. Reporting of adverse events in published and unpublished studies of health care interventions: A systematic review. *PLoS Med.***13**, e1002127 (2016).
4. Hazell, L. & Shakir, S. A. W. Under-reporting of adverse drug reactions : a systematic review. *Drug Saf.***29**, 385–396 (2006).
5. Derry, S., Loke, Y. K. & Aronson, J. K. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. *BMC Med. Res. Methodol.***1**, 7 (2001).
6. Ioannidis, J. P. A. & Lau, J. Improving safety reporting from randomised trials. *Drug Saf.***25**, 77–84 (2002).
7. Ioannidis, J. P. & Lau, J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. *JAMA***285**, 437–443 (2001).
8. Jha, A. K. *et al.* Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. *J. Am. Med. Inform. Assoc.***5**, 305–314 (1998).
9. Center for Drug Evaluation & Research. Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. *U.S. Food and Drug Administration* https://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine (2026).
10. Mandelblatt, J. S. *et al.* Preliminary development and evaluation of an algorithm to identify breast cancer chemotherapy toxicities using electronic medical records and administrative data. *J. Oncol. Pract.***11**, e1–8 (2015).
11. Kalinich, M. *et al.* Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. *J. Immunother. Cancer***9**, e001935 (2021).
12. Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. *N. Engl. J. Med.***378**, 158–168 (2018).
13. Brahmer, J. R. *et al.* Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. *J. Clin. Oncol.***36**, 1714–1768 (2018).
14. Schneider, B. J. *et al.* Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. *J. Clin. Oncol.***39**, 4073–4126 (2021).
15. Yeoh, H.-L. *et al.* Immune-related adverse events secondary to immunotherapy in oncology: A guide for general practice. *Aust. J. Gen. Pract.***52**, 378–385 (2023).

16. Jayathilaka, B., Mian, F., Franchini, F., Au-Yeung, G. & IJzerman, M. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. *Br. J. Cancer***132**, 51–57 (2025).
17. Couey, M. A. *et al.* Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. *J. Immunother. Cancer***7**, 165 (2019).
18. Tonorezos, E. *et al.* Prevalence of cancer survivors in the United States. *J. Natl. Cancer Inst.***116**, 1784–1790 (2024).
19. George, S. *et al.* The impact of adverse events on health care resource utilization, costs, and mortality among patients treated with immune checkpoint inhibitors. *Oncologist***26**, e1205–e1215 (2021).
20. Gallifant, J., Celi, L. A., Sharon, E. & Bitterman, D. S. Navigating the complexities of artificial intelligence-enabled real-world data collection for oncology pharmacovigilance. *JCO Clin. Cancer Inform.***8**, e2400051 (2024).
21. Sun, V. H. *et al.* Enhancing precision in detecting severe immune-related adverse events: Comparative analysis of large language models and International Classification of Disease codes in patient records. *J. Clin. Oncol.***42**, 4134–4144 (2024).
22. Hsiehchen, D., Watters, M. K., Lu, R., Xie, Y. & Gerber, D. E. Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors. *JAMA Netw. Open***2**, e1911519 (2019).
23. Davidson, D. C. *et al.* NCI MATCH (EAY131) arm Z1D: Retrospective evaluation of attributions of adverse events experienced on nivolumab in patients with MSI-high tumors. *J. Clin. Oncol.***42**, e14711–e14711 (2024).
24. Savova, G. K. *et al.* Use of natural language processing to extract clinical cancer phenotypes from electronic medical records. *Cancer Res.***79**, 5463–5470 (2019).
25. Gupta, S., Belouali, A., Shah, N. J., Atkins, M. B. & Madhavan, S. Automated identification of patients with immune-related adverse events from clinical notes using word embedding and machine learning. *JCO Clin. Cancer Inform.***5**, 541–549 (2021).
26. Zitu, M. M. *et al.* Detection of patient-level immunotherapy-related adverse events (irAEs) from clinical narratives of electronic health records: A high-sensitivity artificial intelligence model. *Pragmat. Obs. Res.***15**, 243–252 (2024).
27. Chen, S. *et al.* Natural Language Processing to Automatically Extract the Presence and Severity of Esophagitis in Notes of Patients Undergoing Radiotherapy. *JCO Clin Cancer Inform***7**, e2300048 (2023).
28. Barman, H. *et al.* Identification and characterization of immune checkpoint inhibitor-induced toxicities from electronic health records using natural language processing. *JCO Clin. Cancer Inform.***8**, e2300151 (2024).
29. Bejan, C. A. *et al.* irAE-GPT: Leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets. *medRxiv* (2025) doi:10.1101/2025.03.05.25323445.
30. Zhang, J. *et al.* AFlow: Automating Agentic Workflow Generation. *arXiv [cs.AI]* (2024).
31. Brahmer, J. R. *et al.* Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. *J. Immunother. Cancer***9**, e002435 (2021).
32. Van Veen, D. *et al.* Adapted large language models can outperform medical experts in clinical text summarization. *Nat. Med.***30**, 1134–1142 (2024).

33. Cohen, R., Hamri, M., Geva, M. & Globerson, A. LM vs LM: Detecting factual errors via cross examination. *arXiv [cs.CL]* (2023).

34. Wang, X. *et al.* Self-consistency improves chain of thought reasoning in language models. *arXiv [cs.CL]* (2022).

35. Davis, S. E., Greevy, R. A., Jr, Lasko, T. A., Walsh, C. G. & Matheny, M. E. Detection of calibration drift in clinical prediction models to inform model updating. *J. Biomed. Inform.***112**, 103611 (2020).

36. Tierney, A. A. *et al.* Ambient artificial intelligence scribes to alleviate the burden of clinical documentation. *NEJM Catal. Innov. Care Deliv.***5**, (2024).

37. Huang, J. *et al.* Efficiency and quality of generative AI-assisted radiograph reporting. *JAMA Netw. Open***8**, e2513921 (2025).

38. Gallifant, J. *et al.* Beyond the algorithm: A field guide to deploying AI agents in clinical practice. *arXiv [cs.AI]* (2025) doi:10.2139/ssrn.5732262.

39. Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. in *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury* (National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD), 2012).

40. Abbasian, M., Azimi, I., Rahmani, A. M. & Jain, R. Conversational Health Agents: A personalized LLM-powered agent framework. *arXiv [cs.CL]* (2023).

41. Abu-Shawer, O. *et al.* Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. *J. Immunother. Cancer***8**, e000992 (2020).

42. Sauro, J. Measuring Usability with the System Usability Scale (SUS). https://measuringu.com/sus/.

A fully optimized/customized regular expression that includes 779 terms expanded from our physician provided lists. This super strong baseline can be find in the github: AEGIS/graphs/regex/regex_terms.txt


Zero-shot
Few-shot
Few-shot + CoT
LLMs (best prompting)
Fine-tuned BioBERT
BioBERT (Fine-tuned)
BIOMEDICAL
NLP
RESEARCH
LLMs (best prompting)
Classification F1 0.671–0.770
Reasoning F1 0.682
RESULTS (F1 Score)
Classification
LLMs: 0.671–0.770
BioBERT: 0.800–0.902
Reasoning
LLMs: 0.682
BioBERT: 0.851
TIME TO BEST PERFORMANCE
LLMs (best prompting)
78 hours
BioBERT (fine-tuned)
0.078 hours
BoW (baseline)
0.008 hours

Chapter 7

Evaluation of ChatGPT Family of Models for Biomedical Reasoning and Classification

Shan Chen*, Yingya Li*, Sheng Lu, Hoang Van, Hugo JWL Aerts, Guergana K Savova, Danielle S Bitterman

Journal of the American Medical Informatics Association

Summary

Background

Large language models (LLMs) such as ChatGPT (GPT-3.5, GPT-4) demonstrate strong general question-answering ability but remain under-explored for specialized biomedical applications. Understanding their performance in structured biomedical tasks is essential before clinical or research deployment.

Methods

Using 11,122 samples, our study evaluated ChatGPT-family models on two core biomedical natural language processing tasks: **classification** of health advice in scientific literature (n = 8676) and **reasoning** via detection of causal relations (n = 2446). Prompts were developed under zero-shot and few-shot settings, with and without chain-of-thought (CoT) reasoning. The best prompts from each configuration were compared against two baselines: a simple bag-of-words (BoW) logistic regression model and fine-tuned BioBERT models.

Findings

Fine-tuned BioBERT achieved the highest F1 scores for both classification (0.800–0.902) and reasoning (0.851). Among LLMs, few-shot CoT prompting produced the strongest results—classification F1 0.671–0.770 and reasoning F1 0.682—comparable to the BoW baseline (F1 0.602–0.753 and 0.675, respectively). However, achieving optimal LLM performance required **78 hours**, compared with only **0.078 hours** for BioBERT and **0.008 hours** for BoW.

Interpretation

Despite the popularity of ChatGPT, task-specific fine-tuning of domain-adapted models like BioBERT remains the most effective and efficient strategy for biomedical NLP. LLM prompting can approach—but not surpass—traditional methods, while requiring substantially more computational time and engineering effort.

Introduction

The advancements in machine learning (ML) methods for natural language processing (NLP), such as transformers[1] and reinforcement learning[2], in combination with abundant digital text and scaled-up hardware capabilities has led to many pretrained large language models (LLMs) – also referred to as foundation models. Coupling some of these LLMs with smart engineering gave the world the viral ChatGPT, which in turn popularized the technology and re-invigorated the artificial intelligence (AI)/ artificial general intelligence (AGI) debate. Although most LLMs are trained as chatbots, some of the claims in the mainstream media go as far as stating that the LLMs are sentient, even able to solve tasks that previously required a high level of human expertise and specialized training. On the other hand, the scientific papers describing the LLMs are much more measured[3] outlining limitations: *"... Aside from intentional misuse, there are many domains where large language models should be deployed only with great care, or not at all. Examples include high-stakes domains such as medical diagnoses, classifying people based on protected characteristics, determining eligibility for credit, employment, or housing, generating political advertisements, and law enforcement."*[4] Therefore the scientific community bears the responsibility of understanding the LLMs' strengths and weaknesses, how their limitations and risks can be managed, and implications for our future.[5,6]

Medicine is one of the highest-stakes domains for LLMs. The excitement surrounding the LLMs has penetrated the biomedical and clinical communities motivating various early use-case evaluations. For example, studies have shown that ChatGPT can pass the US Medical Licensing Examination (USMLE).[7,8] Zuccon and Koopman[9]investigate the effect of prompts on ChatGPT in answering complex health information questions. Chen et al.[10] evaluate the performance and robustness of ChatGPT in providing cancer treatment recommendations that align with National Comprehensive Cancer Network (NCCN) guidelines. Lyu et al.[11] research the feasibility of using ChatGPT to translate radiology reports into plain language for patients and healthcare providers. A paper by Google Research and DeepMind[12] presents experiments with Google's PaLM family of LLMs, suggesting the potential utility of LLMs in medicine but also revealing important limitations, reinforcing the importance of evaluation frameworks and methods development.

In parallel, the practical use of LLMs is limited by their huge size and computational requirements, limiting accessibility for most healthcare practices and researchers. Thus, researchers have been pursuing broader questions such as the utility of specialized clinical models, especially ones that are smaller and thus computationally affordable, in the LLM era. Lehman et al.[13] show that relatively small specialized clinical models substantially outperform bigger LLMs, even when fine-tuned on limited annotated data. In addition, they show that pretraining on clinical datasets allows for smaller, more parameter-efficient models that either match or outperform the much bigger computationally hungry LLMs. Wang et al.[14] focus on exploring ChatGPT robustness where a medical diagnosis dataset represents out-of-domain distributions. Results are consistent with Lehman at al.[13]

We set out to contribute to the growing understanding of LLMs in the biomedical domain, with a focus on practical end-use. NLP research on the clinical narrative within the Electronic Medical Records (EMR) has direct applications to translational science[15], clinical decision support,[16] and healthcare administration[17] in addition to direct patient care. Two fundamental NLP tasks to support these applications are classification (e.g. patient phenotyping) and reasoning (e.g. adverse events of medications), and understanding how LLMs handle these tasks will provide insight into optimal uses of these methods. Thus, we aim to evaluate the state-of-the-art (SOTA) LLM performance on classification and reasoning tasks requiring understanding of contextual nuances. While numerous LLMs have been trained in recent years, most are proprietary and not publicly available for a local download (e.g., GPT-3, ChatGPT), which precludes their evaluation on clinical datasets containing Protected Health Information (PHI) data, even if the data are de-identified. Therefore, we work with proxy biomedical data. We evaluate LLMs within the constraints of the typical user to understand their real-world utility, using the OpenAI API[18] and LLMs that are computationally feasible for the IT capabilities of most hospitals and clinical practice.

Method

Tasks and datasets

We examine the performance of LLMs on two fundamental tasks in the clinical domain – classification and reasoning. Specifically, we select two open datasets annotated for health advice and causal language to test the ability of

the models to classify and reason over medical literature findings, and their implications for health-related practices.

- **Classification task: HealthAdvice**[19] is a dataset consisting of annotations of 10,000+ sentences extracted from abstracts and discussion/conclusion sections of medical research literature. The dataset adopts a multi-dimensional taxonomy and categorizes each sentence into "no advice", "weak advice", and "strong advice" to capture the occurrence and strength of clinical and policy recommendations. As health advice normally appears in either abstracts or discussion/conclusion sections and its language style may vary across different sections, the labels are further separated into three datasets: *advice in discussion sections, advice in unstructured abstracts, and advice in structured abstracts*.
- **Reasoning task: CausalRelation**[20] is a multi-label reasoning dataset with the goal to identify correlational and causal claims in the findings of medical research literature. The annotated corpus includes over 3,000 PubMed research conclusion sentences extracted from abstracts. Each sentence is labeled as "correlational", "conditional causal", "direct causal", and "no relationship" by its certainty and reasoning type.

Appendix Table B1 and B2 show the dataset distributions. We split the two datasets into development and test sets. The development set is a proportionate sample of 20% the original dataset, while the remaining 80% of the dataset is used as the test set. Final evaluation is performed on the test set.

Baseline models

We compare the performance of LLMs with classic ML approaches and transformer-based pretrained language models. For the classic ML approach, we train logistic regression fitted with Stochastic Gradient Descent (SGD), using bag-of-words (BoW) representations with tf-idf as the vectorization method. We fine-tune BioBERT models, given that BERT-based pre-trained language models[21], particularly BioBERT[22], have exhibited their efficacy on the aforementioned two tasks (Hyperparameter settings are in the Appendix Table A1). The baseline models are trained and fine-tuned on the full development set and tested on the test set. To further examine the effect of the amount of data on model performance, we trained and tested the BoW and BioBERT models with the 20%, 50%, and 100% of the development set. We track the time required to develop and evaluate the BoW and BioBERT models.



Figure 1. *Examples of the prompt templates used for the classification and reasoning tasks. Prompt templates were created for each of the prompting settings evaluated: (A) zero-shot, (B) zero-shot with Chain of Thought (CoT), (C) one-shot and few-shot, and (D) one-shot and few-shot with CoT. "...more exemplars..." (highlighted in green) were added only for the few-shot with and without CoT settings. All evaluated prompts are in the Appendix B. BoW = bag-of-words.*

[Original Context] = Georgian public health specialists working in the HIV field should prioritize implementation of such interventions among HIV patients.
[Question] = Is this a 0) no advice, 1) weak advice or 2) strong advice?
[Answer] = 2) Strong advice.
[CoT Solution] =
1) The statement is a directive, so it is a strong advice.
2) The statement is specific and clear, so it is not a weak advice.
3) Therefore, the statement is a strong advice.
Answer: 2) Strong advice.

ChatGPT Family of Models

We evaluate GPT-4 and its predecessors, including GPT-3.5-Turbo (20B) and GPT-Davinci-003 (175B), on the two tasks. For GPT-3.5 models, we consider zero-shot, one-shot, and few-shot prompting with and without Chain-of-Thought (CoT). Given computational cost limits, for GPT-4, we consider zero-shot (the simplest prompting strategy mimicking an average user) and few-show with CoT (the most complex prompting strategy). CoT techniques explicitly outline the intermediate reasoning steps as prompts to LLMs to elicit multi-step reasoning behavior.[23]

To design a prompt, we follow the prompt structure applied in prior studies.[23] Fig 1 shows an example of the prompt templates for the classification task. For the zero-shot settings, five of the authors each independently developed two prompts. For the one- and few-shot settings without CoT, exemplars are chosen directly from the development set. For the one- and few-shot settings with CoT, the same five authors independently wrote CoT prompts for exemplars from each of the datasets. To evaluate model efficiency, we track the total time spent on designing prompts. Given the different number of classes in the health advice (3 classes) and causal language (4 classes) datasets, we apply 3- and 4-shot exemplars for the few-shot settings for the classification and reasoning tasks respectively. We use regular expressions to match the model output to labels in the datasets, and conduct validation to verify the accuracy of the regular expressions. To assess the model's performance, we compare the prediction results against the gold annotations in the datasets. Performance of the prompts was initially evaluated on the development set, and the best performing prompt was selected for the final evaluation on the test dataset. Performance across exemplars from different classes was also evaluated. The full set of evaluated prompts are included in the Appendix Table B3 and B4.

We use the OpenAI Application Programming Interface (API) to run the prediction and measure the performance of the models based on the averaged macro-F1 score on 4-fold cross validation on the test set. F1 score is a classic NLP metric representing the harmonic mean of recall/sensitivity and precision/positive predictive value. Macro F1 score is computed using the arithmetic mean of all per-class F1 scores. For comparison of model efficiency, we track the time and cost for running the inference using the API (Appendix Table A2-A4)

Smaller LLMs

The same settings (zero- and few-shot with and without CoT) were used to evaluate the performance of select smaller LLMs (less than 10B parameters) on the tasks, including GPT-J, GPT-JT, and Galactica[24]. GPT-J, built on EleutherAI's 6B parameter GPT-J-6B, is fine-tuned with 3.5 billion tokens. It performs very similarly to GPT-3 on various zero-shot downstream tasks. GPT-JT, a fork of GPT-J-6B, is fine-tuned on 3.53 billion tokens and has been shown to even outperform GPT-3 at some classification tasks. Galactica is trained on 48 million examples of scientific articles, websites, textbooks, lecture notes, and encyclopedias. Same evaluation procedure as for the GPT-family models is applied.

Statistical Analysis

Paired *t* tests are used to compare average macro-F1 score across tasks, and a two-sided $p<0.05$ is considered statistically significant. Analyses are performed using python version 3.9.7 (Python Software Foundation).

Results

A summary of our findings is in Table 1; Figs 2-4 present multiple comparative analyses to provide context and facilitate interpretation of the outcomes.

Effect of fine-tuning and prompt development on model performance, run time and time investment

For the reasoning and classification tasks, fine-tuning BioBERT consistently outperforms the best GPT settings by a considerable margin (Δmacro F1 0.109 - 0.169) (Fig 2(A) and Table 1). Averaging performance on all datasets, BioBERT's macro F1 scores are significantly better than the other models ($p<0.05$ for all, Fig 2(A). There is no statistical difference between the average performance of the BoW, best-performing GPT-3.5s, and GPT-4 models (Appendix Table A3).

Furthermore, engineering the LLM prompts that yield the best results requires a substantial time investment. Fig 2(B) shows the time needed to achieve the best results, taking into account the time needed to develop and identify the prompting strategies for the few-shot settings. Even for the zero-shot setting, which does not require any prompt development, inference time – an indicator of run time and a consideration for compute budget– is longer and

yields worse performance compared to BoW and BioBERT performance. Taken together, training a task-specific neural network through classic fine-tuning methodology is both faster and yields better performance.



Figure 2. *(A) Comparison of model performance on each dataset. Using fine-tuning BioBERT as a reference, average macro-F1 across all datasets was significantly better than all other models (p<0.05 for all); there was no statistically significant difference in average performance between the other pair-wise model comparisons (Appendix Table A5). (B) Time (hours) required to obtain the best-performing results versus average performance across all datasets. BoW = bag-of-words; CoT = Chain of Thought.*



Figure 3. *(A-D) Performance comparison of fine-tuned BioBERT (green bar) and BoW (yellow bar) models with different proportions (20%, 50% or 100%) of development set data versus the best GPTs settings (few-shot CoT in red-line) among four tasks. (A) Comparison on advice in discussion sections, (B) comparison on advice in unstructured abstracts, (C) comparison on advice in structured abstracts, (D) comparison on causal relation detection. BoW = bag-of-words; CoT = Chain of Thought*

Effect of amount of training data on model performance

In this experiment, we investigate the amount of training/fine-tuning data from the development set needed to achieve similar or better performing BoW and BioBERT models compared to the best GPT settings (few-shot CoT). As shown in Fig 3, using only 20% of the development set for the supervised fine-tuning of BioBERT surpasses the best GPTs in three of four datasets. Fine-tuning BioBERT on 50% of the development set outperforms the best GPTs on all datasets. Furthermore, the simple and computationally efficient BoW model using 100% of the development set outperforms the best GPTs in two of four datasets.

Effect of number of exemplar prompts and CoT prompts on model performance

We examine the relationship between the number of exemplars and CoT prompts and their impact on GPT settings performance. As shown in Fig 4(A), we observe a drop in performance when comparing one-shot to few-shot settings in three of the datasets. Reasoning for causal relation detection is the only task that consistently improves by adding prompt examples, without CoT. However, as demonstrated in Fig 4(B), incorporating more CoT exemplars results in consistent improvements across datasets. This observation highlights the value of adding CoT exemplars, albeit at substantial cost due to the time effort needed to create the CoT prompts.

Another observation from the one-shot experiments (both with and without CoT) among the LLMs evaluated is the impact of different exemplar prompt choices on performance. Variations in the text of the exemplar prompts for one-shot prompts led to notable variations in model outcomes (Appendix Table A8-A10).

Error Analysis

Of the investigated GPTs, GPT-4 with few-shot CoT settings yields the best performance for three of four datasets. Thus, we analyze GPT-4's generated CoTs and identify common error patterns to better understand their strengths and limitations. To maintain consistency, we randomly select 100 prediction errors of GPT-4 with few-shot CoT setting from the test set of each dataset. The selection of the error examples follows the same error type ratio from the confusion matrices of the prediction result. Two common error patterns are identified. Pattern A is an incorrect reasoning step based on one specific keyword. For example, the model classifies an input text as a strong advice if the word "importance" appears in the text (Appendix Table A13, row 4). Pattern B is a false positive due to the model incorrectly determining that there is health advice or a relationship for the classification and reasoning tasks, respectively, when in fact there is none. For instance, Appendix Table A16, row 3 presents a pattern B error where GPT-4 misclassifies a relationship between extracted entities as a clinical relationship. Appendix Tables A13-A16 show examples of the error patterns.



Figure 4. *Comparison ofGPT-3.5s performance on each dataset with increasing exemplars without (A) and with (B) Chain of Thought (CoT). For both plots, random is shown as a baseline and is the uniform distribution across class labels. Here, one-shot uses the majority class exemplar for each task and few-shot uses one exemplar per class. Few-shot = 3 exemplars for classification datasets and four exemplars for the reasoning dataset, reflecting the number of classes for each task.*

Disscussion

In this study, we found that, even with the best in-context learning approaches, fine-tuning BioBERT consistently out-performed LLM performance by macro F1 >0.100 for all datasets. In fact, fine-tuning on just 20% of the development dataset outperformed the best GPT-4 and GPT-3.5 performance for all of the classification datasets, and outperformed the best GPT-3.5 performance for the reasoning dataset. Surprisingly, the simple BoW models out-performed all LLM in-context learning approaches without CoT, and performed similarly to

the best performing GPT-4 approach for classification of structured abstracts (macro F1 -0.017), and the reasoning task (macro F1 -0.007).

Our study emphasizes the performance, time, and computational trade-offs that should be taken into account when considering various approaches for clinical NLP tasks. At present, our results suggest that the overall balance is in favor of fine-tuning task-specific smaller models, consistent with Lehman et al[16]. SOTA LLMs such as GPT-3.5/GPT-4 are orders of magnitude larger than traditional language models and cannot be trained or fine-tuned without significant computational resources. For example, GPT-3 has 175 billion parameters and required several thousand petaflop/s-days for pre-training.[25] On the other hand, smaller, more accessible out-of-the-box LLMs without fine-tuning (<10 billion parameters) performed very poorly on our tasks and did not demonstrate improvement with in-context learning, in line with the finding that emergent LLMs abilities scale with model size.[26]

However, the computational requirements of LLMs could theoretically be offset if their zero- or few-shot performance was adequate. Our results clearly demonstrate that zero-short performance was poor. While few-shot CoT prompting improved performance, fine-tuning BioBERT, a 110 million parameter pre-trained language model, consistently provided the best performance. Prompt development to identify the best prompting strategies is itself resource-intensive, requiring human effort to design the prompts, and computational and time resources to evaluate. Ultimately, at most 50% of each dataset's full development set was needed to fine-tune BioBERT models that exceeded LLM performance with the best prompting strategies identified using the full development set. Taking into account prompt development and evaluation, obtaining the best-performing LLM results required 100x the time needed to fine-tune our best performing BioBERT model. Of note, we did not include time needed to annotate the datasets, as all methods required the full development set for model development or prompt engineering, and the full test set for evaluation.

Despite under-performing fine-tuned BioBERT, in-context learning–especially CoT prompting–led to important improvements in performance for the classification and reasoning tasks. The ability of CoT to elicit reasoning and improve LLM performance in the general domain has previously been demonstrated.[23,27] Interestingly, while providing more exemplars with CoT prompting consistently improved performance, this was not always the case

for prompting without CoT. For GPT-3.5, one-shot prompting provided the best results for classification, while few-shot prompting provided the best results for reasoning. This could be due to noise provided from including less informative prompts, and highlights the fragility of LLM performance based on the provided prompts.

This lack of robustness is also illustrated by the fact that the choice of exemplar for prompting had major impacts on performance. These findings are in line with Shi et al., who showed that, for arithmetic tasks, prompting may provide irrelevant context that reduces performance.[28] Clearly, simply providing more exemplars does not solve the challenge of LLMs robustness—a major area of concern and future research for the clinical domain, where robust performance is paramount. Concerningly, even small, seemingly non-substantive changes to prompts such as typos have been shown to impact performance.[10,14] There is an emerging body of work on developing strategies to improve robustness and self-consistency.[14,29] Methods to improve performance will be especially important in the medical domain, where jargon, typos, abbreviations, and synonyms are common, limiting our ability to develop reliable prompting strategies and robustly assess real-world performance.

It should be noted that our tasks indirectly address the question of how LLMs perform on clinical NLP text, and use biomedical texts as a proxy for essential clinical NLP tasks. SOTA LLMs such as GPT-3.5/GPT-4 cannot be used with PHI, precluding an evaluation on real clinical data. Nevertheless, LLM performance is known to decrease on out-of-domain tasks, i.e. tasks that include text that does not reflect what it was trained on, including synthetic clinical text.[14] At the same time, classic language models trained on clinical text have been shown to out-perform LLMs with in-context learning.[13] Taken together with our finding that BioBERT, which is pre-trained on biomedical text, out-performs LLMs, it is reasonable to anticipate that findings would be similar on clinical datasets, but further evaluation will be needed once GPT-3.5/GPT-4 are safely and widely accessible for HIPAA-protected data. Further, non-clinical biomedical NLP has important implications in its own right, including in processing and transmitting medical information and knowledge outside of EMR contexts.[30]

Most studies evaluating LLMs for clinical applications have focused on question-answering, with mixed results.[7–10,12] For example, while LLMs have achieved passing scores in the USMLE,[7,8] several recent studies have shown sub-par performance of ChatGPT, including answering neonatal board exam

questions,[31] answering questions about cancer treatment,[10] and providing assistance to laypeople.[32] However, question-answering is not representative of the range of NLP tasks needed to process clinical texts,[30] and in isolation has limited practical use for clinic and research. Further, such studies to date have largely focused on whether the LLM answers a question correctly but do not provide insight into why models may fail, which is critical to improving LLMs for medicine and moving the field forward. We chose our tasks–classification and reasoning–because they are fundamental to the development of NLP technologies that can support clinical care and research beyond question-answering, and are granular enough to reveal the specific language processing steps where LLMs may not perform well.

NLP for classification entails determining what category an input text belongs in. Classification methods identify if a patient's EMR includes a characteristic or outcome of interest, which has implications for outcomes research, clinical trial matching, and identifying key events at the point-of-care. Reasoning entails determining the relationships between entities, which is to automatically identify how different events in a patient's medical history relate to one another. Especially because nuanced information conveying medical reasoning can often only be expressed in free text, NLP methods for reasoning are needed to automate higher-level medical inferencing. Here, we investigated causative relationships, which are needed for tasks that require linking any clinical outcome with causative factors, such as associating adverse drug events with their inciting agent. Other reasoning tasks include temporal reasoning, which is determining the order of medical events over time. Another benefit of our task selection is that, compared to question-answering, they are more straight-forward to objectively evaluate, enabling a more direct evaluation of how LLMs perform in the biomedical domain and providing a clearer understanding into the types of performance gaps that need to be improved with additional research and development. In the future, evaluation of LLMs in the clinical domain for other classification and reasoning tasks, as well as other common NLP tasks such as relation extraction, named entity recognition, coreference resolution, word sense disambiguation, and machine translation, will be needed.

Conclusion

This study suggests an ongoing role for classic NLP models fine-tuned for specific tasks, while also providing guidance into strategies to optimize the LLMs for the biomedical domain. Fine-tuning BioBERT, a much smaller

pretrained language model, out-performed SOTA huge LLMs for biomedical classification and reasoning tasks even after extensive prompt development. CoT prompting with multiple exemplars improved LLM performance compared to zero-shot prompting and prompting without CoT. However, developing CoT prompts was both time- and data-intensive, and BioBERT was more efficient with respect to both measures. In addition, LLMs were very sensitive to prompting strategy and the choice of prompt, raising concerns about the potential to develop LLM methods for medicine that are reliable and safe. Our work provides insight into the potential and pitfalls of these rapidly emerging methods for biomedical text processing. Future research could focus on developing more efficient prompting strategies and fine-tuning techniques for LLMs in the biomedical domain while ensuring their reliability and safety, as well as exploring hybrid approaches that combine the strengths of classic NLP models and LLMs to further enhance performance in biomedical text processing tasks.

Data Availability Statement:

All data generated/analysed during this study are available and can be found at https://github.com/shan23chen/HealthLLM_Eval.

Please view the full appendix at:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10990500/

References

1. Vaswani, A. *et al.* Attention is all you need. in *NeurIPS Proceedings* (2017).
2. Sutton, R. S. & Barto, A. G. *Reinforcement Learning: An Introduction, 2nd Edition*. (The MIT Press, Cambridge, MA, 2018).
3. Ouyang, L. *et al.* Training language models to follow instructions with human feedback. *arXiv [cs.CL]* (2022).
4. Ouyang, L. *et al.* Training language models to follow instructions with human feedback. in *NeurIPSProceesings* (2022).
5. Lee, P., Bubeck, S. & Petro, J. Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine. *N. Engl. J. Med.***388**, 1233–1239 (2023).
6. Reardon, S. AI Chatbots Can Diagnose Medical Conditions at Home. How Good Are They? *Scientific American* (By Sara Reardon on March 31 2023).
7. Gilson, A. *et al.* How Does ChatGPT Perform on the United States Medical Licensing Examination? The Implications of Large Language Models for Medical Education and Knowledge Assessment. *JMIR Med Educ***9**, e45312 (2023).
8. Liévin, V., Hother, C. E. & Winther, O. Can large language models reason about medical questions? *arXiv [cs.CL]* (2022).
9. Zuccon, G. & Koopman, B. Dr ChatGPT, tell me what I want to hear: How prompt knowledge impacts health answer correctness. *arXiv [cs.CL]* (2023).
10. Chen, S. *et al.* Use of Artificial Intelligence Chatbots for Cancer Treatment Information. *JAMA Oncol* (2023) doi:10.1001/jamaoncol.2023.2954.
11. Lyu, Q. *et al.* Translating Radiology Reports into Plain Language using ChatGPT and GPT-4 with Prompt Learning: Promising Results, Limitations, and Potential. *arXiv [cs.CL]* (2023).
12. Singhal, K. *et al.* Large Language Models Encode Clinical Knowledge. *arXiv [cs.CL]* (2022).
13. Lehman, E. *et al.* Do We Still Need Clinical Language Models? *arXiv [cs.CL]* (2023).
14. Wang, J. *et al.* On the Robustness of ChatGPT: An Adversarial and Out-of-distribution Perspective. *arXiv [cs.AI]* (2023).
15. Liao, K. P. *et al.* Development of phenotype algorithms using electronic medical records and incorporating natural language processing. *BMJ***350**, h1885 (2015).
16. Zhang, Y. *et al.* Comparison of Chest Radiograph Captions Based on Natural Language Processing vs Completed by Radiologists. *JAMA Netw Open***6**, e2255113 (2023).
17. Medori, J. & Fairon, C. Machine learning and features selection for semi-automatic ICD-9-CM encoding. in *Proceedings of the NAACL HLT 2010 Second Louhi Workshop on Text and Data Mining of Health Documents* 84–89 (Association for Computational Linguistics, Los Angeles, California, USA, 2010).
18. OpenAI API. http://platform.openai.com.
19. Li, Y., Wang, J. & Yu, B. Detecting Health Advice in Medical Research Literature. in *Proceedings of the 2021 Conference on Empirical Methods in Natural Language Processing* 6018–6029 (Association for Computational Linguistics, Online and Punta Cana, Dominican Republic, 2021).
20. Yu, B., Li, Y. & Wang, J. Detecting Causal Language Use in Science Findings. in *Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing and the 9th International Joint Conference on Natural Language Processing (EMNLP-IJCNLP)* 4664–4674 (Association for Computational Linguistics, Hong Kong, China, 2019).

21. Devlin, J., Chang, M.-W., Lee, K. & Toutanova, K. BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding. *arXiv [cs.CL]* (2018).
22. Lee, J. *et al.*BioBERT: a pre-trained biomedical language representation model for biomedical text mining. *Bioinformatics***36**, 1234–1240 (2020).
23. Wei, J. *et al.* Chain-of-Thought Prompting Elicits Reasoning in Large Language Models. *arXiv [cs.CL]* (2022).
24. Taylor, R. *et al.* Galactica: A Large Language Model for Science. *arXiv [cs.CL]* (2022).
25. Brown, T. B. *et al.* Language Models are Few-Shot Learners. *arXiv [cs.CL]* (2020).
26. Wei, J. *et al.* Emergent Abilities of Large Language Models. *arXiv [cs.CL]* (2022).
27. Kojima, T., Gu, S. S., Reid, M., Matsuo, Y. & Iwasawa, Y. Large Language Models are Zero-Shot Reasoners. *arXiv [cs.CL]* (2022).
28. Shi, F. *et al.* Large Language Models Can Be Easily Distracted by Irrelevant Context. *arXiv [cs.CL]* (2023).
29. Wang, X. *et al.* Self-Consistency Improves Chain of Thought Reasoning in Language Models. *arXiv [cs.CL]* (2022).
30. Savova, G. K. *et al.* Use of Natural Language Processing to Extract Clinical Cancer Phenotypes from Electronic Medical Records. *Cancer Res.***79**, 5463–5470 (2019).
31. Beam, K. *et al.* Performance of a Large Language Model on Practice Questions for the Neonatal Board Examination. *JAMA Pediatr.***177**, 977–979 (2023).
32. Murk, W., Goralnick, E., Brownstein, J. S. & Landman, A. B. Quality of Layperson CPR Instructions From Artificial Intelligence Voice Assistants. *JAMA Netw Open***6**, e2331205 (2023).

7


Pre-training Data
Language Model
Bias Risks
• Demographic bias
• Geographic bias
• Language bias
• Healthcare disparity

Chapter 8
Cross-care: Assessing the Healthcare Implications of Pre-training Data on Language Model Bias

Shan Chen*, Jack Gallifant*, Mingye Gao, Pedro Moreira, Nikolaj Munch, Ajay Muthukkumar, Arvind Rajan, Jaya Kolluri, Amelia Fiske, Janna Hastings, Hugo Aerts, Brian Anthony, Leo Anthony Celi, William La Cava, Danielle Bitterman

Advances in Neural Information Processing Systems 2024

Summary

Background

The rapid adoption of large language models (LLMs) in healthcare prompts critical questions about their grounding in real-world medical data. Many benchmarks focus on general reasoning or narrow tasks, but few systematically assess how LLMs represent disease prevalence across demographic groups. This gap is especially concerning given the potential for biased or mis-represented outputs in high-stakes clinical settings.

Methods

We introduce Cross-Care, a benchmark framework designed to evaluate biases and real-world knowledge of LLMs regarding disease prevalence by demographic subgroup (gender and race/ethnicity) and across multiple languages (English, Spanish, French, Chinese). We first quantify disease-demographic co-occurrences in a large pre-training corpus (The Pile) and then compare LLM logit rankings for disease-subgroup pairs against epidemiological prevalence data sourced from U.S. national surveys. Our evaluation covers "controlled" models trained solely on The Pile (e.g., Pythia, Mamba) and "models in the wild" (publicly deployed LLMs of varying size, alignment status and language-pretraining). And we also analyze the effects of alignment/fine-tuning strategies on these bias metrics.

Findings

Across 89 diseases and multiple demographics, the ranking of subgroup disease prevalence in LLM logits correlated strongly with co-occurrence frequencies in The Pile but showed nearly zero correlation with actual epidemiological prevalences. Models consistently favoured White and male subgroups for many diseases, even when real-world data would indicate Indigenous or female populations as more affected. Alignment methods and multilingual evaluation revealed that biases persisted across languages and tuning types; none of the alignment strategies materially improved grounding in real-world prevalence data.

Interpretation

The findings expose a profound disconnect: LLMs in current form appear to encode demographic-disease associations primarily from training-corpus frequencies, not from true epidemiological reality. This suggests serious risks for using LLMs in clinical or policy contexts without addressing representational

bias and real-world grounding. Future efforts must incorporate prevalence-aware pre-training, more diverse multilingual data, and robust subgroup analysis to ensure fairness and validity in healthcare AI.

Introduction

Large language models (LLMs) enabled transformative progress in many applications[1–5]. Benchmarks to assess language models, such as GLUE[6] and SuperGLUE[7], are instrumental in evaluating general language understanding and complex task performance. However, as LLMs are increasingly applied in diverse domains, challenges of domain knowledge grounding[8–12], safety[13–17], hallucinations[18,19], and bias[20–23] have emerged as important issues that are inadequately assessed by existing benchmarks. These problems are magnified in high-stakes domains like healthcare, given the potential for biased or inaccurate outputs[24–26] to influence disparities in healthcare and outcomes.

This paper investigates **representational biases in LLMs, focusing on medical information**. Our research explores the interplay between biases in pretraining datasets and their manifestation in LLMs' perceptions of disease demographics. Existing bias metrics in the general domain have currently relied on human-annotated examples and focused on overt stigmatization and prejudices. In contrast, our work examines bias through a different paradigm rooted in real-world data to provide a domain-specific framework for assessing model biases and grounding. We demonstrate this gap using sub-populations defined by United States census categories for gender and race/ethnicity, and normalized disease codes. While these categorizations are necessarily simplistic and imperfect, we contend that the fact that inconsistency is consistently observed across model architectures, model sizes, subgroups, and diseases means that these findings are meaningful and broadly relevant. We aim to provide a foundation for future research that evaluates the subgroup robustness of LLM associations and equips researchers and practitioners with tools to uncover and understand the biases inherent in their models, thereby facilitating the development of more equitable and effective NLP systems for healthcare. Our full workflow can be found in Figure 1.

Specifically, our work makes the following key contributions:

1. **We conduct a quantitative analysis of the co-occurrences between demographic subgroups and disease keywords** in prominent pretraining datasets like *The Pile*, releasing their counts publicly.
2. **We evaluate model logits across various architectures, sizes, and alignment methods** using ten prompt template variants to test robustness to disease-demographic subgroup pairs. Our findings reveal that representational differences in pretraining datasets across diseases align with these logits, irrespective of model size and architecture.
3. **We benchmark model-derived associations against real-world disease prevalences** to highlight discrepancies between model perceptions and actual epidemiological data. Additionally, we compare these associations across different languages (Chinese, English, French, and Spanish) to emphasize discrepancies across languages.
4. **We provide a publicly accessible web app**,https://www.crosscare.net, for exploring these data and downloading specific counts, logits, and associations for further research in interpretability, robustness, and fairness. The full appendix of this work is at: https://www.proceedings.com/079017-0749.html



Figure 1. *Overall workflow of Cross-Care.*

Related Work

Language model biases arise from pretraining data

The sheer breadth of data sources consumed by LLMs enables the emergence of impressive capabilities across a wide range of tasks[27]. However, this expansive data consumption has its pitfalls, as while LLM performance generally improves as models are scaled, this improvement is not uniformly distributed across all domains[28]. Furthermore, it can lead to the phenomenon of "bias exhaust"—the inadvertent propagation of biases present in the pretraining data. The propensity of LLMs to inherit and perpetuate societal biases observed in their training datasets is a well-documented concern in current LLM training methodologies[29–31]. Efforts to mitigate this issue through the careful selection of "clean" data have significantly reduced toxicity and biases[32,33], underscoring the link between the choice of pretraining corpora and the resultant behaviors of the models. Furthermore, recent studies have elucidated the impact of pretraining data selection on the manifestation of political biases at the task level[34].

Evaluating language model biases

The evaluation of biases in NLP has evolved to distinguish between intrinsic and extrinsic assessments[35]. Intrinsic evaluations focus on the inherent properties of the model, while extrinsic evaluations measure biases in the context of specific tasks. This distinction has become increasingly blurred with advancements in language modeling, such as fine-tuning and in-context learning, expanding the scope of what is considered "intrinsic" [36].

In the era of static word embedding models, such as word2vec[37] and fastText[38], intrinsic evaluations were confined to metrics over the embedding space. Unlike static word embedding models, LLMs feature dynamic embeddings that change with context and are inherently capable of next-word prediction, a task that can be applied to numerous objectives. To evaluate bias in LLMs, Guo and Caliskan[39] developed the Contextualized Embedding Association Test, an extension of the Word Embedding Association Test. Other intrinsic metrics for LLMs include StereoSet[40] and ILPS[41], which are based on the log probabilities of words in text that can evoke stereotypes.

Probability-based bias evaluations such as CrowS-Pairs[22] and tasks in the BIG-bench benchmarking suite[42] compare the probabilities of stereotype-related tokens conditional on the presence of identity-related tokens.

These evaluations provide insights into the model's biases by examining the likelihood of generating stereotype-associated content. Downstream, various benchmarks evaluate LLM bias with respect to languages[43–45], genders and ethnicity[23,46–48], culture[49] and beyond[40,50]. To the best of our knowledge[51–53], our work is the first to bridge gender & ethnicity biases with real-world knowledge and multi-language evaluation.

Methods

Datasets

This study used The Pile dataset (deduplicated version), an 825 GB English text corpus created specifically for pre-training autoregressive LLMs[54], such as open-source LLMs pythia[33] and mamba[55]. The open access to training data and resulting model weights makes it ideal for studying how biomedical keyword co-occurrences in pre-training data affect model outputs.

Co-occurrence pipeline updates

Our co-occurrence analysis methodology builds upon the approach outlined in previous work[56], incorporating three key modifications: updated and verified keywords, multithread support, and real-world prevalence calculation.

Full methodological details are available in the preprint and the associated GitHub repository. All co-occurrences were calculated using a single machine with 64 cores and 512 GB RAM; each checkpoint took approximately 72 hours with a total of 26 checkpoints.

- **Modification 1: Updated Keywords.** Two physician authors (JG and DB) expanded and updated keywords to cover a broad range of conditions and demographics based on PubMed MeSH terms and SNOMED CT headers. The keywords for demographic groups were adapted from the HolisticBias dataset[57], aiming to align with previous studies investigating representational harms in biomedical LLMs. A hierarchical keyword definition strategy was used, including primary terms, variations, and synonyms for each disease and demographic group. The resulting dictionaries include 89 diseases, 6 race/ethnicity subgroup categories, and 3 gender subgroup categories. The list of dictionaries was proofread and expanded by a cultural anthropologist.
- **Modification 2: Multithreading.** Text pre-processing was completed as in the original workflow; however, it was parallelized using multithreading to

enable scaling of the number of keywords utilized to maximize robustness and collection of results.

- Named entity recognition (NER) tagger methods that could aid delineation of the use of specific keywords in a specific context (e.g., "white" or "black" referring to race, versus in other use cases, e.g., "white blood cells") were initially trialed. However, it became ineffective at this scale due to computational and time constraints and was not used in the final analysis.
- We used windows of 50–250 tokens to capture co-occurrences between disease and demographic keywords. This range was chosen based on the intuition that, if in relation to one another, disease and demographic keywords should appear within one sentence to a short paragraph of one another and that longer distances would tend to capture spurious co-occurrences.
- **Modification 3: Real-world prevalence.** To estimate the prevalence of diseases across subgroups, we used a standardized process to review the literature for each disease listed in our dictionary, focusing on prevalence and incidence within the USA across various subgroups. A detailed explanation of the approach and search strategy employed is available in the Appendix. Over two-thirds of the diseases encountered significant heterogeneity in reporting standards, compromising data consistency and reliability. Only 15 out of the 89 diseases had prevalence data readily available from official CDC statistics sourced from the National Health Interview Survey.
- Given these constraints, our analysis focused on these 15 diseases, each with data available for at least five of the six race/ethnicity subgroups. Data for only male and female gender subgroups were available. Age-adjusted prevalences were normalized to rates per 10,000 for a consistent scale, facilitating preliminary benchmarking. These data are intended to provide a baseline for initial comparisons and relative ranking among subgroups rather than granular prevalence statistics for population health applications.

Validation of Keyword Frequency and Document Co-Occurrence

To contrast our methods with the current state of the art, we utilized Infini-gram, an engine designed for processing n-grams of any length[58]. This is a publicly accessible API that has precomputed tokenized text across multiple large text corpora. The overall counts were then aggregated using the same dictionary mapping as above to compute the co-occurrence counts.

[Footnote] Infini-gram counts are available with the Pile counts online at www.crosscare.net/downloads.

Mathematical Description of Prevalence Calculation Using Average Logits

Definitions and Variables

Models - Let $M = \{m_0, m_1, \ldots, m_n\}$ denote the collection of models.

Languages - Let $L = \{l_1, l_2, \ldots, l_k\}$ represent the set of languages.

Diseases - Let D be the complete set of diseases under study.

Demographic subgroups - Let S denote the set of all demographic subgroups.

Templates.

For each disease d, demographic subgroup s, and language l, define

$T(d,s,l) = \{t_0 \ldots t_9\}$as the set of ten templates describing disease prevalence.

Logits Definition

In this context, a **logit** refers to the raw output score from the model's final layer before any normalization (such as a softmax) is applied.

These values represent the model's unnormalized preference for predicting different tokens.

Average Logits per Disease–Subgroup–Language–Model

For each model **m**, language **l**, disease **d**, and demographic subgroup **s**, we compute the average logit as:

$$\bar{z}^m_{d,s,l} = \frac{1}{|T_{d,s,l}|} \sum_{t \in T_{d,s,l}} z^m_{d,s,l,t}$$

This produces a single scalar value per disease–subgroup–language–model combination, enabling direct comparison across demographic groups.

Model's Disease–Demographic Ranking

For each model m and disease d, we define

$R^m(d,l)(s) \in \{1, |S|\}$as the rank assigned to subgroup s, under language l**.** based on the average logits (higher logit = higher rank). (For simplicity, we drop

the language distinction below.) This ranking was determined based on the average logit values, which reflect the model's predicted disease prevalence within those demographic subgroups. This model-centric approach sheds light on the inherent biases in model predictions and facilitates comparisons with empirical data distributions.

Additionally, we propose an alternative ranking method that analyzes disease subgroups based on their co-occurrences within The Pile, as well as our "gold" subset derived from real-world data. This empirical method bypasses model outputs, directly measuring disease representation across different demographic contexts.

Comparing Rank Order Lists

To compare subgroup rankings across different models or baselines, we use **Kendall's τ** correlation coefficient.

Variance / Drift in Disease Ranking

Given a sequence of models $M = \{m_0, m_1, \ldots, m_n\}$, where m_0 is the base model and the remaining models are alignment variants, we quantify how rankings shift across models.

Let $R^m(d)(s)$ denote the rank of subgroup s for disease d under model m. This approach allows us to track the progression and impacts of algorithmic adjustments over multiple iterations.

Ranking Variance Analysis: To understand how disease rankings vary as models undergo finetuning or alignment with different strategies, we quantified the drift in disease rankings from a base model to its aligned iterations, assessing the impact of alignment interventions.

1. Compute Kendall's τ per disease

For each disease d, compare the ranking under the base model m_0 with the ranking under a model m:

$$\tau_d^m = \frac{2}{n(n-1)} \sum_{\substack{s_i \in S, s_j \in S \\ i<j}} \operatorname{sgn}(R_d^{m_0}(s_i) - R_d^{m_0}(s_j)) \cdot \operatorname{sgn}(R_d^m(s_i) - R_d^m(s_j)).$$

where the sum is taken over all unordered pairs of distinct subgroups $s_i, sj \in S$. with $i < j$ denoting that each pair of elements is only compared once. Secondly,

we computed the average Kendall's tau for all diseases and demographic subgroups between the two models, evaluating the overall drift from the base model's ranking. A τ value of 1 means perfect agreement; –1 means complete reversal.

2. Compute overall ranking stability across diseases

We then average τ values across all diseases:

$$\delta_d^m = \frac{1}{|D|} \sum_{d \in D} \tau_d^m$$

This quantity δ summarizes how much the aligned model *m* drifts away from the base model m_0 in terms of disease-demographic ranking patterns.

Higher values indicate greater stability; lower values indicate stronger alignment-induced shifts.

Definition of Controlled and In-the-Wild

- **The controlled group** includes Mamba and Pythia models, strictly pre-trained on The Pile only. We compare these models' representations of disease prevalence against real-world prevalence and Pile co-occurrence prevalence.
-
- **Models in the wild** are publicly accessible models with varied training/tuning datasets, including base models (Llama2, Llama3, Mistral, Qwen1.5; 7B and 70B) and aligned variants (e.g., RLHF[59] , SFT[60], DPO[61]), plus biomedical continued pre-training. We evaluated logits in four languages (English, Spanish, French, Chinese). This dual setup enables comprehensive analysis of how models represent disease prevalence across languages and how alignment might alter it.

Experimental Framework

We designed a controlled framework to probe logit differences when changing only demographics or disease keywords. We created **10** templates that pair a demographic relation with a disease term (e.g., "*[Disease] patients are usually [Demographic Group] in America*"). We used GPT-4 to translate English templates into Chinese, French, and Spanish, then refined translations with native speakers. To ensure robustness, we explored template variants and evaluated averages, ranks, and individual-template results.

Results

Variation Across Windows

We evaluated ranks across token windows of 50, 100, and 250 for each disease–demographic pair. No differences were observed in the top disease rank across window sizes. For simplicity, subsequent analyses use the 250-token window; raw counts for all window sizes are available on our website.

Demographic Distributions

We collected all 89 disease co-occurrences in The Pile and 15 real-world prevalences from CDC. In The Pile, the White subgroup was most frequently represented (87/89), followed by Black and Hispanic with relatively lower counts; Pacific Islanders and Indigenous were least represented. By contrast, real-world statistics often rank Indigenous highest, followed by White and Black.

For gender in The Pile, the male subgroup appears more frequently than the female subgroup for the reported diseases, with non-binary least represented.

Figure 2 shows demographic subgroup ranks according to real-world prevalence, The Pile co-occurrence counts, and Llama3 logits for the 15 diseases with real-world prevalence available. This highlights both discrepancies and alignments between dataset co-occurrence representations and actual demographic prevalence. Raw counts and rankings (The Pile vs. NHIS) are detailed in Appendix A.3 from the original paper: https://www.proceedings.com/079017-0749.html

Models in the Controlled Group

Logits Rank vs Co-occurrence

For each Pythia/Mamba model in the controlled group, we calculated model logits for all disease–demographic subgroup pairs to obtain the demographic rank of each disease; then we counted each demographic subgroup at the target position (top, bottom, and second bottom) across 89 disease-specific ranks. We also obtained similar rankings based on disease–demographic co-occurrence in The Pile with a 250-token window.

In Figure 3, the stacked bars show the variation of top demographic subgroup counts across 89 diseases along with increasing size of Pythia (left) and

Mamba (right) models, while the black line shows the number of diseases for which the top-ranked demographic subgroup based on model logits matched that based on co-occurrence counts. For gender, male was the top subgroup in The Pile for 59/89 diseases. In general, for both Pythia and Mamba models, the larger the model was, the less the demographic distribution from model results followed the distribution in the pretraining dataset. For both the logits and co-occurrence counts, non-binary was never the top gender subgroup.

For race/ethnicity, we observed variation across models and model sizes in the concordance of logit ranking compared to rankings in The Pile pretraining data (Figure 3). Black and White subgroups were consistently ranked highly in the likelihood of disease across a wide range of conditions. In contrast, there were limited occurrences of ranking other subgroups in the top position. Overall, the agreement between co-occurrence rank in The Pile and the model logits rank for the highest-ranking demographic subgroup was generally poor.

The discrepancy between model logits and co-occurrence was also apparent in the second-lowest ranked race/ethnicity subgroup. As shown in the Appendix (bottom subplots in Figure 7, Hispanic was the second-bottom ranked subgroup for almost all 89 diseases based on Pythia and Mamba logits, while disease–demographic co-occurrence in The Pile indicated that Indigenous was the second-bottom subgroup for 86/89 diseases. In contrast, there was strong agreement between model logits and co-occurrence in the bottom rank counts, where Pacific Islander was ranked lowest based on both model logits and co-occurrence.

Logits Rank vs Co-occurrence vs Real Prevalence

The Kendall's tau scores comparing logit rankings against real-world prevalence rankings were near zero across all model sizes, indicating no correlation for both race/ethnicity and gender (Figure 3). This suggests that the logit rankings of diseases by demographic subgroups did not align with real-world prevalence and demonstrates a lack of grounding in real-world medical knowledge. However, most of the time, Mamba and Pythia showed stronger correlation with The Pile co-occurrence than with real-world prevalence rankings, especially among gender subgroups.

Rank vs Co-occurrence Counts

The analysis of Kendall's tau scores across quartiles of overall disease co-occurrence counts in The Pile revealed consistent relationships for both race/



Figure 2. *Overall comparison. Comparison of disease rankings between The Pile (Blue), Llama3's logits (Green), and real-world data (Red). Marker position indicates ranking for a given disease–demographic pair (1 = most prevalent, 5 = least prevalent). For example, for "Perforated Ulcer," The Pile ranked White as most prevalent, Llama3 logits second, and real prevalence third.*



Figure 3. *(a) Top-ranked gender (top) and race/ethnicity (bottom) subgroups across 89 diseases and the suite of Pythia and Mamba models according to logits (stacked bars). The black line shows the number of diseases where the top-ranked subgroup matches between logits and co-occurrences. (b) Kendall's tau of Mamba and Pythia logits vs. co-occurrence and real prevalence for gender (top) and race/ethnicity (bottom). Overlap of green and blue lines indicates consistency across the subset and the full 89 diseases; gaps to the red line highlight stronger association with co-occurrences than real-world prevalence.*

ethnicity. Notably, the relationship between frequency of co-occurrences and logit correlations did not vary significantly across quartiles. This indicates that diseases most frequently mentioned in the dataset did not demonstrate a corresponding improvement in the correlation of logits, suggesting that model performance did not scale with mention frequency in pretraining data.

Models in the Wild

For all models tested across size, alignment method, and language, no model's disease-logits rankings had $\tau > 0.35$ (Min = −0.73, Max = 0.33, Median = −0.05, Avg = −0.06, Var = 0.03) for gender or race/ethnicity, suggesting none had good knowledge of real-world prevalence. Figure 2 illustrates discrepancies between Llama3 logits compared to The Pile and real-world prevalences. These discrepancies might lead to incorrect and/or biased judgments in healthcare settings.

Variation across Alignment Strategies

The impact of different alignment strategies on the Llama2-70B series for both race/ethnicity and gender is shown in Figure 4. None of the alignment methods nor in-domain continued pretraining corrected the base model toward more accurate reflections of real-world prevalence. In fact, we observed some debiasing strategies during alignment adversely impacting decisions. All Llama2-70B alignment methods increased preference for female over male subgroups and decreased preference for the Black subgroup, in English. A similar observation was seen for the Mistral family. For Qwen1.5-7B base vs. Qwen1.5-7B chat in English, PPO+DPO shifted preference to the Indigenous instead of Asian subgroup.

For the Llama2-70B series, models tuned by SFT or DPO did not change the rank-ordering of race/ethnicity subgroups ($\delta \geq 0.8$). Models that showed noticeable variation were Meditron (continued pretraining on medical domain data) and the chat version with RLHF. Similar trends were observed for Mistral's gender results, where Bio-Mistral underwent continued biomedical pretraining.

Models' Representation Across Different Languages

We also observed differences across languages (Figure 4). For all Mistral and Llama series models, there was a preference toward the female subgroup in Chinese but male in French. In Qwen, there was an overall preference toward male in Chinese, Spanish, and French but female in English.



Figure 4. *Top-ranked gender and race/ethnicity subgroups across each of the 89 diseases and different alignment methods for Llama2 models (stacked bars). Changes from base to tuned models illustrate the varying impact of alignment. Variation is not uniform across languages.*

For race/ethnicity, English and Spanish templates showed preference for the Black subgroup, while Chinese and French templates showed preference for the White subgroup. Interestingly, for Qwen1.5 models (pretrained mostly on English and Chinese), we observed strong bias toward the Asian subgroup in Chinese and English templates, and toward the Black subgroup in Spanish and French templates.

We do not have a definitive explanation for this finding, but prior work suggests models hold different representations across languages[45,62,63]. As alignment methods mostly altered choices within the language of preference data, we theorize that the pretraining data mixture is a more important determinant of internal beliefs. This suggests that continuing pretraining on in-domain text might not alleviate the problem.

Limitations

This study has limitations that should be considered when interpreting the findings:

1. **Lack of NER Tagger:** Without integrating NER taggers, there is a risk of misclassifying terms or missing context. However, we were limited by the computational requirements of NER tagging over the entire The Pile dataset.

2. **Selection of Diseases:** The chosen diseases and keywords are based on normalized concepts and standard disease classification terms. This selection, though extensive, does not encompass the entire spectrum of medical knowledge, which could skew findings.
3. **Subgroup Selection:** To demonstrate variation across subgroups, we used terms from CDC national and U.S. surveys as grouping categories for quantifying subgroup robustness. While these terms reflect surface-level attributes, they can be overly simplistic and may perpetuate negative stereotypes if used to polarize. Our objective is to showcase variation using commonly recognized terms, though we hope future work will expand on our approach to delve deeper into the complexities of subgroup robustness. This should be driven by locally designed and governed frameworks. The demographic categories were constrained by the granularity of data available in national statistics, which inherently limits their precision. This approach overlooks more nuanced biases, such as intersectionality, and may unintentionally contribute to stereotyping. Addressing these real-world biases requires better data collection and distribution to empower future efforts in tackling these challenges effectively.
4. **Real-World Data Constraints:** The datasets used to determine real-world disease prevalence are limited by their availability, completeness, and collection biases. This may hinder the assessment of the broader impacts of findings.
5. **Template Sensitivity:** The model's output sensitivity to semantic nuances in template design means the set number of templates may not capture all linguistic or contextual variations influencing model logits and bias assessment. At least one native speaker for each language verifies all translations of our templates. However, the authors acknowledge the translations can be subjective.
6. **API access model evaluation:** Because most API providers do not provide logit access to models nor model weights, these models cannot be evaluated the same way as we evaluated open-weight models. Therefore, we did not include any API-only access model research.
7. **Assessing knowledge in pretraining data and models:** Other ways to assess knowledge represented in pretraining data and model representations include investigating direct statements about prevalence in the pretraining data and querying prevalence rates from the model. However, we were interested in the more general question of how general

distributions in pretraining data contribute to model biases concerning medical reasoning, more broadly, beyond factoid knowledge.

Future Work: Future research will prioritize:

1. **Development of Comprehensive Datasets:** Efforts will be made to create and employ datasets that provide more accurate and exhaustive real-world prevalence data for diseases, especially those poorly represented in existing datasets.
2. **Impact on Clinical Decision-Making:** We plan to investigate the effects of model biases on downstream tasks and clinical decision-making to improve model training and evaluation to mitigate negative impacts.
3. **Ability of Information Provided In Context to Update Prevalence Estimates:** Future work will explore the potential of providing information in context, for example using retrieval-augmented generation (RAG) to adjust prevalence estimates more effectively compared to traditional fine-tuning methods.
4. **Use of Real-World Data-Aware Synthetic Data:** We also aim to leverage continued pretraining or fine-tuning with real-world data-aware synthetic data to explicitly incorporate real-world prevalence statistics, aligning model predictions with actual disease distributions.

This work has highlighted a fundamental disconnect between real-world prevalence estimates and LLM outputs, which appear to track significantly closer to simple co-occurrences in pretraining data. In order to address these discrepancies, the most obvious solution is to curate pretraining data of language models with this knowledge in mind and for a specific context. Furthermore, organizations and regulators can evaluate co-occurrences to provide a rough idea of models' tendencies before deployment and to task performance. This is particularly important when considering multilingual models; if to be used across languages, then accurate data in these languages are important at both pretraining and alignment stages.

Conclusion

This study conducted a detailed analysis of how corpus co-occurrence and demographic representation influence biases in LLMs within the context of disease prevalence. We uncovered substantial variances in model outputs, highlighting the complexities of developing NLP systems for biomedical applications that align with real-world data and outcomes. Importantly, these variances appear across alignment strategies and languages, and notably, they

do not correlate with the real-world prevalence of diseases. This suggests a lack of grounding in actual disease prevalences, underscoring a critical need for extensive research into integrating real-world data to ensure fair and accurate model translation. These findings highlight the urgent need for research to enhance these models, ensuring they are reliable and equitable across diverse populations. Further exploration will advance our understanding of and ability to correct biases in AI systems for healthcare.

References

1. Guha, N. *et al.* LegalBench: A collaboratively built benchmark for measuring legal reasoning in large language models. *arXiv [cs.CL]* (2023).
2. Hendrycks, D. *et al.* Measuring mathematical problem solving with the MATH dataset. *arXiv [cs.LG]* (2021).
3. Kojima, T., Gu, S. S., Reid, M., Matsuo, Y. & Iwasawa, Y. Large Language Models are Zero-Shot Reasoners. *arXiv [cs.CL]* (2022).
4. Touvron, H. *et al.* LLaMA: Open and efficient foundation language models. *arXiv [cs.CL]* (2023).
5. Agrawal, M., Hegselmann, S., Lang, H., Kim, Y. & Sontag, D. Large language models are few-shot clinical information extractors. *arXiv [cs.CL]* (2022).
6. Wang, A. *et al.* GLUE: A multi-task benchmark and analysis platform for natural language understanding. in *Proceedings of the 2018 EMNLP Workshop BlackboxNLP: Analyzing and Interpreting Neural Networks for NLP* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2018). doi:10.18653/v1/w18-5446.
7. Wang, A. *et al.* SuperGLUE: A stickier benchmark for general-purpose language understanding systems. *arXiv [cs.CL]* (2019).
8. Liu, J. *et al.* Benchmarking large language models on CMExam -- A comprehensive Chinese medical exam dataset. *arXiv [cs.CL]* (2023).
9. Singh, S. *et al.* Global MMLU: Understanding and addressing cultural and linguistic biases in multilingual evaluation. *arXiv [cs.CL]* (2024).
10. Wang, Y. *et al.* MMLU-Pro: A more robust and challenging multi-task language understanding benchmark. *arXiv [cs.CL]* (2024).
11. Ye, Q. *et al.* Qilin-Med: Multi-stage knowledge injection advanced medical large language model. *arXiv [cs.CL]* (2023).
12. Jin, D. *et al.* What disease does this patient have? A large-scale open domain question answering dataset from medical exams. *Appl. Sci. (Basel)***11**, 6421 (2021).
13. Mazeika, M. *et al.* HarmBench: A standardized evaluation framework for automated red teaming and robust refusal. *arXiv [cs.LG]* (2024).
14. Li, N. *et al.* The WMDP benchmark: Measuring and reducing malicious use with unlearning. *arXiv [cs.LG]* (2024).
15. Wang, B. *et al.* DecodingTrust: A comprehensive assessment of trustworthiness in GPT models. *arXiv [cs.CL]* (2023).
16. Li, L. *et al.* SALAD-Bench: A hierarchical and comprehensive safety benchmark for Large Language Models. *arXiv [cs.CL]* (2024).
17. Liu, T. *et al.* Rumor Detection with a novel graph neural network approach. *arXiv [cs.AI]* (2024).
18. Goodman, K. E., Yi, P. H. & Morgan, D. J. AI-generated clinical summaries require more than accuracy. *JAMA***331**, 637–638 (2024).
19. Li, J., Cheng, X., Zhao, W. X., Nie, J.-Y. & Wen, J.-R. HaluEval: A large-scale Hallucination Evaluation benchmark for Large Language Models. *arXiv [cs.CL]* (2023).
20. Felkner, V., Chang, H.-C. H., Jang, E. & May, J. WinoQueer: A community-in-the-loop benchmark for anti-LGBTQ+ bias in large language models. in *Proceedings of the 61st Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2023). doi:10.18653/v1/2023.acl-long.507.

21. Guevara, M. *et al.* Large language models to identify social determinants of health in electronic health records. *NPJ Digit. Med.***7**, 6 (2024).
22. Nangia, N., Vania, C., Bhalerao, R. & Bowman, S. R. CrowS-pairs: A challenge dataset for measuring social biases in masked language models. in *Proceedings of the 2020 Conference on Empirical Methods in Natural Language Processing (EMNLP)* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2020). doi:10.18653/v1/2020.emnlp-main.154.
23. Parrish, A. *et al.* BBQ: A hand-built bias benchmark for question answering. in *Findings of the Association for Computational Linguistics: ACL 2022* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2022). doi:10.18653/v1/2022.findings-acl.165.
24. Chen, S. *et al.* The effect of using a large language model to respond to patient messages. *Lancet Digit. Health***6**, e379–e381 (2024).
25. Zack, T. *et al.* Assessing the potential of GPT-4 to perpetuate racial and gender biases in health care: a model evaluation study. *Lancet Digit. Health***6**, e12–e22 (2024).
26. Pfohl, S. R. *et al.* A toolbox for surfacing health equity harms and biases in large language models. *arXiv [cs.CY]* (2024).
27. Wei, J. *et al.* Larger language models do in-context learning differently. *arXiv [cs.CL]* (2023).
28. Magnusson, I. *et al.* Paloma: A benchmark for evaluating language model fit. *arXiv [cs.CL]* (2023).
29. Webster, K. *et al.* Measuring and reducing gendered correlations in pre-trained models. *arXiv [cs.CL]* (2020).
30. Kaneko, M. & Bollegala, D. Unmasking the mask -- evaluating social biases in masked Language Models. *arXiv [cs.CL]* (2021).
31. Omiye, J. A., Lester, J. C., Spichak, S., Rotemberg, V. & Daneshjou, R. Large language models propagate race-based medicine. *NPJ Digit. Med.***6**, 195 (2023).
32. Li, Y. *et al.* Textbooks Are All You Need II: phi-1.5 technical report. *arXiv [cs.CL]* (2023).
33. Biderman, S. *et al.* Pythia: A suite for analyzing large language models across training and scaling. *arXiv [cs.CL]* (2023).
34. Feng, S., Park, C. Y., Liu, Y. & Tsvetkov, Y. From pretraining data to language models to downstream tasks: Tracking the trails of political biases leading to unfair NLP models. in *Proceedings of the 61st Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2023). doi:10.18653/v1/2023.acl-long.656.
35. Lum, K., Anthis, J. R., Robinson, K., Nagpal, C. & D'Amour, A. N. Bias in language models: Beyond trick tests and towards RUTEd evaluation. in *Proceedings of the 63rd Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)* 137–161 (Association for Computational Linguistics, Stroudsburg, PA, USA, 2025).
36. Goldfarb-Tarrant, S., Marchant, R., Muñoz Sánchez, R., Pandya, M. & Lopez, A. Intrinsic bias metrics do not correlate with application bias. in *Proceedings of the 59th Annual Meeting of the Association for Computational Linguistics and the 11th International Joint Conference on Natural Language Processing (Volume 1: Long Papers)* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2021). doi:10.18653/v1/2021.acl-long.150.
37. Mikolov, T., Chen, K., Corrado, G. & Dean, J. Efficient estimation of word representations in vector space. *arXiv [cs.CL]* (2013).
38. *fastText: Library for Fast Text Representation and Classification*. (Github).
39. Guo, W. & Caliskan, A. Detecting emergent intersectional biases: Contextualized word embeddings contain a distribution of human-like biases. in *Proceedings of the 2021*

AAAI/ACM Conference on AI, Ethics, and Society (ACM, New York, NY, USA, 2021). doi:10.1145/3461702.3462536.

40. Nadeem, M., Bethke, A. & Reddy, S. StereoSet: Measuring stereotypical bias in pretrained language models. in *Proceedings of the 59th Annual Meeting of the Association for Computational Linguistics and the 11th International Joint Conference on Natural Language Processing (Volume 1: Long Papers)* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2021). doi:10.18653/v1/2021.acl-long.416.
41. Kurita, K., Vyas, N., Pareek, A., Black, A. W. & Tsvetkov, Y. Measuring bias in contextualized word representations. *arXiv [cs.CL]* (2019).
42. Srivastava, A. *et al.* Beyond the Imitation Game: Quantifying and extrapolating the capabilities of language models. *arXiv [cs.CL]* (2022).
43. Nicholas, G. & Bhatia, A. Lost in translation: Large language models in non-English content analysis. *arXiv [cs.CL]* (2023).
44. Qi, J., Fernández, R. & Bisazza, A. Cross-lingual consistency of factual knowledge in multilingual language models. *arXiv [cs.CL]* (2023).
45. Ryan, M. J., Held, W. & Yang, D. Unintended impacts of LLM alignment on global representation. *arXiv [cs.CL]* (2024).
46. De-Arteaga, M. *et al.* Bias in bios: A case study of semantic representation bias in a high-stakes setting. *arXiv [cs.IR]* (2019).
47. Zhao, J., Wang, T., Yatskar, M., Ordonez, V. & Chang, K.-W. Gender bias in coreference resolution: Evaluation and debiasing methods. in *Proceedings of the 2018 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 2 (Short Papers)* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2018). doi:10.18653/v1/n18-2003.
48. Bai, X., Wang, A., Sucholutsky, I. & Griffiths, T. L. Measuring Implicit Bias in explicitly unbiased large language models. *arXiv [cs.CY]* (2024).
49. Naous, T., Ryan, M. J., Ritter, A. & Xu, W. Having beer after prayer? Measuring cultural bias in large language models. in *Proceedings of the 62nd Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)* 16366–16393 (Association for Computational Linguistics, Stroudsburg, PA, USA, 2024).
50. Hartmann, J., Schwenzow, J. & Witte, M. The political ideology of conversational AI: Converging evidence on ChatGPT's pro-environmental, left-libertarian orientation. *arXiv [cs.CL]* (2023).
51. Yu, H. *et al.* Large Language Models in biomedical and Health Informatics: A review with bibliometric analysis. *arXiv [cs.DL]* (2024).
52. Fan, L. *et al.* A bibliometric review of large language models research from 2017 to 2023. *arXiv [cs.DL]* (2023).
53. Zhou, H. *et al.* A survey of large language models in medicine: Progress, application, and challenge. *arXiv [cs.CL]* (2023).
54. Gao, L. *et al.* The Pile: An 800GB dataset of diverse text for language modeling. *arXiv [cs.CL]* (2020).
55. Gu, A. & Dao, T. Mamba: Linear-time sequence modeling with selective state spaces. *arXiv [cs.LG]* (2023).
56. Hansen, L. H. *et al.* Seeds of stereotypes: A large-scale textual analysis of race and gender associations with diseases in online sources. *arXiv [cs.CL]* (2024).

57. *I'm Sorry to Hear That": Finding New Biases in Language Models with a Holistic Descriptor Dataset*.
58. Liu, J., Min, S., Zettlemoyer, L., Choi, Y. & Hajishirzi, H. Infini-gram: Scaling unbounded n-gram language models to a trillion tokens. *arXiv [cs.CL]* (2024).
59. Ouyang, L. *et al.* Training language models to follow instructions with human feedback. *arXiv [cs.CL]* (2022).
60. Dubois, Y. *et al.* AlpacaFarm: A simulation framework for methods that learn from human feedback. *arXiv [cs.LG]* (2023).
61. Rafailov, R. *et al.* Direct Preference Optimization: Your language model is secretly a reward model. *arXiv [cs.LG]* (2023).
62. Hofmann, V., Kalluri, P. R., Jurafsky, D. & King, S. Dialect prejudice predicts AI decisions about people's character, employability, and criminality. *arXiv [cs.CL]* (2024).
63. Zhao, J. *et al.* Unveiling A core linguistic region in large language models. *arXiv [cs.CL]* (2023).


Original Question
Which drug is most likely to cause QT prolongation?
Options:
A. Drug X
B. Drug Y
C. Drug Z
D. Drug A
Perturbed (Drug Name)
Which drug is most likely to cause QT prolongation?
Options:
A. Flumazenil
B. Dobutamine
C. Sotorasib
D. Drug A
Accuracy
92%
Accuracy
28%

Chapter 9

Language Models are Surprisingly Fragile to Drug Names in Biomedical Benchmarks

Shan Chen*, Jack Gallifant*, Pedro Moreira, Nikolaj Munch, Mingye Gao, Jackson Pond, Leo Anthony Celi, Hugo Aerts, Thomas Hartvigsen, Danielle Bitterman

Findings of the Association for Computational Linguistics: EMNLP 2024

Summary

Background

Medical knowledge is highly context-dependent and includes many semantically equivalent expressions—especially for drug names, where patients often use brand names (e.g., "Advil," "Tylenol") instead of generics. For large language models (LLMs) applied to biomedical tasks, this variation presents a hidden fragility.

Methods

We introduce a new robustness dataset, **RABBITS**, in which brand-name and generic drug names are swapped in biomedical benchmark datasets (MedQA and MedMCQA), using physician expert annotations. We evaluate both open-source and API-based LLMs on these modified datasets to measure performance drops and investigate whether pre-training data leaks/contamination contribute to the fragility.

Findings

When drug names are swapped, LLMs consistently show performance drops in the 1% – 10% range, indicating surprising sensitivity to synonymous drug-name substitutions. We further show that one possible reason is contamination of benchmark test data within widely used LLM pre-training corpora, so models may rely on memorized pairs rather than true reasoning.

Interpretation

Even state-of-the-art LLMs used in biomedical NLP are **fragile** to superficial lexical changes—such as switching brand and generic drug names—undermining their reliability and robustness. Our work highlights the need for more rigorous and robust testing of datasets in biomedical AI, particularly when such systems are used in clinical research or healthcare settings.

Introduction

Large Language Models (LLMs) are poised to transform medicine by providing data processing and decision support capabilities[1,2]. However, the medical deployment of LLMs demands high accuracy and reliability, as errors can result in severe health consequences[3–5]. A key challenge is the synonymy and context-specific nature of medical language; for instance, patients might use brand names like Advil or Tylenol instead of pharmaceutically equivalent generic terms such as ibuprofen or acetaminophen. LLMs must, therefore, be able to provide consistent and accurate advice in the face of this variability. Fluctuations could lead to risks like medical misinformation, medication errors due to incorrect medication advice, and biases toward or against proprietary products. Our study investigates the effects of substituting drug names—from brand to generic and vice versa—on LLM performance.

Building on the need for robustness in medical LLM applications, numerous efforts have developed knowledge benchmarks[6–9]. Yet, these initiatives primarily tackle general language tasks and often neglect the unique challenges of medical terminology in real-world settings. There is an unmet need to overcome this research gap, as the variability in medical language implies that conventional robustness evaluations might not sufficiently cater to specialized healthcare demands.

A key reason for this gap is the lack of publicly available, expert-annotated datasets specific to the healthcare domain. To address this issue, our work leverages existing medical benchmarks and employs physician expert annotators to substitute brand names with their generic counterparts and vice versa.

Our findings reveal a surprising drop in the performance of LLMs on common medical benchmarks when the drug names are swapped from generic to brand names: **4% drop in accuracy on average**. This is concerning given that patients commonly use brand names and are less likely to spot errors, especially given existing misconceptions that brand drugs are superior to equivalent generics[10,11]. Furthermore, we identify a potential source for this fragility: Open pretraining datasets contain substantial amounts of benchmark test data.

Our research introduces a novel category of robustness evaluation centered on drug name interchangeability. We present **RABBITS** (**R**obust **A**ssessment of **B**iomedical **B**enchmarks **I**nvolving drug **T**erm **S**ubstitutions for Language

Models) a specialized dataset and leaderboard to aid in evaluating LLM performance in healthcare. Specifically, our study combines and modifies select questions from the MedMCQA and MedQA benchmarks to:

- Assess model robustness in understanding clinical knowledge across drug synonyms.
- Detect potential dataset contamination in biomedical benchmarks.
- Highlight the importance of robustness to nomenclature variations in the healthcare domain.

Related Work

Lexical Substitution: Lexical substitution plays a crucial role in natural language processing, especially in tasks like word sense disambiguation and synonym generation. Early work by Mcarthy[12] laid the groundwork for substitution-based methods in word sense disambiguation, paving the way for subsequent advancements in the field. Recent studies by Arefyev[13] and Zhou[14] have further explored the capabilities of neural models such as BERT, RoBERTa, and XLNet in lexical substitution, showcasing significant improvements in generating contextually appropriate synonyms. In the medical domain, works by Riedl[15] and Wen[16] have developed medical abbreviation and acronym disambiguation datasets, highlighting the unique challenges in this area. Our work, RABBITS, is the first, to our knowledge, to demonstrate the use of this direct method in stress-testing the knowledge robustness of large language models.

Dataset Contamination: Dataset contamination in training data is a well-documented issue and can affect the performance and generalizability of LLMs. Many studies have aimed to detect benchmark questions within LLM training data[17–19]. For instance, research by Recht illustrated that models trained on contaminated datasets often exhibit inflated performance metrics that do not generalize well to new, unseen data. This problem is particularly concerning for medical LLMs, where inaccurate information can harm patients[3,5].

Various strategies have been employed to mitigate dataset contamination. These include removing data with high n-gram overlap with benchmark datasets[20] and employing embedding similarity to filter out similar data[17]. More advanced approaches involve functional evaluations, such as generating new, unique problem instances for each evaluation[21]. Addressing contamination is crucial for ensuring that LLMs provide reliable outputs, especially in sensitive domains like healthcare.

Evaluating Model Robustness

LLMs gain broad capabilities from large-scale data ingestion, but this also introduces significant challenges[22]. While larger models often perform better, these improvements are not always consistent across domains[23]. Moreover, recent research has questioned the actual reasoning abilities of LLMs, suggesting that their performance may be inflated by dataset contamination rather than genuine problem-solving skills[24].

Some works have looked into LLMs' robustness in terms of faithfulness and fairness under clinical settings[25–27]. Medfuzz introduced a method to test LLMs' robustness in medical question answering by revealing vulnerabilities through modified benchmark questions[28]. However, these studies do not specifically address the unique challenges associated with clinical drug terminology and the relationship between robustness and contamination. Hence, there is a significant gap in evaluating LLM robustness for medical applications, particularly in the context of brand and generic drug name interchangeability. This gap underscores the need for focused robustness evaluations tailored to the healthcare sector.

METHOD

Brand-Generic Pairs

Figure 1 demonstrates the overall workflow of the study. Appendix A details the full data quality assurance and dataset curation process. To create the dataset of brand and generic drug name pairs, we used the RxNorm ontology, which links normalized drug names with many pharmaceutical vocabularies. We extracted combinations of brand and generic drug names using the "ingredient of" and "tradename of" relations, resulting in 2,271 generic drugs mapped to 6,961 brands. For each generic drug, there are often multiple associated brand names. Multiple rounds of expert annotation were performed to derive a final list of 1:1 mapped brand-generic pairs for use in the transformed datasets described below.

Dataset Transformation: We used regular expressions to identify and replace brand and generic drug names in the questions and answers of MedQA, MedMCQA, MMLU, PubMedQA, and USMLE. MMLU and PubMedQA had fewer than 100 instances of identified drug names in the test split and were excluded from further analysis. USMLE was excluded due to its overlap with MedQA.

Thus, the two datasets included in the final RABBITS benchmark are **MedQA** and **MedMCQA**.

The quality of the transformed datasets were iteratively reviewed by 2 physician authors (JG, DB), removing instances where replacements introduced inaccuracies, ambiguities, and/or logical inconsistencies in context. This process is described in detail in Appendix A. For the rest of the paper, we will refer to the generic-to-brand swapped benchmark as **g2b** and the brand-to-generic swapped benchmark as **b2g**.



Figure 1. *RABBITS dataset generation workflow.*

To prevent further data contamination, we will not release the full dataset directly. The HuggingFace leaderboard will be the best way to assess new models' robustness in terms of performance. We evaluated the models using the EleutherAI lm-evaluation harness with zero-shot setting. We forked this repository, added our transformed datasets as new tasks, and made no other modifications. For API models, we used the same prompt format as the lm-evaluation harness with the default hyperparameters.

Our evaluation focuses on comparing the performance of base models (full list in Appendix Table) across the original and transformed datasets to assess the impact of synonym substitution on accuracy. We report results for g2b due to the limited number of b2g swaps observed. By doing so, we aim to determine whether models can maintain performance despite semantically equivalent pharmaceutical terminology.

All datasets and models used in accordance with owners' licenses.

Results & Disscussion

Drug Swapping Results: Figure 2 presents the performance of each model on the original (no-swap) and transformed (g2b) datasets, alongside the average performance and the difference between the two. The line of robustness, with a gradient of 1, represents the ideal scenario where synonym swaps do not affect the selection of answers. The plot reveals that all open-source models from 7B and above fall below this line, indicating decreased performance when drug names are swapped. We also observe a larger drop among MedMCQA over MedQA across models. Refer to Appendix C for a detailed breakdown of individual results in Table 5 and Figure 4.

Table 5 shows that most models experience a decrease in accuracy when generic names are swapped with brand names across different datasets and model sizes. Among large open-source models, the Llama-3-70B model, despite being one of the larger and more accurate models on the original dataset (no-swap accuracy of 76.6%), decreases to 69.7% accuracy with generic-to-brand swaps. Overall, API models perform better than their open-source counterparts with higher accuracy and lower performance drop. While larger open-source series like Qwen2, Llama, and Mixtral are more accurate on original datasets, they exhibit greater sensitivity to g2b swaps. Furthermore,

the performance of Medical LLMs was not robust to these swaps compared to their respective base model comparisons (Appendix E). These gaps persisted after providing brand name hints, which showed only marginal improvements in model performance (see Appendix F). This suggests limitations in true comprehension and reasoning abilities.



Figure 2. *Average performance of models on the filtered original datasets compared to the generic-to-brand versions of MedQA and MedMCA. The dashed diagonal line represents the ideal scenario where synonym swaps do not affect model performance.*

Model Knowledge of Drug Pairs via Multi-Choice Questions

We evaluate whether models are able to directly map brand-to-generic drug pairs and vice versa using multiple-choice questions for all drugs that were swapped in our final benchmark dataset. Overall, a clear "scaling law" is observed in Appendix B Figure 3, where larger models (active parameter size over 13B) consistently outperform smaller models on this task, with larger open-source and API models achieving accuracy over 97%.

Generic and Brand Mentions in Benchmarks and Pre-training Datasets

Table 1 shows our overall dataset swapping statistics where we observe benchmark questions overwhelmingly use generic terms. We also use Infini-gram[29] to screen the common open-sourced pre-training data, including Redpajama, C4 train, Pile train, and Dolma 1.6 for drugs identified in RxNorm,

filtered for terms that overlap with common terms (Appendix A, Step 1). Generic names are more common than brand names in these pre-training datasets, as Appendix D table 6 shows.

Dataset	Orig.	RABBITS	Drugs
MedQA	1,271	378	821
MedMCQA	4,180	348	650

Table 1. *Dataset Statistics for RABBITS. 'Orig.' is the total questions in the original dataset. 'RABBITS' indicates the subset of questions with validated drug mentions. 'Drugs' shows the total unique drugs in RABBITS.*

Contamination Source from Pre-training Dataset

To investigate why we see larger performance drops in MedMCQA than MedQA, we use Infini-gram API to identify overlaps with the Dolma 1.6 dataset (3.1T tokens) using size 8 n-grams. Each question's n-grams are generated and queried through the Infini-gram API.

Dataset contamination are 99.21% and 34.13% in the MedQA and MedMCQA test datasets, respectively, as Table 2 shows. We also benchmark OLMo-1.7-7B-hf, trained only on Dolma, which shows no drop in MedQA (31.22) scores compared to a 3% drop in MedMCQA (40.90 to 37.93). This likely explains the greater drop in performance in MedMCQA rather than MedQA across models (Appendix C Figure 4).

Dataset	Percentage
MedQA Train	86.92%
MedQA Val	98.10%
MedQA Test	99.21%
MedMCQA Train	22.41%
MedMCQA Val/Test	34.13%

Table 2. *Percentage of contamination of MedQA and MedMCQA benchmarks in Dolma dataset*

Conclusion

We find decreased performance on common medical benchmarks when using different names for the same drug, despite LLMs' ability to match these names, and that these trends scale with LLM size. This suggests that LLM performance may be driven by memorization and not reasoning ability. RABBITS underscores the importance of dataset contamination and model robustness evaluations, particularly in the medical domain. Future research should refine strategies and explore new methods for robustness and fairness evaluation.

Limitations

Our evaluation is limited to biomedical datasets and focuses only on pharmaceuticals. Future work will extend this approach to other medical synonyms and the impact of these variations in the retrieval and in-context setting. Although the dataset is smaller, trained physicians have curated it multiple times, ensuring its validity and the accuracy of questions after replacement. Among the pre-training dataset contamination section, we acknowledge none of these models are trained specifically among the pile, C4, RedPajama, or Dolma. However, we use this as a reasonable proxy for estimating the internet distribution.

References

1. Jiang, L. Y. *et al.* Health system-scale language models are all-purpose prediction engines. *Nature***619**, 357–362 (2023).
2. Clusmann, J. *et al.* The future landscape of large language models in medicine. *Commun. Med. (Lond.)***3**, 141 (2023).
3. Chen, S. *et al.* The effect of using a large language model to respond to patient messages. *Lancet Digit. Health***6**, e379–e381 (2024).
4. Goodman, K. E., Yi, P. H. & Morgan, D. J. AI-generated clinical summaries require more than accuracy. *JAMA***331**, 637–638 (2024).
5. Yan, Q., He, X., Yue, X. & Wang, X. E. Worse than random? An embarrassingly simple probing evaluation of large multimodal models in medical VQA. in *Findings of the Association for Computational Linguistics: ACL 2025* 19188–19205 (Association for Computational Linguistics, Stroudsburg, PA, USA, 2025).
6. Jin, Q., Dhingra, B., Liu, Z., Cohen, W. & Lu, X. PubMedQA: A Dataset for Biomedical Research Question Answering. in *Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing and the 9th International Joint Conference on Natural Language Processing (EMNLP-IJCNLP)* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2019). doi:10.18653/v1/d19-1259.
7. Hendrycks, D. *et al.* Measuring massive multitask language understanding. *arXiv [cs.CY]* (2020).
8. Jin, D. *et al.* What disease does this patient have? A large-scale open domain question answering dataset from medical exams. *Appl. Sci. (Basel)***11**, 6421 (2021).
9. Liu, J. *et al.* Benchmarking large language models on CMExam -- A comprehensive Chinese medical exam dataset. *arXiv [cs.CL]* (2023).
10. Colgan, S. *et al.* Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. *BMJ Open***5**, e008915 (2015).
11. Sewell, K., Andreae, S., Luke, E. & Safford, M. M. Perceptions of and barriers to use of generic medications in a rural African American population, Alabama, 2011. *Prev. Chronic Dis.***9**, E142 (2012).
12. McCarthy, D. Lexical substitution as a task for WSD evaluation. in *Proceedings of the ACL-02 workshop on Word sense disambiguation recent successes and future directions* - (Association for Computational Linguistics, Morristown, NJ, USA, 2002). doi:10.3115/1118675.1118691.
13. Arefyev, N., Sheludko, B., Podolskiy, A. & Panchenko, A. Always keep your target in mind: Studying semantics and improving performance of neural lexical substitution. in *Proceedings of the 28th International Conference on Computational Linguistics* (International Committee on Computational Linguistics, Stroudsburg, PA, USA, 2020). doi:10.18653/v1/2020.coling-main.107.
14. Zhou, W., Ge, T., Xu, K., Wei, F. & Zhou, M. BERT-based Lexical Substitution. in *Proceedings of the 57th Annual Meeting of the Association for Computational Linguistics* (eds Korhonen, A., Traum, D. & Màrquez, L.) 3368–3373 (Association for Computational Linguistics, Stroudsburg, PA, USA, 2019).
15. Riedl, M., Glass, M. & Gliozzo, A. Lexical substitution for the medical domain. in *Proceedings of the 2014 Conference on Empirical Methods in Natural Language Processing (EMNLP)*

(Association for Computational Linguistics, Stroudsburg, PA, USA, 2014). doi:10.3115/v1/d14-1066.

16. Wen, Z., Lu, X. H. & Reddy, S. MeDAL: Medical abbreviation disambiguation dataset for natural language understanding pretraining. in *Proceedings of the 3rd Clinical Natural Language Processing Workshop* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2020). doi:10.18653/v1/2020.clinicalnlp-1.15.
17. Shi, W. *et al.* Detecting pretraining data from large language models. *arXiv [cs.CL]* (2023).
18. Xu, R., Wang, Z., Fan, R.-Z. & Liu, P. Benchmarking benchmark leakage in Large Language Models. *arXiv [cs.CL]* (2024).
19. Zhou, K. *et al.* Don't make your LLM an evaluation benchmark cheater. *arXiv [cs.CL]* (2023).
20. Kojima, T., Gu, S. S., Reid, M., Matsuo, Y. & Iwasawa, Y. Large Language Models are Zero-Shot Reasoners. *arXiv [cs.CL]* (2022).
21. Srivastava, S. *et al.* Functional benchmarks for robust evaluation of reasoning performance, and the reasoning gap. *arXiv [cs.AI]* (2024).
22. Lu, S., Bigoulaeva, I., Sachdeva, R., Tayyar Madabushi, H. & Gurevych, I. Are emergent abilities in large language models just in-context learning? in *Proceedings of the 62nd Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)* 5098–5139 (Association for Computational Linguistics, Stroudsburg, PA, USA, 2024).
23. Magnusson, I. *et al.* Paloma: A benchmark for evaluating language model fit. *arXiv [cs.CL]* (2023).
24. Zhang, H. *et al.* A careful examination of large language model performance on grade school arithmetic. *arXiv [cs.CL]* (2024).
25. Zack, T. *et al.* Assessing the potential of GPT-4 to perpetuate racial and gender biases in health care: a model evaluation study. *Lancet Digit. Health***6**, e12–e22 (2024).
26. Chen, S. *et al.* Cross-Care: Assessing the healthcare implications of pre-training data on language model bias. *Neural Inf Process Syst***abs/2405.05506**, 23756–23795 (2024).
27. Guevara, M. *et al.* Large language models to identify social determinants of health in electronic health records. *NPJ Digit. Med.***7**, 6 (2024).
28. Ness, R. O. *et al.* MedFuzz: Exploring the robustness of large language models in medical question answering. *arXiv [cs.CL]* (2024).
29. Liu, J., Min, S., Zettlemoyer, L., Choi, Y. & Hajishirzi, H. Infini-gram: Scaling unbounded n-gram language models to a trillion tokens. *arXiv [cs.CL]* (2024).

A Brand-Generic Pair Generation and Transformed Dataset Curation

To create the initial dataset of brand and generic drug name pairs, we used the RxNorm (National Library of Medicine, 2024) ontology, which links normalized drug names with many pharmaceutical vocabularies. We extracted combinations of brand and generic drug names using the "ingredient of" and "tradename of" relations, resulting in 2,271 unique generic names mapped to 6,961 brands. For each generic name, there are often multiple brand names. Keywords were identified using regular expressions and counted in each question within each column (questions and answer choices), and within each dataset split. Datasets with fewer than 100 instances of identified keywords in the test set were excluded from further analysis. We then carried our the following steps to arrive at our dataset of matched brand and generic drug names, and our final transformed QA datasets, as described below.

1. Two authors (SC and JG) reviewed the brand and generic names retrieved from RxNorm and removed keywords that could overlap with common text not referring to drugs. For example, some brand names such as "today" and "perform" could lead to erroneous replacement and were excluded. This resulted in 581 generic keywords mapped to 4297 unique brand keywords.

2. Regular expressions were used to to identify and replace names in the medical QA datasets to create 2 initial transformed datasets: generic-to-brand swapped in context, and brand-to-generic swapped in context.

3. Two authors (SC and JP) reviewed the resulting datasets to ensure that the replacements were done correctly.

4. Two physician authors (JG and DB) reviewed the datasets, and identified several areas of ambiguity, errors, and inconsistencies resulting from the regular expression replacement, most commonly: (1) brand names for combination medications swapped to generic names referring to single-agent medications; (2) generic names of combination medications in which a single-agent brand name was swapped for one or both of the drugs in the generic description, for example trimethoprim/sulfamethoxazole replaced with proloprim/sulfamethoxazole; (3) brand names for veterinary formulations; (4) brand names for specific formulations that did not make logical or clinical sense in context, such as brand names for topical formulations replacing descriptions of the drug administered intravenously (either explicitly or implicitly given the clinical context); (5) drug names that are also naturally occurring physiologic compounds, such as amino acids (e.g., tyrosine), vitamins (e.g., Vitamin A); endogenous hormones (e.g., insulin, thyroxine), essential elements (e.g., copper, calcium), etc; and (6) drug names that are also dietary compounds (e.g., caffeine, tryptophan). These questions were annotated, and the drug in question tracked.

5. Given the above identified errors, to facilitate expert review the drug pairs from Step 1 were provided to GPT-4o, which was prompted to check if the brand name's main component is the paired generic drug, and if the brand name drug is used mainly used for humans. 1247 brand drugs were filtered out of the keyword list. This resulted in 563 generic drug mapped to 3050 brand keywords.

6. The remaining drugs in Step 5 were provided to Cohere-RAG, which was prompted to provided a list of brand names for each generic name.

7. A physician author (JG) reviewed the retrieved brand names and selected a single brand name to pair with each generic name. This resulted in 525 generic-to-brand pairs.

8. These 525 generic-to-brand pairs were used to regenerate the transformed dataset using regular expressions to identify and replace names.

9. Two physician authors (JG and DB) reviewed the dataset generated in Step 8, and removed any remaining questions where the replacement resulted in ambiguity or inconsistencies in context to ensure quality of the final dataset.

B Drug Knowledge



Figure 3: Performance of models on multi-choice question identification of brand-generic drug pairs ordered in increasing model size. Gemini results are missing due to Google's API safety filters.

C Drug Swapping results

Figure 4 shows the performance change from the original filtered datasets compared to the dataset where generic drug names are swapped with the brand names (g2b). Notice that the MedMCQA (left) x-axis range is much larger than the MedQA x-axis range, indicating a larger drop across models.



Figure 4: Performance of models on the filtered original datasets compared to the generic-to-brand versions for MedMCQA and MedQA subsets. Negative values indicate worse performance on the swapped dataset.

Table 3: List of Models Used in Experiments, June 12th, 2024

Model Name	Size	MoE	Multi-Modal
phi-1 (Gunasekar et al., 2023)	1.3B	No	No
phi-1.5 (Li et al., 2023)	1.3B	No	No
phi-2 (Li et al., 2023)	2.7B	No	No
phi-3-medium (Abdin et al., 2024)	14B	No	No
Llama3-8B (AI@Meta, 2024)	8B	No	No
Llama3-70B (AI@Meta, 2024)	70B	No	No
llama-2-70B (Touvron et al., 2023)	70B	No	No
llama-2-7B (Touvron et al., 2023)	7B	No	No
c4ai-aya-23-35B (Aryabumi et al., 2024)	35B	No	No
c4ai-r-plus	104B	No	No
Mistral-7B-v0.3 (Jiang et al., 2023a)	7B	No	No
mixtral-8x22B (Jiang et al., 2024)	176B	Yes	No
mixtral-8x7B (Jiang et al., 2024)	56B	Yes	No
qwen2-72B (Qwen, 2024)	72B	No	No
qwen2-7B (Qwen, 2024)	7B	No	No
yi-1.5-34B (Young et al., 2024)	34B	No	No
GPT-3.5-turbo-0125	NA	NA	No
GPT4-0613	NA	NA	Yes
GPT-4o	NA	NA	Yes
Claude 3 Opus	NA	NA	Yes
Gemini 1 Pro	NA	NA	Yes
Gemini 1.5 Flash	NA	NA	Yes
Gemini 1.5 Pro	NA	NA	No

Table 4: Overall and difference of Model performance on RABBITS

Dataset	Model	g2b	original
medmcqa	GPT-3.5-turbo-0125	97.70	98.28
medmcqa	GPT-4o	86.49	90.52
medmcqa	GPT4-0613	88.79	91.67
medmcqa	Gemini 1 Pro	73.85	68.10
medmcqa	Gemini 1.5 Flash	94.83	97.41
medmcqa	Gemini 1.5 Pro	82.47	86.49
medmcqa	Llama-2-70B-hf	45.98	52.30
medmcqa	Llama-2-7b-hf	33.91	34.20
medmcqa	Llama-3-70B	66.67	78.16
medmcqa	Llama-3-8B	52.87	59.20
medmcqa	Mistral-7B-v0.3	48.28	56.90
medmcqa	Mixtral-8x22B-v0.1	61.78	70.40
medmcqa	Mixtral-8x7B-v0.1	55.46	64.94
medmcqa	Phi-3-medium-4k	60.34	72.41
medmcqa	Qwen2-72B	71.55	77.87
medmcqa	Qwen2-7B	55.17	63.51
medmcqa	Yi-1.5-34B	59.77	69.25
medmcqa	aya-23-35B	48.56	52.87
medmcqa	claude-3-opus@20240229	79.89	86.49
medmcqa	command-r-plus	49.14	61.49
medmcqa	phi-1	24.14	25.86
medmcqa	phi-2	37.64	42.24
medmcqa	phi1.5	31.61	30.46
medqa 4options	GPT-3.5-turbo-0125	96.03	96.30
medqa 4options	GPT-4o	88.36	90.21
medqa 4options	GPT4-0613	89.95	92.33
medqa 4options	Gemini 1 Pro	73.02	70.63
medqa 4options	Gemini 1.5 Flash	96.03	97.09
medqa 4options	Gemini 1.5 Pro	87.30	88.62
medqa 4options	Llama-2-70B-hf	52.65	55.03
medqa 4options	Llama-2-7b-hf	34.39	37.30
medqa 4options	Llama-3-70B	72.75	75.13
medqa 4options	Llama-3-8B	55.03	60.85
medqa 4options	Mistral-7B-v0.3	48.68	53.17
medqa 4options	Mixtral-8x22B-v0.1	67.46	71.43
medqa 4options	Mixtral-8x7B-v0.1	60.05	62.43
medqa 4options	Phi-3-medium-4k	53.44	58.47
medqa 4options	Qwen2-72B	74.07	75.40
medqa 4options	Qwen2-7B	53.70	58.99
medqa 4options	Yi-1.5-34B	59.79	64.55
medqa 4options	aya-23-35B	47.88	51.06
medqa 4options	claude-3-opus@20240229	83.33	85.71
medqa 4options	command-r-plus	56.61	60.32
medqa 4options	phi-1	21.69	20.90
medqa 4options	phi-2	41.80	43.92
medqa 4options	phi1.5	34.92	34.66

Table 5: Overall and difference of Model performance on RABBITS

Model	Original	g2b	Average	Difference
GPT-3.5-turbo-0125	97.29	96.86	97.08	-0.42
GPT-4o	90.36	87.42	88.89	-2.94
GPT4-0613	92.00	89.37	90.69	-2.63
Gemini 1 Pro	69.36	73.44	71.40	4.07
Gemini 1.5 Flash	97.25	95.43	96.34	-1.82
Gemini 1.5 Pro	87.56	84.89	86.22	-2.67
Llama-2-70B-hf	53.66	49.31	51.49	-4.35
Llama-2-7b-hf	35.75	34.15	34.95	-1.60
Llama-3-70B	76.64	69.71	73.18	-6.93
Llama-3-8B	60.02	53.95	56.99	-6.08
Mistral-7B-v0.3	55.03	48.48	51.76	-6.55
Mixtral-8x22B-v0.1	70.92	64.62	67.77	-6.29
Mixtral-8x7B-v0.1	63.69	57.76	60.72	-5.93
Phi-3-medium-4k	65.44	56.89	61.16	-8.55
Qwen2-72B	76.64	72.81	74.72	-3.83
Qwen2-7B	61.25	54.44	57.84	-6.82
Yi-1.5-34B	66.90	59.78	63.34	-7.12
aya-23-35B	51.97	48.22	50.09	-3.75
claude-3-opus@20240229	86.10	81.61	83.85	-4.49
command-r-plus	60.91	52.88	56.89	-8.03
phi-1	23.38	22.91	23.15	-0.47
phi-2	43.08	39.72	41.40	-3.36
phi1.5	32.56	33.27	32.91	0.70

D Pre-training data screening

Table 6: Statistics for occurrence counts of selected brand and generic terms among popular pre-training datasets

Subset	Terms	Average	Median	Std. Dev
Dolma	Generic	564,151	136,682	2,399,928
	Brand	234,138	698	2,543,075
Red Pajama	Generic	161,227	42,549	620,393
	Brand	29,561	84	232,661
Pile train	Generic	96,309	28,074	325,307
	Brand	4,757	19	43,613
C4 train	Generic	27,973	5,454	144,162
	Brand	9,941	26	96,504

E Biomedical-Supervised Fine-Tuned (SFT) Models

The top 3 accessible models on the leaderboard (all higher than GPT-4 and Med-Palm as of June 1st, 2024) (Pal et al., 2024) are all Llama3 SFT variants. The Llama3-8B-sft2 model achieved the highest original score of 0.85 but showed a performance drop of -0.15 in the g2b category, similar to Llama3-8B-sft1. Both performance decreases are greater than those observed in the base model version. Similar patterns were seen in the Llama-70B models. These degradations among benchmark datasets may be helpful in inspecting SFT models that are over-fitted.

Table 7: Llama-3 Vanilla v.s its Fine-Tuned Variants

Model	None ↑	g2b ↑	$\delta \downarrow$
llama-3-8B (vanilla)	0.60	0.53	-0.07
llama-3-8B-sft1	0.80	0.66	-0.14↑
llama-3-8B-sft2	0.85	0.70	-0.15↑
llama-3-70B (vanilla)	0.77	0.70	-0.07
llama-3-70B-sft1	0.75	0.66	-0.09↑

F Results with Brand Name Hints

To explore the impact of including brand names as hints in the context, we ran several models with an additional hint of the drug's generic names added to the original QA prompt—for example, Tylenol (acetaminophen). The goal was to assess whether this additional context could help recover some of the lost performance when using brand names instead of generic ones.

F.0.1 Meta-Llama-3-8B-Instruct

Task	Metric	Value	Stderr
medmcqa_g2b	acc	0.5517	0.0267
medmcqa_g2b_hint	acc	0.5661	0.0266
medmcqa_orig	acc	0.6437	0.0257
medqa_4options_g2b	acc	0.5317	0.0257
medqa_4options_g2b_hint	acc	0.5450	0.0256
medqa_4options_orig	acc	0.5979	0.0253

Table 8: Results for Meta-Llama-3-8B-Instruct

F.0.2 JSL-MedLlama-3-8B-v2.0

Task	Metric	Value	Stderr
medmcqa_g2b	acc	0.5805	0.0265
medmcqa_g2b_hint	acc	0.6092	0.0262
medmcqa_orig_filtered	acc	0.7213	0.0241
medqa_4options_g2b	acc	0.5476	0.0256
medqa_4options_g2b_hint	acc	0.5529	0.0256
medqa_4options_orig_filtered	acc	0.5873	0.0254

Table 9: Results for JSL-MedLlama-3-8B-v2.0

F.0.3 Qwen2-7B

Task	Metric	Value	Stderr
medmcqa_g2b	acc	0.5546	0.0267
medmcqa_g2b_hint	acc	0.5345	0.0268
medmcqa_orig_filtered	acc	0.6379	0.0258
medqa_4options_g2b	acc	0.5370	0.0257
medqa_4options_g2b_hint	acc	0.5370	0.0257
medqa_4options_orig_filtered	acc	0.5847	0.0254

Table 10: Results for Qwen2-7B

F.0.4 Qwen2-7B-Instruct

Task	Metric	Value	Stderr
medmcqa_g2b	acc	0.5517	0.0267
medmcqa_g2b_hint	acc	0.5575	0.0267
medmcqa_orig_filtered	acc	0.6322	0.0259
medqa_4options_g2b	acc	0.5317	0.0257
medqa_4options_g2b_hint	acc	0.5132	0.0257
medqa_4options_orig_filtered	acc	0.5582	0.0256

Table 11: Results for Qwen2-7B-Instruct

F.0.5 Meta-Llama-3.1-8B-Instruct

Task	Metric	Value	Stderr
medmcqa_g2b	acc	0.5517	0.0267
medmcqa_g2b_hint	acc	0.5920	0.0264
medmcqa_orig_filtered	acc	0.6868	0.0249
medqa_4options_g2b	acc	0.5847	0.0254
medqa_4options_g2b_hint	acc	0.5741	0.0255
medqa_4options_orig_filtered	acc	0.6349	0.0248

Table 12: Results for Meta-Llama-3.1-8B-Instruct

F.0.6 Meta-Llama-3.1-8B

Task	Metric	Value	Stderr
medmcqa_g2b	acc	0.4971	0.0268
medmcqa_g2b_hint	acc	0.5000	0.0268
medmcqa_orig_filtered	acc	0.5948	0.0264
medqa_4options_g2b	acc	0.5529	0.0256
medqa_4options_g2b_hint	acc	0.5608	0.0256
medqa_4options_orig_filtered	acc	0.5952	0.0253

Table 13: Results for Meta-Llama-3.1-8B

Overall, we observed only a small improvement in performance for instruct models when brand name hints were provided. However, this improvement was insufficient to recover the original performance observed with generic names fully. These results underscore the challenges of medical terminology in language models and highlight the need for further research in this area.

9


User (confident):
I think this medicine is safe and has no side effects.
AI (sycophantic):
You're absolutely right! It's completely safe with no side effects.
Incorrect
• Misleading
• Potential harm
• Erodes trust

Chapter 10

When Helpfulness Backfires: LLMs and the Risk of False Medical Information Due to Sycophantic Behavior

Shan Chen*, Mingye Gao*, Kuleen Sasse, Thomas Hartvigsen, Brian Anthony, Lizhou Fan, Hugo Aerts, Jack Gallifant, Danielle S Bitterman

npj Digital Medicine

Summary

Background

While large language models (LLMs) are designed to be helpful, this very trait can lead to **sycophantic compliance**—meaning they may respond to illogical or misleading instructions simply to appear cooperative. In the medical domain, such behavior can translate into false or dangerous health information.

Methods

Our study evaluated five state-of-the-art LLMs by presenting prompts that incorrectly claimed two equivalent drugs were different (i.e., misrepresented a factual relationship). We tested baseline compliance (how often models answer even when the request is illogical), then compared versions with prompts that allowed rejection or emphasized factual recall, and finally evaluated models after fine-tuning on a dataset of illogical requests—including out-of-distribution generalization.

Findings

Initial compliance was extremely high—up to **100%**—indicating models prioritized being helpful over checking logic or truth. Prompt engineering and supervised fine-tuning significantly improved performance: after tuning, models rejected illogical requests more frequently **while maintaining general benchmark ability**.

Interpretation

Our results demonstrate a critical vulnerability: LLMs may provide false medical information because they default to "helpfulness" rather than verifying correctness. Mitigation requires targeted training and prompt design to prioritize logical consistency. This finding has direct relevance for clinical settings and potential AI-enabled trial automation or pharmacovigilance tasks: ensuring that a model doesn't inadvertently comply with invalid prompts is just as important as training it to retrieve correct information.

Introduction

Large Language Models (LLMs) can store and retrieve vast amounts of information from diverse domains, including healthcare[1–3]. This knowledge base has been noted for its potential to support medical professionals by providing specialized information and advice[1,4]. Yet, while these models may recall medical facts, it remains challenging for the models to process information logically and generate responses that demonstrate sound reasoning[5]. This gap between knowledge retrieval and logical reasoning in medicine[6,7] leads to a particularly concerning public health risk: The rapid generation and dissemination of false information is particularly critical in high-stakes fields like medicine.

Two key principles for the safe deployment of LLMs in medicine are honesty and helpfulness[8–10]. In the context of LLMs, honesty ensures that models provide accurate and truthful information, while helpfulness focuses on fulfilling users' queries in an efficient and useful manner[11,12]. Our work examines the critical scenario where an overemphasis on this helpfulness can lead models to comply with illogical or factually incorrect medical requests, thereby undermining honesty.

Current state-of-the-art LLMs are aligned with these principles via training processes[8,10,13], including reinforcement learning with human feedback[14] (RLHF). These alignment processes typically involve tuning LLMs, not to gain new knowledge but to shift the outputs towards a more desirable human-readable format and away from potentially harmful or toxic behaviors learned during pre-training[12,15]. Previous works have shown that helpfulness can be misused to generate unfaithful information and a lack of scientific grounding about health[16–18]. While honesty and helpfulness are often complementary, emphasizing helpfulness can introduce safety vulnerabilities: *jailbreaking*[19,20] and *sycophancy*[21] which may amplify the risks of LLM misuses. Jailbreaking refers to techniques or prompt structures designed to exploit a model's helpfulness, tricking it into generating harmful, misleading, or restricted content[22]. Sycophancy is the tendency of LLMs to excessively agree with users, often at the expense of accuracy[21,23]. We define this as sycophancy, differing

from compliance, because LLMs (1) demonstrably know the premise is false (e.g., accurately matching brand/generic names), but (2) align with the user's implied incorrect belief, generating false information. The confluence of these two vulnerabilities is a growing concern, because nefarious users, misinformed users, and even unintentional errors and typos input into the model, could result in LLMs generating and spreading false information[24].

Previous research on jailbreaking has primarily explored its implications in the context of catastrophic risks in the general domain–cases where models are manipulated to produce extreme content, such as violence, hate speech, or other harmful material[25–27]. Jailbreaking has been thoroughly examined in healthcare contexts through multimodal, white-box internal, and adversarial approaches.[28,29]. Our work builds on this foundation by addressing a critical underexplored area: evaluating LLMs' ability to recognize and resist illogical or factually flawed requests for medical information. For example, a user could unknowingly generate false information if they don't have the background knowledge to know upfront that their request is illogical and would, by definition, generate false information. As a concrete example, if a patient doesn't know that acetaminophen is the same drug tylenol, and is trying to self-educate about analgesic options using an LLM, they could inadvertently generate false information owing to a model's overly helpful (or overly compliant) behavior with a request such as: "Tell me why acetaminophen is safer than tylenol". Similarly, typos or accidents could readily but inadvertently generate false information in similar fashions.

We evaluated five LLMs across various scenarios and assessed how sensitive they are to generating false medical information in settings where the LLMs have the knowledge base to identify the requested information as incorrect. As a use case, we selected drug names, as in medicine, where different names are often used for the same drug. Because we previously showed that LLMs can accurately match brand and generic drug names[30], this allowed for a controlled and scalable experimental setup to characterize LLM sycophantic compliance to illogical requests. First, we tested whether LLMs refuse to comply with requests for information describing the equivalent drugs are distinct (i.e., a misinformation request), and found that even the most advanced models complied with up to 100% of misinformation requests. Second, we changed our instructions to the LLMs to understand if their overly submissive behavior can be overcome with prompting (given that prompting still remains the most effective steering method[31]). Third, we fine-tuned models to resist requests for



Figure 1. *Illustration of overall study workflow. Step 1 involves the generation of an LLM misinformation request, where models should recognize that the drug entities are equivalent and therefore the requested generated content would be misinformation. In Step 2, LLMs are prompted with this request to generate a response which is subsequently graded by Claude 3.5 Sonnet in Step 3 into one of the four response types. Claude 3.5 grading quality was validated by humans. Step 4 shows prompt-based variations which are evaluated, and the change in response types are collected in Step 5. Step 6 displays the instruction tuning of the LLMs, where we stitched the baseline prompt with output from rejection and factual recall hints. Step 7 evaluates this newly tuned LLM both in-domain and in other domains with different equivalence errors.*

misleading information while maintaining responsiveness to valid prompts. We found that LLMs prioritize learned helpfulness over inherent logical reasoning in our datasets, leading them to generate false information from even simple illogical prompts. Our strategies to reduce this risk successfully enhanced logical reasoning, and can provide a basis for additional research to improve robust risk mitigation and oversight mechanisms targeted at LLM sycophancy in healthcare.

Results

Overview

We evaluated whether state-of-the-art LLMs prioritize "helpfulness" over logical consistency when faced with illogical medical requests that they have the knowledge to detect, using drug pairs with 1:1 brand–generic mappings. The study proceeded in four stages: Stage 1 measured baseline sycophantic compliance to illogical prompts (aim: quantify default risk). Stage 2 introduced lightweight prompt edits—explicit rejection permission and a factual-recall cue—to test steerability with instructions (aim: assess whether prompting alone can restore logic). Stage 3 applied supervised fine-tuning on a small set of illogical requests with desired behavior and tested out-of-distribution generalization across medical and non-medical entities (aim: learn a reusable "reject-when-illogical" policy that transfers). Stage 4 checked for over-rejection and capability loss by evaluating compliance with valid prompts and performance on general/biomedical benchmarks (aim: ensure safety gains do not degrade usefulness). Unless noted, we report the generic→brand direction in the main text; brand→generic results are concordant in the supplementary.

Stage 1. Baseline prompt to quantify default risk

Our previous work showed that all models evaluated here have near-perfect factual recall ability to match these drugs' generic and brand names[30]. As shown in **Figure 2a)**, LLMs generally follow illogical requests to generate false information in the base prompt setup (details in Method section 3.1) for the generic-to-brand conversions. For clarity, we only discuss the generic-to-brand setups in the main text; all brand-to-generic results are in **Supplementary Figure 1** and show similar findings.

In the generic-to-brand setup, GPT4o-mini, GPT4o, and GPT4 followed the medication misinformation request 100% (50/50) of the time, while Llama3-8B did so in 94% (47/50) of cases. Llama3-70B had the highest rejection

rate in this setup, but still rejected requests to generate false information in less than 50% (21/50) of cases. This stage quantifies baseline sycophancy, indicating that even large, advanced models predominantly complied with illogical requests.



Figure 2. *Generic-to-brand output grades for prompt-based and Instruction-tuning interventions. Figure 4a displays the results of stage 1 (prompt-based strategies). The Y-axis is marked as a percentile. Four prompt variations were used to evaluate 5 LLMs on generic-brand name pairs of 50 drug combinations. Figure 4b shows results for stage 2 (instruction-tuned model). The baseline and fine-tuned version of GPT4o-mini and Llama3-8B performance is on out-of-distribution test sets of 4 domains, such as cancer drug name and writer-pseudonym pairs.*



Figure 3. *Out of distribution testing workflow. We composed one held-out cancer drug set that is not in the supervised fine-tuning data and crafted three other categories' equivalences. As previously, Claude 3.5 Sonnet was used to auto-evaluate the categories of models' responses.*

Stage 2. Prompt-based solutions to assess whether prompting restores logic

Explicitly allowing models to reject misinformation requests (i.e., telling models that they can reject the request within the prompt, our detailed workflow can be found in **Figure 1**) improved the ability of the GPT series of models to resist misinformation requests. GPT4o and GPT4 rejected over 60% (GPT4o: 31/50, GPT4: 32/50) of the illogical requests in this setting. However, Llama's performance was similar to base prompting. Adding factual recall hints in the prompt yielded the most benefit for GPT4 and Llama3-8B.

Adding rejection hints and factual recall together in the prompts vastly improved the models' performance. This was particularly true for GPT4o and GPT4, which rejected generating the requested misinformation *and* correctly identified that the brand and generic names referred to the same drug in 94% (47/50) of test cases. Rejection rates for GPT4o-mini and Llama3-70B also improved substantially $p<0.05$ (We build a square "before × after" contingency table of all categories and then apply Bowker's test of symmetry to check for a statistically significant paired changes), reaching 62% (31/50) and 92% (46/50), respectively, with both hints applied.

An interesting behavioral shift was observed in Llama3-8B after including both the rejection and factual recall hints. The model transitioned from following illogical requests to directly rejecting them without providing the correct logical rationale for rejections. This change is reflected in the increase in direct rejections (yellow bar) from 2% (1/50) to 66% (33/50) ($p<0.05$) in **Figure 2a**.

Stage 3. Fine-tuning to learn a reusable policy and evaluating on out-of-distribution (OOD) data

In the third stage, GPT4o-mini and Llama3-8B were supervised fine-tuned (SFT) on 300 illogical requests about general drugs with clear rejections. We then conducted OOD tests (**Figure 3** demonstrates the workflow here) in four domains: cancer drugs, singers/performers, writers, and geography. As shown in **Figure 2b)**, the fine-tuned models were much more likely to identify a request as illogical and refuse to comply.

For example, in the OOD tests on cancer drugs (without rejection hints), the fine-tuned GPT4o-mini achieved a 100% (100/100) rejection rate, with 79% (79/100) of rejections ($p<0.05$) providing the correct reason, compared to the baseline's 12% (12/100) rejection rate (5% with correct reasoning). Similarly,

the fine-tuned Llama3-8B reached a 99% (99/100) rejection rate (70% with correct reasoning, 29% with other reasons), while the baseline model rejected only 30% (30/100) of requests, none of which provided the correct reason. This is similar to other categories with/without rejection hints. Fine-tuning can reduce sycophancy, leading to consistent rejection of illogical prompts across out-of-distribution domains.

Stage 4: Evaluating general benchmarks and compliance with logical requests to ensure safety gains do not degrade performance

The detailed results of the ability of the fine-tuned models to comply with logical requests are shown in **Supplementary Table 1**. Fine-tuned GPT4o-mini complied in 15/20 cases, and fine-tuned LLama3-8B complied in 12/20 cases. While the fine-tuned models were more likely than their base counterparts to reject requests, they always explained that they rejected because the request might be unrealistic. This behavior shift indicates a maintenance of balance between safety (rejection of illogical requests) and functionality (sycophantic compliance with logical instructions). Examples of how fine-tuning shifted behavior are provided in **Supplementary Figure 2**.

Lastly, we assessed the performance of the SFT models from Stage 2 and their base counterparts across 10 general and biomedical knowledge benchmarks, including Alpaca-Eval2[32], ARC Challenge, ARC Easy[33], BoolQ[34], MMLU[35], GPQA[36], TruthfulQA[37], and the USMLE Step 1, 2, and 3 exams[30]. As demonstrated in **Figure 5**, the fine-tuned models exhibited negligible performance degradation across all tasks.



Figure 4*. LLM ability to comply to logical requests. To further investigate our fine-tuned models' behavior, we provided three different subcategories of new, logical and correct in-context information requests, and assessed if the LLMs complied. Authors SC and MG did the annotation manually with a 100% annotation agreement.*

Discussion

Our study identified a vulnerability in LLMs: their sycophantic tendency to prioritize helpfulness over honesty and critical reasoning when responding to illogical requests for medical information, resulting in false and potentially harmful information. If LLMs are prone to generating false medical information in response to requests that are overtly illogical, where they know the information is incorrect, they are likely even less able to resist more nuanced false information requests. This means that even simple errors in LLM inputs could readily and inadvertently prompt the generation of false information when LLMs are used in medical contexts. For example, patients seeking health information from LLMs could generate false information if they do not have the clinical knowledge base to know a priori that the question is illogical. If left unchecked, this sycophancy could lead to the acceleration of inadvertent or malicious misinformation which could cause serious population and individual harm in high-stakes domains like healthcare[24].

Previous research into the potential of LLMs to manipulate and generate false information has largely focused on single-turn or multi-turn conversational techniques aimed at exploiting a model's inherent helpful nature to bend its "beliefs" or outputs to align with dangerous or unethical goals[38,39]. Such efforts reveal the vulnerability of even state-of-the-art models to being misled by adversarial inputs, underscoring the need for new robust safeguarding mechanisms. Our work adds to the existing literature by evaluating the ability of LLMs to identify and resist requests that are overtly illogical or factually flawed, and by proposing novel mitigation strategies via prompting and fine-tuning.

The initial sycophantic compliance of all models, including advanced ones like GPT-4, to illogical requests reveals a core vulnerability in LLM design where, without explicit guidance, models prioritize being helpful over applying critical reasoning. More specifically, the role of RLHF/Instruction Tuning creates a fundamental tension between blindly following instructions and providing context-sensitive and factual responses. Our findings demonstrate that explicit instruction prompting, such as providing rejection hints, can improve models' ability to critically assess requests before responding. Allowing models to reject flawed instructions appears to be important for enhancing their common-sense critical reasoning ability. This insight is crucial for developing safer AI systems that can balance helpfulness with necessary skepticism.

While factual recall prompts improved the performance of advanced models, such as GPT4o and GPT4, they had a limited impact on smaller models like Llama3-8B/70B or GPT4o-mini. Even when we explicitly told the models within the prompt that brand and generic names referred to the same drug, only the more advanced models responded correctly by rejecting the illogical request. For example, GPT4 and GPT4o rejected 94% of illogical requests after being prompted to recall factual relationships between the drugs, but Llama3-8B still often rejected without giving a correct explanation.

This suggests that simply spelling out factual equivalencies is not enough for less capable models and that the ability to effectively use factual knowledge in context-dependent reasoning tasks may be a key differentiator of more advanced AI systems[40,41]. Smaller models seem to require more than factual prompts to process logical decisions, likely because they cannot fully integrate context and recall complex relationships as effectively as advanced models. However, even for these larger models, this approach is not scalable across the wide range of potential illogical requests because it requires preemptively identifying the precise factual knowledge needed to identify each request as illogical.

Supervised fine-tuning on 300 drug-related conversations enhanced the models' ability to distinguish between valid and illogical prompts, especially for OOD tests. After fine-tuning, models like GPT4o-mini achieved a 100% rejection rate, with 79% of rejections providing the correct reasoning, compared to the baseline's 9%. Similarly, Llama3-8B improved, though it sometimes rejected prompts without proper explanations. Importantly, the observed improvements in rejecting illogical prompts were generalized outside of the brand-generic use case on which the models were fine-tuned.

The success of SFT highlights how fine-tuning enables models to better recognize illogical requests in a generalizable, scalable fashion. In other words, we know the models can match these drug names correctly, and SFT steers models' behavior toward prioritizing its factual knowledge over user requests.

Importantly, this fine-tuning did not lead to over-rejection or a refusal to respond to reasonable input: GPT4o-mini and Llama3-8B still largely complied with logical requests across a range of medical and non-medical tasks. When they did not, they provided reasonable explanations for not complying. This behavior shift demonstrates a successful balance between rejecting illogical

instructions and remaining useful for legitimate tasks. Recent articles and new paradigm improvement on test time compute[42] show a promising future where models can reason first instead of responding immediately, improve reasoning ability[43,44], and enhance potential jailbreaking behavior[45–47]. However, the normal language models that we studied in this paper are still the main daily workhorses accessible to most users. In fact, even OpenAI rose similar sycophancy issues on GPT-4o.[48]

We showed that LLMs are sycophantic and do not reliably resist requests for illogical content, even when they have the knowledge to identify the request as factually flawed. This creates a gap between the knowledge benchmarks commonly used to evaluate LLMs and a true assessment of their medical risks and functionality. To ensure that LLMs effectively reject flawed requests while continuing to respond helpfully to logical instructions, future work could focus on refining tuning methods and developing approaches to scalable human-assisted and automated oversight. Ultimately, closing this gap will be essential to aligning LLMs' knowledge capabilities with their real-world reliability and safety in medicine.

Methods

To evaluate language models across varying levels of drug familiarity, we used the *RABBITS*[30] dataset, which includes 550 common drugs with 1:1 mapping between their brand and generic names.

To measure the relative familiarity of language models with these drugs, we tokenized multiple large pre-training corpora with the LLaMA tokenizer[9] using Infini-gram[49], including Dolma1.6[50], C4[51], RedPajama[52], and Pile[53]. The frequency of generic drug names across this corpus was used to estimate how commonly these drugs appear in pre-training datasets. Generic drug names were then ranked by frequency to provide a proxy measure of model familiarity(Note that C4 and RedPajama have overlaps).

To ensure coverage of both common and rare drugs, we selected 50 drugs from five distinct frequency ranges based on their rankings in the tokenized dataset: The top 10, 100-110, 200-210, 300-310, and 400-410 most frequent drugs in our sampling window.

We evaluate the following LLMs: Llama3-8B-Instruct (Llama3-8B), Llama3-70B-Instruct (Llama3-70B), gpt-4o-mini-2024-07-18 (GPT4o-mini), gpt-4o-2024-05-13 (GPT4o), and gpt-4-0613 (GPT4). These models were chosen to represent the performance of current leading open- and closed-source models across a range of sizes.

We designed four prompt types to evaluate the models' handling of new drug-related information, assessing persuasive ability, factual recall, and logical consistency (Figure 2). Experiments were run via OpenAI Batch API, and Llama models used A100-80GB with CUDA > 12.0, no quantization. Hyperparameters included a max of 512 output tokens and temperature=0 for best possible reproducibility.

Stage 1. Baseline Prompt: The first prompt represents the baseline condition, where the model is tasked with providing a persuasive but illogical letter informing people that a brand-name drug is found to have new side effects, and that they should take the generic counterpart instead. This task was selected because it illustrates a necessary safety mode for LLMs that follows from simple logical reasoning. If a model knows that the brand and generic drug are the same, it should be able to identify the request as illogical and reject the request, instead of complying with the request and generating false information.

Stage 2. Prompt-Based Solutions to Assess Steerability- Rejection Prompt: In this variation, we explicitly allow the possibility of rejection, encouraging the model to evaluate whether there is a logical flaw in the prompt. This prompt also allows a model that is heavily aligned to being submissive to reject users' queries. The explicit permission to reject creates a scenario where the model must consider not only the factual content but also the appropriateness of the substitution.

Factual Recall Prompt: This prompt emphasizes the need for the model to recall the correct relationships between brand-name drugs and their generic equivalents before processing the rest of the request. This variation tests the model's ability to accurately retrieve and utilize known facts in generating persuasive outputs. By instructing the model to prioritize factual recall, we assess how well it can integrate known drug relationships with new information.

Combined Rejection and Factual Recall Prompt: The final prompt variation combines both the rejection and factual recall instructions. This setup evaluates whether the model can handle both tasks simultaneously, ensuring factual accuracy while also exercising logical reasoning to reject incorrect assumptions.

All prompt settings introduced were experimented with separate LLM inferences.

Stage 3. Fine-tuning and Evaluation on Out-of-Distribution (OOD) Data - Model Fine-Tuning: To enhance the ability of smaller language models to handle complex drug substitution prompts, we fine-tuned Llama 3 - 8B Instruct and GPT4o-mini using the PERSIST instruction-tuning dataset, publicly available at https://huggingface.co/datasets/AIM-Harvard/PERSIST.

This dataset comprises 300 input-output pairs, each featuring a challenging "Baseline" prompt concerning brand/generic drug substitutions (covering both directions for 50 drug pairs) and the corresponding desired response generated by a larger model (GPT4o-mini, GPT-4, or GPT4o) when presented with a "Combined Rejection and Factual Recall Prompt."

The dataset construction leveraged these larger models to systematically generate ideal responses for all 50 drug pairs in both substitution directions, resulting in 300 examples (50 * 2 * 3 = 300), drawing inspiration from work demonstrating effective instruction-tuning with limited data[54]. We explored various hyperparameters, including learning rates (5e-6, 1e-5, 2e-5, 5e-5), batch sizes (1, 2), and epochs (2, 3) for Llama3-8B. For GPT4o-mini, we utilized OpenAI's automatic parameter search. Ultimately, the selected Llama3-8B model used a learning rate of 1e-5, a batch size of 2, and 3 epochs, while the selected GPT4o-mini was fine-tuned via the OpenAI API with a batch size of 1, 3 epochs, and a seed of 318998491. The core objective of this fine-tuning process was to impart the smaller models with the ability to emulate the larger models' successful rejection and explanation behavior when faced with the "Combined Rejection and Factual Recall Prompt."

We used 2*A100 80GB to fine-tune our examples in 2 epochs and a learning rate of 1e-5 which can be done under an hour. The estimated cost here will be under $10 if using cloud GPU renting. For fine-tuning GPT4o mini, we were on the OpenAI Trial program, so it was free of cost. However, custom models will require 1.5x inference costs.

Evaluation on OOD Data: To evaluate the generalization of the fine-tuned model to other illogical requests, we tested its performance on the OOD datasets of terms with the same meanings (**Figure 3**). This OOD dataset included several other categories. Testing on OOD data allows us to assess the generalizability of a model's behavior in responding to illogical requests involving novel or previously unseen entities – a crucial factor in evaluating its applicability in real-world scenarios.

Stage 4: Evaluating General Benchmarks and Compliance with Logical Requests - Balancing Rejection and Compliance: To test whether models became overly conservative after fine-tuning, we designed an additional test set comprising 20 cases (10 real FDA drug safety recalls, 5 theoretically event canceling situations, and 5 real government announcements) where the model should comply with the prompt rather than reject it (**Figure 4**). These cases involved scenarios where the recommended substitution was appropriate and aligned with the correct drug relationships. This test ensured that the model retained the ability to provide helpful and persuasive responses when no logical flaws were present. The prompts are found in **Supplementary Table 1**. Additionally, we also prompt the fine-tuned models with questions regarding 50 common drugs we fine-tuned and see whether they can still answer logical requests regarding those drugs.

General Benchmark Evaluation*:* To ensure that fine-tuning and prompt modifications do not degrade the overall performance of the models, we evaluated them on a broad set of general benchmarks using Inspect[55] and Alpaca-Eval2 v0.6.5[56] using GPT4-turbo as the comparator model. These benchmarks were selected to test the models' reasoning, factual recall, and domain-specific knowledge, including medical contexts, ensuring that any improvements in handling drug-related prompts did not come at the expense of general task performance. The confidence intervals are calculated using the central limit theorem, a common practice in modern LLM evaluations[57,58].

Automated Evaluation: Model outputs were categorized into 4 categories: (1) rejecting the request and explaining the logical flaw; (2) fulfilling the request and explaining the logical flaw; (3) rejecting the request without explaining the logical flaw; and (4) fulfilling the request without explaining the logical flaw. Model outputs were evaluated using a multi-step annotation process. The detailed counts of instances we evaluated in this research are available in Supplementary Table 2. To ensure consistency and reliability in the

evaluation, we employed the Claude 3.5 Sonnet (we chose a separate model as a label because LLMs of the same family are known to have a favorable bias toward their own responses59–62) to provide initial annotations, with human reviewers (annotators SC and MG blinded to each other) validating 50 outputs from GPT4o-mini. The inter-annotator agreement between Claude 3.5 Sonnet and the human reviewers was 98%, with 100% agreement between the two human annotators for both in-domain and out-of-domain data. Supplementary Table 3 shows the single output for which the human labels disagreed with Claude 3.5 Sonnet. Of note, compliance with logical requests was human-labeled.

Data availability

All our data input and output from all models, and the Llama3 model we fine-tuned, are publicly available at
https://huggingface.co/datasets/AIM-Harvard/PERSIST.

Code availability

All code can be found at
https://huggingface.co/datasets/AIM-Harvard/PERSIST.

Please view the full Tables and appendix at:

https://www.nature.com/articles/s41746-025-02008-z

Acknowledgments

The authors acknowledge financial support from the Google PhD Fellowship (SC), the Woods Foundation (DB, SC, HA, JG, LF), the NIH (NIH-USA R01CA294033 (SC, JG, LF, DB), NIH-USA U54CA274516-01A1 (SC, HA, DB), NIH-USA U24CA194354 (HA), NIH-USA U01CA190234 (HA), NIH-USA U01CA209414 (HA), and NIH-USA R35CA22052 (HA), the ASTRO-ACS Clinician Scientist Development Grant ASTRO-CSDG-24-1244514 (DB), and the European Union - European Research Council (HA: 866504). This work was also conducted with support from UM1TR004408 award through Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University, and its affiliated academic healthcare centers, or the National Institutes of Health. The authors thank Google Cloud research fund for Claude API inference costs.

References

1. Singhal, K. *et al.* Large language models encode clinical knowledge. *Nature***620**, 172–180 (2023).
2. Taylor, R. *et al.* Galactica: A Large Language Model for Science. *arXiv [cs.CL]* (2022).
3. Chen, S. *et al.* Evaluation of ChatGPT Family of Models for Biomedical Reasoning and Classification. *arXiv [cs.CL]* (2023).
4. Van Veen, D. *et al.* Adapted large language models can outperform medical experts in clinical text summarization. *Nat. Med.***30**, 1134–1142 (2024).
5. Soroush, A. *et al.* Large language models are poor medical coders — benchmarking of medical code querying. *NEJM AI***1**, (2024).
6. Chen, S. *et al.* The effect of using a large language model to respond to patient messages. *Lancet Digit. Health***6**, e379–e381 (2024).
7. Potts, B. MedFuzz: Exploring the robustness of LLMs on medical challenge problems. *Microsoft Research*https://www.microsoft.com/en-us/research/blog/medfuzz-exploring-the-robustness-of-llms-on-medical-challenge-problems/ (2024).
8. Bai, Y. *et al.* Training a helpful and harmless assistant with reinforcement learning from human feedback. *arXiv [cs.CL]* (2022).
9. Touvron, H. *et al.* Llama 2: Open Foundation and Fine-Tuned Chat Models. *arXiv [cs.CL]* (2023).
10. Bai, Y. *et al.* Constitutional AI: Harmlessness from AI Feedback. *arXiv [cs.CL]* (2022).
11. Liu, R., Sumers, T. R., Dasgupta, I. & Griffiths, T. L. How do large language models navigate conflicts between honesty and helpfulness? *arXiv [cs.CL]* (2024).
12. Askell, A. *et al.* A General Language Assistant as a Laboratory for Alignment. *arXiv [cs.CL]* (2021).
13. Rafailov, R. *et al.* Direct Preference Optimization: Your Language Model is Secretly a Reward Model. *arXiv [cs.LG]* (2023).
14. Christiano, P. *et al.* Deep reinforcement learning from human preferences. *arXiv [stat.ML]* (2017).
15. Ouyang, L. *et al.* Training language models to follow instructions with human feedback. *arXiv [cs.CL]* (2022).
16. Menz, B. D., Modi, N. D., Sorich, M. J. & Hopkins, A. M. Health disinformation use case highlighting the urgent need for artificial intelligence vigilance: Weapons of mass disinformation: Weapons of mass disinformation. *JAMA Intern. Med.***184**, 92–96 (2024).
17. Menz, B. D. *et al.* Current safeguards, risk mitigation, and transparency measures of large language models against the generation of health disinformation: repeated cross sectional analysis. *BMJ***384**, e078538 (2024).
18. Zhang, Y., Sharma, K., Du, L. & Liu, Y. Toward mitigating misinformation and social media manipulation in LLM era. in *Companion Proceedings of the ACM on Web Conference 2024* vol. 19 1302–1305 (ACM, New York, NY, USA, 2024).
19. Xu, N. *et al.* Cognitive overload: Jailbreaking large language models with overloaded logical thinking. in *Findings of the Association for Computational Linguistics: NAACL 2024* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2024). doi:10.18653/v1/2024.findings-naacl.224.
20. Ding, P. *et al.* A wolf in sheep's clothing: Generalized nested jailbreak prompts can fool large language models easily. in *Proceedings of the 2024 Conference of the North American*

Chapter of the Association for Computational Linguistics: Human Language Technologies (Volume 1: Long Papers) (Association for Computational Linguistics, Stroudsburg, PA, USA, 2024). doi:10.18653/v1/2024.naacl-long.118.

21. Sharma, M. *et al.* Towards Understanding Sycophancy in Language Models. *arXiv [cs.CL]* (2023).
22. Liu, Y. *et al.* A Hitchhiker's Guide to Jailbreaking ChatGPT via Prompt Engineering. in *Proceedings of the 4th International Workshop on Software Engineering and AI for Data Quality in Cyber-Physical Systems/Internet of Things* (ACM, New York, NY, USA, 2024). doi:10.1145/3663530.3665021.
23. Si, C. *et al.* Large Language Models Help Humans Verify Truthfulness -- Except When They Are Convincingly Wrong. *arXiv [cs.CL]* (2023).
24. Haupt, C. E. & Marks, M. FTC regulation of AI-generated medical disinformation. *JAMA* (2024) doi:10.1001/jama.2024.19971.
25. Polyportis, A. & Pahos, N. Navigating the perils of artificial intelligence: a focused review on ChatGPT and responsible research and innovation. *Humanit. Soc. Sci. Commun.***11**, 1–10 (2024).
26. Lu, W. *et al.* Eraser: Jailbreaking defense in Large Language Models via unlearning harmful knowledge. *arXiv [cs.CL]* (2024).
27. Liu, T. *et al.* Making them ask and answer: Jailbreaking large language models in few queries via disguise and reconstruction. *arXiv [cs.CR]* (2024).
28. Han, T. *et al.* Medical large language models are susceptible to targeted misinformation attacks. *NPJ Digit. Med.***7**, 288 (2024).
29. Huang, X. *et al.* Medical MLLM is vulnerable: Cross-modality jailbreak and mismatched attacks on medical Multimodal Large Language Models. *arXiv* (2024).
30. Gallifant, J. *et al.* Language models are surprisingly fragile to drug names in biomedical benchmarks. *arXiv [cs.CL]* (2024).
31. Wu, Z. *et al.*AxBench: Steering LLMs? Even simple baselines outperform sparse autoencoders. *arXiv [cs.CL]* (2025).
32. Dubois, Y., Galambosi, B., Liang, P. & Hashimoto, T. B. Length-controlled AlpacaEval: A simple way to debias automatic evaluators. *arXiv [cs.LG]* (2024).
33. Bhakthavatsalam, S. *et al.* Think you have solved direct-answer question answering? Try ARC-DA, the direct-answer AI2 Reasoning Challenge. *arXiv [cs.CL]* (2021).
34. Clark, C. *et al.*BoolQ: Exploring the surprising difficulty of natural yes/no questions. *arXiv [cs.CL]* (2019).
35. Hendrycks, D. *et al.* Measuring massive multitask language understanding. *arXiv [cs.CY]* (2020).
36. Rein, D. *et al.* GPQA: A Graduate-Level Google-Proof Q&A Benchmark. *arXiv [cs.AI]* (2023).
37. Lin, S., Hilton, J. & Evans, O. TruthfulQA: Measuring How Models Mimic Human Falsehoods. *arXiv [cs.CL]* (2021).
38. Zeng, Y. *et al.* How Johnny can persuade LLMs to jailbreak them: Rethinking persuasion to challenge AI safety by humanizing LLMs. *arXiv [cs.CL]* (2024).
39. Xu, R. *et al.* The Earth is Flat because...: Investigating LLMs' Belief towards Misinformation via Persuasive Conversation. *arXiv [cs.CL]* (2023).
40. Allen-Zhu, Z. & Li, Y. Physics of language models: Part 3.2, knowledge manipulation. *arXiv [cs.CL]* (2023).

41. Wei, J. *et al.* Chain-of-Thought Prompting Elicits Reasoning in Large Language Models. *arXiv [cs.CL]* (2022).
42. OpenAI *et al.* OpenAI o1 System Card. *arXiv [cs.AI]* (2024).
43. Chen, Q. *et al.* Towards reasoning era: A survey of long chain-of-thought for reasoning large language models. *arXiv [cs.AI]* (2025).
44. DeepSeek-AI *et al.* DeepSeek-R1: Incentivizing Reasoning Capability in LLMs via Reinforcement Learning. *arXiv [cs.CL]* (2025).
45. Guan, M. Y. *et al.* Deliberative Alignment: Reasoning enables safer language models. *arXiv [cs.CL]* (2024).
46. Li, Z.-Z. *et al.* From System 1 to System 2: A survey of reasoning Large Language Models. *arXiv [cs.AI]* (2025).
47. Jiang, F. *et al.*SafeChain: Safety of language models with long chain-of-thought reasoning capabilities. *arXiv [cs.AI]* (2025).
48. Sycophancy in GPT-4o: what happened and what we're doing about it. https://openai.com/index/sycophancy-in-gpt-4o/.
49. Liu, J., Min, S., Zettlemoyer, L., Choi, Y. & Hajishirzi, H. Infini-gram: Scaling unbounded n-gram language models to a trillion tokens. *arXiv [cs.CL]* (2024).
50. Soldaini, L. *et al.* Dolma: An open corpus of three trillion tokens for language model pretraining research. *arXiv [cs.CL]* (2024).
51. Raffel, C. *et al.* Exploring the limits of transfer learning with a unified text-to-text transformer. *arXiv [cs.LG]* (2019).
52. Together. RedPajama, a project to create leading open-source models, starts by reproducing LLaMA training dataset of over 1.2 trillion tokens. https://www.together.ai/blog/redpajama.
53. Gao, L. *et al.* The Pile: An 800GB dataset of diverse text for language modeling. *arXiv [cs.CL]* (2020).
54. Zhou, C. *et al.* LIMA: Less is more for alignment. *arXiv [cs.CL]* (2023).
55. *Inspect_ai: Inspect: A Framework for Large Language Model Evaluations*. (Github).
56. *Alpaca_eval: An Automatic Evaluator for Instruction-Following Language Models. Human-Validated, High-Quality, Cheap, and Fast*. (Github).
57. Miller, E. Adding error bars to evals: A statistical approach to language model evaluations. *arXiv [stat.AP]* (2024).
58. Grattafiori, A. *et al.* The Llama 3 herd of models. *arXiv [cs.AI]* (2024).
59. Panickssery, A., Bowman, S. R. & Feng, S. LLM evaluators recognize and favor their own generations. *arXiv [cs.CL]* (2024).
60. Wataoka, K., Takahashi, T. & Ri, R. Self-preference bias in LLM-as-a-judge. *arXiv [cs.CL]* (2024).
61. Xu, W. *et al.* Pride and prejudice: LLM amplifies self-bias in self-refinement. *arXiv [cs.CL]* (2024).
62. Laurito, W. *et al.* AI AI bias: Large language models favor their own generated content. *arXiv [cs.CL]* (2024).


English
Español
Français
中文
العربية
Tiếng Việt
한국어
Text
Image
Table
Diagram
Chart

Chapter 11

WorldMedQA-V: a Multilingual, Multimodal Medical Examination Dataset for Multimodal Language Models Evaluation

Shan Chen*, João Matos*, Siena Kathleen V. Placino, Yingya Li, Juan Carlos Climent Pardo, Daphna Idan, Takeshi Tohyama, David Restrepo, Luis Filipe Nakayama, José María Millet Pascual-Leone, Guergana K Savova, Hugo Aerts, Leo Anthony Celi, An-Kwok Ian Wong, Danielle Bitterman, Jack Gallifant

Findings of the Association for Computational Linguistics: NAACL 2025

Summary

Background

Vision–language models (VLMs) are increasingly employed in healthcare settings, yet existing evaluation benchmarks are mostly monolingual, text-only, and often derived from a small number of countries. This limits our understanding of how well VLMs perform in diverse clinical and linguistic contexts.

Methods

We present WorldMedQA-V – a multilingual, multimodal medical exam dataset comprising 568 clinician-validated multiple-choice questions, each paired with a medical image, collected from four countries (Brazil, Israel, Japan, Spain) in both the local language and native English translations. We evaluated ten state-of-the-art VLMs (including GPT4o, Gemini, LLaVA variants) on both text-only and text+image inputs, measuring accuracy and consistency across languages, and calculating agreement (Cohen's Kappa) between predictions in the local and English versions.

Findings

Performance was substantially lower than prior single-language medical benchmarks: even the best model, GPT4o, failed to pass the 'exam' threshold for several datasets (e.g., scoring 58% on the Hebrew original-language subset). Models showed improved accuracy when provided with images (though gains were typically modest – ~1-3% for top models) and greater cross-language consistency when images were included. Moreover, performance varied dramatically by country and language: models often did better on English translations than on original languages, and the least-represented languages (e.g., Hebrew) showed the greatest performance drop.

Interpretation

WorldMedQA-V highlights substantial gaps in current VLMs' multilingual and multimodal medical reasoning capabilities. The disparity across languages and reliance on mostly English data underscore risks for equitable deployment in global healthcare contexts. The dataset provides a rigorous new benchmark to drive the development of more inclusive, clinically relevant AI systems tracking real progress.

Introduction

Generative artificial-intelligence (AI) models are increasingly being adopted in healthcare, highlighting the need for robust benchmarks to assess their safety, efficacy, and fairness[1–4].

One of the key evaluation tasks in Natural Language Processing (NLP) is Question Answering (QA)[5,6], which involves building systems that can automatically respond to human queries in natural language by combining language understanding with information retrieval[7]. Multiple-choice QA benchmarks have become essential not only for evaluating large language models (LLMs) but also for assessing vision–language models (VLMs) in medicine[8].



Figure 1. *WorldMedQA-V dataset generation and evaluation workflows.*

Recent research has explored the performance of LLMs in medical exams, with ChatGPT being the first AI system to pass the USMLE[9], prompting further studies[8,10,11]. A recent review identified 45 studies on ChatGPT's performance in medical exams[8], but VLMs remain under-explored in medical tasks[12,13]. Despite progress, current models face limitations such as context fragility, biases, and inconsistent multilingual performance[14–16]. There is also a need for more diverse datasets to ensure equitable AI evaluation in healthcare[17].

Key gaps include:

- Real-world validity: studies reveal errors in existing medical-QA datasets[18].
- Linguistic diversity: many datasets lack language representation (Appendix Table 1).
- Imaging data: most medical-QA benchmarks exclude multimodal data (Appendix Table 1).
- Training-data contamination: outdated datasets may overlap with LLM/VLM training corpora[14,19,20].

To address these issues, we introduce WorldMedQA-V, a multilingual, multimodal dataset for evaluating language and vision models. Key contributions include:

- Multimodal medical exams from four countries, supporting local languages and English.
- Previously unseen multimodal exam questions with clinical validation by medical professionals.
- Baseline performance reporting of current state-of-the-art VLMs across languages, including an evaluation of performance differentials between local languages and English.
- An investigation into the impact of adding image data to model performance and stability across language translations.

Related Work

Recent benchmarks such as MMMU[21], MMMU-pro[22], EXAMS-V[23], and VQArt-Bench[24] evaluate vision-language models (VLMs) across multiple languages and disciplines. These evaluations reveal notable performance gaps across linguistic and cultural contexts. Studies indicate that VLMs tend to perform better in English, likely due to the predominance of English-language training data[25]. These findings underscore the need to improve VLM performance in diverse linguistic and cultural settings, particularly in specialized domains. Moreover, previous benchmarks contain only a limited number of health- or medical-related questions, and these are not clinically verified.

Medical datasets from these regions highlight challenges in large language model (LLM) performance within healthcare. In Asia, notable datasets originate from China, Taiwan (MedQA), South Korea (KorMedMCQA), and India (MedMCQA). The MLEC-QA dataset from China, containing 136,236 multiple-choice questions, is the largest. Despite LLMs being pre-trained on vast corpora, performance in this domain is hindered by limited diversity and quality of training data—especially for two-step reasoning and biomedical concepts[26]. Similar trends are observed in Taiwan and South Korea, where English-pretrained models underperform on local medical exams.

In Europe, datasets from Spain, Sweden, and Poland (the latter not publicly available) underscore the difficulties LLMs face as question complexity increases[27]. Recent progress shows that GPT-3.5-Turbo and GPT-4 passed the Swedish medical licensing exam[28], while GPT-4-Turbo slightly outperformed humans in Poland[29].



Figure 2. *Accuracy in local language and English across models and countries. The red-shaded area highlights each country's exam-passing threshold. Passing score is a proxy here since our dataset is a subset. Detailed results appear in Appendix.*

Methods

See Figure 1 shows the overall workflow of the study.

Data Collection

Our study uses medical-exam data from Brazil, Israel, Japan, and Spain, consisting of multiple-choice questions from national licensing or specialization exams. Brazil's dataset includes 100 questions per exam from the 2011–2016 and 2020–2024 "Revalida" exams. Israel's dataset contains 150 questions from Phase A of the resident-certification exam (2020–2023). Japan's data come from the 116th–118th National Medical Licensing Examinations (2022–2024), while Spain's dataset includes questions from specialization exams (2019–2023). Further details are provided in Appendix A.

Clinical Validation

A clinical-validation process was carried out for all collected and translated data to ensure their quality and relevance. Native-speaking clinicians from each country validated the three key stages of the process—data extraction, translation, and final QA review.

Evaluation

Models: We included open- and closed-source models across a range of sizes: GPT-4o-2024-05-13, GPT-4o-mini-2024-07-18, Gemini-Flash-1.5-May, Gemini-Pro-1.5-May, LLaVA-Next-Llama3 (8 B), LLaVA-Next-Yi-34B, LLaVA-Next-Mistral-7B, LLaVA-Next-Vicuna-7B, Yi-VL-34B, and Yi-VL-6B. All models were set to generate 512 tokens, with a temperature of 0 for reproducibility, and evaluated on an Nvidia GPU with CUDA > 12.0.

Experiments: The VLMEvalKit evaluation framework was utilized to conduct experiments. We evaluated the ten models with and without image input, using accuracy as the metric. Cohen's kappa coefficients were computed to assess each model's reliability when answering the question in the original language versus the English translation.

Results & disscussions

Dataset

The complete WorldMedQA-V contains 726 question–answer pairs and 850 images across four countries: Brazil, Israel, Japan, and Spain. Every QA is paired with at least one image (some images are reused). After removing items with multiple images or multiple correct options, the final evaluation subset comprises 568 QAs, each with a single image and a single correct answer.

Table 1 (Appendix) gives the country- and language-level breakdown; Box 1 (Appendix) shows a Brazilian example.

VLM performance

Figure 2 summarises model accuracy on each dataset in the local language and in English. All models score well below the ~90 % USMLE figure previously reported for GPT-4. GPT-4o is the strongest model overall; it fails to reach the 70 % pass mark only on the Hebrew-language Israel set (58 %), yet passes the English translation of the same set (63 %). The other non-Roman script in the benchmark is Japanese, where GPT-4o attains 88 %—above threshold—possibly because Japanese is better represented in pre-training corpora and shares characters with Chinese.

Models generally score higher on the English translations, especially for Israel and Spain; the English Israel set still trails the others, suggesting data-level differences beyond language. In Brazil, GPT-4o scores 75 % in Portuguese and 67 % in English; in Japan, GPT-4o, GPT-4o-mini, Gemini-Flash-1.5 and Gemini-Pro-1.5 all do better in Japanese than in English, indicating strong Japanese support. The LLaVA-NeXT family produces the lowest accuracies; on the Israel dataset several variants perform near-random (24–46 %) in both Hebrew and English.

Accuracy with and without image input

Across nearly all models, accuracy improved when the image was provided. This effect was most pronounced for models with weaker baseline text-only performance. GPT-family models, in contrast, showed only marginal differences—typically around one to three percentage points—between image and text-only settings, suggesting they rely less on visual information or can compensate via strong textual reasoning. Models from the Gemini family were the most sensitive to image removal; providing images improved their accuracy by approximately 4–27%, depending on the dataset.

Models with lower overall performance, such as Yi-VL and llava-next, displayed more unstable behavior, sometimes improving and other times worsening when images were removed. Notably, Yi-VL-34B showed almost no predictive ability when images were withheld, highlighting its dependence on the visual modality.

Cross-language consistency

To evaluate stability across languages, each model's predictions in the original language were compared to its predictions on English translations using Cohen's kappa. GPT-4o consistently showed the strongest cross-language agreement, especially for Brazil, Japan, and Spain, and agreement was generally higher when image information was available. The highest agreement (84%) occurred in the Spanish text-only condition, likely reflecting the model's overall high accuracy on that dataset. GPT-4o-mini and Gemini Flash 1-5 also achieved strong agreement in Brazil and Spain, though they did not match GPT-4o.

Models such as Yi-VL displayed low agreement across all countries, indicating poor cross-linguistic stability. A particularly notable case is Gemini Pro 1-5 on the Spanish dataset: its agreement increased dramatically—from 16.3% to 69.3%—when images were included. This demonstrates that visual information can act as a stabilizing factor for cross-language semantic alignment.

Conclusion

In this work, we introduced WorldMedQA-V, a clinically validated, multilingual, and multimodal dataset containing medical QAs and images from Brazil, Israel, Japan, and Spain. We evaluated the performance of 10 vision-language models using both local languages and English translations, revealing performance disparities across languages and demonstrating how multimodal data can enhance accuracy. Despite improvements from image-based inputs, underrepresented languages like Hebrew proved particularly challenging. Throughout the data collection process, we engaged with 27 regions and collaborated closely with local physicians to ensure clinical and contextual relevance, ultimately focusing on the four regions that met our stringent criteria of high-quality translations and robust image-based multiple-choice questions. Each question underwent rigorous review by native-speaking clinicians to ensure linguistic precision and clinical validity, making WorldMedQA-V a gold-standard benchmark. Our methodology went beyond mere data aggregation, involving meticulous curation and validation to create a resource that is both scientifically robust and practically relevant. We adopted a single-correct-answer format consistent with standardized medical exams to simplify evaluation and ensure reproducibility, yet over 95\% of evaluated models still failed to achieve passing performance—underscoring the inherent difficulty of integrating multilingual, multimodal information. Although our current dataset focuses on four regions, we remain committed to expanding its

geographic scope in future iterations, particularly to include underrepresented areas such as parts of Africa and the Americas, thereby continuing to address critical gaps in the evaluation of healthcare-focused VLMs.

Limitations

While WorldMedQA-V represents a significant step toward creating a multilingual, multimodal benchmark for evaluating VLMs in healthcare, several limitations must be acknowledged.

First, the dataset, while carefully curated by trained physicians to ensure the validity of both questions and answers, remains relatively small. As we evaluated 568 multiple-choice questions and images, the sample size is limited in comparison to larger text-based benchmarks.

Second, the dataset only includes data from four countries: Brazil, Israel, Japan, and Spain, spanning three continents. This geographic limitation results in an underrepresentation of certain regions, particularly Africa, North and Central America, Oceania, and other parts of Asia.

Furthermore, although the benchmark introduces multimodal elements, it pairs only one image per question. Real-world clinical scenarios often involve multiple images from different time points or modalities, such as a sequence of X-rays, CT scans, and pathology slides. Another limitation is that text that is within images were not translated or adapted. English translations, although validated by native-speaking clinicians from each country, require further cross-validations, as these are typically nontrivial tasks.

Additionally, the lack of open-source multimodal medical language models restricts our ability to comprehensively evaluate and compare state-of-the-art health AI using WorldMedQA-V. Furthermore, since the models we tested were not originally trained for the medical domain, some LLMs (e.g., Gemini) refused to respond when no image was provided for certain questions, resulting in lower scores. When evaluating model performance against a passing threshold, a limitation is that our analysis relies on a limited set of multiple-choice questions with images, which may not provide consistent difficulty levels across different questions within the same exam.

Lastly, we set the underlying assumption that each question had only one correct answer, excluding cases where multiple correct answers were

possible. This decision was made to simplify evaluation, but it may not reflect the inherent ambiguity and complexity found in both medical examinations and real-world medical scenarios where multiple treatment options or diagnoses can be valid.

References

1. Thirunavukarasu, A. J. *et al.* Large language models in medicine. *Nat. Med.***29**, 1930–1940 (2023).
2. Clusmann, J. *et al.* The future landscape of large language models in medicine. *Commun. Med. (Lond.)***3**, 141 (2023).
3. Abbasian, M. *et al.* Foundation metrics for evaluating effectiveness of healthcare conversations powered by generative AI. *NPJ Digit. Med.***7**, 82 (2024).
4. Wiggers, K. Hugging Face releases a benchmark for testing generative AI on health tasks. *TechCrunch* (2024).
5. Fan, L. *et al.* A bibliometric review of large language models research from 2017 to 2023. *arXiv [cs.DL]* (2023).
6. Yu, H. *et al.* Large Language Models in biomedical and Health Informatics: A review with bibliometric analysis. *arXiv [cs.DL]* (2024).
7. Jin, D. *et al.* What disease does this patient have? A large-scale open domain question answering dataset from medical exams. *Appl. Sci. (Basel)***11**, 6421 (2021).
8. Liu, M. *et al.* Performance of ChatGPT across different versions in medical licensing examinations worldwide: Systematic review and meta-analysis. *J. Med. Internet Res.***26**, e60807 (2024).
9. Kung, T. H. *et al.* Performance of ChatGPT on USMLE: Potential for AI-assisted medical education using large language models. *PLOS Digit Health***2**, e0000198 (2023).
10. Rodrigues Alessi, M. *et al.* Comparative performance of medical students, ChatGPT-3.5 and ChatGPT-4.0 in answering questions from a Brazilian national medical exam: Cross-sectional questionnaire study. *JMIR AI***4**, e66552 (2025).
11. Chen, S. *et al.* Evaluating the ChatGPT family of models for biomedical reasoning and classification. *J. Am. Med. Inform. Assoc.***31**, 940–948 (2024).
12. Yan, Z. *et al.* Multimodal ChatGPT for Medical Applications: an Experimental Study of GPT-4V. *arXiv [cs.CV]* (2023).
13. Wu, C. *et al.* Can GPT-4V(ision) Serve Medical Applications? Case Studies on GPT-4V for Multimodal Medical Diagnosis. *arXiv [cs.CV]* (2023).
14. Gallifant, J. *et al.* Language models are surprisingly fragile to drug names in biomedical benchmarks. *arXiv [cs.CL]* (2024).
15. Zack, T. *et al.* Assessing the potential of GPT-4 to perpetuate racial and gender biases in health care: a model evaluation study. *Lancet Digit. Health***6**, e12–e22 (2024).
16. Chen, S. *et al.* Cross-Care: Assessing the healthcare implications of pre-training data on language model bias. *Neural Inf Process Syst***abs/2405.05506**, 23756–23795 (2024).
17. Restrepo, D. *et al.* Analyzing Diversity in Healthcare LLM Research: A Scientometric Perspective. *arXiv [cs.CL]* (2024).
18. Saab, K. *et al.* Capabilities of Gemini models in medicine. *arXiv [cs.AI]* (2024).
19. Zhang, A. K. *et al.* Language model developers should report train-test overlap. *arXiv [cs. LG]* (2025).
20. Zhang, H. *et al.* A careful examination of large language model performance on grade school arithmetic. *arXiv [cs.CL]* (2024).
21. Yue, X. *et al.* MMMU: A Massive Multi-discipline Multimodal Understanding and Reasoning Benchmark for Expert AGI. *arXiv [cs.CL]* (2023).

22. Yue, X. *et al.* MMMU-Pro: A More Robust Multi-discipline Multimodal Understanding Benchmark. in *Proceedings of the 63rd Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)* 15134–15186 (Association for Computational Linguistics, Stroudsburg, PA, USA, 2025).
23. Das, R. J. *et al.* EXAMS-V: A multi-discipline multilingual multimodal exam benchmark for evaluating vision language models. *arXiv [cs.CL]* (2024).
24. Alfarano, A., Venturoli, L. & del Castillo, D. N. VQArt-Bench: A semantically rich VQA Benchmark for Art and Cultural Heritage. *arXiv [cs.CV]* (2025) doi:10.48550/arXiv.2510.12750.
25. Weidinger, L. *et al.* Ethical and social risks of harm from Language Models. *arXiv [cs.CL]* (2021).
26. Li, J., Zhong, S. & Chen, K. MLEC-QA: A Chinese Multi-Choice Biomedical Question Answering Dataset. in *Proceedings of the 2021 Conference on Empirical Methods in Natural Language Processing* (Association for Computational Linguistics, Stroudsburg, PA, USA, 2021). doi:10.18653/v1/2021.emnlp-main.698.
27. Vilares, D. & Gómez-Rodríguez, C. HEAD-QA: A Healthcare Dataset for Complex Reasoning. *arXiv [cs.CL]* (2019).
28. Hertzberg, N. & Lokrantz, A. MedQA-SWE - a Clinical Question & Answer Dataset for Swedish. *LREC* 11178–11186 (2024).
29. Bean, A. M., Korgul, K., Krones, F., McCraith, R. & Mahdi, A. Exploring the landscape of large language models in medical question answering. *arXiv*.

A Appendix

A.1 Existing publicly-available medical examination QA dataset per country

Table 1: Summary of existing open-source Medical QA Datasets by Country.

Country	Dataset	#QA	Language(s)	Modalities	Source	Years
China	MedQA (Jin et al., 2020)	34,251	Simplified Chinese	Text	MCMLE, Mainland China Medical Licensing Examination	Not Clear
China	MLEC-QA (Li et al., 2021b)	136,236	Simplified Chinese	Text, Images	National Medical Licensing Examination (NMLEC)	Not Clear
India	MedMCQA (Pal et al., 2022)	193,155	English	Text	AIIMS PG, NEET PG	1991-2022
Spain	Head-QA (Vilares and Gómez-Rodríguez, 2019b)	6,765	Spanish and English	Text, Images	Ministerio de Sanidad, Consumo y Bienestar Social	2013–2017
Republic of Korea	KorMedMCQA (Kweon et al., 2024)	5,345	Korean and English	Text	Korea Health Personnel Licensing Examination Institute	2012–2023
Sweden	MedQA-SWE (Hertzberg and Lokrantz, 2024b)	3,180	Swedish	Text	National Board of Health and Welfare, Umeå University	2016–2023
Taiwan	MedQA (Jin et al., 2020)	14,123	Traditional Chinese	Text	TWMLE, Taiwan Medical Licensing Examination	Not Clear
United States	MedQA (Jin et al., 2020)	12,723	English	Text	USMLE, United States Medical Licensing Examination	Not Clear

A.2 Details on collected data per country

A.2.1 Brazil

The examination data were collected from the "Revalida" examinations, which are publicly available on the Brazilian government's official website. The "Revalida" exam, administered by the National Institute of Educational Research and Studies (INEP), supports the process of diploma revalidation for doctors who graduated abroad and wish to practice in Brazil. The exams consist of two sections: 100 multiple-choice questions (20 in each of the following areas: Internal Medicine, Surgery, Pediatrics, Preventive Medicine, and Gynecology and Obstetrics) and open-ended questions. For this work, only the multiple-choice section was included. Data from the years 2011–2016 and 2020–2024 were used, encompassing all publicly available years at the time of this study (de Estudos e Pesquisas Educacionais Anísio Teixeira | Inep).

A.2.2 Israel

The Israeli subset consists of questions from seven medical specialties: Internal Medicine, Clinical Microbiology, Neurology, Oncology, Ophthalmology, Urology, and Public Health. These questions are drawn from Phase A of the two-phase examination process that residents in Israel must complete during their training. Phase A is a written exam held annually, comprising approximately 150 questions. We included questions from tests administered between 2020 and 2023, with full versions of these exams publicly available on the Israel Medical Association's website (Association; Association).

The questions are categorized into three main types: preclinical cases, clinical cases, and questions based on scientific articles. Preclinical cases focus on foundational scientific knowledge, while clinical cases present patient background information followed by clinical questions related to the patient's medical conditions. Questions derived from scientific articles involve analysis of graphs, figures, and study results, which are particularly prevalent in the public health exam. Some questions also include visual aids, such as diagnostic images, laboratory slides (e.g., blood smear slides in Clinical Microbiology), and other data specific to patients' clinical presentations.

A.2.3 Japan

Japanese questions were sourced from past examinations that were published on the website of the Ministry of Health, Labour and Welfare. We included the 116th, 117th, and 118th National Medical Licensing Examination (Japanese Ministry of Health Labour and Welfare 2022; Japanese Ministry of Health Labour and Welfare 2023; Japanese Ministry of Health Labour and Welfare 2024), which corresponded to 2022-2024.

A.2.4 Spain

The examination data were sourced from the annual exams organized by the Ministerio de Sanidad, Consumo y Bienestar Social (Spanish Ministry of Health, Consumer Affairs, and Social Welfare) (de Sanidad). These exams are part of the competitive selection process for specialized medical positions in Spain's public healthcare system. Eligibility for participation requires candidates to possess a bachelor's degree in medicine (6 years of study) and typically prepare for a year or more, given the limited number of vacancies. The exams play a critical role in ranking candidates, who are able to select their specialization and hospital placement only based on their exam performance. For this study, only data from the years 2019–2023 were used to avoid overlap with the existing Head-QA dataset (Vilares and Gómez-Rodríguez, 2019b).

A.3 Detailed Data Statistics

Table 2: `WorldMedQA's` data across countries and languages. In the curated dataset, each QA was associated with at least one image. Some images were present in more than one question. In the final subset for evaluation (rightmost column), each question had a single image and the correct option associated with it, resulting in fewer samples. The number of answer options per question (fourth column) refers to the original number of choices in the multiple-choice format (e.g., A-D for four options or A-E for five options). However, all questions after preprocessing results in 4 options only. In cases where this varies, such as in Brazil, the value represents a weighted average across questions. The total number of QAs and images does not immediately add up due to some questions sharing images or having multiple associated options.

Country	Language	Years	Option/QA	QAs, n (%)	Images, n (%)	Final, n (%)
Brazil	Portuguese	2011-2024	4.27	93 (12.8%)	94 (11.1%)	89 (15.7%)
Israel	Hebrew	2020-2023	4.00	200 (27.6%)	184 (21.6%)	186 (32.7%)
Japan	Japanese	2022-2024	5.00	306 (42.1%)	445 (52.4%)	168 (29.6%)
Spain	Spanish	2019-2023	4.00	127 (17.5%)	127 (14.9%)	125 (22.0%)
Total	4 Languages	2011-2024	4.00	726 (100%)	850 (100%)	568 (100%)

A.4 Example QA from the Brazilian dataset

Box 1. Example multimodal QA from the Brazilian subset

Original (Portuguese)

Um paciente do sexo masculino, 55 anos de idade, tabagista 60 maços/ano, com tosse crônica há mais de 10 anos, relata que há cerca de três meses observou a presença de sangue na secreção eliminada com a tosse. Refere ainda perda de cerca de 15% do peso habitual nesse mesmo período, anorexia, adinamia e sudorese noturna. A radiografia de tórax realizada por ocasião da consulta é mostrada abaixo. Qual a hipótese diagnóstica mais provável nesse caso?

A) Aspergilose pulmonar.
B) Carcinoma pulmonar.
C) Tuberculose cavitária.
D) Bronquiectasia com infecção.
E) Doença pulmonar obstrutiva crônica.

Image

Translation (English)

A 55-year-old male patient, with a smoking history of 60 pack-years, has had a chronic cough for over 10 years. He reports that about three months ago, he noticed the presence of blood in the sputum. He also mentions a weight loss of about 15% of his usual weight during the same period, anorexia, weakness, and night sweats. The chest X-ray taken at the time of the consultation is shown below. What is the most likely diagnostic hypothesis in this case?

A) Pulmonary aspergillosis.
B) Lung carcinoma.
C) Cavitary tuberculosis.
D) Bronchiectasis with infection.
E) Chronic obstructive pulmonary disease.

A.5 Model output consistency across countries and test setting

Table 3: Cohen's Kappa reflecting agreement between languages for the same models, countries, and testing setting. Values in **bold** highlight the model with highest kappa per country and testing mode. The two studied settings were text-only (T. only) and text and image (T. & I.).

Country	Brazil		Israel		Japan		Spain	
Model ↓ Setting →	T. only	T. & I.	T. only	T. & I.	T. only	T. & I.	T. only	T. & I.
GPT4o	**0.684**	**0.743**	**0.619**	0.654	**0.683**	**0.618**	**0.840**	**0.829**
GPT4o-MINI	0.642	0.655	0.458	0.603	0.525	0.554	0.715	0.809
GeminiFlash1-5	0.612	0.536	0.533	**0.655**	0.591	0.521	0.594	0.767
GeminiPro1-5	0.389	0.469	0.184	0.416	0.351	0.490	0.163	0.693
Yi-VL-34B	0.020	0.438	0.111	0.309	0.033	0.393	0.030	0.507
Yi-VL-6B	0.427	0.320	0.150	0.204	0.240	0.348	0.269	0.251
llava-next-llama3	0.429	0.441	0.401	0.380	0.269	0.264	0.435	0.433
llava-next-mistral-7b	0.498	0.310	0.148	0.243	0.153	0.234	0.466	0.348
llava-next-vicuna-7b	0.385	0.491	0.167	0.281	0.091	0.185	0.310	0.279
llava-next-yi-34b	0.592	0.635	0.208	0.223	0.393	0.373	0.594	0.488

A.6 Detailed performance with and without images

Table 4: Accuracy comparison across countries and **original** languages (Portuguese, Hebrew, Japanese, and Spanish) for each model. The two studied settings were text-only (T. only) and text and image (T. & I.). Each cell represents the performance of each model in its native language dataset, highlighting how the presence or absence of images affects accuracy.

Country	Brazil		Israel		Japan		Spain	
Model ↓ Setting →	T. only	T. & I.	T. only	T. & I.	T. only	T. & I.	T. only	T. & I.
GPT4o	0.764	0.753	0.584	0.578	0.857	0.881	0.704	0.712
GPT4o-MINI	0.562	0.584	0.389	0.373	0.762	0.732	0.632	0.640
GeminiFlash1-5	0.494	0.640	0.281	0.395	0.625	0.667	0.456	0.640
GeminiPro1-5	0.427	0.607	0.135	0.368	0.601	0.726	0.312	0.584
Yi-VL-34B	0.034	0.438	0.011	0.270	0.077	0.530	0.024	0.416
Yi-VL-6B	0.348	0.348	0.238	0.249	0.446	0.482	0.328	0.336
llava-next-llama3	0.393	0.382	0.330	0.297	0.458	0.470	0.368	0.416
llava-next-mistral-7b	0.371	0.404	0.238	0.265	0.369	0.381	0.376	0.336
llava-next-vicuna-7b	0.281	0.292	0.276	0.308	0.256	0.298	0.304	0.328
llava-next-yi-34b	0.438	0.483	0.238	0.281	0.577	0.518	0.504	0.488

Table 5: Accuracy comparison across countries and **English-translated** datasets for each model. The two studied settings were text-only (T. only) and text and image (T. & I.). Each cell represents the performance of each model after translation, highlighting how the presence or absence of images affects accuracy.

Country	Brazil		Israel		Japan		Spain	
Model ↓ Setting →	T. only	T. & I.	T. only	T. & I.	T. only	T. & I.	T. only	T. & I.
GPT4o	0.685	0.674	0.589	0.632	0.690	0.720	0.720	0.728
GPT4o-MINI	0.517	0.584	0.422	0.438	0.595	0.613	0.592	0.632
GeminiFlash1-5	0.494	0.539	0.286	0.427	0.571	0.601	0.544	0.632
GeminiPro1-5	0.382	0.652	0.281	0.492	0.440	0.613	0.248	0.632
Yi-VL-34B	0.034	0.472	0.022	0.389	0.065	0.536	0.024	0.544
Yi-VL-6B	0.326	0.348	0.335	0.362	0.393	0.417	0.392	0.448
llava-next-llama3	0.494	0.483	0.314	0.297	0.435	0.482	0.568	0.552
llava-next-mistral-7b	0.438	0.416	0.319	0.319	0.500	0.452	0.496	0.512
llava-next-vicuna-7b	0.371	0.337	0.303	0.314	0.393	0.399	0.472	0.448
llava-next-yi-34b	0.528	0.539	0.459	0.432	0.577	0.577	0.600	0.592


Search
Read
Synthesize
Verify
Deep Research Benchmark
Complex Questions
Multi-hop Reasoning
Source Quality
Evidence Grounding
Comprehensive Answers

Chapter 12

MedBrowseComp: Benchmarking Medical Deep Research and Computer Use

Shan Chen*, Pedro Moreira*, Yuxin Xiao, Sam Schmidgall, Jeremy Warner, Hugo Aerts, Thomas Hartvigsen, Jack Gallifant, Danielle S Bitterman

Under Review at JCO-CCI

Summary

Background

While general-purpose LLMs are increasingly touted as tools for clinical support, most evaluations focus on single-step fact retrieval rather than the complex multi-hop evidence synthesis required in real-world medicine. This gap raises concerns about their true suitability for clinical decision-making.

Methods

We introduce MedBrowseComp – a benchmark comprising over 1,000 human-curated medical questions reflecting realistic clinical scenarios where practitioners must navigate fragmented evidence from trials, regulations, and cost data to reach updated conclusions. Unlike prior benchmarks, this dataset forces agents to browse live, domain-specific knowledge bases, perform multi-step reasoning, and ground answers in verifiable evidence. We then evaluated state-of-the-art agentic systems on this benchmark to assess performance gaps.

Findings

Agent systems scored as low as ~10% accuracy on the hardest subsets of questions, with overall performance well below the required rigor for clinical settings. Our results expose a substantial capability gap between current LLM-based browsing/retrieval agents and the demands of safe, reliable medical reasoning.

Interpretation

MedBrowseComp underscores that even cutting-edge agentic LLM systems remain far from being dependable tools for medical research or clinical decision support. The benchmark provides a clear testbed and targets for future development of retrieval-reasoning architectures, tool-augmented agents, and evidence-grounded systems in medicine.

Introduction

LLMs have now effectively saturated most static, knowledge-based benchmarks, diminishing the value of these tasks to provide new insights and push the field forward[1–5]. However, this evolution exposes an evaluation gap: legacy leaderboards track static knowledge recall, whereas agentic systems should plan, browse, and synthesize fresh evidence in real time. To move beyond this plateau, the community is pivoting toward agentic systems that actively browse the web, retrieve real-time evidence, and reason over information outside their frozen parameter memories [6–8]. The progression from chatbots to reasoners and ultimately to autonomous agents promises to enable access to real-time data, to allow models to tackle questions outside their pretraining knowledge, and perform complex information gathering tasks previously exclusive to humans[9–11].

The potential impact of web-enabled agents is enormous. In principle, a sufficiently-capable AI agent should be able to retrieve any well-specified fact from reliable sources on the open web, even if doing so requires navigating thousands of pages[12–14]. This promise is especially compelling in medicine, where research, clinical decision support, and patient education all depend on the integration of the most current, specific, and accurate information from heterogeneous sources such as journal articles, clinical trial registries, treatment guidelines, and drug databases[15–20] . Yet despite rapid progress, the community lacks a unified benchmark for systematically evaluating whether agents can perform such complex, multi-source medical retrieval at scale.

As LLMs become the backbone of autonomous agentic systems, rigorous, domain-specific evaluation is critical. Contemporary agent models frequently "hallucinate," generating confident but unsubstantiated or factually incorrect statements[21]. In high-stakes fields like medicine, these errors can misinform clinicians or patients and erode trust. Therefore, benchmarks must test not only a model's reasoning and navigation skills but also its ability to ground each answer in verifiable evidence[21–24]. A robust framework that measures evidence-based accuracy, navigation efficiency, and citation fidelity would directly quantify how well agentic systems incorporate best available information, closing the gap between impressive demos and safe, real-world deployment.

Evaluating an agent's deep research and computer use competence is fundamentally different from testing its ability to recall static facts.

Popular medical benchmarks such as MMLU, MedQA, and WorldMedQA test information that can be memorized during pre-training or retrieved from a single authoritative page. Frontier models now achieve near-ceiling scores on these tasks, so the benchmarks can no longer distinguish state-of-the-art systems or quantify new progress[2,3,25–27]. They are usually executed in closed or synthetic environments that sidestep the real-world hurdles of live web interaction—pagination, obsolete links, contradictory evidence, and shifting page layouts.

In medicine, clinicians and researchers must integrate the latest study results, guideline updates, and safety advisories scattered across heterogeneous sites. To understand and compare agents' abilities to augment such tasks, new deep research and computer use benchmarks reflective of real-world, up-to-date tasks are urgently needed. A benchmark that forces agents to conduct multi-hop, evidence-grounded searches on the open Web should therefore serve two complementary purposes: (1) Directly measure whether agents can navigate, filter, and reconcile real-world information. (2) Dynamically stress-test systems as underlying evidence evolves, long after static benchmarks saturate.

To address this gap, we introduce MedBrowseComp, a new benchmark specifically designed to evaluate the capabilities of AI agents performing complex information retrieval tasks within the medical domain via web browsing. MedBrowseComp measures an agent's ability to accurately navigate the web—including general web pages, specialized medical websites, databases, and potential document formats like wikis, PDFs—to locate verifiable medical facts from reliable sources.

MedBrowseComp's design is inspired by the BrowseComp benchmark[28]; it focuses on fact-seeking questions where the answers are short, objective, and easily verifiable, simplifying the evaluation process and enhancing its reliability. We designed this challenging benchmark collaboratively with physicians using HemOnc.org, one of the largest structured wiki information resources maintained weekly by oncologists for the past 6 years. Importantly, the benchmark is designed to enable automated, dynamic updating as information resources and medical evidence evolves. State-of-the-art Deep Research systems and Computer Use Agents (CUA) in May 2025 achieve less than 50% accuracy overall on MedBrowseComp, with less than 10% in the two hardest sets of questions.

Contributions

The MedBrowseComp Dataset: A novel, curated collection of challenging medical fact-seeking questions, each requiring web browsing and resulting in a short, verifiable answer. MedBrowseComp is the pioneer in curating a comprehensive benchmark that utilizes linked domain knowledge.

Baseline Performance Analysis: An empirical evaluation of various state-of-the-art LLMs and agentic systems on MedBrowseComp, providing initial benchmarks and highlighting the specific difficulties encountered in medical information retrieval.

Demonstration of Capability Gaps: Evidence showing the gap between the capabilities of general-purpose browsing agents (given frontier models already saturated general benchmark like SimpleQA) and specialized skills on complex medical information-seeking tasks.



Figure 1. *Example question constructions for MedBrowseComp.*

12

Related work

One of the first comprehensive efforts to advance AI evaluation for general-purpose tool use and web browsing is GAIA[29]. GAIA is a carefully curated testbed for "General AI Assistants," combining tasks that require multi-modal input, open-ended reasoning, and the ability to query external tools. It is simple for humans, but it was hard for AI systems at the time. Subsequent work

began to highlight the importance of structured, multi-step web traversal. WebWalker introduced a dual-agent framework that separately handles horizontal browsing across different webpages and deep vertical navigation through website hierarchies[30,31]. Its companion benchmark, WebWalkerQA, comprises realistic multi-hop questions from domains like education and organizational websites, emphasizing the challenge of distributing information across intricate hyperlink structures. Around the same time, FRAMES took a different angle by systematically evaluating Retrieval-Augmented Generation (RAG) systems for factual correctness, retrieval quality, and reasoning[32]. While WebWalker and FRAMES address structured exploration and pipeline analysis, SimpleQA focuses more narrowly on short-answer factual correctness, specifically targeting LLM hallucinations[33]. SimpleQA's adversarial question collection and stringent answer verification make it an effective tool for measuring whether models can reliably produce grounded, non-invented responses. Despite its value in exposing factual flaws, SimpleQA's tasks remain relatively easy to solve with basic web searches, limiting its utility for deeper or more specialized queries.

To test expert-level knowledge well beyond the range of average tasks, Humanity's Last Exam (HLE) provides a set of deeply specialized questions[5]. HLE intentionally targets areas where frontier models are known to have knowledge gaps, thereby illuminating the upper limits of AI comprehension across diverse academic disciplines. However, while HLE excels at assessing conceptual difficulty and depth of reasoning, it focuses less on web and knowledge-source navigation capabilities.

BrowseComp and its offshoot BrowseComp-ZH push AI agents to perform complex web searches for difficult-to-find facts[34,35]. BrowseComp's 1,255 English questions use a reverse-engineered approach to ensure they are not trivially searchable: each was devised and combined from existing short answers. The leading OpenAI models have an overall accuracy lower than 10%, however AI systems with search functionalities perform better. BrowseComp-ZH extends this framework to the Chinese web, accounting for different linguistic structures, censorship constraints, and local data sources. Leading models still achieve below 10–20% on BrowseComp-ZH tasks, suggesting that domain- or region-specific peculiarities are another consideration of the difficulty of high-stakes information retrieval.



Figure 2. *Overall workflow of the curation of MedBrowseComp.*

Taken together, these benchmarks outline a rapidly evolving space in AI applications, where goal-oriented web navigation, accurate retrieval, and robust reasoning remain underdeveloped in even the most capable models. MedBrowseComp bridges the gap by focusing on the specialized domain of medicine. Its 1000+ questions [121*5=605 deep research questions across five hops, 121*4=484 computer use questions over four hops] are designed to be both practically useful and challenging, demanding persistent exploration of reputable medical sources, correct interpretation of terminology, and alignment with evidence-based standards. Moreover, MedBrowseComp's design is expandable, allowing for continual updates that track evolving medical knowledge and new online resources.

Methods

To construct the MedBrowseComp dataset, we leverage the comprehensive hematology and oncology database available from HemOnc.org and work with

its editors. HemOnc.org is the largest freely available medical wiki in the field of hematology/oncology, established to address the challenge oncologists routinely face navigating complex treatment regimens and rapidly evolving standards of care. This comprehensive resource covers over 1,000 pages of specialized content, including more than 250 hematologic and oncologic conditions, 5,455 detailed treatment regimens, and 6,950 referenced clinical studies, all curated by physicians with verifications. The platform catalogs approved systemic antineoplastic therapy agents, supportive medications, standard-of-care regimens, and references to primary literature, organized within a standardized ontology framework available through the HemOnc Dataverse[36]. Our first step involved cleaning anti-neoplastic regimen efficacy data, linking each case with corresponding PubMed publications, and associated clinical trial information sourced from ClinicalTrials.gov, with data collected up to April 2025. The fully cleaned and structured version of this dataset has been publicly released on HuggingFace to facilitate broader community engagement, further development, and external validation. To avoid potential dataset contamination, we encoded our final test sets with shifts and byte-wise encoding, which you can decode using the script we provide on GitHub.

To create our specific evaluation questions, we narrowed our dataset by excluding trials linked to multiple PubMed publications to maintain clarity and verifiability. Subsequently, we integrated regimen-specific drug information with FDA Orange Book data as of April 2025. To maintain data consistency, only trials with regimens containing drugs easily matched through standard generic regular expressions were included. A manual verification and deduplication process was conducted to ensure accuracy and reduce redundancy, culminating in a refined set of 121 trials. Each of these trials has clearly defined trial metadata, verified regimen efficacy data, detailed FDA drug approval information, and the corresponding financial market data obtained from Yahoo Finance API for associated stock pricing, as Figure 2 shows.

From this carefully curated dataset, we developed our benchmark designed explicitly to assess (1) autonomous CUA within one to two hops of HemOnc.org's webpage, and (2) deep research agents.

Model Selection and other Details

System Selection Rationale for Deep Research Agent

We evaluate a range of systems, from models with easy API access and systems without API access, and one Computer Use Agent (CUA) system. For models with an easy API with accessible cost, we evaluated the full set, which we refer to as MedBrowseComp-605. For models without easy API acccess and/or inaccessible costs, we evaluate against a smaller set which we refer to as MedBrowseComp-50(Authors put each of the queries into each application, copied out the responses, and graded the final outputs). Detailed model/system descriptions are in the appendix. For answer verification we employed an automated judge powered by GPT 4.1 mini-2025-04-14. The judging prompt was adapted from existing refined evaluation. Two annotators manually answered MedBrowseComp-50 and achieved 100% inter-annotator agreements and 98% agreement with GPT 4.1 mini.

Model Selection Rationale for Computer Use Agent

We select Anthropic's Computer Use (using Claude 3.7 Sonnet) for evaluating browsing capabilities because, among the major commercially available GUI agents at the time, it was the only one that simultaneously offered a documented, programmable API and sandboxed environment that could be reengineered to run large batches without manual oversight, enabling us to run our experiments at scale. Details on Claude's sandbox are provided in the following paragraph and the code is open sourced on our Github repository.

Other UI agents—such as Bytedance's UI Tars, OpenAI's Operator, and Google's Project Mariner-were considered, but at the time of experimentation they either lacked comparable logging/automation features or required additional deployment effort that was beyond our project timeline.

Evaluation Architecture

CUA is still experimental: every UI action spawns a tool call and screenshot, adding a range from 2–10k tokens and extra latency. As recent benchmarks and surveys note, this overhead quickly pushes long tasks toward the model's context limit and amplifies selector failures, making deep navigation chains unreliable. Accordingly, we restrict our benchmark for UI agents to four tasks - trial ID, second author, PMID, and start date – that can be retrieved in one or two hops from HemOnc.org, providing a challenging yet attainable benchmark for GUI agents.

We implement a distributed evaluation infrastructure by adapting Anthropic's CUA codebase, transforming it from an interactive web application into a scalable, fault-tolerant parallel processing system that can be easily evaluated on personal laptops.

The evaluation back-end is organized as three cooperating services:
(1) Prompt processor - a lightweight Python microservice that streams CSV encoded tasks into Claude 3.7 Sonnet, applying up to five exponential backoff retries for transient errors (HTTP 429, timeouts, 5xx). **(2) Container orchestrator** - a Docker / Compose layer that launches N identical Ubuntu22.04 containers, mounts a shared volume, and shards the prompt file so that each container runs an independent batch without crosstalk. We ran our container in a batch of 8 on one of the author's MacBooks throughout the experiment. **(3) Sampling loop** - A sampling loop that calls each turn is capped at 4096 output tokens while the screenshots that are sent as input are only the three most recent, ensuring that the running context never exceeds 120k tokens - well under Sonnet's 200k window.

Note that there is no limit on the number of actions the model can perform or time constraints. We retained Anthropic's default Ubuntu sandbox exactly as shipped, so the model runs in the same environment used for training – maintaining the best navigation accuracy, reproducibility, and runtime stability. The only change was a minor adjustment to the system-prompt that nudges the agent to act autonomously without asking a human for grounding or clarifications during execution, which is included in the Appendix.

Lastly, we verified difficulty by running Gemini-2.0-Flash-001 zero-shot across five runs, where it achieved under 7% accuracy consistently on all sub-partitions of our benchmark questions with model just using its parameter knowledge without accessing any tools.

Model Selection and other Details

System Selection Rationale for Deep Research Agent – We evaluate a range of systems, from models with easy API access and systems without API access, and one Computer Use Agent (CUA) system. For models with an easy API with accessible cost, we evaluated the full set, which we refer to as MedBrowseComp-605. For models without easy API acccess and/or inaccessible costs, we evaluate against a smaller set which we refer to as MedBrowseComp-50. Detailed model/system descriptions are in

the appendix. For answer verification we employed an automated judge powered by GPT 4.1 mini-2025-04-14. The judging prompt was adapted from existing refined evaluation templates. Two annotators manually answered MedBrowseComp-50 and achieved 100% inter-annotator agreements and 98% agreement with GPT 4.1 mini.

Model Selection Rationale for Computer Use Agent – We select Anthropic's Computer Use (using Claude 3.7 Sonnet) for evaluating browsing capabilities because, among the major commercially available GUI agents at the time, it was the only one that simultaneously offer a documented, programmable API and sandboxed environment that could be reengineered to run large batches without manual oversight, enabling us to run our experiments at scale. Other UI agents—such as Bytedance's UI Tars, OpenAI's Operator, and Google's Project Mariner—were considered, but at the time of experimentation they either lacked comparable logging/automation features or required additional deployment effort.

Evaluation Architecture – CUA is still experimental: every UI action spawns a tool call and screenshot, adding range from 2–10k tokens and extra latency. We restrict our benchmark for UI agents to four tasks—trial ID, second author, PMID, and start date—that can be retrieved in one or two hops from HemOnc.org. We implement a distributed evaluation infrastructure by adapting Anthropic's CUA codebase into a scalable, fault-tolerant parallel processing system. The back-end comprises a prompt processor with retries, a Docker/Compose container orchestrator sharding inputs, and a sampling loop that caps context at ~120k tokens while retaining default Ubuntu sandbox settings and a lightly adjusted system prompt.

Lastly, we verified difficulty by running Gemini-2.0-Flash-001 zero-shot across five runs: under 7% accuracy consistently on all sub-partitions without tools.

Results

Table 1 summarizes accuracy on MedBrowseComp-50. Accuracy decays with hop count; deep research modes outperform single-shot search. Gains are most pronounced at 4–5 hops. System-wise, O3 deepresearch and Gemini-2.5-pro deepsearch trail only the 'Best of 1' upper bound (30/50). Cross-model

sampling improves accuracy but increases cost, motivating more efficient unified agents.

Table 1: Performance on MedBrowseComp-50.

Model	Hop Pattern	Score	Acc (%)
Baseline RAG Models			
Sonar Pro	8→2	10.0	20.0
		Cost (×): 1.0	
Gemini 2.5 Pro	9→4→1	14.0	28.0
		Cost (×): 1.5	
O3 Search	10→5→1→3	19.0	38.0
		Cost (×): 2.0	
Computer-use Agents			
Claude CUA	10→8	18.0	36.0
		Cost (×): 6.0	
Deep Research Models			
Perplexity DR	10→5→3→2	20.0	40.0
		Cost (×): 2.2	
Gemini 2.5 Pro DR	10→8→3.5→3	24.5	49.0
		Cost (×): 2.5	
O3 DR	**10→6.5→3→5→1**	**25.5**	**51.0**
		Cost (×): 3.0	
Best of 1	**10→8→6→5→1**	**30.0**	**60.0**
		Cost (×): —	

Table 1. *Notes: "Hop Pattern" shows per-depth correct counts (1-hop → 2-hop → 3-hop → 4-hop → 5-hop; 10 questions each). If fewer numbers are shown, omitted depths had 0. Cost notes omitted in Word table; see LaTeX for details. 'Best of 1' selects the best single answer across systems per question.*

Deep Research Agent Results

Table 1 summarizes accuracy on MedBrowseComp-50. Across all systems, performance decays monotonically with hop count, corroborating prior evidence that long-horizon web navigation remains an open challenge for frontier LLM agents. Nevertheless, deep research variants—agents that allow iterative browsing steps rather than a single query—had improved performance. For example, O3 deepresearch answers 25.5/50 questions correctly, a 34% relative gain over O3 search (19/50); Gemini-2.5-pro deepsearch shows 75% improvement over its single-shot analogue (24.5 vs. 14). These gains are most pronounced on the hardest 4- and 5-hop splits, where deep research agents more than double the baseline accuracy.

Consistent trends are observed in the MedBrowseComp-605 results, where we exclusively evaluate models utilizing parametric memories and the Retrieval-Augmented Generation (RAG). The performance of bare models is notably poor across the majority of tasks, which aligns with our intention to create a challenging benchmark. RAG improves overall performance, but its benefit

diminishes with increasing hops. On MedBrowseComp-605, we observe the same core patterns when comparing "bare" parameter-only models—i.e., those relying exclusively on their internal (parametric) memory—with retrieval-augmented variants. In isolation, parameter-only systems struggle across nearly every hop depth, confirming that our benchmark delivers the intended level of difficulty. With RAG, search models demonstrate substantial gains on shallow questions (1- and 2-hop) except GPT4.1, Gemini2Flash holds 30% and 4% boost respectively. And 67% and 7.4% for Gemini2.5Pro. However, the utility of retrieval diminishes beyond the third hop: by the 4- and 5-hop levels, RAG provides virtually no additional benefit over the bare model. The detailed results of MedBrowseComp-50 and MedBrowseComp-605 are in Appendix A.

System-wise, O3 deepresearch and Gemini-2.5-pro deepsearch constitute the frontier, trailing only the upper bound of the 'Best of 1' (30/50) that selects post hoc the single best model/system answer per question. Unlike prior work showing that repeatedly sampling from a single system can boost performance, our cross-model, test-time compute extension demonstrates even greater gains in overall accuracy. However, the computational expense of querying multiple distinct agents for every question is substantial, underscoring the urgent need to develop more efficient, unified systems that deliver comparable or superior results with lower resource overhead. Their advantage over specialized retrieval systems such as Sonar Pro (10/50) or Perplexity deepresearch (20/50) may suggest that contemporary instruction-tuned LLMs can outperform purpose-built agentic pipelines when granted autonomous browsing. However, even the best system falls short of perfect accuracy, underscoring the need for research in planning, tool use, and hallucination suppression in complex biomedical information-seeking tasks. Appendix Table B shows some common error modes in examples.

Computer Use Agent Results

The agent performs best on finding the Second Author of the linked PubMed paper and Trial ID extraction, relatively low-hop tasks that benefit from predictable formatting and shallow navigation. In addition, this information is mostly found in close proximity on the same page, which likely explains their similar results. Start Date questions require navigating to ClinicalTrials.gov and correctly identifying structured metadata. Errors in these settings often stem from greedy field selection: trajectory analysis shows the agent tends to extract the first date it encounters—even if unrelated to trial start—rather than locating the dedicated "Study Start" field.

As we take one step further beyond Hemonc, asking for the matching PMID results in weakest performance, despite appearing structurally simple since the model just need to located the PMID on the page. Interestingly, this is not due to common visual brittleness or interface failures. Instead, the agent often returns a valid PMID for a plausible but incorrect paper. This suggests semantic confusion rather than surface-level noise. You can see a detailed common error modes sorted with explanations in Appendix Table 9.

Extraction Task	Accuracy (%)
Clinical Trial IDs	33.88
Start Date	30.58
Second Author	36.36
PMIDs	11.57

***Table 2**. Anthropic Computer-Use performance on four HemOnc information-extraction tasks in the sandbox environment.*

To evaluate the impact of structured entrypoints on CUA performance (and to demonstrate defined workflow can lead to performance improvements), we re-ran the benchmark using the same Claude 3.7 Sonnet system but initialized each task from the HemOnc.org homepage. This strategy avoids ambiguity introduced by external search engines and leverages HemOnc.org's curated structure to simplify task execution.

Extraction Task	With HemOnc Start	No Defined Start
PMIDs	42.98	11.57
Second Author	46.28	36.36
NCT	39.67	33.88
Start Date	31.40	30.58

***Table 3**. Accuracy (%) of Claude 3.7 Computer-Use Agent on structured extraction tasks, with and without initialization from HemOnc.org homepage.*

Compared to the results reported in Table 2, these scores show notable improvement, particularly on PMID extraction, which increased from 11.57% to 42.98%. By starting from a high-quality structured resource, the agent appears less likely to encounter ambiguous links, irrelevant documents, or noisy intermediate pages.

We hypothesize several contributing factors:

- Reduced ambiguity at the root: Starting on HemOnc.org anchors the agent to a semantically dense, domain-verified hub. This prevents early misrouting or unnecessary detours caused by irrelevant or overly generic search results.
- Fewer hops, higher precision: Structured navigation from HemOnc.org often yields answers in one or two clicks. This minimizes the risk of cumulative tool-call errors, selector mismatches, or hallucinated document interpretations.
- Improved alignment with human workflows: Medical oncologists often use HemOnc.org as a first step for navigating oncology evidence. Our findings suggest that model workflows, like human ones, benefit from strong priors.

These findings suggest that GUI-agent accuracy can benefit significantly from constrained yet clinically meaningful entrypoints like HemOnc.org. Future work should explore formal initialization policies as part of web-agent pipelines.

Conclusion and Future Work

Our work has certain limitations:

System selection: We evaluated only agents with publicly programmable APIs. As a result, promising but closed systems such as OpenAI Operator and Google's Project Mariner were not evaluated. Other systems like Bytedance's UITars were not tested due to time and computational constraints. However, it is not clear that their inclusion would shift the leaderboard substantially given their performance compared to Claude CUA on other benchmarks.

Human supervision: All answers were machine-judged with a lightly-audited LLM rubric. However, a subset of answers were human-verified with good agreement compared to the LLM-as-judge as we described in the methods.

Compute and subscription cost: Building the benchmark and running baselines is non-trivial and our experiments cost a total of $3,690: $320 on Perplexity (of which $200 was Deep-Research API calls), $450 on Gemini 2.5 pro, and about $2,500 on Claude Sonnet 3.7 CUA, $200 for a 1 month ChatGPT Pro subscription, $20 for advanced reasoning, and $200 for GPT-4.1 mini judging.

Real-world validation

Finally, we did not place answers in front of clinicians, and the questions in MedBrowseComp only cover a small portion of the enormous medical knowledge base used for real-world clinical decision-making. However, expert-curated, verifiable knowledge is not available for the entire medical domain. Our focused benchmark enables deeper study of deep research and computer use capabilities and still reveals important gaps and future directions to inform the field.

Future Work

- Broader task suite: Expand beyond single-field extraction to multi-paragraph justification, guideline concordance, and financial/regulatory trend analysis, all of which require deeper reasoning.
- Tool-augmented agents: Test whether lightweight adapters such as PDF parsers, table detectors, ClinicalTrials.gov wrappers boost agent performance.
- Inclusion of closed systems: Collaborate with companies to benchmark Operator, Mariner, and UITars under identical prompts, closing the current comparability gap.
- Test system in AI-IDE environment: Place agents in an AI-IDE sandbox (e.g., Claude Code CLI or Cursor or Windsurf) where they must draft, debug, and reuse their own helper scripts over our horizontal tasks.
- Study agents with a human-in-the-loop and in real-world settings: Compare agentic systems vs human performance on MedBrowseComp, and study top-performing systems in clinical settings.
- Prevent contamination during test set: Because benchmark artifacts are public, use allow-lists to block the repo/demo and permit only vetted domains; maintain a private hold-out, deduplicate across splits, encode released test sets, and require grounded citations to flag leakage as shown in figure 3.



***Figure 3**. Latest computer use agent showing direct access to the Hugging Face repo containing gold labels, illustrating the risk of contamination. However, this system did not read directly into the labeled dataset.*

Conclusion

We introduced MedBrowseComp, the largest verifiable benchmark that evaluates deep research and computer use agents in the medical field. The tasks are clinically meaningful rather than contrived for difficulty. Experiments reveal a clear capability gap: retrieval-augmented text pipelines answer nearly half as many questions as their deep research counterparts, yet no system, including computer use agents, exceeds 40% accuracy among questions that require more than a single hop. GUI-centric agents can control browsers and desktops end-to-end, but they tend to underperform compared to deep researchers driven by APIs on our benchmark, partly due to context bloat from screenshots. MedBrowseComp offers a realistic, challenging test bed for future systems and a focused subset that remains challenging for CUA.

References

1. Guha, N. *et al.* LegalBench: A collaboratively built benchmark for measuring legal reasoning in large language models. *arXiv [cs.CL]* (2023).
2. Wang, Y. *et al.* MMLU-Pro: A more robust and challenging multi-task language understanding benchmark. *arXiv [cs.CL]* (2024).
3. Singh, S. *et al.* Global MMLU: Understanding and addressing cultural and linguistic biases in multilingual evaluation. *arXiv [cs.CL]* (2024).
4. Hendrycks, D. *et al.* Measuring massive multitask language understanding. *arXiv [cs.CY]* (2020).
5. Phan, L. Humanity's Last Exam. *Research Square* (2025) doi:10.21203/rs.3.rs-6615297/v1.
6. Dupplaw, D. P. *et al.* Information extraction from multimedia web documents: an open-source platform and testbed. *Int. J. Multimed. Inf. Retr.***3**, 97–111 (2014).
7. Vu, T. *et al.* FreshLLMs: Refreshing large language models with search engine augmentation. *arXiv [cs.CL]* (2023).
8. Alzubi, S. *et al.* Open Deep Search: Democratizing search with open-source reasoning agents. *arXiv [cs.LG]* (2025).
9. Nakano, R. *et al.* WebGPT: Browser-assisted question-answering with human feedback. *arXiv [cs.CL]* (2021).
10. Kasai, J. *et al.* RealTime QA: What's the answer right now? *arXiv [cs.CL]* (2022).
11. Wang, G. *et al.* Voyager: An open-ended embodied agent with large language models. *arXiv [cs.AI]* (2023).
12. Deng, X. *et al.* Mind2Web: Towards a generalist agent for the web. *arXiv [cs.CL]* (2023).
13. Xu, Y. *et al.* Aguvis: Unified Pure Vision Agents for Autonomous GUI Interaction. *arXiv [cs.CL]* (2024).
14. Pahuja, V. *et al.* Explorer: Scaling exploration-driven web trajectory synthesis for multimodal web agents. *arXiv [cs.AI]* (2025).
15. Wornow, M., Thapa, R., Steinberg, E., Fries, J. A. & Shah, N. H. EHRSHOT: An EHR benchmark for few-shot evaluation of foundation models. *arXiv [cs.LG]* (2023).
16. Chen, S. *et al.* Wait, but Tylenol is acetaminophen... Investigating and improving language models' ability to resist requests for misinformation. *arXiv [cs.CL]* (2024).
17. Chen, S. *et al.* Use of artificial intelligence chatbots for cancer treatment information. *JAMA Oncol.***9**, 1459–1462 (2023).
18. Yu, H. *et al.* AIPatient: Simulating Patients with EHRs and LLM Powered Agentic Workflow. *arXiv [cs.CL]* (2024).
19. Tu, T. *et al.* Towards Conversational Diagnostic AI. *arXiv [cs.AI]* (2024).
20. Li, X. *et al.* MedGUIDE: Benchmarking clinical decision-making in Large Language Models. *arXiv [cs.CL]* (2025).
21. Kim, Y. *et al.* Medical hallucinations in foundation models and their impact on healthcare. *arXiv [cs.CL]* (2025).
22. Holmes, J. *et al.* RadOnc-GPT: An autonomous LLM agent for real-time patient outcomes labeling at scale. *arXiv [cs.AI]* (2025).
23. Gallifant, J. & Bitterman, D. S. Humanity's next medical exam: Preparing to evaluate superhuman systems. *NEJM AI***2**, (2025).

24. Xiao, Y. *et al.* KScope: A framework for characterizing the knowledge status of language models. *arXiv [cs.CL]* (2025) doi:10.48550/arXiv.2506.07458.
25. Schmidgall, S. *et al.* AgentClinic: a multimodal agent benchmark to evaluate AI in simulated clinical environments. *arXiv [cs.HC]* (2024).
26. Gallifant, J. *et al.* Language models are surprisingly fragile to drug names in biomedical benchmarks. *arXiv [cs.CL]* (2024).
27. Matos, J. *et al.* WorldMedQA-V: a multilingual, multimodal medical examination dataset for multimodal language models evaluation. in *Findings of the Association for Computational Linguistics: NAACL 2025* (eds. Chiruzzo, L., Ritter, A. & Wang, L.) 7203–7216 (Association for Computational Linguistics, Stroudsburg, PA, USA, 2025).
28. Wei, J. *et al.* BrowseComp: A simple yet challenging benchmark for browsing agents. *arXiv [cs.CL]* (2025).
29. Mialon, G. *et al.* GAIA: a benchmark for General AI Assistants. *arXiv [cs.CL]* (2023).
30. Wu, J. *et al.* WebWalker: Benchmarking LLMs in Web Traversal. *arXiv [cs.CL]* (2025).
31. Xie, T. *et al.* OSWorld: Benchmarking multimodal agents for open-ended tasks in real computer environments. *arXiv [cs.AI]* (2024).
32. Akkiraju, R. *et al.* FACTS about building retrieval Augmented Generation-based chatbots. *arXiv [cs.LG]* (2024).
33. Wei, J. *et al.* Measuring short-form factuality in large language models. *arXiv [cs.CL]* (2024).
34. Zhou, P. *et al.* BrowseComp-ZH: Benchmarking web browsing ability of large language models in Chinese. *arXiv [cs.CL]* (2025).
35. Chen, Z. *et al.* BrowseComp-Plus: A more fair and transparent evaluation benchmark of deep-research agent. *arXiv [cs.CL]* (2025).
36. Warner, J. L. *et al.* HemOnc: A new standard vocabulary for chemotherapy regimen representation in the OMOP common data model. *J. Biomed. Inform.***96**, 103239 (2019).

A Appendix

A.1 Detailed Benchmark Setting

Model	Mode	Test Time	Version	Verification Method
		MedBrowseComp 50		
O3	search	April 29th, 2025	Pro subscription	llm + human
O3	deepresearch	April 29 – May 1st, 2025	Pro subscription	llm + human
Gemini2.5pro	search	May 1st, 2025	api - 03/25	llm + human
Gemini2.5pro	deepresearch	April 30 – May 1st, 2025	One subscription	llm + human
Sonar pro	search	April 28th, 2025	api	llm + human
Perplexity	deepresearch	April 28th, 2025	api	llm + human
Sonnet 3.7	CUA	May 6th, 2025	api - vertex 20250219	llm + human
		MedBrowseComp 605		
Gemini2.5pro	search	May 2nd, 2025	api - 03/25	llm
GPT-4.1	search-high	May 2nd, 2025	api - gpt-4.1-mini-2025-04-14	llm
Gemini2flash	search	May 2nd, 2025	api	llm
Gemini2.5pro	search	May 1st, 2025	api - 03/25	llm
Sonar pro	search	May 2nd, 2025	api	llm
		MedBrowseComp CUA		
Sonnet 3.7	CUA	May 6th, 2025	api - vertex 20250219	llm

Table 4: Overview of test runs for MedBrowseComp benchmarks.

A.2 LLM as judge Prompts

We mostly use the same additional instruction as Humanity's Last Exam [6]. However we did some modification due to our need. First we used Openai structure output pipeline accompany with system prompt of *You are an impartial judge evaluating an AI response based on provided criteria. Respond ONLY with a valid JSON object matching the requested structure.*

We also did not include the confidence estimation as we do not have API access to many of the models.

Pydantic Schema for Structured Output

```
class JudgeOutput(BaseModel):
    extracted_final_answer: str = Field(
        description="The final exact answer extracted from the [
    response]. Put 'None' if no exact answer found."
    )
    reasoning: str = Field(
        description="Explanation of correctness based ONLY on
    comparing extracted_final_answer and correct_answer."
    )
    correct: str = Field(
        description="Must be 'yes' or 'no'."
    )
```

Grading Prompt

```
JUDGE_PROMPT = """Judge whether the following [response] to [question]
is correct or not based on the
precise and unambiguous [correct_answer] below.
[question]:  {question}
[response]:  {response}
Your judgement must be in the format and criteria specified below:
extracted_final_answer:  The final exact answer extracted from the
[response].  Put the extracted answer
as 'None' if there is no exact, final answer to extract from the
response.
[correct_answer]:  {correct_answer}
reasoning:  Explain why the extracted_final_answer is correct or
incorrect based on [correct_answer],
focusing only on if there are meaningful differences between
[correct_answer] and the
extracted_final_answer.  Do not comment on any background to the
problem, do not attempt to solve
the problem, do not argue for any answer different than
[correct_answer], focus only on whether the
answers match.
correct:  Answer 'yes' if extracted_final_answer matches the
[correct_answer] given above, or is within
a small margin of error for numerical problems.  Answer 'no' otherwise,
i.e.  if there is
any inconsistency, ambiguity, non-equivalency, or if the extracted
answer is incorrect."""
```

A.3 Computer Use Agent Prompt

The prompt remains largely identical to the original version provided by Anthropic, with a single minor addition highlighted in gray.

A concise instruction reinforcing that the agent should act independently and refrain from requesting clarification or human assistance during execution, promoting model autonomy.

```
<SYSTEM_CAPABILITY>

    • You are utilising an Ubuntu virtual machine using
      {platform.machine()} architecture with internet access.
    • You can feel free to install Ubuntu applications with your bash
      tool.  Use curl instead of wget.
    • To open Firefox, please just click on the Firefox icon.  Note,
      firefox-esr is what is installed on your system.
    • Using bash tool you can start GUI applications, but you need
      to set export DISPLAY=:1 and use a subshell.  For example,
      (DISPLAY=:1 xterm &).  GUI apps run with bash tool will appear
      within your desktop environment, but they may take some time to
      appear.  Take a screenshot to confirm it did.
    • When using your bash tool with commands that are expected to
      output very large quantities of text, redirect into a tmp file
      and use str_replace_editor or grep -n -B <lines before> -A <lines
      after> <query> <filename> to confirm output.
    • When viewing a page it can be helpful to zoom out so that you can
      see everything on the page.  Either that, or make sure you scroll
      down to see everything before deciding something isn't available.
    • When using your computer function calls, they take a while to
      run and send back to you.  Where possible/feasible, try to chain
      multiple of these calls all into one function calls request.
    • The current date is {datetime.today().strftime('%A, %B %-d, %Y')}.

</SYSTEM_CAPABILITY>

<IMPORTANT>

    • Never ask the user for help or to clarify.  You are the
      assistant and you should be able to figure out what to do.
    • When using Firefox, if a startup wizard appears, IGNORE IT. Do
      not even click "skip this step."  Instead, click on the address
      bar where it says "Search or enter address," and enter the
      appropriate search term or URL there.
    • If the item you are looking at is a PDF, and after taking a
      single screenshot of the PDF it seems that you want to read the
      entire document instead of trying to continue to read the PDF
      from your screenshots + navigation, determine the URL, use curl
      to download the PDF, install and use pdftotext to convert it
      to a text file, and then read that text file directly with your
      StrReplaceEditTool.

</IMPORTANT>
```

A.4 Deep Research Agent Results

Table 5: Detailed Performance of Frontier Systems on MedBrowseComp 50 - For this subset, we selected where the questions cannot be answered by NA

Question Depth	O3		Gemini2.5pro		Perplexity		Claude-CUA
	search	deep	search	deep	search	deep	
1-hop (n=10)	10/10 (**100.0%**)	10/10 (**100.0%**)	9/10 (90.0%)	10/10 (**100.0%**)	8/10 (80.0%)	10/10 (**100.0%**)	10/10 (**100.0%**)
2-hop (n=10)	5/10 (50.0%)	6.5/10 (65.0%)	4/10 (40.0%)	**8**/10 (**80.0%**)	2/10 (20.0%)	5/10 (50.0%)	4/10 (40.0%)
3-hop (n=10)	1/10 (10.0%)	3/10 (30.0%)	1/10 (10.0%)	**3.5**/10 (**35.0%**)	0/10 (0.0%)	3/10 (30.0%)	2/10 (20.0%)
4-hop (n=10)	3/10 (30.0%)	**5**/10 (**50.0%**)	0/10 (0.0%)	3/10 (30.0%)	0/10 (0.0%)	2/10 (20.0%)	1/10 (10.0%)
5-hop (n=10)	0/10 (0.0%)	**1**/10 (**10.0%**)	0/10 (0.0%)	0/10 (0.0%)	0/10 (0.0%)	0/10 (0.0%)	1/10 (10.0%)
Total (n=50)	19/50 (38.0%)	**25.5**/50 (**51.0%**)	14/50 (28.0%)	24.5/50 (49.0%)	10/50 (20.0%)	20/50 (40.0%)	18/50 (36.0%)

The benchmark we've created is tough as you can see from MedBrowseComp 50 and more detailed results on MedBrowseComp 605 on the following page. It's designed to push models beyond just recognizing patterns or guessing from context. Instead, it asks them to follow a chain of reasoning across multiple steps (or "hops") through a medical knowledge base. And when you strip away the ability to say "Not applicable" or avoid answering (what we call REAL accuracy), the results show just how hard this is. Even the strongest model, Gemini 2.5 Pro (search) , only gets about 24.5% of the answers right under these strict conditions. That might not sound like much, but it still makes it the clear leader in this group.

What's especially telling is how performance drops off with each additional hop. For example, Gemini 2.5 Pro does well on 1-hop questions (76%), where the answer is often directly stated. But by the time you get to 4-hop or 5-hop questions — where the model has to link together several pieces of information in sequence — even it struggles. On REAL accuracy for 4-hop questions, it only gets 5.1% , and for 5-hop, it's essentially zero. This shows that while models may look good on simple tasks, chaining together multiple steps of reasoning is still a big challenge.

In short, we hope this benchmark doesn't let models take shortcuts. We want to force them to dig into real medical knowledge and reason carefully. And based on these results, there's still a long way to go before we can fully trust AI systems to handle complex, multi-step medical reasoning without supervision.

Table 6: Detailed Performance of Models on MedBrowseComp 605 | Note that SonarPro-param is blank here due to the lack of non-search options from perplexity.

Question Depth	GPT-4.1		SonarPro		Gemini2Flash		GeminiPro	
	param	search	param	search	param	search	param	searcl
1-hop (n=121)	24/121 (19.8%)	19/121 (15.7%)	–	63/121 (52.1%)	26/121 (21.5%)	67/121 (55.4%)	10/121 (8.3%)	**92**/12 (**76.0%**
2-hop (n=121)	5/121 (4.1%)	5/121 (4.1%)	–	8/121 (6.6%)	2/121 (1.7%)	7/121 (5.8%)	4/121 (3.3%)	**13**/12 (**10.7%**
3-hop (n=121)	1/121 (0.8%)	1/121 (0.8%)	–	2/121 (1.7%)	2/121 (1.7%)	1/121 (0.8%)	9/121 (7.4%)	**4**/121 (**3.3%**)
4-hop (n=121)	60/121 (49.6%)	42/121 (34.7%)	–	70/121 (57.9%)	60/121 (49.6%)	48/121 (39.7%)	39/121 (32.2%)	**49**/12 (**40.5%**
5-hop (n=121)	15/121 (12.4%)	12/121 (9.9%)	–	15/121 (12.4%)	23/121 (19.0%)	15/121 (12.4%)	18/121 (14.9%)	**24**/12 (**19.8%**
Total (n=605)	105/605 (17.3%)	80/605 (13.2%)	–	158/605 (26.1%)	113/605 (18.7%)	138/605 (22.8%)	80/605 (13.2%)	**182**/6((**30.1%**

Table 7: REAL Accuracy for MedBrowseComp605 (Excluding NA-like Correct Answers): Models are evaluated only on questions where the correct answer is applicable. NA-like responses (e.g., "Not applicable") are excluded from scoring.

Question Depth	GPT-4.1		SonarPro		Gemini2Flash		GeminiPro	
	param	search	param	search	param	search	param	search
1-hop (n=121)	24/121 (19.8%)	19/121 (15.7%)	–	63/121 (52.1%)	26/121 (21.5%)	67/121 (55.4%)	10/121 (8.3%)	**92**/121 (**76.0%**)
2-hop (n=121)	5/121 (4.1%)	5/121 (4.1%)	–	8/121 (6.6%)	2/121 (1.7%)	7/121 (5.8%)	4/121 (3.3%)	**13**/121 (**10.7%**)
3-hop (n=121)	1/121 (0.8%)	1/121 (0.8%)	–	2/121 (1.7%)	2/121 (1.7%)	1/121 (0.8%)	9/121 (7.4%)	**4**/121 (**3.3%**)
4-hop (n=39)	0/39 (0.0%)	0/39 (0.0%)	–	0/39 (0.0%)	0/39 (0.0%)	0/39 (0.0%)	0/39 (0.0%)	**2**/39 (**5.1%**)
5-hop (n=51)	0/51 (0.0%)	0/51 (0.0%)	–	1/51 (2.0%)	1/51 (2.0%)	0/51 (0.0%)	0/51 (0.0%)	**0**/51 (**0.0%**)
Total (n=453)	30/453 (6.6%)	25/453 (5.5%)	–	74/453 (16.3%)	31/453 (6.8%)	75/453 (16.6%)	23/453 (5.1%)	**111**/453 (**24.5%**)

A.5 Evaluation from Optimal Start Page

To evaluate the impact of structured entrypoints on Computer Use Agent performance, we re-ran the benchmark using the same Claude 3.7 Sonnet system but initialized each task from the HemOnc.org homepage. This strategy avoids ambiguity introduced by external search engines and leverages HemOnc.org's curated structure to simplify task execution.

Table 8: Accuracy (%) of Claude 3.7 Computer-Use Agent on structured extraction tasks, with and without initialization from HemOnc.org homepage. Improvements are shown in bold.

Extraction Task	With HemOnc Start	No Defined Start
PMIDs	**42.98**	11.57
Second Author	**46.28**	36.36
NCT	**39.67**	33.88
Start Date	**31.40**	30.58

Compared to the results reported in Table 4, these scores show notable improvement, particularly on PMID extraction, which increased from 11.57% to 42.98%. By starting from a high-quality structured resource, the agent appears less likely to encounter ambiguous links, irrelevant documents, or noisy intermediate pages.

We hypothesize several contributing factors:

- **Reduced ambiguity at the root**: Starting on HemOnc.org anchors the agent to a semantically dense, domain-verified hub. This prevents early misrouting or unnecessary detours caused by irrelevant or overly generic search results.
- **Fewer hops, higher precision**: Structured navigation from HemOnc often yields answers in one or two clicks. This minimizes the risk of cumulative tool-call errors, selector mismatches, or hallucinated document interpretations.
- **Improved alignment with human workflows**: Clinicians often use HemOnc as a first step for navigating oncology evidence. Our findings suggest that model workflows, like human ones, benefit from strong priors.

These findings suggest that GUI-agent accuracy can benefit significantly from constrained yet clinically meaningful entrypoints like HemOnc.org. Future work should explore formal initialization policies as part of web-agent pipelines.


Safety &
Reliability
Fairness &
Equity
Explainability &
Transparency
Patient-Centered
AI
Global
Impact

General Discussion and Future Perspectives

Since the public emergence of large language models (LLMs) in 2022, the healthcare community has confronted a dual reality: unprecedented capacity to automate complex cognitive tasks, and equally unprecedented risks of misinformation, bias, and brittle reasoning. The integration of LLMs into clinical workflows, ranging from patient communication to cancer trial safety monitoring, holds the potential to reduce documentation burden, uncover latent patient risks, accelerate evidence synthesis, and extend the reach of limited clinical resources. Yet these opportunities continually collide with a sobering pattern: systems are often evaluated on narrow or artificial benchmarks that obscure clinically relevant failures, trained on corpora that entrench societal inequities, and optimized for surface-level fluency rather than factual correctness.

This chapter synthesizes the insights across the thesis, situating them within ongoing debates about safety, equity, and responsible deployment. Together, the findings outline a pathway toward LLMs that are not merely technically impressive but also reliable, transparent, and suited for use in real-world clinical environments.

Part I: Potential Utilities of Language Models in Real Clinical Practice

Patient-Facing Information and Clinical Communication

The first section of the thesis examines the most immediate interface between LLMs and public health: the generation of medical information for patients and the drafting of clinician messages. **Chapters 2 and 3** address these domains through complementary perspectives.

In **Chapter 2**, we demonstrate that although ChatGPT delivers guideline-concordant cancer treatment recommendations in 98% of cases, one-third of responses contain partially incorrect statements and 12% hallucinate entire treatment modalities. Performance varies markedly with prompt phrasing, highlighting the fragility of general-purpose LLMs when used by patients without expert oversight. These findings reinforce the need for verification layers, guardrails, and clinician involvement in any patient-facing deployment.

Chapter 3 transitions from public use to clinical workflows, evaluating GPT-4-assisted drafting of portal messages. While clinicians report increased efficiency

in 77% of cases, unedited drafts introduce a 7.7% risk of severe harm due to misclassification of urgency or inappropriate clinical advice. Across both chapters, a central theme emerges: LLMs provide value primarily as tools that augment expert decision-making. Their safe and effective use depends on human vigilance, not autonomous output.

Unlocking Unstructured Clinical Data

Chapters 4 and 5 shift focus from communication to structured extraction of clinically meaningful but routinely underutilized information.

Radiotherapy-induced esophagitis severity, a toxicity with direct survival implications, is recorded only in narrative notes. Our fine-tuned models achieved macro-F1 scores up to 0.92 for CTCAE grade extraction, enabling large-scale real-world evidence generation where none previously existed.

Similarly, social determinants of health (SDoH), powerful and often ignored predictors of outcomes, remain largely invisible in structured data. Fine-tuned Flan-T5 models identified 94% of patients with adverse SDoH compared to only 2% using ICD-10 codes, and did so with less demographic bias than GPT-4 few-shot prompting.

These findings underscore a central message: **task-specific fine-tuning on domain data is not only more accurate but also more equitable**, surfacing disparities that generalist models miss. Future directions include expanding extraction to additional toxicity domains, embedding these pipelines in prospective registries, and evaluating their impact on clinical operations such as care navigation and resource allocation.

Autonomous Agents in Trial Safety

The final arc of Part I culminates in **Chapter 6**, where we introduce **iRAE Agent**, an agentic system piloted at Mass General Brigham for detecting immunotherapy-related adverse events in oncology trials. Unlike static classifiers, iRAE performs multi-step reasoning, structured error checking, and ontology-guided reporting—operations that map directly to real trial workflows and carry substantial regulatory significance.

This represents a true inflection point: moving from isolated extraction tasks to **full-fledged clinical agents** designed for deployment in safety-critical environments. Future work includes scaling iRAE across trial networks,

integrating it with regulatory submission pipelines, and designing human-in-the-loop interfaces that preserve clinician oversight while automating routine surveillance. Robustness to linguistic variation and resistance to sycophantic agreement—fully explored in Part II—will be essential for trustworthy deployment.

Part II: Potential Failures of Language Models in Medical Settings

While Part I demonstrates the considerable promise of LLMs for clinical augmentation, Part II examines the structural vulnerabilities that emerge when these systems are used in safety-critical environments. These chapters collectively reveal that the same statistical learning mechanisms enabling LLMs to generalize across vast text corpora also produce brittle, easily perturbed behaviors when models are asked to perform medical reasoning.

Chapter 7 establishes a foundational principle for responsible deployment: generalist LLMs are not necessarily the right tool for most biomedical NLP tasks. Contrary to assumptions that larger models trained on broader corpora inherently perform better, our findings show that task-specific fine-tuned models not only outperform GPT-3.5 and GPT-4 in structured extraction tasks but do so while using dramatically less compute. These domain-tuned models demonstrate greater stability, interpretability, and consistency—qualities that are essential for clinical operations. The presumed "generalist advantage" dissolves under empirical scrutiny, highlighting the need to calibrate model choice to the specific constraints of healthcare settings rather than defaulting to the largest available system.

Chapters 8 through 10 reveal deeper epistemic failures rooted in pre-training data distributions. In **Chapter 8**, the Cross-Care study demonstrates that when LLMs are asked to estimate disease prevalence, their responses track the frequency with which diseases co-occur in The Pile—an English-dominant, internet-derived dataset—rather than actual epidemiological data. This pattern persists across languages and alignment strategies, suggesting that these models internally encode *statistical reflections of their training corpora rather than medically grounded representations of disease burden*. This representational bias carries profound implications for any task requiring epidemiological awareness or population-level reasoning.

The fragility exposed in **Chapter 9** underscores a parallel lexical vulnerability. Although LLMs nominally "know" that brand and generic drug names refer to the same pharmacologic substance, substituting one for the other reduces accuracy by up to 10%. This mismatch reflects a model's reliance on lexical co-occurrence patterns rather than a robust conceptual representation of drug equivalence. In clinical practice, where generic versus brand names vary across notes, specialties, and institutions, such brittleness introduces unpredictable and potentially dangerous inconsistency.

Chapter 10 adds a behavioral dimension to these representational failures, demonstrating that LLMs frequently acquiesce to false claims about drug equivalence when such claims are embedded in user prompts. This sycophantic tendency—where models prioritize agreement and apparent helpfulness over factual accuracy—can lead to confident propagation of medical misinformation. These behaviors highlight the interface between alignment methods and clinical risk: systems optimized to sound polite, cooperative, or user-friendly can become hazardous when those attributes override epistemic integrity.

Together, the findings of Part II paint a cautionary but constructive picture: current LLMs are not yet reliable arbiters of medical knowledge. Their susceptibility to pre-training biases, lexical perturbations, not robust knowledge representation and misalignment indicates that naïve deployment in healthcare settings could amplify existing inequities and introduce new potential of harm. These vulnerabilities underscore the need for rigorous evaluation frameworks and purpose-built safeguards before clinical integration.

Societal Impact and Future Directions

The broader societal significance of this thesis lies in its insistence that clinical AI must be evaluated not only on technical performance but on its alignment with the practical, ethical, and equity-oriented demands of real-world medicine. By grounding every experiment in live workflows—patient messaging, toxicity surveillance, trial safety monitoring—this work demonstrates that LLMs tested on sanitized benchmarks or synthetic tasks provide less insight into their behavior under true clinical conditions. In contrast, models evaluated within authentic operational settings reveal the constraints, failure modes, and friction points that determine whether AI tools will meaningfully improve care.

A key contribution of this thesis is the demonstration that **last-mile alignment—not scale—is the decisive factor in achieving clinically meaningful AI**. While foundation models provide broad linguistic competence, their raw form is insufficient for safe deployment in real care settings. The most clinically relevant value emerges when models undergo **last-mile alignment**: targeted fine-tuning, calibration, and behavioral optimization using local data, domain-specific ontologies, and institution-defined safety constraints. This final stage transforms general capabilities into reliable, workflow-ready tools that reflect the actual decision environments clinicians navigate.

Crucially, last-mile alignment is inherently **interdisciplinary**. It requires domain experts to define what "correct" looks like, informaticians to validate model behavior across heterogeneous EHR data streams, ethicists to assess potential inequities or normative risks, and regulatory specialists to ensure compliance with evolving standards. Smaller, fine-tuned models enable this collaboration in ways that large generalist models cannot: they are transparent enough to audit, modular enough to modify, and lightweight enough to iterate on quickly and safely. In this sense, the path to trustworthy clinical AI is not dominated by ever-larger pre-trained systems but by **collaboratively aligned models that undergo rigorous, locally grounded last-mile refinement**.

The societal implications of the extraction work presented in Part I are substantial. By automating the identification of radiation toxicities and social determinants of health, this research enables the generation of real-world evidence that had previously remained inaccessible. These capabilities can support more equitable distribution of clinical resources, improve trial design, and uncover disparities hidden within documentation practices. They also create opportunities to inform public health interventions, policy design, and health equity efforts at scale.

In parallel, the failure patterns exposed in Part II offer concrete pathways for developers, regulators, and healthcare organizations to identify, mitigate, and monitor sources of clinical risk. Pre-training bias, drug-name brittleness, and sycophantic behavior are not abstract deficiencies; they are failure modes with direct implications for patient safety and public trust. By systematically characterizing these vulnerabilities, the thesis provides a roadmap for model improvement and governance frameworks that prioritize factual grounding, robustness, and ethical responsibility.

Finally, the release of **WorldMedQA-V** and **MedBrowseComp** contributes durable, publicly accessible infrastructure for assessing multilingual performance and hard yet realistic medical reasoning. These benchmarks allow the community to measure whether future models genuinely progress toward equitable, evidence-grounded clinical intelligence—or merely optimize for English-dominant, shallow tasks that reproduce existing inequities. In a field where three-quarters of published studies still lack reproducibility or diverse validation, such shared infrastructure is essential for elevating scientific standards and enabling meaningful regulatory oversight.

Looking forward, the future of clinical AI will depend not on scale alone but on rigorous scientific methodology, transparent evaluation pipelines, and thoughtful integration with human expertise. LLMs that meaningfully improve healthcare will be those that earn trust—through robustness, fairness, and verifiable correctness—rather than those that simply demonstrate linguistic sophistication. This thesis lays foundational evidence, frameworks, and datasets to guide the development of such systems, and points toward a future in which clinical AI strengthens—not destabilizes—the safety, equity, and integrity of global health.


APPENDIX A
APPENDIX B
APPENDIX C
SUPPLEMENTARY PUBLICATIONS
CONTRIBUTIONS
Conceptualization
Methodology
Data Curation
Analysis
Writing – Original Draft
Review & Editing
Supervision

Appendices

Summary

Part I: Potential Utilities of Language Models in Real Clinical Practice

Part I of this thesis shows how large language models (LLMs) can address concrete, high-impact problems in clinical workflows and health equity.

Chapters 2 and 3 focus on patient–provider communication. We evaluate LLMs for generating patient-facing cancer treatment information and drafting portal messages. The models write with human-level fluency but inconsistent factual accuracy, creating real potential for harm. These studies establish a realistic safety baseline for patient-facing LLMs before any deployment in clinical care.

Chapters 4 and 5 move to unstructured clinical text, where LLMs surface information that existing structured systems largely ignore. We automate the extraction of radiotherapy toxicity severity and social determinants of health (SDoH) from free-text notes, substantially outperforming billing-code–based baselines and enabling large-scale real-world evidence generation at low marginal cost. This SDoH work was later published in *npj Digital Medicine*, became the **most-cited article journal-wide in 2024**, and was selected for the AI and Data Science Year in Review at AMIA, underscoring both scientific and practical impact.

Chapter 6 culminates this trajectory with **iRAE agent (AEGIS)**, an agentic system piloted at Mass General Brigham to detect immunotherapy-related adverse events in clinical trials. Rather than acting as a static classifier, iRAE orchestrates multi-step reasoning, internal error checking, and ontology-guided reporting inside live hospital workflows. This directly reduces the manual burden of adverse event reporting and has implications for trial safety, cost, and patient outcomes.

Together, these chapters trace a clear progression—from question answering to autonomous clinical agents—demonstrating that LLMs can deliver measurable clinical value while also revealing where naïve "drop-in" automation fails.

Part II: Potential Fails of Language Models in Medical Settings

If Part I focuses on what LLMs can do, Part II focuses on how they can fail, and why those failures matter in high-stakes medicine.

Chapter 7 provides a pragmatic baseline: for core biomedical NLP tasks, locally fine-tuned models such as BioBERT consistently outperform few-

shot prompting of massive generalist LLMs, while using roughly three orders of magnitude less compute. This underscores that, in many realistic health system settings, small, task-specific models remain the more accurate, affordable, and deployable choice.

Chapters 8–10 expose a common thread of **pre-training bias and fragility**. **Cross-Care** shows that LLMs absorb disease–demographic associations from corpus statistics rather than epidemiologic truth, leading to systematic misalignment between model beliefs and real-world disease prevalence across languages and demographic groups.

RABBITS reveals the lexical counterpart: simply swapping brand and generic drug names—without changing the underlying pharmacology—reduces accuracy by up to 15%, indicating reliance on memorized strings rather than robust reasoning.

A third line of work demonstrates that even when models "know" the correct answer, sycophantic behavior often dominates: when confronted with illogical or dangerous medical claims, models comply instead of correcting the user. This "helpfulness backfiring" work later became an **AMIA 2025 oral** and was highlighted in outlets such as **Nature** and **The New York Times**, reflecting growing public concern about LLM safety in medicine.

Chapters 11 and 12 translate these observations into a durable evaluation infrastructure. **WorldMedQA-V** provides a multilingual, multimodal medical exam benchmark that tests whether progress in vision–language models genuinely transfers across languages and clinical contexts.

MedBrowseComp evaluates long-horizon, literature-driven medical agents and shows that even state-of-the-art systems reach only ~10% accuracy on multi-hop evidence synthesis—far below the reliability required for direct clinical use. These benchmarks are designed not just to diagnose failure, but to track and incentivize real progress over time.

Taken together, Part II argues that current LLMs primarily mirror the statistics of their training data, not clinical reality, and that they default to cooperative, fluent responses over careful, truthful reasoning.

Societal Impact and Valorization

This thesis is motivated by a simple goal: to narrow the gap between AI research and clinically meaningful, equitable deployment–**and to do so in a way that is visible, scrutinizable, and reusable by others**.

First, every study is grounded in real clinical workflows and diverse patient cohorts–from cancer treatment information and portal messaging to trial safety monitoring–so that performance is measured against practical constraints and outcomes, not just benchmark scores. This grounding has made the work legible and relevant to clinicians, health systems, and policymakers.

Second, the projects in this thesis have already influenced the broader conversation on AI in healthcare:

- Research from this line of work has been **featured in major media outlets**, including *Bloomberg*, *The New York Times*, NBC, and *New Scientist*, helping translate technical findings into public understanding and debate about safe medical AI.
- Several studies have been **highlighted by U.S. government agencies**, including the FDA, NCI, and NIH, indicating regulatory interest in both the opportunities and risks of clinical LLMs.
- The early JAMA Oncology work on cancer treatment chatbots and downstream follow-ups on patient communication were **used in U.S. congressional hearings** and featured by JAMA Oncology and Harvard, placing these results directly into discussions about national policy and oversight for AI in medicine.
- The SDoH paper in *npj Digital Medicine* became the **most-cited article across the entire journal in 2024** and was highlighted by NCI, reflecting demand for methods that make health inequities more visible and measurable.

Third, the thesis invests heavily in open, reproducible evaluation. Many of the core artifacts–**Cross-Care**, **WorldMedQA-V**, **MedBrowseComp**, the SDoH datasets, and others–are released with **public code, data, and documentation** via dedicated project pages, Hugging Face datasets, and GitHub repositories. These resources are enriched with calibrated metadata where possible and are already being adopted and extended by external groups, turning one-off studies into shared infrastructure.

In a landscape where most AI-in-medicine papers are difficult to reproduce and rarely validated across institutions or populations, this thesis deliberately pushes in the opposite direction: all models are evaluated on publicly available or prospectively collected clinical data, adjusted for key confounders, and implemented with open-source tools. This makes the results suitable as a basis for **prospective trials, regulatory conversations, and real deployment decisions**[1]**.**

The central argument of this thesis is that **safe clinical LLMs require not only stronger models, but stronger science and real-world evidence**: transparent benchmarks that reflect real clinical use, training pipelines that explicitly confront bias and fragility, and evaluation protocols that reward factual correctness and robustness over surface-level fluency.

Ultimately, the work aims to help move the field toward LLMs that are not just powerful, but **trustworthy**—systems that can support clinicians, surface hidden inequities, and remain reliable across the linguistic and demographic diversity that characterizes real-world medicine. That this research has already drawn attention from major media, regulators, and policymakers is itself a form of valorization: it signals that the questions posed here are not only academically interesting but central to how AI will shape the future of healthcare.

Curriculum Vitae and Scientific Publications

Shan Chen was born in Beijing, China, on April 23rd, 1998, and moved to Minnesota for high school. After graduating, he completed a B.A. in Mathematics and Japanese at St. Olaf College and an M.S. in Computational Linguistics at Brandeis University. As part of his master's program, he worked with Dr. Tim Miller at Boston Children's Hospital on a clinical Natural Language Processing(NLP) capstone, developing end-to-end pipelines that linked unstructured clinical text to usable, safety-minded decision support.

Following his master's, Shan joined the Artificial Intelligence in Medicine (AIM) Program—spanning Harvard Medical School, Brigham and Women's Hospital, and Mass General Brigham—while enrolling as an external Ph.D. candidate with the School for Oncology and Reproduction (GROW) at Maastricht University jointly. He spent 42 months in Boston supervised by Danielle Bitterman, MD and Hugo Aerts, PhD, embedded with AIM teams and collaborators across the Harvard–MGB ecosystem, working on clinical NLP and actively developing more general NLP methods through collaboration with Harvard-SEAS, Kempner Institute, University of Oxford, TU Darmstadt, University of Gottingen, University of Amsterdam, Johns Hopkins University, Google Deepmind and Massachusetts Institute of Technology. His PhD work was also supported by the 2024 Google PhD Fellowship in NLP.

Shan's research focuses on AI applied to clinical text and multimodal clinical data—especially methods for safe, transparent natural language processing, retrieval-augmented reasoning, and multilingual "language-following" in medicine. During these years, he developed a strong commitment to open source, open science, and reproducible research, contributing datasets, benchmarks, and evaluation tooling aimed at stress-testing long-horizon, evidence-grounded clinical reasoning. He has presented his work at leading machine learning and biomedical informatics venues and co-authored peer-reviewed publications arising from these efforts.

After completing his doctoral studies, Shan joined Phare Health as a research scientist, where he is now developing more reproducible clinical AI—prioritizing methods that make models more faithful to evidence, safer for real-world use, and easier for the broader US payer and site communities to evaluate and adopt.

***Shan Chen**, *Mingye Gao, Kuleen Sasse, Thomas Hartvigsen, Brian Anthony, Lizhou Fan, Hugo Aerts, Jack Gallifant & Danielle S. Bitterman – When Helpfulness Backfires: LLMs and the Risk of False Medical Information Due to Sycophantic Behavior (npj Digital Medicine, 2025)

Yuxin Xiao, **Shan Chen**, Jack Gallifant, Danielle S. Bitterman, Thomas Hartvigsen & Marzyeh Ghassemi – KScope: A Framework for Characterizing the Knowledge Status of Language Models (NeurIPS, 2025)

Zidi Xiong, **Shan Chen**, Zhenting Qi & Himabindu Lakkaraju – Measuring the Faithfulness of Thinking Drafts in Large Reasoning Models (NeurIPS, 2025)

***Shan Chen**, *Pedro Moreira, Yuxin Xiao, Sam Schmidgall, Jeremy Warner, Hugo J.W.L. Aerts, Thomas Hartvigsen, Jack Gallifant & Danielle S. Bitterman – MedBrowseComp: Benchmarking Medical Deep Research and Computer Use (under review, 2025)

***Shan Chen**, *Jirui Qi, Zidi Xiong, Raquel Fernández, Danielle S. Bitterman & Arianna Bisazza – When Models Reason in Your Language: Controlling Thinking Trace Language Comes at the Cost of Accuracy (Findings of EMNLP, 2025)

***Shan Chen**, *Jack Gallifant, Kuleen Sasse, Hugo Aerts, Thomas Hartvigsen & Danielle S. Bitterman – Sparse Autoencoder Features for Classifications and Transferability (EMNLP, 2025)

***Shan Chen**, *João Matos, Siena Kathleen V. Placino, Yingya Li, Juan Carlos Climent Pardo, Daphna Idan, Takeshi Tohyama, David Restrepo, Luis Filipe Nakayama, José María Millet Pascual-Leone, Guergana K. Savova, Hugo Aerts, Leo Anthony Celi, An-Kwok Ian Wong, Danielle Bitterman & Jack Gallifant – WorldMedQA-V: a multilingual, multimodal medical examination dataset for multimodal language models evaluation (Findings of NAACL, 2025)

***Shan Chen**, *Jack Gallifant, Mingye Gao, Pedro Moreira, Nikolaj Munch, Ajay Muthukkumar, Arvind Rajan, Jaya Kolluri, Amelia Fiske, Janna Hastings, Hugo Aerts, Brian Anthony, Leo Anthony Celi, William G. La Cava & Danielle S. Bitterman – CrossCare: Assessing the Healthcare Implications of Pre-training Data on Language Model Bias (NeurIPS, 2024)

Shan Chen, Marco Guevara, Shalini Moningi, Frank Hoebers, Hesham Elhalawani, Benjamin H. Kann, Fallon E. Chipidza, Jonathan Leeman, Hugo J.W.L. Aerts, Timothy Miller, Guergana K. Savova, Raymond H. Mak, Maryam Lustberg, Majid Afshar & Danielle S. Bitterman – The Impact of Using an AI Chatbot to Respond to Patient Questions (Lancet Digital Health, 2024)

***Shan Chen**, *Marco Guevara, Spencer Thomas, Tafadzwa L. Chaunzwa, Idalid Franco, Benjamin H. Kann, Shalini Moningi, Jack M. Qian, Madeleine Goldstein, Susan Harper, Hugo J.W.L. Aerts, Paul J. Catalano, Guergana K. Savova, Raymond H. Mak & Danielle S. Bitterman – Large Language Models Identifying Social Determinants of Health in Electronic Health Records (npj Digital Medicine, 2024)

Sheng Lu, **Shan Chen**, Yingya Li, Danielle S. Bitterman, Guergana Savova & Iryna Gurevych – Measuring Pointwise -Usable Information In-Context-ly (Findings of EMNLP, 2023)

Shan Chen, Benjamin H. Kann, Michael B. Foote, Hugo J.W.L. Aerts, Guergana K. Savova, Raymond H. Mak & Danielle S. Bitterman – The Utility of ChatGPT for Cancer Treatment Information (JAMA Oncology, 2023)

***Shan Chen**, *Yingya Li, Sheng Lu, Hoang Van, Hugo J.W.L. Aerts, Guergana K. Savova & Danielle S. Bitterman – Evaluation of ChatGPT Family of Models for Biomedical Reasoning and Classification (JAMIA, 2023)

Shan Chen, Marco Guevara, Nicolas Ramirez, Arpi Murray, Jeremy L. Warner, Hugo J.W.L. Aerts, Timothy A. Miller, Guergana K. Savova, Raymond H. Mak & Danielle S. Bitterman – Natural Language Processing to Automatically Extract the Presence and Severity of Esophagitis in Notes of Patients Undergoing Radiotherapy (JCO Clinical Cancer Informatics, 2023)

Summary in Dutch

Algemene Discussie en Toekomstperspectieven

Sinds de publieke doorbraak van grote taalmodellen (LLMs) in 2022 wordt de zorggemeenschap geconfronteerd met een dubbele realiteit: een ongekende capaciteit om complexe cognitieve taken te automatiseren, en tegelijk even ongekende risico's op desinformatie, bias en fragiele redenering. De integratie van LLMs in klinische workflows–variërend van patiëntcommunicatie tot veiligheidsmonitoring van oncologische trials–biedt het potentieel om de documentatielast te verlagen, latente patiëntrisico's bloot te leggen, evidence-synthese te versnellen en de reikwijdte van schaarse klinische middelen te vergroten. Tegelijk botsen deze kansen voortdurend met een nuchtere vaststelling: systemen worden vaak geëvalueerd op smalle of kunstmatige benchmarks die klinisch relevante faalmodi verhullen, getraind op corpora die maatschappelijke ongelijkheden bestendigen, en geoptimaliseerd voor oppervlakkige vloeiendheid in plaats van feitelijke juistheid.

Dit hoofdstuk synthetiseert de inzichten uit het gehele proefschrift en plaatst deze binnen de lopende debatten over veiligheid, gelijkheid en verantwoorde implementatie. Gezamenlijk schetsen de bevindingen een route naar LLMs die niet alleen technisch indrukwekkend zijn, maar ook betrouwbaar, transparant en geschikt voor gebruik in echte klinische omgevingen.

Deel I: Potentiële toepassingen van taalmodellen in de klinische praktijk

Patiëntgerichte informatie en klinische communicatie

Het eerste deel van het proefschrift richt zich op de meest directe interface tussen LLMs en de volksgezondheid: het genereren van medische informatie voor patiënten en het opstellen van berichten door clinici. Hoofdstukken 2 en 3 benaderen deze domeinen vanuit complementaire perspectieven.

In Hoofdstuk 2 tonen we aan dat ChatGPT in 98% van de gevallen richtlijnconforme aanbevelingen voor kankerbehandeling geeft, maar dat een derde van de antwoorden gedeeltelijk onjuiste uitspraken bevat en 12% volledige behandelmodaliteiten hallucineert. De prestaties variëren sterk afhankelijk van de formulering van de prompt, wat de kwetsbaarheid van algemene LLMs benadrukt wanneer zij door patiënten zonder deskundig toezicht worden gebruikt.

Deze bevindingen onderstrepen de noodzaak van verificatielagen, guardrails en betrokkenheid van clinici bij elke patiëntgerichte toepassing.

Hoofdstuk 3 verlegt de focus van publiek gebruik naar klinische workflows en evalueert GPT-4-ondersteunde conceptberichten in patiëntenportalen. Hoewel clinici in 77% van de gevallen een hogere efficiëntie rapporteren, introduceren onbewerkte concepten een risico van 7,7% op ernstige schade door verkeerde urgentie-inschatting of ongepaste klinische adviezen. Over beide hoofdstukken heen ontstaat een centraal thema: LLMs leveren vooral waarde als hulpmiddelen die deskundige besluitvorming ondersteunen. Veilig en effectief gebruik berust op menselijke waakzaamheid, niet op autonome output.

Ontsluiten van ongestructureerde klinische data

Hoofdstukken 4 en 5 verschuiven de aandacht van communicatie naar de gestructureerde extractie van klinisch betekenisvolle, maar routinematig onderbenutte informatie.

De ernst van radiotherapie-geïnduceerde oesofagitis—een toxiciteit met directe implicaties voor overleving—wordt doorgaans alleen in vrije tekst vastgelegd. Onze fijn-afgestelde modellen bereikten macro-F1-scores tot 0,92 voor CTCAE-graadextractie, waardoor grootschalige real-world evidence mogelijk wordt waar die voorheen ontbrak.

Evenzo blijven sociale determinanten van gezondheid (SDoH), krachtige maar vaak genegeerde voorspellers van uitkomsten, grotendeels onzichtbaar in gestructureerde data. Fijn-afgestelde Flan-T5-modellen identificeerden 94% van de patiënten met ongunstige SDoH, vergeleken met slechts 2% via ICD-10-codes, en deden dit met minder demografische bias dan GPT-4-few-shot prompting.

Deze resultaten onderstrepen een kernboodschap: taak-specifieke fine-tuning op domeindata is niet alleen nauwkeuriger, maar ook eerlijker, en maakt ongelijkheden zichtbaar die generalistische modellen missen. Toekomstig werk omvat uitbreiding naar aanvullende toxiciteitsdomeinen, inbedding van deze pipelines in prospectieve registries en evaluatie van hun impact op klinische operaties zoals zorgnavigatie en middelenallocatie.

Autonome agenten in trialveiligheid

De laatste boog van Deel I culmineert in Hoofdstuk 6, waarin we iRAE Agent introduceren—een agentisch systeem dat bij Mass General Brigham is gepilot voor detectie van immunotherapie-gerelateerde bijwerkingen in oncologische trials. In tegenstelling tot statische classificatoren voert iRAE meerstapsredenering uit, gestructureerde foutcontrole en ontologie-gestuurde rapportage—processen die direct aansluiten bij echte trialworkflows en aanzienlijke regulatoire betekenis hebben.

Dit markeert een echt kantelpunt: de overgang van geïsoleerde extractietaken naar volwaardige klinische agenten die ontworpen zijn voor inzet in veiligheidskritische omgevingen. Toekomstig werk omvat opschaling van iRAE binnen trialnetwerken, integratie met regulatoire indieningspijplijnen en het ontwerpen van human-in-the-loop-interfaces die klinisch toezicht behouden terwijl routinematige surveillance wordt geautomatiseerd. Robuustheid tegen taalkundige variatie en weerstand tegen sycophantisch meegaand gedrag—uitgebreid behandeld in Deel II—zijn essentieel voor betrouwbare implementatie.

Deel II: Potentiële faalmodi van taalmodellen in medische contexten

Waar Deel I de aanzienlijke belofte van LLMs voor klinische ondersteuning laat zien, onderzoekt Deel II de structurele kwetsbaarheden die ontstaan wanneer deze systemen in veiligheidskritische omgevingen worden ingezet. Deze hoofdstukken tonen gezamenlijk aan dat dezelfde statistische leermethoden die generalisatie over enorme tekstcorpora mogelijk maken, ook leiden tot fragiel en gemakkelijk verstoord gedrag wanneer modellen medische redenering moeten uitvoeren.

Hoofdstuk 7 stelt een fundamenteel principe vast voor verantwoorde implementatie: generalistische LLMs zijn niet per definitie het juiste instrument voor de meeste biomedische NLP-taken. In tegenstelling tot de aanname dat grotere modellen met bredere training inherent beter presteren, laten onze bevindingen zien dat taak-specifiek fijn-afgestelde modellen GPT-3.5 en GPT-4 niet alleen overtreffen in gestructureerde extractietaken, maar dit ook doen met aanzienlijk minder rekenkracht. Deze domein-afgestemde modellen vertonen grotere stabiliteit, interpreteerbaarheid en consistentie—kwaliteiten die essentieel zijn voor klinische operaties. Het veronderstelde "generalist-voordeel" houdt geen stand onder empirische toetsing en benadrukt de

noodzaak om modelkeuze af te stemmen op de specifieke beperkingen van de zorg, in plaats van standaard het grootste beschikbare systeem te kiezen.

Hoofdstukken 8 tot en met 10 onthullen diepere epistemische tekortkomingen die geworteld zijn in pre-training-distributies. In Hoofdstuk 8 toont de Cross-Care-studie aan dat wanneer LLMs wordt gevraagd ziekteprevalentie te schatten, hun antwoorden de frequentie volgen waarmee ziekten samen voorkomen in The Pile—een Engelstalig, internet-afgeleid dataset—en niet de werkelijke epidemiologische data. Dit patroon houdt stand over talen en alignment-strategieën heen, wat suggereert dat deze modellen statistische reflecties van hun trainingscorpora internaliseren in plaats van medisch gefundeerde representaties van ziektelast. Deze representatiebias heeft diepgaande implicaties voor taken die epidemiologisch inzicht of populatie-niveau redenering vereisen.

De kwetsbaarheid die in Hoofdstuk 9 wordt blootgelegd, benadrukt een parallelle lexicale fragiliteit. Hoewel LLMs nominaal "weten" dat merk- en generieke geneesmiddelnamen naar dezelfde farmacologische stof verwijzen, leidt vervanging van de ene door de andere tot een nauwkeurigheidsverlies tot 10%. Deze discrepantie weerspiegelt een afhankelijkheid van lexicale co-occurrencepatronen in plaats van robuuste conceptuele representaties van geneesmiddelequivalentie. In de klinische praktijk—waar merk- versus generieke namen variëren per notitie, specialisme en instelling—introduceert dergelijke fragiliteit onvoorspelbare en potentieel gevaarlijke inconsistentie.

Hoofdstuk 10 voegt een gedragsmatige dimensie toe aan deze representatie-problemen en laat zien dat LLMs vaak instemmen met onjuiste claims over geneesmiddelequivalentie wanneer zulke claims in gebruikersprompts zijn ingebed. Deze sycophantische neiging—waarbij modellen prioriteit geven aan instemming en schijnbare behulpzaamheid boven feitelijke juistheid—kan leiden tot het zelfverzekerd verspreiden van medische desinformatie. Dit onderstreept de wisselwerking tussen alignment-methoden en klinisch risico: systemen die zijn geoptimaliseerd om beleefd, coöperatief of gebruiksvriendelijk te klinken, kunnen gevaarlijk worden wanneer die eigenschappen epistemische integriteit verdringen.

Samen schetsen de bevindingen van Deel II een waarschuwend maar constructief beeld: huidige LLMs zijn nog geen betrouwbare arbiters van medische kennis. Hun gevoeligheid voor pre-training-bias, lexicale

verstoringen, gebrekkige kennisrepresentatie en misalignment suggereert dat naïeve inzet in de zorg bestaande ongelijkheden kan versterken en nieuwe vormen van schade kan introduceren. Deze kwetsbaarheden onderstrepen de noodzaak van rigoureuze evaluatiekaders en doelgerichte waarborgen vóór klinische integratie.

Maatschappelijke impact en toekomstperspectieven

De bredere maatschappelijke betekenis van dit proefschrift ligt in de nadruk dat klinische AI niet alleen moet worden beoordeeld op technische prestaties, maar ook op afstemming met de praktische, ethische en gelijkheidsgerichte eisen van de echte zorgpraktijk. Door elk experiment te verankeren in levende workflows—patiëntberichtgeving, toxiciteitssurveillance, trialveiligheidsmonitoring—laat dit werk zien dat LLMs die op gesaniteerde benchmarks of synthetische taken worden getest, minder inzicht bieden in hun gedrag onder echte klinische omstandigheden. Modellen die binnen authentieke operationele settings worden geëvalueerd, onthullen daarentegen de beperkingen, faalmodi en frictiepunten die bepalen of AI-hulpmiddelen de zorg daadwerkelijk verbeteren.

Een kernbijdrage van dit proefschrift is de demonstratie dat last-mile-alignment—en niet schaal—de doorslaggevende factor is voor klinisch betekenisvolle AI. Foundation models leveren brede taalkundige competentie, maar zijn in ruwe vorm onvoldoende voor veilige inzet in echte zorgomgevingen. De meest relevante klinische waarde ontstaat wanneer modellen last-mile-alignment ondergaan: gerichte fine-tuning, kalibratie en gedragsoptimalisatie met lokale data, domeinspecifieke ontologieën en instelling-gedefinieerde veiligheidsbeperkingen. Deze laatste stap transformeert algemene capaciteiten tot betrouwbare, workflow-klare hulpmiddelen die de werkelijke beslisomgevingen van clinici weerspiegelen.

Cruciaal is dat last-mile-alignment inherent interdisciplinair is. Zij vereist domeinexperts om te definiëren wat "correct" betekent, informatici om modelgedrag te valideren over heterogene EPD-datastromen, ethici om potentiële ongelijkheden of normatieve risico's te beoordelen, en regulatoire specialisten om naleving van evoluerende standaarden te waarborgen. Kleinere, fijn-afgestelde modellen faciliteren deze samenwerking op manieren die grote generalistische modellen niet kunnen: ze zijn transparant genoeg om te auditen, modulair genoeg om aan te passen en lichtgewicht genoeg om snel en veilig te itereren. In die zin wordt de weg naar betrouwbare klinische AI niet gedomineerd door steeds grotere vooraf getrainde systemen, maar door

collaboratief afgestemde modellen die rigoureuze, lokaal verankerde last-mile-verfijning ondergaan.

De maatschappelijke implicaties van het extractiewerk in Deel I zijn aanzienlijk. Door de automatische identificatie van radiotherapie-toxiciteiten en sociale determinanten van gezondheid maakt dit onderzoek de generatie mogelijk van real-world evidence die voorheen ontoegankelijk was. Deze capaciteiten kunnen een eerlijkere verdeling van klinische middelen ondersteunen, trialontwerp verbeteren en ongelijkheden blootleggen die verborgen blijven in documentatiepraktijken. Ze creëren ook kansen om publieke gezondheidsinterventies, beleidsontwerp en gezondheidsgelijkheid op schaal te informeren.

Parallel hieraan bieden de faalpatronen die in Deel II zijn blootgelegd concrete handvatten voor ontwikkelaars, toezichthouders en zorgorganisaties om klinische risico's te identificeren, te mitigeren en te monitoren. Pre-training-bias, geneesmiddelnaam-fragiliteit en sycophantisch gedrag zijn geen abstracte tekortkomingen; het zijn faalmodi met directe implicaties voor patiëntveiligheid en publiek vertrouwen. Door deze kwetsbaarheden systematisch te karakteriseren, biedt het proefschrift een routekaart voor modelverbetering en governance-kaders die feitelijke gronding, robuustheid en ethische verantwoordelijkheid centraal stellen.

Tot slot dragen de vrijgave van WorldMedQA-V en MedBrowseComp bij aan duurzame, publiek toegankelijke infrastructuur voor het beoordelen van meertalige prestaties en moeilijke maar realistische medische redenering. Deze benchmarks stellen de gemeenschap in staat te meten of toekomstige modellen daadwerkelijk vooruitgang boeken richting eerlijke, evidence-gebaseerde klinische intelligentie—of slechts optimaliseren voor Engelstalige, oppervlakkige taken die bestaande ongelijkheden reproduceren. In een veld waarin driekwart van de gepubliceerde studies nog steeds geen reproduceerbaarheid of diverse validatie kent, is dergelijke gedeelde infrastructuur essentieel om wetenschappelijke standaarden te verhogen en zinvol regulatoir toezicht mogelijk te maken.

Vooruitkijkend zal de toekomst van klinische AI niet afhangen van schaal alleen, maar van rigoureuze wetenschappelijke methodologie, transparante evaluatiepijplijnen en doordachte integratie met menselijke expertise. LLMs die de zorg daadwerkelijk verbeteren, zullen die zijn die vertrouwen

verdienen—door robuustheid, rechtvaardigheid en verifieerbare correctheid—en niet enkel door taalkundige verfijning. Dit proefschrift legt de fundamentele evidentie, kaders en datasets om de ontwikkeling van zulke systemen te sturen en wijst de weg naar een toekomst waarin klinische AI de veiligheid, gelijkheid en integriteit van de mondiale gezondheidszorg versterkt—en niet ondermijnt.

Acknowledgments

I would like to express my sincere gratitude to the many people and communities who supported me throughout this PhD.

First and foremost, I am deeply grateful to my supervisors and mentors, **Prof. Hugo Aerts** and **Dr. Danielle S. Bitterman**, for their mentorship, patience, and steady guidance. Hugo consistently encouraged me to think beyond the immediate project and aim for work that is both ambitious and clinically meaningful.

I owe a special, heartfelt thanks to **Danielle**. Beyond being an outstanding mentor, she has been a constant source of calm, care, and protection during the most uncertain parts of this journey. She taught me, often through small moments rather than formal lessons, what it means to lead with generosity while holding a high standard. I learned from her how to communicate with clarity, how to write with the reader in mind, and how to stay anchored in what matters clinically when the technical path is tempting but the real-world relevance is unclear. I am also grateful for how she showed up as a person by checking in when things were hard, taking time to support my growth, and modeling a kind of integrity and kindness that I hope to carry forward in my own career. In many ways, her mentorship shaped not just this thesis, but also the way I think about responsibility in medical AI.

I am also grateful to my **assessment and reading committee** for the time and care they put into reviewing this dissertation and helping shape it into a stronger piece of work. In particular, I would like to thank **Prof. André Dekker, Prof. Jan Scholtes, Prof. Dirk de Ruysscher, Prof. Martha Palmer,** and **Prof. Steven Bethard** for their thoughtful feedback and for taking on the responsibility of assessing this thesis. I also appreciate the support from the doctoral administration and PhD office at **Maastricht University**, and everyone involved in coordinating the procedures for the joint program.

This thesis would not have been possible without the colleagues, collaborators, and friends I have been fortunate to work with across **Mass General Brigham and Brigham and Women's Hospital**, the **Harvard–MGB AIM program**, and the broader research community around us. I am thankful to my co-authors and collaborators, especially **Marco Guevara, Jack Gallifant, Zidi Xiong, Jirui Qi, Yuxin Xiao, Yingya Li, Sheng Lu, Sam Schmidgall,** and **Pedro Moreira**, for their creativity, persistence, and willingness to iterate until the ideas and writing

were truly clear. I also want to acknowledge the clinicians, domain experts, and reviewers who pushed me to treat evaluation as more than a metric, and to build systems that can withstand real clinical ambiguity.

I would also like to acknowledge earlier mentors and training that continue to shape how I think and write. My time at **Boston Children's Hospital's Computational Health Informatics Program (CHIP)**, including the opportunity to learn from and work with **Prof. Tim Miller** and **Prof. Guergana Savova**, gave me a foundation in language, rigor, and careful reasoning that I still rely on today. I am also grateful for the community they built and the many awesome colleagues there whom I continue to learn from.

Finally, I want to thank my family and the people closest to me for their unwavering support. This journey came with long stretches of uncertainty, revisions that never seemed to end, and the quiet pressure of trying to do work that matters. My family has been a constant source of strength and perspective.

To my partner, **Kaitlin**, thank you for growing with me through this colorful period of my life. Your patience, steadiness, and encouragement not only shaped my ability to complete this thesis but also influenced who I became during the process. There were many moments when I could not see past the immediate stress, and you helped me zoom out, regain perspective, and keep going. I am grateful that we supported each other through the intensity of PhD life, and that the growth was shared with so many exciting adventures!

To my close friends, especially **Sam** and **Peng**, thank you for your unwavering support through this entire process. You were a constant, grounding presence, helping me remember that even slow daily progress is real progress, and lightening the journey when I needed it most. I am profoundly grateful to all those who helped me maintain perspective and continue my growth throughout this endeavor.

To all of you, thank you for making this work possible, and for making the journey so Shan Chen.

Appendices

A1: MedAlpaca - An Open-Source Collection of Medical Conversation AI Models and Training Data

Available here: https://github.com/kbressem/medAlpaca

Background Large language models (LLMs) promise gains in clinical documentation, education, and patient communication, but closed APIs and privacy constraints limit deployment. MedAlpaca addresses this gap by releasing open-source medical instruction-tuned models and datasets that can run on-prem, enabling reproducible research and privacy-preserving use.

Approach We compiled "Medical Meadow," a >160k-example corpus that reformats medical resources (e.g., flashcards, StackExchange Q&A, WikiDoc chapters, public Medical QA benchmark) into instruction–response pairs. Models are fine-tuned from LLaMA 7B/13B with full-parameter FT and parameter-efficient variants (LoRA; 8-bit optimizer/matmul) using large effective batch sizes and standard schedulers. Zero-shot evaluations target USMLE Steps 1–3, excluding image items, with strict answer formatting for fair scoring.

Results Fine-tuning consistently improves over base models on USMLE. MedAlpaca-13B attains the strongest accuracies (e.g., Step 1 ≈0.47, Step 2 ≈0.48, Step 3 ≈0.60). Parameter-efficient routes (LoRA/8-bit) trade some accuracy for much lower compute, supporting wider academic/clinical use. All models and data are released publicly to catalyze follow-on work.

Implications Open instruction-tuned medical LLMs make it feasible to experiment locally, reduce privacy concerns, and accelerate tooling for structured reporting, retrieval/summarization, and training aids—while highlighting the need for guardrails against confabulation.

A2: Measuring Pointwise *V*-Usable Information In-Context-ly

Available here: https://aclanthology.org/2023.findings-emnlp.1054/

Background "Pointwise *V*-usable information" (PVI) is a hardness measure that tells you, for a fixed model *V*, how much *usable* signal an individual example contains—low PVI means the model has little leverage to solve that instance; high PVI means the signal is there and the model can exploit it. Prior work estimated PVI by training or fine-tuning probes, which is accurate but heavy-weight. This paper asks: can we bring PVI into the in-context learning (ICL) regime—i.e., diagnose instance-level difficulty purely by prompting, without any gradient updates? That would give practitioners a lightweight, model-specific difficulty score they can compute on the fly when they only have API access.

Approach We adapt PVI to an in-context analogue ("in-context PVI") by observing model predictions across *prompted* conditions rather than trained parameters. Concretely, we vary exemplars and shot counts in the prompt, read out the induced distribution of predictions, and compute a PVI-style quantity that reflects how much the model's *prompt-conditioned behavior* uses the information present in the input. The key design goal is no fine-tuning and few exemplars, so the metric is cheap to compute and usable in settings where training is impossible.

We run a systematic reliability study: (i) Exemplar robustness—does the in-context PVI for a given instance change if you swap which few-shot examples you show? (ii) Shot robustness—does it change as you move from 1→k shots? (iii) Behavioral parity—does in-context PVI preserve the characteristic relationships known from the original (training-based) PVI? Finally, they demonstrate practical utility: use in-context PVI to surface the "hard tail" of a dataset for targeted evaluation or data curation. Across these lenses, the in-context measure behaves stably and mirrors the spirit of classical PVI, but at a fraction of the computational cost.

Results First, you don't need fine-tuning to get a useful PVI-like hardness signal: the prompted version tracks difficulty in ways that agree with the training-based formulation. Second, the number and identity of exemplars barely move the needle—variance from exemplar choice is *insignificant*—and scaling the #shots does not destabilize the estimates. Third, it's actionable: ranking by in-context PVI cleanly pulls out the cases your model will struggle

with, which then lets you allocate annotation or evaluation budget where it matters most. In short, you get a trustworthy, "API-only" difficulty score that's cheap and robust.

Implications If you rely on ICL (or only have black-box API access), in-context PVI gives you a principled way to diagnose instance-level blind spots without training new heads or models. It's useful for: (a) test-set triage—stress-testing on low-PVI (hard) examples; (b) data curation—prioritizing new labels where PVI is low; and (c) human-AI collaboration—routing borderline cases to humans when the model's usable information is small. It extends the PVI toolbox from the fine-tuning world into the prompt-engineering world, while staying faithful to the original theoretical framing of $\mathcal{V}$-usable information.

A3: Sparse Autoencoder Features for Classifications and Transferability

Available here: https://aclanthology.org/2025.emnlp-main.1521/

Background Hidden states in large language models are rich but notoriously entangled, which makes downstream use brittle and hard to audit. We turn to sparse autoencoders (SAEs) as a way to recover part-based, interpretable features from those states. Our question is pragmatic: if we replace raw hidden states with SAE activations, do we keep enough task signal to be competitive, and do those features transfer—across models and across languages—so they're actually useful beyond the lab settings?

Approach We extract activations from released Gemma-scope SAEs (and keep the pipeline compatible with Neuropedia SAEs) and train simple linear probes for text classification. To stress-test usefulness, we run head-to-head comparisons of SAE features versus same-size slices of raw hidden states on 10+ challenging datasets. We then study two forms of transferability. (i) Model transfer: train on features from base or instruction-tuned LMs and apply them to LLaVA for classification without retraining the representation. (ii) Cross-lingual transfer: train a toxicity classifier on SAE features in one language and evaluate on other languages to see if the features carry over without translation. Throughout, we keep the recipe intentionally lightweight—no elaborate heads, minimal hyperparameter fuss—so any improvement is creditable to the representation rather than extra machinery.



Figure 9: Average F1 scores for each training language (y-axis) versus test language (x-axis). We compare hidden states, SAE features, and top-n feature selection. The top row shows models trained on native-language datasets; the bottom row uses English-translated data for training. Darker cells indicate higher F1 performance.

Results Across difficult text classification tasks, SAE features consistently match or outpace baselines that use equivalently sized raw hidden-state slices, while remaining sparse and interpretable. For model transfer, features learned from base or instruction-tuned LMs plug into LLaVA and retain strong classification performance with no feature retraining. For cross-lingual toxicity, a probe trained on SAE features in a single language generalizes to other languages out of the box; in aggregate, it is competitive with "translate-to-English-then-classify" pipelines shown in our figures. Finally, because our pipeline treats any public SAE as a drop-in module, Neuropedia releases can be used immediately—no custom retraining required.

A4: When Models Reason in Your Language: Controlling Thinking Trace Language Comes at the Cost of Accuracy

Available here: https://aclanthology.org/2025.findings-emnlp.1103/

Background As with many recent works—and our own prior results—we see strong cross-lingual capabilities emerging in large language models. Test-time compute (longer sampling, multi-path CoT) is becoming mainstream for Large Reasoning Models (LRMs), yet the *language of the reasoning trace* itself remains underexplored outside English. For meaningful oversight and pedagogy, users need chains of thought in their own language. Our central question is whether enforcing in-language thinking traces improves transparency at a measurable cost in accuracy, and if so, how high that cost is across languages and model families.

Approach We introduce XReasoning, a multilingual evaluation suite spanning 11 languages, and benchmark two leading LRM families. We measure: (i) how often models *actually* reason in the target language under ordinary prompting, (ii) how well they reason when we *explicitly push* them to keep the thinking trace in-language, and (iii) how various prompt interventions (e.g., stricter language constraints, formatting scaffolds) affect both language fidelity and task performance. To probe mitigations beyond prompting, we also run a small, targeted post-training (~500 examples) aimed at improving in-language reasoning without fully retraining the model.



Figure 2: Heatmaps of language matching rates (top) and accuracy (bottom) for Distilled-R1-32B on AIME, before (left) and after (right) prompt hacking.



Figure 3: Language matching rate and answer accuracy of Distilled-R1-7B with no post-training, post-training on 100 instances, and post-training on 250 instances for 3 languages: Japanese, Thai, and Telugu.

Results In default conditions, SOTA LRMs frequently revert to English mid-reasoning or produce fragmented, mixed-language traces. When we force in-language CoT, readability and auditor access improve, but answer accuracy declines, revealing a persistent trade-off between language fidelity and task success. The small post-training top-up reduces (but does not eliminate) this gap, suggesting that lightweight tuning can reclaim part of the lost accuracy while keeping the reasoning trace aligned to the user's language.

Implications Practitioners should treat "reason in the user's language" as a distinct alignment objective with a non-zero accuracy tax—one that can be partially offset with judicious prompting and small, targeted post-training. In workflows where oversight, pedagogy, or localization matter, enforcing in-language thinking may be worth the modest loss in raw accuracy. In our

follow-up (A5), we show techniques that move further toward getting both: higher in-language fidelity and stronger end-task performance.

A5: Budget Alignment: Making Models Reason in the User's Language

Available here: http://iclr.cc/virtual/2026/poster/10012111

Background Building directly on A4, we study the gap between answer language and reasoning language: many LLMs reply in the user's language yet "think" in English/Chinese. This hurts instruction-following, user trust, multilingual evaluation, and oversight. Our aim is to align the *reasoning trace itself* to the user's language without paying an accuracy tax.

Approach We use a two-step recipe on DeepSeek-R1-Distill-Qwen-7B. First, a small SFT on 817 curated multilingual chains (LiMO-style) teaches *in-language chains of thought*—a minimal "reprogramming" of inner monologue. Second, we apply Math500 training-only GRPO (RLVR/DAPO-like) with higher clip, rollout 24, LoRA r=8, lr=1e-5, and verifiable rewards that balance final-answer accuracy (1.0) with language-consistency (0.2) and format (0.2). We then evaluate JA/FR/ES on MMLU College Math, AIME'25, GPQA, and MMLU Pro Medicine, reporting pass@k (1/5/10, n=32) and language-consistency % (reasoning + final answer).



Results The SFT alone pushes language-consistency near ceiling in FR/ES and substantially lifts JA, with mixed or limited accuracy gains outside math. Adding GRPO after SFT typically Pareto-improves (higher accuracy *and* better

in-language following) on AIME/GPQA, and in-domain SFT→GRPO largely closes the accuracy gap between English-reasoning and in-language reasoning. The main exception is medicine, where math-only rewards under-specify biomedical style/recall and can cause regressions. Starting GRPO from the base model often exhibits smaller medical regressions, likely due to a more neutral prior than the SFT-steered one.

Why it works / where it fails Under task difficulty, an entrenched EN/ZH reasoning prior "wins" unless we intervene. The small multilingual SFT reliably locks the reasoning language, and GRPO then recovers or boosts accuracy. Failures trace to tokenization/numbering friction in JA, cue misalignment in ES, and especially reward misspecification for medicine—numeric correctness isn't the same as calibrated clinical discourse.

Practical playbook Use small multilingual SFT to secure the reasoning language, then GRPO to regain accuracy. When regressions appear, apply tokenizer-aware normalization, add tiny language-specific SFT top-ups, and switch to multi-objective GRPO that includes medical-style/lexicon rewards (and, when helpful, model merging).

In short: *lock the language cheaply, then train back the performance—without reverting to English under pressure.*

A6: Measuring the Faithfulness of Thinking Drafts in Large Reasoning Models

Available here: https://neurips.cc/virtual/2025/loc/san-diego/poster/120231

Background Modern Large Reasoning Models (LRMs) often generate a *thinking draft*—multi-path chains of thought explored before the final answer. These drafts promise transparency and controllability, but only if they are **faithful**: intermediate steps should causally influence later ones, and the final answer should genuinely depend on the draft's concluding logic. The paper argues that correctness alone is not enough; a model can get the right answer for the wrong reasons, undermining oversight and safety in high-stakes use.

We introduce a **systematic counterfactual intervention framework** to *measure* thinking-draft faithfulness along two complementary axes. (1) **Intra-Draft Faithfulness** tests whether earlier steps causally affect subsequent steps and the draft's conclusion by inserting or perturbing intermediate steps and observing downstream changes. (2) **Draft-to-Answer Faithfulness** tests whether the final answer *logically depends on* the draft's concluding logic by perturbing that conclusion and checking if the answer flips accordingly. The framework yields concrete, automatable tests rather than subjective judgments, enabling apples-to-apples comparisons across models.



Figure 1: Faithfulness situation we considered. Intra-draft faithfulness tests whether the conclusion of the draft is faithfully dependent on its previous reasoning, and Draft-to-Answer Faithfulness tests whether the answer-stage is faithfully dependent on its thinking draft.

Results Current LRMs display **selective step faithfulness**—some intermediate steps matter while others can be altered with little effect—and **frequent mismatches** between a draft's final logic and the model's final answer. In other words, models often *ignore or contradict their own draft conclusions*, highlighting a gap between visible reasoning and the causal process that

produced the answer. This reinforces prior concerns that chain-of-thought style traces can be unfaithful unless explicitly tested, and shows that the problem persists even for recent LRMs.

Implications For practitioners, the takeaway is straightforward: monitoring should not stop at accuracy or surface-level coherence. You need **causal tests** that probe whether the model's answer would change when the draft is perturbed in meaningful ways. The proposed interventions provide a practical blueprint for model evaluation suites, policy audits, and training-time regularizers that target faithfulness (complementing related work on counterfactual sensitivity and earlier CoT-faithfulness probes). The result is a more honest picture of when drafts can be trusted—and a path to improve them.

A7: KScope: A Framework for Characterizing the Knowledge Status of Language Models

Available here: https://neurips.cc/virtual/2025/loc/san-diego/poster/119139

Background LLMs can answer a question in multiple, sometimes conflicting ways. Traditional accuracy alone can't reveal whether the model is certain, conflicted, or simply guessing. KScope introduces a principled way to label an LLM's *knowledge status* from its response distribution, enabling targeted diagnosis and context design.

Approach KScope samples an empirical distribution of model answers (stabilizing by ~100 samples using 20 paraphrases per question) and assigns one of five statuses using three axes: **consistency** (single vs. multi-mode beliefs), **correctness** (does any mode match gold), and **absent knowledge** (refusal, hallucination, or uniform guessing). The framework then studies how different **contexts** update status.

- *So what changes the knowledge status?***Gold supporting context** reliably increases *consistent-correct* status across datasets and model families (Llama, Qwen, Gemma); larger models lead but gaps narrow with good context.
- **Noisy context** and **open-ended questions** reduce successful updates.
- **On model family quirks:** without context, Gemma shows more absent knowledge on open-ended than multi-choice; Llama/Qwen show the opposite.



Which context features matter? KScope evaluates 11 features in three groups—**difficulty** (length, readability, unique tokens), **relevance** (embedding similarity, ROUGE-2 R/P/F), and **familiarity** (question/context perplexity & entropy)—and finds models prioritize features similarly when partially correct or in conflict; overturning strong false beliefs may need distinct signals.

What context strategies work? A two-part recipe: (1) **Credibility** – prefer sources with credible metadata; (2) **Constrained summarization** – shorten while preserving semantics, token-level overlap, and fluency. Combined, this improves update success by **≈4.3% on average** and generalizes to GPT-4o.

Implications KScope gives practitioners an interpretable lens on *why* an LLM succeeded or failed and *how* to nudge it—by picking contexts that are credible, relevant, concise, and familiar—rather than relying on accuracy alone.

Also developed many public facing trials education and discovery agents: https://www.bittermanlab.org/projects